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The UK Medical Research Council's Framework for developing complex public health 
interventions outlines distinct methodological phases. This thesis explores application 
of the first four phases (theoretical, modelling, exploratory trial, definitive RCT) in 
developing a novel intervention to reduce stroke recurrence. 
An ethnographic approach was used entailing: in-depth interviews with stroke patients; 
observations in stroke clinics; participant observation; diaries; informal discussion with 
staff; in-depth interviews with key informants. 
The theoretical phase was used to conduct empirical research into stroke secondary 
prevention. Important considerations for intervention development were uncovered. 
According to The Framework, these findings should have been used to define 
intervention components. In practice, theoretical findings were used as much in 
legitimising pre-defined research ideas as in defining them. Analysis of the modelling 
phase revealed that intervention design was influenced by `interference', that is social, 
political and economic factors (including skill mix, priorities of the research team, 
resource constraints, time constraints and what could feasibly evaluated using RCT 
methods). The exploratory trial was used to pilot test the intervention and refine trial 
methods but did not specifically follow Framework recommendations. In the definitive 
RCT, despite adhering to Framework recommendations, the intervention was not 
delivered as intended. Problems emerged relating to trial process, intervention 
implementation and environmental changes. While these may influence trial outcomes, 
interview data suggested that patients valued the intervention as an information 
resource, for promoting continuity and as a tool for empowering them to manage their 
own risk factors. 
3 
This thesis critiques The Framework as a tool for guiding research and improving 
interpretation of RCT outcomes. `Interference' and problems of implementation are 
likely to be as important as theoretical work in influencing RCT outcomes. Process 
evaluation using ethnographic methods embedded within the RCT may help in 
interpreting trial outcomes but conflict between the two research paradigms cannot be 
ignored. 
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Chapter 1. Introduction 
1.1. Background to the thesis 
I first became interested in methods for developing `complex interventions' through my 
work on the Stop Stroke study, which began in 1999. My involvement in Stop Stroke 
included conducting a series of research studies into current practice and into patient 
and professional understanding of stroke secondary prevention. It was anticipated that 
this research would inform the development of a new complex intervention to prevent 
stroke recurrence, which would subsequently be evaluated in a randomised controlled 
trial (RCT). A year into the study the UK Medical Research Council (MRC) published a 
framework for developing and evaluating complex interventions using RCT methods. ' 
Although the Stop Stroke study was already in progress, from that point on we (the 
other study investigators and I) began to cite `The Framework' when describing our 
approach to intervention development, stating that it had guided the research process. 
Over the past six years The MRC Framework for complex interventions has become 
increasingly popular. By 2004 presentation of a conference paper discussing The 
Framework would guarantee an enthusiastic audience. 2 To date, The Framework has 
been cited in over 160 peer-reviewed publications including being used to support 
methods of intervention development which pre-dated its publication, 
3 and has been 
used particularly to support the incorporation of qualitative or mixed methods into 
research designs. 4'5 Yet The Framework is not universally accepted and its subsequent 
publication in the British Medical Journal6 rekindled a debate over the appropriateness 
of RCT methods for evaluating so called `complex' interventions. 
79 
As I will discuss in Chapter 2, this was not the first or most detailed framework to be 
published on the development of health services research (HSR) interventions, nor was 
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it the first time researchers had recommended applying the principles of evidence based 
medicine outside of the usual clinical context. As a consequence I was interested to find 
out why this framework in particular (which at first glance appeared to provide little 
practical guidance for our research), had sparked so much interest and how it could be 
applied in practice. Using qualitative methods embedded within a RCT, in this thesis I 
use Stop Stroke as a case study with which to investigate the application of the MRC 
Framework. 
1.2. Introduction to Stop Stroke, a case study 
In the next section I provide an overview of the Stop Stroke study, starting with an 
introduction to stroke disease, followed by a discussion of secondary prevention 
strategies for stroke and an outline of the Stop Stroke intervention. 
1.2.1. What is a stroke? 
The World Health Organisation define as a stroke as `focal or global neurological 
impairment of sudden onset and lasting more than 24 hours'. 1° Strokes can be 
distinguished from other types of neurological impairment in that the impairment is 
considered to be of vascular origin. " Strokes can be divided into three distinct subtypes, 
cerebral infarction (due to a blood clot) intracerebral haemorrhage (bleeding inside the 
brain) and subaracnoid haemorrhage (bleeding between the brain and the covering 
membrane). 12 Cerebral infarction can be further classified according to pathological 
assumptions, 13 or the resulting clinical impairment. 14 Neurological symptoms of 
vascular origin lasting less that 24 hours with no lasting impairment are distinguished 
from stroke and defined as mini-strokes or transient ischaemic attack (TIA). 
18 
The consequences of stroke are varied but commonly include physical and 
psychological impairments including: weakness, stiffness or impairment of limbs; 
incontinence; cognitive impairment (including memory loss or problems with sight); 
difficulty with speech and language (dysphasia and dysarthria); pain; fatigue and 
problems with sleep; and mood changes (including anxiety and depression). " 
1.2.1. The impact of stroke 
Stroke is the most common cause of adult disability and third most common cause of 
death in the developed world. ' 5 Stroke affects mainly older people with the majority 
(just under three-quarters) of cases occurring in people over the age of 65 years. 16,17 
Estimates of the recurrence risk vary depending on how recurrence is defined. '8"9 
Recent estimates suggest that the risk of recurrence within three months of an incident 
stroke is approximately 18%18 and the risk of any major vascular event within 10 years 
after a stroke or TIA may be as high 54%. 20 
Estimates of stroke impact and recovery vary depending on how the consequences of 
stroke are defined and measured. " A recent study of stroke survivors in South London 
estimated that only two fifths were independent in activities of daily living one year 
post stroke and that just under half experienced some form of handicap' as a result of 
stroke related impairment or disability. 22 In the Royal College of Physicians of England 
(RCP) Sentinel Audit of Stroke, just over a fifth of previously independent stroke 
survivors were discharged to institutional (residential or hospital) accommodation. 23 
However, the majority of stroke survivors with disabilities live in the community, 
' Definitions of disability and handicap were defined used World Health Organisation classifications 
where handicap is defined as 'a disadvantage for a given individual, resulting from an impairment or a 
disability, that limits or prevents the fulfilment of a role that is normal (depending on age, sex, social and 
cultural factors) for that individual. 21 In this study disability was measured using the Barthel Index and 
handicap measured using the Frenchay Activities Index. 
19 
relying on the support of informal carers such as family and friends. 24.25 Thus families 
and carers for people with stroke may also be affected by the consequences. 
Stroke is costly both at an individual level and for wider society and with the increasing 
older population, stroke prevention is becoming an important public health priority 
worldwide. In the UK this is reflected in recent public health policy documents such the 
National Service Framework for Older People, 26 as well as in the development of 
guidelines on treatment and prevention. 27 
1.2.2. Stroke prevention and secondary prevention 
The causes of stroke are complex with many different factors independently associated 
with higher rates of stroke. These include clinical factors (high blood pressure, diabetes, 
high cholesterol, coronary heart disease and atrial fibrillation), lifestyle factors 
(smoking, diet, alcohol consumption and obesity), genetic factors (ethnicity, rare blood 
disorders), social and demographic factors (age, poverty, ethnicity), some of which are 
amenable to health service intervention, some of which are more appropriately 
addressed through policy19 and some of which are not amenable to change at all. 
Prevention of first ever stroke (primary prevention) is known to be particularly difficult 
to achieve through health service intervention. 28,29 Those who have had one stroke are at 
particularly high risk (15-fold increased risk) compared to the general population30 and 
it is thought that subsequent strokes may cause additional if not more severe damage to 
the brain, leading to death, additional disability or dependence on health services. 31,32 
Consequently researchers have recommended that health service attention be redirected 
to target those most at risk such as preventing recurrent stroke (secondary prevention). 29 
In 2000 The RCP produced evidence-based guidelines for stroke management (later 
updated in 2002 and 2004). 27,33 Recommended strategies for achieving optimal 
20 
secondary prevention include keeping blood pressure, cholesterol and body weight 
within clinically defined `safe limits' (through taking medication, restricting food intake 
and increasing levels of exercise), keeping blood sugar levels controlled in those 
diagnosed with diabetes, taking antithrombotic medications (such as aspirin and 
warfarin) to prevent blood clots from forming, giving up smoking and moderating the 
amount of alcohol consumed. These strategies are not dissimilar to those recommended 
for prevention of other vascular diseases or for primary stroke prevention. Existing 
epidemiological studies have demonstrated inadequacies in secondary prevention 
management. For example research in South London conducted prior to the Stop Stroke 
study demonstrated inadequacies in prescribing of antithrombotic and anti-hypertensive 
medication. A quarter of those appropriate for aspirin, a third of those appropriate for 
anti-hypertensive medication and two thirds of those appropriate for warfarin were 
found to be inadequately treated three months post stroke. 34 Some studies conducted 
since the start of Stop Stroke have demonstrated improved management over time. 35 36 
However, most also report that inadequacies remain in relation to medication 
prescribing and adherence to medication or lifestyle recommendations. 3541 
1.2.3. The Stop Stroke intervention 
`Stop Stroke' is part of a project to improve secondary prevention management after 
stroke. The study started with an investigation of current secondary prevention to 
inform development of an intervention (as explained in section 1.1. ). The intervention 
was subsequently tested in a pilot evaluation to investigate the feasibility of 
implementing the intervention and is currently being evaluated for efficacy in a cluster 
RCT involving 120 general practices. Key outcomes include blood pressure control, 
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smoking cessation and aspirin use. A detailed description of the intervention is 
presented in Chapter 7. 
1.3. Aims, objectives and organisation of the thesis 
Using Stop Stroke as a case study, this thesis investigates the process of using the MRC 
Framework to develop and evaluate a complex intervention. A second aim is to explore 
the use of qualitative methods in understanding and enhancing RCT evaluations. Social 
studies of science and technology have demonstrated the importance of structural, 
cultural, political and economic influences in the construction of scientific knowledge, 
including the development of clinical evidence. 42,43 Authors have demonstrated how 
such influences may bias our understanding of the efficacy of pharmaceutical 
therapies. 44 46 Less is known about how social, economic or political processes 
influence the development of evidence in relation to complex health and social 
interventions. This thesis uses an ethnographic approach, incorporating a range of 
qualitative methods to investigate the application of The Framework in this context and 
aims to address the following objectives: 
0 To develop a clearer definition of the concept of a complex intervention (Chapter 2) 
9 To critically review the literature on methods for developing and evaluating 
complex interventions, including the use of RCTs and qualitative methods (Chapter 
2) 
" To systematically review the methods used to develop and evaluate complex 
interventions in stroke care (Chapter 3) 
" To investigate the relationship between theoretical and methodological rigour in 
intervention development and study outcome (Chapter 3) 
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" To investigate the use of in-depth interview methods in intervention development 
(Chapter 5) 
" To investigate the use of non-participant observation methods in intervention 
development (Chapter 6) 
9 To investigate the application of the MRC Framework in complex intervention 
development (Chapters 5,6 and 7) 
9 To investigate the application of the MRC Framework in RCT evaluation of 
complex interventions (Chapter 8) 
" To investigate the use of ethnographic methods, embedded within a RCT, to 
evaluate intervention implementation (Chapter 8) 
" To investigate the use of qualitative methods alongside a RCT to understand 
outcomes (Chapter 9) 
" To discuss the practical, ethical, clinical and social implications of the findings from 
Chapters 2-8 for complex intervention development (Chapter 10). 
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Chapter 2. Challenges for complex intervention development 
This chapter begins with a discussion of what is meant by the term `complex 
intervention' and how complexity has been defined in the literature. An overview of 
methods for developing and evaluating complex interventions is presented including 
key arguments for and against the use of RCTs in this context. The discussion includes 
an introduction to the MRC Framework and other models of health care evaluation and 
an introduction to the use of qualitative methods in the context of complex intervention 
development. 
2.1. What are complex health interventions? 
Although many clinical interventions could in one way or another be defined as 
complex, an exact definition of a `complex intervention' within the public health/HSR 
context is unclear. This is illustrated by the rather vague MRC definition: 
`The greater the difficulty in defining precisely what exactly are the active ingredients of an 
intervention and how they relate to each other, the greater the likelihood that you are dealing 
with a complex intervention. "(p 1) 
Within public health and HSR use of the term is relatively new. To develop a clearer 
definition I conducted a literature search" on how the term `complex intervention' had 
been defined by authors in published reports. The search identified 154 reports 
(including articles, editorials and letters), 58 of which discussed complicated 
" In September 2005 1 conducted a literature search using two online databases (Science Citation Index 
and Social Science Citation Index) via Web of Science, with the words `complex intervention' entered as 
a key phrase. All types of report (letters, editorials, review articles and original research articles) were 
included provided that the term `complex' was used to refer to health interventions. Studies were 
categorised according to whether they focused on pharmacological therapies, surgical interventions or 
other health services or public health interventions. Articles referring to health services and public health 
interventions were retrieved and the way the authors had defined `complex' further coded into categories 
listed above. 
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pharmacological or surgical procedures not relevant in this context and 98 of which 
were relevant to this thesis. As in the MRC Framework, many authors did not provide 
an explicit definition, characterising complexity by what it was not rather than what it 
was (in other words simple interventions were defined and complex interventions 
assumed to be those which did not fit these criteria) and some authors suggested that 
any non-pharmacological intervention was complex. The more specific characteristics 
of complex interventions relate to four main themes including disease group, the 
components of the intervention, the way the intervention was implemented or the 
methods used in evaluation. There were some contradictions between authors over these 
characteristics. For example in some reports the authors described educational 
interventions as being complex; 47-50 in others, educational interventions were only 
defined as complex if the education component was accompanied by other components 
such as counselling, decision support, feedback, emotional support, or coordination. 5 55 
In some reports educational interventions were considered complex if there was 
something about the method of delivery that was complex; for example, if the education 
was delivered using multiple strategies or if it was delivered using novel methods of 
delivery such as a peer-led or advocate-led educational interventions. 
56'57 By contrast, in 
one report educational interventions were cited specifically as examples of 
interventions, which were non-complex. 58 To clarify for the purposes of this thesis I 
would propose that complexity can be more easily understood as comprising a number 
of different layers (Figure 1). 
All interventions, whether single or multiple component, whether tailored or 
standardised can be seen as complex to a certain extent. However, for some types of 
intervention, complexity refers to only one layer (such as being targeted at a complex 
disease group) while others have multiple layers (targeted at a complex disease group 
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Figure 1. Layers of complexity in complex interventions. 
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and have multiple components which are therefore difficult to implement and evaluate). 
Depending on the type of intervention and the different layers of complexity, the 
challenges for development and evaluation of interventions are likely to be very 
different. It is these challenges that will be investigated in this thesis. 
2.2. Methods for developing and evaluating complex interventions 
With the emergence of evidence-based healthcare in the 1980s and 90s there have been 
calls over the past decade, for clinical interventions to be evaluated in terms of efficacy, 
cost and subsequently, the strengthening of methods to achieve this. 
59-61 
Different methods exist for investigating and evaluating health care. 
62 Current 
epidemiological thought proposes a hierarchy of evidence for determining the efficacy 
of an intervention, at the top of which (the `gold standard') is the RCT, or meta-analyses 
of multiple RCTs. 63,64 
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2.2.1. Randomised controlled trials 
The RCT as we understand it today has evolved predominantly over the past 50 years65 
although there was evidence of comparative studies of medicinal treatments as early as 
the 18`h Century. 66,67 Pocock defines a trial as `a planned experiment to elucidate the 
most appropriate treatment of future patients with a given medical condition' (p 1)65. 
Results are used from a sample of patients to make inferences about how treatment 
should be conducted in a wide population. 
A RCT in its most basic sense can be described as a prospective experimental study 
involving random allocation of participants to one of two (or more) groups, to compare 
the effect of the treatment against no treatment or an appropriate alternative. 62 Rothman 
and Greenland define `clinical trials' as particular types of experiment involving people 
who already have a defined disease. 62 They distinguish the clinical trial from other types 
of epidemiological experiment in which there is absence of disease (those involving the 
general population, which they term `field trials'), or those in which the intervention is 
delivered on a community-wide basis rather than an individual basis (termed 
`community intervention trials'). 
Regardless of where the experiment takes place or who the participants are, one of the 
basic assumptions of the RCT method is that it is possible to isolate the impact of the 
intervention on a given outcome. In a typical laboratory experiment, this may be 
relatively straightforward since, it is possible to control the environment in which an 
interaction takes place. However, in the context of clinical trials (involving human 
participants), controlling the environment is more complicated and it is therefore more 
difficult to isolate the impact of the intervention alone. 68 Using a comparison or control 
group and allocating subjects to the groups in a random fashion were methods designed 
to overcome these problems. Studies which incorporate only one of these methods, for 
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example those that do not use randomisation or use before and after comparisons with 
no appropriate control group, are not thought to properly fulfil the methodological 
requirements for producing robust unbiased research evidence and are sometimes 
termed `quasi experimental69 (in Rothman & Greenland, p6862). 
2.2.2. Randomised controlled trials and complex interventions 
RCTs have mostly been used within the pharmaceutical industry to evaluate the efficacy 
of new drugs, as a result of concerns for patient safety"'. However, since the 1970s, 
RCT testing has also been applied to existing therapies (p29)63 and is a pre-requisite for 
development of other types of clinical intervention including non-pharmacological 
procedures, technologies and devices. 7' As Oakley has illustrated, the experimental 
method also has a long history in the social sciences particularly in the fields of 
psychology and sociology, 72"74 and in the past decade there have been calls to strengthen 
the `evidence base' for complex interventions, for example in areas such as 
rehabilitation. 75 Such calls reflect broader changes in relation to the construction of 
medical knowledge, that is the increased contribution of academia to medicine and the 
assumption that knowledge should be based on unbiased evaluations of treatments 
rather than subjective estimations of impact or `good intentions'. 12,76 
However, there has been considerable debate in the literature over the appropriateness 
of using RCT methods in this context. 77 79 Some argue that the only method of 
establishing evidence of the efficacy of an intervention is through the use of RCT 
"' Although policies for drug regulation have evolved throughout the 20-21S' centuries, recent 
developments have largely evolved in response to drug related tragedies such as the thalidomide disaster 
in the 1960s. Such tragedies prompted the regulating bodies at the time (the Food and Drugs 
Administration, FDA in the US and the Committee on the Safety of Drugs, CSD in the UK) to introduce 
recommendations to ensure that all drugs were properly tested and safe before marketing. 7° 
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methods73 and that concerns for patient safety apply equally to public health and social 
interventions. 76 Others, including the World Health Organisation (WHO), disagree: 
'RCTs are inappropriate for evaluating health promotion, they are often misleading and 
unnecessarily expensiveiBO (p5). 
While some of the arguments clearly stem from `paradigm wars' within health and 
social sciences (between those who believe in a positivist rather than a constructivist 
approach, or between those who prefer the use of a particular type of evaluation 
method), 81'82 much of this debate probably also stems from a lack of definition of the 
meaning of complexity. While it may be relatively straightforward to use RCT methods 
to assess the impact of a simple educational intervention (such as a patient leaflet 
delivered within a hospital setting), assessment may prove more difficult if the 
intervention has multiple non-standardised components, is delivered at a community- 
level or aims to have an impact on something more difficult to measure such as 
improved social capital. 83 Those conducting social studies of evidence-based medicine 
have argued that forcing non-pharmacological interventions to be evaluated using RCT 
methods ensures that only those interventions amenable to RCT evaluation (which 
excludes many population based or social interventions) will be researched. 
84 
For a number of reasons it is difficult to evaluate some types of complex interventions 
using the experimental method. These will now be outlined. 
2.2.2.1. Difficult to randomise participants 
In the case of complex interventions, randomised allocation of participants or 
identification of suitable controls can sometimes prove difficult, particularly where the 
intervention is designed to influence individual outcomes via organisational or 
community change. In such instances it would not be possible to randomise individual 
participants. Special procedures such as `cluster randomisation' have been developed to 
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allow for group allocation in statistical analyses. 85 There have been some examples of 
novel community interventions in health care which have incorporated such cluster 
designs. 57'86 However, although specialist statistical techniques may be able to 
compensate for some difficulties of evaluation, they cannot address problems such as 
what to do if an appropriate control community or group cannot be found, (for example 
in evaluating national-level interventions such as media campaigns). 
2.2.2.2. Difficult to identify the active ingredients 
Some health promotion specialists argue that RCT methods are often inappropriate for 
evaluating complex interventions that comprise multiple components since it is difficult 
to identify which components of the intervention are the `active ingredients. '88 Certain 87 
types of complex intervention such as counselling, cognitive behavioural therapy or 
educational interventions often require the intervention to be tailored to the individual 
participant, meaning that the active part of the intervention is not standardised. Thus it 
is difficult to know what dose is required to achieve a given outcome when generalising 
research findings to a wider population. It is argued that since complex interventions 
often incorporate multiple components, the intervention becomes a `black box' such 
that, when final outcomes are measured it is not possible to interpret which parts of the 
intervention have been successful. 87 However, others suggest that multiple components 
and tailoring of individual components are not necessarily a problem for applying RCT 
methods since in such cases the package or intervention concept remains standardised 
rather than the components themselves. 7 
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2.2.2.3. Difficult to evaluate success 
Both Tones and Nutbeam argue that choice of outcome measures used to evaluate 
success in complex intervention trials has not always been appropriate. 8'87 They argue 
that health promotion interventions often aim to change outcomes over the longer term 
(up to 10 years or more) and although theoretically not a problem, practically it may be 
difficult to conduct a trial for such a long time. Large numbers of participants would be 
likely to drop out making it difficult to recruit required numbers and difficult to 
interpret the results. Nutbeam also argues that in many cases shorter-term process 
outcomes cannot be appropriately measured using the usual quantitative indicators of 
success. 87 Others argue that multi-disciplinary interventions also pose cultural and 
organisational challenges for implementation that make the conduct of RCTs difficult 
over and above the complexity of the intervention itself. 77'89 For example, the different 
agendas of researchers, managers and practitioners9° or the different epistemological 
orientations and status of researchers from different disciplines. 89 
2.3. The MRC Framework for complex intervention development. 
In order to improve our understanding of complex interventions, the MRC published a 
framework for guiding development and evaluation. 1'6iv The Framework aims to guide 
intervention development by breaking down the process into five phases, paralleling 
those used in the pharmaceutical industry in developing drug therapies (Figure 2). 
The pharmaceutical model, involves pre-clinical testing which refers to drug 
development before it is tested in humans (including compound development in the 
laboratory and animal testing), followed by four sequential phases of testing in humans: 
" The Framework was published twice, firstly by the MRC as a framework for guiding development and 
evaluation of RCT studies of complex interventions and subsequently in the British Medical Journal as a 
framework for all complex intervention development in general. 
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phase I trials investigate clinical pharmacology and toxicity; phase II involves the initial 
clinical investigation for treatment effect in humans; phase III trials involve the full- 
scale evaluation of treatment; and phase IV trials focus on post-marketing surveillance 
to determine uptake of the intervention. 91'92 In the MRC Framework the first 
`theoretical' phase corresponds to a pre-clinical phase of pharmaceutical development, 
in this case where the theoretical assumptions are defined and the hypotheses are 
generated. The second phase, `modelling', corresponds to Phase I in the pharmaceutical 
model and refers to the process of identifying the intervention components and the 
mechanisms by which they will influence outcomes. The MRC Framework includes a 
section on using qualitative research methods in the theoretical and modelling phases of 
intervention development, in which the authors recommend the use of qualitative 
methods to address unanswered questions particularly in relation to understanding the 
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`active ingredients' of the intervention. ' The third phase, `exploratory trial', corresponds 
to a phase II pharmaceutical trial in which the components are finalised and a protocol 
for the main trial is defined. The fourth phase `definitive RCT' corresponds to a phase 
III pharmaceutical trial in which the intervention is compared to a suitable control to 
establish efficacy; and the final phase `long-term implementation' corresponds to a 
phase IV pharmaceutical trial in which the definitive RCT results are investigated in an 
uncontrolled setting. 
The MRC Framework can be seen as novel on two accounts. Firstly, it acknowledges 
the difficulty of applying RCT methods to complex interventions and secondly it 
stresses the importance of considering alternative approaches (qualitative methods) to 
investigating aspects of healthcare. In this context, The Framework can be seen as 
something of a `scientific revolution'. 93 
2.4. Alternative frameworks for complex intervention development 
The MRC Framework has been criticised, in particular by those in the field of health 
promotion (where most of the interventions developed can be termed `complex') for its 
focus on using RCT methods. 9 Many health promotion specialists argue that the choice 
of evaluation method should depend on the `ideology' underpinning the intervention 
and the health question to be answered. It is the ideological underpinning of the 
interventions that dictates the types of methods appropriate. For example, Naidoo & 
Willis (2003) outline five different approaches to developing health promotion 
interventions. 83 These include (i) a medical approach, (ii) a behavioural approach, (iii) 
an educational approach, (iv) an empowerment approach and (v) a social change 
approach. The first three approaches (medical, behavioural and educational) are based 
on medical and psychological theories of health and focus on intervening at an 
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individual level, either treating the individual directly with medicinal or surgical 
intervention (medical model), or improving health outcomes through individual 
education and behaviour change. The last two (empowerment and social change 
models) focus on intervention at a social level either through empowering communities 
locally (community development) or through tackling inequalities on a broader national 
level (social change model). They argue that it is difficult to evaluate interventions 
incorporating certain types of approach using RCT methods (in particular, it is difficult 
to evaluate community empowerment or social change interventions). 
The MRC Framework does not distinguish between interventions using different 
approaches, neither does it distinguish between interventions designed to influence 
short-term outcomes (such as improving knowledge) from those intended to achieve 
long-term outcomes (such as wealth distribution). The authors of The Framework make 
no reference to the health promotion literature, possibly suggesting that it is really only 
intended to be used to evaluate the first three types of health promotion intervention 
(medical, behavioural and educational models). 
2.5. Formative, process and outcomes evaluation 
Within the health promotion and social science literature, alternative frameworks have 
been proposed for guiding evaluation of social or complex health interventions. 
Thorogood & Coombes suggest that different types of evaluation should be conducted 
to evaluate different aspects of programmes and conducted at different time points. 94 
They identify three different types of evaluation necessary in programme development, 
formative, process and outcomes evaluation. Formative evaluation refers to research 
used to inform intervention development; process evaluation refers to research 
concerned with the implementation of the programme and its impact on processes 
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leading to the eventual outcomes; and outcome evaluation refers to research into the 
impact of the programme on the final endpoint that the programme aims to influence. 94 
They describe a circular rather than linear relationship between the phases, meaning 
there is no definitive end to the research process. In other words, outcome evaluation 
should form the formative research required for the next programme and so on. Naidoo 
& Willis also outline three types of evaluation in health promotion: process, impact and 
outcome evaluation (p376). 83 They suggest that process evaluation (also called 
formative or illuminative evaluation) investigates participants' perceptions of the 
intervention and aims to identify factors, which act as facilitators or barriers to the 
intervention working. Impact evaluation refers to the immediate effects of the 
intervention on short-term outcomes (including patient knowledge, attitudes, health 
behaviours). Outcome evaluation is defined as assessment of the impact of the 
intervention on longer-term outcomes, such as health outcomes. They suggest that 
impact evaluation may be the one most accessible to evaluation using RCT methods. 
There appears to be some variation across the literature over what exactly is meant by 
these different terms. Patton suggests that formative evaluation might include a process 
evaluation rather than the two being mutually exclusive `phases', depending on its 
purpose95. In other words, if it is used at the end of a study to refine future versions of 
the intervention then it can be defined as formative evaluation; if it is used simply to 
explain outcomes then it is not `formative', in this case it really depends on the end 
point of the study. Patton also uses the term implementation evaluation, which can be 
viewed as part of a process evaluation but focusing specifically on how the intervention 
is implemented. He quotes Walter Williams, who in 1976 said that 
`the lack of concern for implementation is currently the crucial impediment to improving 
complex operating programs, policy analysis and experimentation in social policy areas' 
(in Patton, p279). 
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Impact evaluation as defined by Naidoo & Willis appears to refer more to the method of 
evaluation than the purpose since, for some, the short term outcomes (impact 
evaluation) may be seen as part of the processes involved in the eventual success or 
failure of the intervention, even though they are not studied using statistical 
techniques. 83 
If the MRC Framework is visualised in the context of these health promotion 
definitions, the first three phases (theoretical, modelling and exploratory trial) can be 
seen as formative research and the main RCT can be seen as impact evaluation with the 
longer term implementation phase corresponding with `outcome evaluation'. The MRC 
model also suggests a circular relationship between the different phases of intervention 
development. However, unlike the other models it does not include a process evaluation 
phase. Thus the MRC Framework can be seen as a simplified version of these health 
promotion models of evaluation, with the focus being on detailing the formative 
research phases to inform intervention development but including little guidance at the 
process, impact or outcome evaluation stage. Such simplifications do not automatically 
negate the status of The Framework as innovative since according to Kuhn, scientific 
revolutions occur not as a sudden shift in thinking but as part of a process of change, 
which reflects changes in broader social thinking. 93 
2.6. Action planning models 
As stated earlier, the MRC Framework is not the only evaluation model to have 
dissected intervention development processes into separate phases. Action planning 
models, 96 used within health promotion, organisational science and the military for 
strategic development, break down the planning process into distinct phases, some with 
similarities to those defined in the MRC Framework. Three of the best known models 
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include the model by Dignan & Carr, 97 the Precede-Proceed Model98 and the Pabcar 
model. 99 Dignan & Carr suggest five phases to intervention development including: 
community analysis (analysis of community needs); targeted assessment (identification 
of key problems to address); programme plan development (identification of methods to 
address problems); implementation (consideration of implementation problems); 
evaluation (evaluation tools put in place). In the precede-proceed model, nine distinct 
phases are identified including six phases to diagnose needs and/or problems: social 
diagnosis; epidemiological diagnosis; behavioural and environmental diagnosis; 
educational and organisational diagnosis; administrative and policy diagnosis. The 
intervention is devised based on these diagnoses within the context of available 
resources and ability of the health promotion team to address them. The intervention is 
then implemented (phase seven) and three phases of evaluation used to understand 
impact (process evaluation; impact evaluation; outcome evaluation). 98 The Pabcar 
model recommends seven iterative phases: identify problem and target group; develop 
interventions and outcome based objectives; pilot research; assess intervention in terms 
of social impact; consideration of ethics, economic costs and efficacy; further pilot if 
necessary; implement intervention; monitor problem, evaluate intervention and change 
if required. 99 
Each of these models is slightly different in the number and focus of the phases 
included but they have in common, three distinct differences when compared to the 
MRC Framework. Firstly, each model suggests the type of theoretical investigation or 
analysis which should be conducted, including a form of social or community diagnosis 
of the problem to be addressed; secondly, each model incorporates implementation and 
process evaluations as distinct phases in addition to the impact or outcome evaluation; 
thirdly none of the models identifies a specific method that should be used in outcomes 
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evaluation and none of them specifically reference the use of RCT methods. In fact the 
authors of the Pabcar model suggest that RCT methods may be inappropriate for 
outcome evaluation since successful implementation requires ongoing monitoring, 
evaluation and change, something not permitted within the context of a RCT. 99 
2.7. Using qualitative methods in intervention development and evaluation 
Although often considered to be of low status in the evidence-based medicine hierarchy 
for generating research evidence, 82' 100 health promotion specialists and indeed clinicians 
and social scientists are increasingly arguing for the use of `qualitative methods', if not 
instead of, then alongside or embedded within RCT methods for investigating 
interventions. 73,81°82,100-102 The phrase `qualitative method' is often used to refer to 
specific data collection techniques such as in-depth interviewing, focus groups studies 
or participant observation (as in the MRC Framework). In this thesis, I use the term to 
refer to data collection tools within a specific paradigm, that is techniques for 
understanding phenomena when adopting a `non-positivist' approach. In a non- 
positivist tradition (for example a constructivist approach), the researcher does not 
subscribe to traditional scientific principles such as attempting to expose or report 
scientific `truth' or testing specific hypotheses. Rather, the aim is to construct ideas, ask 
questions, generate hypotheses or theorise about how and why particular phenomena 
occur in the way that they do. Such approaches are traditionally rooted in the disciplines 
of anthropology, sociology and social psychology103 (although these disciplines do not 
exclusively subscribe to non-positivist approaches). 
Use of qualitative methods within public health and HSR is becoming increasingly 
common, although not without criticism from theorists. It is argued that atheoretical 
attempts by HSR researchers to apply the tools for the trade (interviews for example) 
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have led to research that contributes little to our understanding of health, or to our 
understanding of cultural, psychological or social phenomena. ' 03,104 
Whether appropriate or not, qualitative methods have been used for a number of 
different purposes in relation to intervention development and evaluation including: to 
improve communication of trial process to patients to improve trial recruitment; 105,106 to 
understand users' views or experience prior to intervention development; 107"109 to 
develop trial methods including outcome measures; 10""' to understand intervention 
implementation; 12-16 as a data monitoring procedure to ensure patient safety; ' 17,118 and 
to investigate the impact of the intervention on trial participants' experiences. ' 19,120 Two 
studies have even incorporated qualitative methods into intervention studies as a result 
of the MRC Framework. ' 17,121 However, there has been little critique of this approach 
and while some have suggested that the use of formative or process evaluation may be 
problematic, 87"22,123 it is more generally accepted that process evaluation poses no 
methodological problems when used alongside more traditional RCT 
methods. 
73'86,95,1 oQ 115,117 
In this thesis the challenges of using qualitative methods in intervention and evaluation, 
including embedding process evaluation within a RCT will be investigated in the 
context of Stop Stroke intervention and trial evaluation. 
2.8. Summary 
Finding the best way to develop and evaluate complex interventions has become an 
increasingly important question in public health and clinical practice over the past 
decade. In clinical research the RCT is held to be the `gold standard' method of 
evaluation for producing objective research evidence. But the application of RCT 
methods in complex intervention evaluation can be problematic. The MRC Framework 
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was designed to guide those contemplating complex intervention development. It has 
not yet been demonstrated whether the framework will make a difference. However, 
similar health promotion models for intervention development suggest that in order to 
understand the impact and outcomes of complex intervention studies, research should 
include process and implementation evaluations, something omitted from the MRC 
Framework. Further research is needed to investigate the application of The Framework 
in practice. In this thesis I investigate The Framework as a measure of quality in 
intervention development and in subsequent chapters as a practical tool for guiding 
development and evaluation of the Stop Stroke intervention. 
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Chapter 3. Review of complex intervention development in stroke care 
3.1 Introduction 
In this chapter I focus specifically on the development of complex interventions in 
stroke care, presenting findings from a systematic review of empirical studies of 
complex interventions in stroke care. Although the focus of the Stop Stroke study is on 
secondary prevention, due to the paucity of intervention studies in this area the review 
has been broadened to include all complex interventions studies in prevention and 
stroke management. I have previously reviewed the efficacy of complex interventions in 
stroke care' 24. In this review I aim to investigate the theoretical grounding and research 
methods used to develop and evaluate interventions and explore the relationship 
between intervention and study design and the eventual success or failure of the 
intervention. The following questions will be addressed: (i) what complex interventions 
have been developed in the context of stroke prevention and management; (ii) what 
theories and methods have been used to develop and evaluate these interventions; and 
(iii) what influence does theoretical and methodological quality have on study 
outcomes? 
3.2. Methods 
The review included published evaluations of complex interventions in stroke 
prevention and management. Since there is little clarity over the definition of a 
`complex intervention' (Chapter 2), for the purposes of this review I defined complex 
interventions as educational or psychosocial interventions aimed at changing 
knowledge, beliefs or behaviours. Specific rehabilitation or therapy interventions and 
those targeted at service organisation were excluded. These were: diagnostic tools; non- 
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pharmacological therapies (including complementary medicine, physiotherapy, 
occupational therapy, speech and language therapy, cognitive-behavioural therapy); 
stroke units; early discharge interventions; integrated stroke care-pathways. 
The review was not restricted by language or study design but interventions evaluated 
only in preliminary analyses or pilot studies were excluded. 
3.2.1. Search strategy 
I used multiple search strategies to identify articles for inclusion: electronic online 
database searches; hand searching of individual journals; and a `grey literature' search. 
Five online databases were searched: MEDLINE 1966-2005; EMBASE 1980-2005; 
PsychInfo 1967-2005; Science Citation Index (SCI) and Social Science Citation Index 
(SSCI) 1900-2005. Recent journals (2000-2005) were hand searched to crosscheck for 
articles not identified by the electronic search (Stroke, Cerebrovascular Diseases, 
Lancet, New England Journal of Medicine, JAMA, BMJ, Health Education Research, 
Health Psychology, British Journal of Health Psychology, Social Science and Medicine, 
Patient Education and Counseling, Journal of Advanced Nursing, Health Promotion 
International). Existing reviews, UK health education and health policy documents were 
searched, as were the reference lists of included articles. Both a MeSH subject heading 
search and a key word search were conducted (last searched November 2005). The 
choice of search terms was guided by the MRC Framework' and included multiple key 
words and phrases". Articles describing the theoretical or methodological development 
of included studies were retrieved in addition to those documenting the evaluation itself. 
For the subject-heading search the following strategy was used: 
1) Subject headings `stroke', `cerebrovascular accident', `cerebrovascular disorders' were combined 
using the Boolean operator 'OR'. 
2) Subject headings `prevention', `primary prevention', `secondary prevention', 'recurrence', `risk 
management', `disease management', 'patient care', `health care delivery', 'rehabilitation', `social 
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I conducted the search myself and rated studies for inclusion. Where it was unclear 
whether or not a study should be included, relevant articles were retrieved and discussed 
with one of my supervisors (CM) until consensus was achieved. In one case where the 
article could not be retrieved, the authors were contacted to request the full article. 
Decisions on four studies published in languages other than English were made based 
on translations of the abstract. The key article of the one study judged to be relevant, 
was retrieved in Chinese and translated in full. 
I categorised interventions by study aim and target group. Data were extracted into pre- 
designed tables to ensure standardisation across studies. 
3.2.2. Analysis 
Since the review focused on the influence of theoretical and methodological 
development rather than on intervention efficacy, a meta-analysis was not conducted. 
A number of criteria exist for evaluating study quality but most are not relevant in the 
context of this review (for example `blinding' is a less relevant criterion to assess most 
complex interventions where it is impossible to conceal from intervention recipients or 
support', `counselling', `education', `health promotion', `decision making', `primary healthcare', 'health 
care psychology', `medical psychology', `clinical psychology', `compliance', `patient compliance', 
`guideline adherence', `access to information', `access to healthcare', `behaviour', `screening', `health 
screening', `knowledge', `health knowledge' were combined using the Boolean operator `OR'. 
3) subject headings `intervention studies', evaluation studies', `randomised controlled trials' were 
combined with the Boolean operator 'OR'. 
The results of searches 1), 2) and 3) were combined with the Boolean operator `AND'. 
For the key word search the following strategy was used: 
1) The key words: `stroke', `cerebrovascular' were combined with the Boolean operator `OR' 
2) The key words: `intervention', `trial' were combined with the Boolean operator 'OR' 
3) The key words: `prevention', `management', `behaviour', `behavior', 'recurrence', `recovery', 
`rehabilitation', `knowledge', `compliance', `adherence', `concordance', `access', `education', 
`counselling', `counseling', `complex', 'social', `community', `decision support', 'psychological', 
`psychosocial', `quasi experiment*, `quasi randomised', 'pre test post test', `time series' were combined 
with the Boolean operator `OR'. 
The results of the searches 1) 2) and 3) were combined with the Boolean operator 'AND'. 
The results of the MeSH subject heading and key word searches were then combined with the Boolean 
operator `OR'. 
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providers whether or not they have received the intervention). 125 Instead, I defined 
quality criteria using the MRC Framework recommendations for study development. 
Studies were first classified according to the reported development process and whether 
the intervention was theoretically grounded (Table 1). 
Table 1. Criteria to assess theoretical quality. 
Quality assessment Theoretical justification 
A) well grounded The intervention itself was informed by some 
form of literature review and in addition by either 
an established theoretical framework or empirical 
investigation conducted by the authors. 
B) moderately grounded A detailed analysis of at least one of the 
following was reported: an established theoretical 
framework; evidence from a published systematic 
review supporting the intervention; empirical 
investigation conducted by the authors; or review 
of empirical studies conducted by the authors 
supporting the intervention. 
C) minimally grounded A brief overview of literature was reported in 
support of the intervention or a detailed review of 
the study area but not specifically in support of 
the intervention. 
D) no theoretical grounding Interventions did not report any research/cite any 
literature to support the use of the intervention. 
Secondly, they were classified according to the chosen evaluation methods: RCT versus 
other designs; outcome measures (primary and secondary outcomes and use of 
standardised assessment measures) and consideration of statistical power. I considered it 
unlikely that studies would report explicit `phases' of intervention development since 
the MRC Framework is not routinely used for this purpose. Studies might also pre-date 
The Framework. 
The impact of interventions on outcomes (study `success') was defined using three 
criteria: interventions demonstrating a significant beneficial impact on all primary 
44 
outcomes were defined as `successful'; those having a beneficial impact on at least one 
but not all primary outcomes were defined as `partially successful'; those which either 
failed to demonstrate an impact on any primary outcomes, or demonstrated a 
detrimental impact were defined as `failed'. Simple frequencies were used to describe 
study characteristics and x2 tests used to explore associations between aspects of study 
design and outcomes. 
3.3. Results 
Over 12000 references were identified and 733 retrieved yielding 95 articles covering 
67 complex intervention studies. Six hundred and thirty-eight articles were excluded: 
293 were not evaluation studies; 217 referred to specific interventions excluded from 
the review; 98 were not stroke specific; 21 reported pilot or preliminary findings only; 
nine were not `complex'. Of the included studies, 40 were evaluated using RCTs and 27 
using quasi-experimental, observational and/or qualitative designs. Interventions 
covered four broad themes: those aimed at changing professional behaviours in 
preventing and managing stroke (Table 2); those targeted at people from the general 
population and patients to improve primary and secondary prevention (Table 3); and 
those targeted at stroke patients and carers to improve recovery and adjustment after 
stroke (Table 4). Professional interventions included locally disseminated guidelines, 
126- 
129 stroke orders or protocols, 130-135 a tool to aid clinical decision making 
136; and training 
and/or academic detailing. 107,137-145 Primary prevention interventions included 
information and feedback, ' 58,163 media campaigns, 
149,160 peer support and education, '54 
patient decision- aids, ' 50,161,162 and multi-factorial educational, screening and monitoring 
programmes. '46,152,153,155,156,159,165,166 Secondary prevention interventions included a 
shared medical record, 
148 an intervention incorporating a shared record plus 
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monitoring, '5' and multi-faceted interventions incorporating educational and 
psychosocial components. 147,157,164 Interventions to improve adjustment and recovery 
included information booklets/records, '67, '70,188,189,192,193 education, training and 
counselling" o, 111,172-175,177,181-183,185,186,194,195,198,199 and social or emotional support. 9,75-90 
There were significant differences in the success of studies in different areas (x2=12.64, 
df=4, p=0.013). Interventions to improve recovery, in particular social support or 
information interventions were less likely to succeed, 12 (41.3%) failed compared to 3 
(15.0%) primary/secondary prevention interventions and 3 (17.7%) professional 
interventions. However, prevention interventions and professional interventions were 
also less likely to have been evaluated using RCT methods (9,45% and 6,35% 
respectively compared to 24,80% of interventions to improve recovery). 
3.3.1. Theoretical grounding 
Theoretical grounding was difficult to establish from published reports since most 
studies presented only a brief introduction to the study area and an overview of the 
methods. Forty-two of the 67 studies reported some form of theoretical grounding for 
their intervention (Tables 2-4) but only 14 were judged to be theoretically well 
developed (an `A' rating). Table 5 presents a list of theoretical research in support of the 
interventions. While most studies included some form of literature review, this was not 
necessarily in support of the chosen intervention. Only eight studies reported attempts to 
systematically review the literature or cited an existing systematic review. Nineteen 
studies referenced published theoretical frameworks to support their intervention choice 
(mostly from the psychological literature) and 13 conducted empirical research to 
inform intervention development. 
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Table 5. Theoretical quality: summary of studies with theoretical support for 
interventions. 
Evidence from: Studies 
Systematic review N=8 
120,136,15 1,152.174,187,195 
Published theoretical frameworks: N=19 
Family systems theory 120,154,170,172,173 
Lazarus & Folkman/stress-buffer theories 179j84,198 
Counselling-enabling/social problem solving theory 16.182 
Self efficacy/health locus of control 177 
Prochaska & DiClemente -` Stages of Change' 164 
Weinstein - bias in health perception 158 
Orem/Bobath - self care nursing (patient 110.137.145 
empowerment) 
Chronic care model (patient-centred care) 147 
Shared decision-making models 150 
Rogers - Diffusion-innovation theory 
142 
Empirical Research: N=12 
Testing applicability of theoretical model 
177,182 
Testing intervention components 
110,130,159,177.190,193 
Canvas user views/ service needs 
3.112.140,145,161,195 
3.3.2. Outcome assessment 
Study outcome measures are presented in Table 6. A range of single item questions, 
standardised/published scales (53 in total), or author-developed scales (15) were used. 
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Table 6. Summary of primary outcome measures. 
Measure: Professional Primary or secondary Recovery & 
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146,148,150. I52,161, I64 
N=6 N=2 






Measure: Professional Primary or secondary Recovery & 
interventions prevention adjustment 
Family functioning, carer - - N=6 
burden/stress/competence 170,173,182,184,185,187 
Global health outcomes N=l N=2 N=l 
145 147,148 171 
Patient choice/decision N=1 N=1 N=1 
making 145 161 167 
Author designed outcome measures (with or without validation) were mostly used to 
assess knowledge or satisfaction with care but also to assess self-rated quality of life, 
health expectations, `recovery-efficacy', illness perceptions, assertiveness, decision- 
making and confidence. There was no association between type of measure (single item 
or scale), measure development (published or author developed) and study outcomes. 
Most studies used multiple measures to evaluate impact. Twenty-one RCTs and 16 
quasi-experimental/observational studies listed three or more primary outcomes of 
interest with 10 RCTs and 12 non-RCTs listing five or more primary outcomes (Tables 
2-4). Studies with large numbers of primary outcomes (5 or more) were statistically less 
likely to be completely successful than those with fewer outcomes (5,22.7% compared 
to 17,38.6%) but were also less likely to fail (2,9.1% compared to 16,36.4% 
respectively, 2=12.1, df=2. p=0.002). 
3.3.3. Methodological quality 
There were significant differences in the success of interventions using different 
evaluation methods (x =17.2, df=2, p<0.001). Only 4/28 non-RCT studies distinguished 
between primary and secondary outcomes, 111.137,153,160 but all achieved at least partial 
success and 12 (44.4%) achieved all of their aims. One study conducted a qualitative 
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evaluation of a family nursing intervention concluding that all aspects of the 
intervention were useful but did not specifically test a hypothesis. 120 Ten (25.6%) trials 
were successful, 11 (28.2%) were partially successful but nearly half (18,46%) were 
unsuccessful. Sixteen (41.0%) RCT studies included a power calculation; 6/21 RCT 
studies with multiple (>2) primary outcomes reported considering statistical power 
(Table 7). One study considered power for 4/7 primary outcomes and although it was 
still slightly underpowered (it did not reach the target recruitment figures) it was 
successful in influencing all of the outcomes for which power was estimated. 1 85 In the 
only study to consider power for all measures, the authors anticipated that the 
intervention would lead to a 25% difference between groups in all risk factor control 
outcomes. 15' The intervention did not have the anticipated impact, the authors 
concluding that risk factor control rates in the control group were better than expected 
and consequently that the study was underpowered. 
Only one RCT study reported conducting any form of exploratory trial of the 
intervention prior to the main study. It was used to test the feasibility of implementing a 
telephone intervention to provide nursing follow-up to improve adjustment and 
recovery and to test the validity of outcome measures. 182 In one of the social support 
intervention studies, the authors had already conducted a RCT of one of the intervention 
components (the information pack)190'192 that could be described as a pilot evaluation. 
The authors also conducted research to inform their power calculation prior to the main 
trial and this work could be defined as the "modelling phase" of development. However, 
since this was the only study that did so, the relationship between study quality and 
success is difficult to assess. Studies reporting a power calculation to inform trial 
methods were no more likely to have been successful than those which did not report 
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3,3.4. Impact of study quality on outcomes 
After adjusting for aspects of methodological quality (study design and statistical 
power) there was no evidence that theoretical development was associated with success 
in primary outcomes. Six RCT studies were judged to be theoretically well developed 
and included a power calculation; two of these were successful, 147170 two were partially 
successful 182°187'190and two unsuccessful. 3,194 Of the two successful interventions, the 
first had a significant impact on family functioning, which remained stable in the 
intervention group but declined over time in the control group10; the second had a 
significant effect on an author-defined (and validated) global well-being score (0.53 
effect size) but the implications of this for clinical practice are difficult to interpret. '47 
Five non-RCT studies were also considered well developed; one of these was 
successful, 47 three were partially successful' 10'130'137 and one did not test a specific 
hypothesis. 12° If the theoretically moderately well developed studies ('B' rated) and well 
developed studies (`A' rated) are combined, the findings remain the same with no clear 
evidence that theoretical or methodological quality was associated with improved 
outcome. 
3.3.5. Articles identified since the last search 
A recent search on complex intervention (28`x' July 2006) identified a further six 
intervention studies relevant to this review and it is important to consider whether 
inclusion of these studies would influence the main findings. The new studies included 
three interventions aimed to improve recovery after stroke: a nurse support worker 
intervention for patients and carers202; a web-based education and peer-led support 
intervention, 203 and an arts-based reading service for stroke inpatients . 
20' Two 
interventions focused on primary and secondary stroke prevention (both stroke patients 
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and high risk groups): a pharmacist-led risk management intervention to improve 
management of atrial fibrillation 205; and a nurse-led education and coordination 
intervention to improve risk factor management for patients after carotid 
endarterectomy. 206 One study evaluated a workbook and training intervention for 
community health workers aiming to improve risk factor management for African 
American women. 207 No interventions were rated as theoretically `well grounded'. Two 
studies did not conduct statistical evaluation of the intervention. 204'207 Of the remaining 
four, all were at least partially successful. 
Two studies were evaluated using RCT methods. 202'206 Neither conducted a pilot 
evaluation and only one conducted a power calculation to estimate sample size 
requirements (Table 8). This study used six key outcome measures but estimated power 
for only one of these (depression) and was substantially underpowered. The study 
demonstrated partial success in influencing outcomes. 
This analysis does not challenge the previous findings that few complex intervention 
studies are theoretically or methodologically well developed according to MRC 
recommendations. The findings do not help in understanding the association between 
methodological quality and outcome. 
3.4. Discussion 
This review aimed to investigate theoretical and methodological quality in the 
development and evaluation of complex interventions in stroke care and the impact of 
this on study outcomes. The 67 included interventions investigated a range of health 
outcomes. The majority of interventions identified were targeted at an individual level 
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social or environmental level. This may reflect the chosen search criteria since 
environmental and social interventions are more likely to be targeted at the general 
population and aim to prevent a range of diseases. Such studies might not have been 
found unless they included stroke specific outcomes. In interpreting findings from this 
review, it is also important to note that the focus was solely on complex interventions 
for stroke and it is possible that intervention development in other disciplines is better, 
worse or different to the development of the interventions analysed here. 
Observational or quasi-experimental studies tended to yield better outcome success than 
RCT designs. Differences may reflect difficulties in demonstrating success using RCT 
methods, 208'209 but may also be influenced by publication bias, since journals are more 
likely to publish studies if there is a significant treatment effect. 46 If journals are less 
likely to publish non-significant results for observational or quasi-experimental studies 
than for RCTs, then interventions evaluated in RCTs would appear to be less successful 
than those evaluated using other methods. 
Study design may also explain the apparent lack of success of interventions focusing on 
patient and carer adjustment and recovery since these studies were more likely to be 
evaluated in RCTs. There were few RCT studies evaluating interventions in primary or 
secondary prevention, possibly reflecting problems of recruitment, randomisation and 
follow-up, for relevant community interventions. Such interventions may also present 
ethical difficulties due to the requirement that researchers withhold the intervention 
from some groups/patients. 57"°8 For the studies included in this review, a number of 
novel quasi-experimental methods were used in an attempt to overcome such 
difficulties, including matched controls, time-lag controls, or 'before and after' studies, 
with or without qualitative evaluation. 
'53,15 "57,159 However, the MRC Framework 
suggests that these methods are inadequate for evaluating efficacy since non-random 
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allocation of participants may lead to bias. Using the MRC Framework (with its focus 
on RCTs) as a marker of quality in complex intervention evaluation may lead to 
exclusion of those interventions which best serve the needs of disadvantaged groups 
(since these groups are more difficult to identify, recruit and retain in research 
studies). 210 It may also lead to exclusion of interventions that have the most impact on 
longer-term population health goals (such as mortality rates or behaviour change). 
Although, theoretically, longer-term follow-up is not a problem of RCTs, in practice 
RCTs are more difficult and expensive to conduct over long periods of time. 8' 
One of the potential strengths of the MRC Framework is that it sets standards for 
theoretical and methodological development within a RCT design such as highlighting 
the importance of considering statistical power. However, a substantial proportion of the 
RCTs in this review did not include a power calculation to justify sample size. No 
relationship was found between reporting a power calculation and study success, 
possibly because many of the studies that did not conduct a power calculation were still 
adequately powered; conversely not all of the studies that reported a power calculation 
did achieve statistical power. Exploratory evaluations prior to the main study could have 
been used to make more realistic estimates of intervention impact. Authors could then 
have adjusted sampling or outcome measures at the outset. 
For most of the studies there was little evidence that authors considered the theoretical 
development, or the mechanisms by which the intervention was expected to influence 
outcomes. However, this was not necessarily the fault of the investigators. For example 
in two social support intervention studies the interventions were existing services rather 
than services designed specifically for the study. 171,180 
Lack of clarity about the mechanisms by which interventions work, makes it difficult to 
pool the results of similar studies in systematic reviews or meta-analyses, since although 
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intervention components appear similar, we do not know whether interventions are 
delivering similar 'packages' of care. In one systematic review of problem solving 
interventions for carers after stroke, the authors concluded that poor theoretical and 
methodological quality coupled with a diverse range of intervention components made 
it impossible to draw conclusions about efficacy. 211 Similar problems have been 
reported in systematic reviews of other complex stroke interventions such as 
information and education. 212 
Requirements for study design and presentation of results inevitably change over time 
and this review is limited in that inferences about study development are based on 
published or reported information only. It is possible that some studies did actually 
conduct empirical work or pilot their interventions but did not report it. 213 However, it is 
concerning that so few studies reported an appropriate literature review or considered 
established theory. It would not be acceptable within a standard clinical trial to test out a 
pharmaceutical intervention in a phase III study without sufficient understanding of the 
mechanisms by which the drug influences bodily processes. Yet complex health service 
interventions seem to be developed based on ad-hoc assumptions and evaluated using 
methods where at the end of the study it is impossible to understand the reasons for 
success or failure. 
Complex interventions often aim to influence a number of outcomes, or outcomes that 
are difficult to encapsulate in a single measure. In just over half of the studies multiple 
outcome measures were used. In some cases, authors may have incorporated multiple 
measures in the hope that by `hedging their bets' it would enhance the chance of at least 
one of the measures showing a significant result. Non-RCT studies were particularly 
poor at specifying the main outcomes of interest and this may also explain why they 
were less likely to have failed. However, not identifying the key outcomes of a study in 
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which multiple outcomes are assessed suggests poor theoretical development and that 
the study question itself is insufficiently clear. 
Whether using the recommendations of the MRC Framework to assist development will 
improve our understanding of interventions in the future is unclear. There did not 
appear to be any convincing evidence that being theoretically or methodologically well 
developed improved outcomes. The one study that explicitly reported using the MRC 
Framework in development was unsuccessful. 3 The Framework does not guarantee 
success but in the case of this intervention, despite apparently following recommended 
procedures we are still no clearer about why the intervention failed. An evaluation of 
intervention implementation (process evaluation95'M5) could have enlightened our 
understanding. 
3.4.1. Summary 
In this chapter the MRC Framework was used to retrospectively assess theoretical and 
methodological quality of previous intervention studies in stroke. The implications of 
these findings for future complex intervention development and for the application of 
the MRC Framework are discussed further in Chapter 10. For the remainder of the 
thesis I investigate prospective application of the MRC Framework in guiding 
intervention development. 
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Chapter 4. Methods for investigating application of The Framework 
4.1. Introduction 
In this chapter I present an outline of the methods for investigating how the MRC 
Framework' was used to develop and evaluate the Stop Stroke intervention. Specific 
methods were used to investigate particular phases of The Framework, thus the methods 
are presented under separate section headings. The combined findings are used to 
understand the overall use of The Framework as a research tool and in exploring the 
wider social and political context in the discussion presented in Chapter 10. 
The theoretical phase of Stop Stroke development (Chapters 5 and 6) incorporated a 
range of methods including statistical analysis of the South London Stroke Register 
(SLSR) and qualitative research with stroke patients, carers and professionals. Since the 
focus of this thesis is to explore the use of qualitative methods in intervention 
development and evaluation, here I outline only the qualitative methods used. Details of 
the methods for the quantitative studies are presented in the published findings from 
SLSR analysis 34,214,215 (see also Appendix 1). 
To investigate the modelling, exploratory trial and definitive RCT phases of Stop Stroke 
development I used an ethnographic approach. 216,217 This involved using a range of data 
collection and analysis methods including participant observation, diaries, informal 
discussion with staff, in-depth interviews with key informants and semi-structured 
interviews with stroke patients. A chapter-by-chapter outline of the methods for each 
research component is presented below. 
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4.2. Methods for investigating patients' and carers' experiences and understanding 
of secondary prevention 
To investigate secondary prevention from the point of view of the patients and carers 
themselves (Chapter 5) I used in-depth interviews. The choice of methods for this part 
of the research was pre-defined (by the other Stop Stroke investigators and me) since 
these interviews were conducted as part of Stop Stroke intervention development. 
However, the work remains relevant to this thesis since I am presenting it as a case 
study for how in-depth interviews can be used to inform intervention development. 
Ethics approval for this part of the research was obtained from Guy's and St Thomas' 
Hospitals ethics committee as part of the Stop Stroke study. 
4.2.1. Identifying the patients and carers 
Since the investigators also managed the ongoing SLSR, the register provided a 
convenient and appropriate sampling frame from which to identify patients for in-depth 
study. The SLSR is a prospective inner city population based register of stroke 
incidence since 1995. At the time this research was conducted, the SLSR covered 22 
wards of North Lambeth and North Southwark, an estimated population of 234,533.17 It 
collects data on patients' socio-demographic characteristics, health service use and risk 
factor control at various time points (prior to the stroke, at three months and one year 
post stroke). 
Previous statistical analyses of SLSR data on risk factor management conducted as part 
of the intervention development process were used to inform sample selection. 
34,214 
Existing statistical coding from these studies was used to classify patients into 
categories according to their risk factor control, for example to identify those with 
physiological and behavioural risk factors at the time of stroke (atrial fibrillation, 
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hypertension. diabetes, smoking, heavy alcohol use and obesity). Similarly, statistical 
coding from these studies was used to identify patients suitable for particular 
pharmacological therapies (aspirin, warfarin and antihypertensives) and to categorise 
patients according to their subsequent risk factor control (tablet taking and change in 
behavioural risk factor control since the stroke) . 
34,214 Lists of patients were produced for 
each category and used to select a sub-sample of patients for interview. 
Originally the aim of the research team had been to use extreme or `deviant case' 
sampling 218 (p230) to compare experiences of secondary prevention between a group of 
patients defined as having 'optimal' risk factor management and a group defined as 
having 'poor' risk factor management. The lead stroke clinician felt that most of the 
patients under his care could be classified as either having good secondary prevention 
management or poor secondary prevention management. In practice, classifying patients 
into extreme categories according to the SLSR data was not as straightforward as 
anticipated. For example patients might have one risk factor managed and not the 
others. It proved impossible to select two comparable groups for interview, in particular 
because so few patients fell into the `optimal' risk management category. 
Instead maximum variation sampling218 was used to select a non-random heterogeneous 
sample of 20 people with a range of socio-demographic and risk factor characteristics 
requiring different types of secondary prevention management. The selection of patients 
for interview evolved from the previous analyses of the SLSR. We had demonstrated 
that particular groups (older patients, those with more severe disability and those from 
White ethnic groups) had poorer control of particular risk factors (for example White 
stroke survivors were more likely to continue smoking, drink heavily and were less 
likely to be taking recommended medication. 
34,214 This information was used to help 
guide sample selection. It was also hypothesised that different risk factors would raise 
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different management issues. For example risk factors treated with over the counter 
medication would present different challenges for secondary prevention to those treated 
with prescribed medication. Thus sample selection was designed to include participants 
with a diverse range of risk factors and management strategies. 
4.2.2. Consent and data collection 
Interviews took place between September 1999 and January 2000. I contacted each 
patient by telephone and invited them to participate in an interview in their own home. I 
explained that the study aimed to help people who had already had one stroke, from 
having further strokes and that I wished to discuss their experiences since the stroke: 
what had happened to them; the health services they had received; and their views on 
preventing further strokes. 
I used a topic guide of open-ended questions rather than a structured questionnaire to 
guide the interview so that patients would have the opportunity to discuss secondary 
prevention in the context of their own experience rather than providing responses to pre- 
specified questions. There is considerable support for the use of in-depth interviews in 
this context and they have been used previously to investigate patients' experiences of 
stroke. 219-222 I asked patients about a range of topics covering their experiences of 
secondary prevention since the stroke and their understanding of secondary prevention. 
For a list of topics covered see Appendix 2. If patients raised issues relevant to 
secondary prevention I asked them to discuss these in more detail, or took notes and 
revisited the issues later in the interview. 
Family members or 'informal carers', 223 were also sometimes present during the 
interviews and in such cases they were also invited to participate. It is commonly 
reported that stroke patients rely on informal carers for physical and emotional 
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support, 24'223,224 and I hypothesised that carers would also play an important role in 
secondary prevention practices. Their contributions were considered not as a `proxy' for 
the opinions of the stroke patients themselves but provided additional insights into the 
challenges for secondary prevention management. 
4.2.3. Interview analysis 
All interviews were audio taped and then transcribed in full. Audio taping is 
recommended for recording interview data since it allows better flow of conversation, 
enhances validity of data and speeds up the interview processes (p146). 225 In one 
interview the patient asked not to be recorded since she felt embarrassed about her 
communication difficulties and in this interview I took detailed field notes, which I later 
wrote up for analysis. 
There are no hard and fast rules for analysing this type of qualitative data but most 
authors recommend a process of `coding up'226, that is organising the data into 
categories or themes and reorganising them to tell a coherent 'story'. 227 Analysis of the 
patient interviews involved reading each transcript and coding phrases, sentences or 
paragraphs of text into summary codes. Data were ordered by placing similar codes 
together under broader categories and were then linked to an overall theme. 
228 This 
process was circular, with codes and categories checked against original transcripts to 
ensure they represented the views of participants and that discourse was not taken out of 
context of its original meaning. `' 
" Further discussion of analysis methods is presented elsewhere: analysis of interviews to explore 
patients' and carers' understanding of secondary prevention, p113-4; analysis of field notes to investigate 
delivery of secondary prevention, p95 and p142-4; analysis of field notes to investigate the process of 
intervention development, p96-7 and p171-2; analysis of field notes to investigate evaluation of the 
intervention, p101-3 and p212; analysis of interview data to explore the impact of the intervention, p108- 
9 and p259. The coding process was conducted manually as described above. The codes emerged from 
the data rather than being driven by previous theory. At the time the research was conducted funds were 
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4.2.4. Validity 
There is little consensus concerning the best way to ensure validity in qualitative 
analysis. To ensure quality in interviewing, the first two transcripts of the interviews 
were checked by a third party (CM). The coding process was not conducted separately 
by multiple researchers as some recommend. 229 However, the process and categories 
generated were discussed with CM during analyses. 
Some suggest that theme 'counts' should be presented as an indicator of the weight of 
each theme identified'230 otherwise known as content analysis. 231 Others suggest the use 
of different research approaches or methods to `corroborate' the findings through 
triangulation. 232 However, content analysis can be criticised in this context for its 
assumption that the number of times a theme arises is indicative of its importance. This 
positivist approach to analysis may not be appropriate for assessing qualitative data 
generated using alternative epistemological assumptions (p191). 233 Triangulation may 
also present problems for establishing validity since combining multiple methods can 
often lead to confusion rather than consensus in interpretation. 216 Instead I used two 
methods to try to enhance the validity of these findings, negative case testing, 
218 and 
respondent validation, 234 (feedback of findings to stroke patients). Negative case testing 
involved seeking cases that did not fit the emerging categories and considering 
alternative explanations for patients' experiences and understandings. 218 I fed back the 
findings of the interviews to stroke patients and carers in two contexts: at the Caribbean 
not available to use a computerised qualitative data analysis package. However, after subsequently 
completing a course on the software package NVivo, I decided that this would not enhance rigour or 
validity and continued with my own method of analysis. The main themes emerging from this interview 
analysis are outlined on p114 and include: health service management of secondary prevention, 
understanding of the causes of stroke (preventability), priorities after stroke and the way stroke is 
conceptualised as an acute event or chronic disease. 
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Medicine conference in 2000 and to the Stroke Research User Involvement group in 
2006 set up as part of a local stroke service modernisation initiative. 235 This is not 
strictly respondent validation (p156)234 since I did not feed back the findings to those 
who had originally taken part in the interviews but this did at least ensure that those 
who had experienced a stroke could comment on my interpretations. In practice the 
participant feedback was supportive of the findings, with participants commenting on 
how their experiences concurred with particular themes. However, there were ethical 
concerns about what I had done in instances where problems with management had 
been identified (for example what I had done in response to a patient with depression 
not feeling that she could leave the house anymore). The ethical challenges of 
conducting qualitative research studies will be discussed further in the methods sections 
presented below and in Chapter 10. 
4.3. Methods for investigating secondary prevention delivery in the stroke clinic 
To investigate delivery of secondary prevention on risk factor management after stroke 
(Chapter 6) I used a different type of qualitative method, non-participant observation at 
two stroke outpatient clinics in inner city London. Non-participant observation is not a 
clearly defined method but may include the recording of quantitative or qualitative data 
or both. It has been previously used in clinical research to investigate the process of 
acute stroke care. 236 In the context of this research I used the method to observe the 
delivery of stroke secondary prevention delivery in its natural setting (the consultation) 
but without participating in the interaction itself. Non-participant observation had the 
advantage that I could study secondary prevention as it occurred rather than simply 
relying on patients' or professionals' reports of what happens. I already had an insight 
into patients' perspectives on risk factor management but since secondary prevention 
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was not a particularly meaningful concept, patients themselves had little insight into 
why they had or had not received secondary prevention services. 
As with the research presented in Chapter 5, the work was conducted primarily as part 
of the Stop Stroke study. However, it remains relevant to the PhD since it represents the 
use of alternative types of qualitative method to inform intervention development. 
4.3.1. Sampling 
Ideally it would have been desirable to observe secondary prevention practice in the 
primary care setting in addition to the outpatient setting since secondary prevention 
requires long-term management of risk factors in the community. However, this 
presented practical difficulties given the small number of stroke survivors visiting any 
one GP (each GP is estimated to see approximately one to two stroke patients per year) 
and the impossibility of knowing when a stroke patient might present to his/her GP. By 
contrast, stroke clinics had the advantage of large numbers of stroke patients attending 
at a regular time. 
Initially observations were to be conducted at only one elderly care outpatient clinic 
(clinic one), which represents the most common environment for care of stroke patients 
in the UK. 237 Theoretical sampling was used, with consultations observed over 
sequential weeks and data analysis starting while observation was ongoing. Data 
collection at clinic one was terminated after 10 weeks when observations ceased to 
provide data on new concepts. Once analysis had begun it appeared that some findings 
might be specific only in the elderly care context. For example, as others have 
highlighted, if clinical management is influenced by intellectual interest then health 
professional reactions to aspects of management may differ between specialties. 
238 
Equally, since previous studies have shown that patients' understanding of future risk is 
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influenced by the embodied experience of stroke, 239 it was hypothesised that patients' 
residual disability caused by the stroke might influence interaction in the consultation. 
This was also supported by the SLSR analyses. 34,214,215 Thus the research team decided 
to conduct observations at a second clinic. The TIA and minor stroke clinic (clinic two) 
was chosen because the team had links with a clinician at a local clinic who was 
interested to take part but this forum also provided a suitable contrast to clinic one. It 
was anticipated that patients attending this clinic would have less severe symptoms and 
that there would be a larger proportion of younger patients who might not have access 
to elderly care services. Data collection at clinic one took place between January 2001 
and April 2001. Data collection at clinic two took place from September 2001 until 
January 2002. 
In justifying the methodology, it is important to consider whether observation of only 
two specialist clinics was likely to provide findings representative of other secondary 
prevention services provided in less specialised settings. The study aimed to represent 
the clinics and health professionals concerned but were not necessarily representative of 
all secondary prevention services. However, since observation involved national stroke 
experts delivering secondary prevention in a specialised setting (the `best case scenario' 
for stroke care) it is likely that theoretical issues for development of services raised from 
these observations will be at least as important if not more important in less specialised 
settings. 
4.3.2. Consent 
Consent to participate was obtained from consultant physicians at the outset; junior 
doctors whose consultations were observed were asked for consent to participate at the 
start of each clinic. At the start of each consultation the professional introduced me (the 
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observer) to the patient and any accompanying relatives, friends and carers. He or she 
then explained the purpose of the research and if the patient agreed to participate, I 
remained in the consultation room sitting to one side of the participants in order to 
minimise interference in the usual doctor-patient interaction. In some exceptional cases 
I was asked to join in the consultation (I was asked direct questions by the professionals 
or patients or I was asked to assist the professional in his/her practice). 
4.3.3. Data recording 
I used a structured observation schedule to record participant characteristics including 
skill mix of health professionals, age, ethnicity, mobility and risk factors of patients; 
and consultation characteristics including length of consultation and patterns of 
questioning (Appendix 3). The observation schedule was designed by me guided by 
observation of two clinics prior to the main study. I also took detailed hand written field 
notes on the context of the consultation and content of the discussion between health 
professional and patient. Details of discussion between different health professionals 
and informal comments made outside the formal consultation but relevant to the 
consultation were also noted. I did not aim to ask direct questions of health 
professionals but in some cases the professional continued to discuss aspects of 
secondary prevention with me after the consultation had finished and in such cases I 
added these discussions to my notes since it helped to contextualise the clinic 
discussions. Field notes were written up directly after the consultation to enhance 
validity of data and key points about the interview documented. 
In hindsight it may have been helpful to interview the professionals after each clinic 
since this might have provided additional insights into their understanding of secondary 
prevention. However, practically it would have been difficult to interview professionals 
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after each consultation or even each clinic given the time constraints of the busy clinics. 
Equally, since I was using a `non-participatory' approach I did not wish to intervene in 
any way that might influence professionals' practice in subsequent consultations (the 
Hawthorne effect). 216 It is also questionable whether such interviews would have helped 
in interpreting professionals' management strategies since what people say and what 
they do in practice are often not the same. 104v" Field notes were chosen as the method of 
data collection rather than audio taping since this allowed me to contextualise 
discussions between doctor and patient including details of non-verbal interaction 
between professional and patient. I also felt that hand written field notes would cause 
less interference with consultation processes than other methods such as video taping 
which might have inhibited dialogue between patient and professional. Taping alone 
would have prevented capture of interaction between patients and professionals outside 
the consultation room (such as in the examination room, corridor or other consulting 
room). In practice, it became clear that my sitting in the consultation room recording 
field notes did interfere with the usual consultation: 216 I was asked questions by 
participants; in one consultation I was asked not to observe the consultation by the 
professional; and in one consultation I was asked to stop recording field notes by the 
patient's son. There were also examples of the professionals altering their practice as a 
result of my presence (this is discussed further in Chapter 6). Thus in hindsight it may 
have been more appropriate to have audio taped the interviews to increase data validity 
since tape-recording is strongly recommended for recording human interaction. 240 
As part of the Stop Stroke development process I conducted interviews with two consultants and two 
junior doctors about their understanding of secondary prevention. However, participants' responses more 
closely reflected perceptions of appropriate practice rather than the doctors' own practice. Thus adding 
interview methods to help interpret the observational data may have raised more questions than it 
resolved. However, this would be an interesting area for further study. 
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4.3.4. Analysis 
Field notes from the two clinics were analysed for emerging themes (as described in the 
methods section for Chapter 5). Data from each clinic were first analysed separately to 
explore similarities and differences in secondary prevention delivery between the 
clinics. However, although the demographics of clinic participants and the structure of 
the consultation differed between clinics, there were more similarities than differences 
in the way secondary prevention topics were discussed and so data were subsequently 
merged and analysed together. 
4.3.5. Validation of findings 
Copies of findings were sent to the consultants at each clinic for respondent validation 
together with a summary of the key points. Consultants were asked to provide 
comments and to highlight anything they were not comfortable with. Only consultant 
one provided comments, which included saying that he felt embarrassed when reading 
through some of the quotations of dialogue (and the language used) in the clinics. lie 
also queried a statement made about professionals being `subjective' in their approach 
to risk factor management. As a result of the comments I revisited the findings and the 
original data before making some changes. This did not however, result in marked 
changes to interpretation. 
4.4. Methods for evaluating application of The Framework in development 
In Chapter 71 present the first part of the process evaluation of intervention 
development and evaluation conducted specifically to explore the use of the MRC 
Framework as a tool for guiding development. For this investigation and that presented 
in Chapter 81 used an ethnographic approach incorporating a range of methods 
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including participant observation. Ethnography is a commonly used method within 
social science research but its use is relatively novel within public health, although there 
have been some recent examples of ethnographic studies of intervention 
development. 89,113,116 
4.4.1. Data collection and analysis 
The principal method of data collection for this investigation involved participant 
observation. Data collection started when I began working on the Stop Stroke study in 
March 1999 and continued until the start of the definitive RCT on 21 S` July 2003.1 was 
also able to collect some data retrospectively, since the investigators gave me access to 
documents on study development that were written prior to my joining the study. These 
included documentation of meetings, emails, letters, presentations (overheads, power 
point slides), posters and informal correspondence (memos, notes) related to the study 
from 1999-2003. From the start of my PhD in 2001 1 also kept a diary of Stop Stroke 
processes. Diaries have a strong history within anthropology as a tool for recording and 
representing fieldwork (see for example Geertz241) and in my case the diary included a 
record of events, instructions, decisions and my own thoughts on the trial. I also 
recorded details of study participants, their skills, roles and responsibilities in relation to 
the study. Specific time points did not influence my recording; rather I made notes or 
expressed thoughts when important events had occurred. This mode of recording 
inevitably influenced the type of data collected and has also influenced my 
interpretation of events since I was more likely to write in the diary if there was 
something I felt strongly about. In hindsight this seemed to happen more often when I 
was unhappy with something or someone or when I identified problems than when 
things were running smoothly. It is likely that my interpretation of processes will reflect 
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better the difficulties of intervention development rather than the process of intervention 
development per se. 
I organised diary and documentary data chronologically for analysis. As with the 
previous two chapters, I analysed the data for themes relating to the process of 
intervention development and the use and impact of the MRC Framework. I produced a 
timeline of key events and processes, which I coded and categorised into broader 
themes influencing intervention development. 
4.4.2. Justification of my position as both intervention developer and evaluator 
Given that my position within the research team is fundamental to how the findings are 
interpreted, I feel that it is important to be reflexive and include upfront a discussion of 
my position as both intervention developer and evaluator within the team. 
Being both the key researcher on Stop Stroke intervention development and the 
evaluator is unusual within the context of public health research methods. However, it 
meant that I was a true participant observer and had a number of advantages in terms of 
allowing me access to the development processes. 
Bruyn (1966) identifies six criteria for ensuring quality in ethnographic work, defined as 
the `Humanistic Approach' (Bruyn in Fielding 1993). 227 These include: i) amount of 
time the researcher is in the setting; ii) the physical location of the researcher in relation 
to the group studied; iii) variation in status of participants and activities observed; iv) 
familiarity with language; v) how close one is to the participants in terms of social 
relationships and vi) allowing participants to comment on interpretations of data. As an 
insider my ethnographic study fulfilled many of these recommendations. Apart from the 
first nine months of the trial (Chapter 9) I was located on site, had close working 
relationships with trial staff and investigators from junior researchers to senior 
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investigators throughout intervention development and evaluation. Before conducting 
analysis I had worked with all core investigators for over six years and trial staff for 
over two years and was familiar with team and trial language. I had regular contact with 
the principal investigator and other investigators on the study; I had conducted all the 
data collection and analysis for the research components of intervention development 
(theoretical phase); I was involved in discussions and meetings to decide on 
intervention design; I was involved in developing the intervention components 
(modelling phase); and I assisted in pilot testing the intervention (exploratory trial 
phase). Since I was part of the stroke team I also had close relationships with those 
working on the SLSR (involved in data collection for components of the intervention) 
and the team statisticians involved in designing the RCT evaluation. 
Being a `true' participant observer may also have resulted in a number of disadvantages. 
For example some might argue that as a true participant in intervention development it 
is not possible for me to also evaluate my own and my colleagues' work. Reflexivity is 
a strategy designed to overcome such problems, that is understanding how one's own 
experiences and background influence our understanding of phenomena. 218 I will go on 
to discuss this and the difficulties of being `reflexive' 242'243 in this context but at this 
stage I would argue, as others have, that only by making a `practical contribution' 
would it have been possible for me to gain the insight into the development processes 
that I did. As an external participant I would have seen only a `filtered' version of such 
processes. 244 The challenges of gaining trust and access and the importance of insider- 
outsider relations within the context of programme development have been discussed 
elsewhere, for example by Knox in her study of a web design company specialising in 
online advertising campaigns245 and by Mosse in his study of an aid programme to 
develop a poverty focused rain-fed farming project in India. 244 Both Knox and Mosse 
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highlight how the data they gathered were influenced by their positions within the 
respective organisations and their contributions to the work of these organisations. In 
Mosse's study he was both a consultant anthropologist working for the programme and 
a researcher investigating the programme. He argues that as an `insider' working within 
the team, he had access to programme information not available to 'outsiders'. He cites 
Kaufmann (p112)246 in explaining how as an `outsider' access to certain sorts of 
information is limited: 
`junior staff withhold or reveal information strategically in order to conceal poor 
performance or to negotiate position in the organisation or with outsiders... while 
professionals and bureaucrats hide behind official models and policy jargon' (p12). '" 
Certainly within my own previous experience of interviewing junior and senior 
clinicians to gain feedback on Stop Stroke development (Chapter 7), these ideas rang 
true. When I asked about their opinions of the importance of various secondary 
prevention strategies the junior clinicians were unwilling to put forward opinions until 
they knew what the senior clinician had advised; the senior clinician did not express 
opinions at all and simply repeated what was published in recommended guidelines. 
4.4.3. Ethical and methodological challenges 
My closeness to the study provided me with opportunities for investigation that would 
not otherwise have been possible had I been external to the team (access to people, 
documents and processes). However, this `closeness' to the study also presented me 
with some ethical and methodological challenges including problems of `reflexivity' 
and confidentiality. My first challenge in conducting participant observation in this 
context was my ability to be `reflexive' about my own work. The process of reflexivity 
can be defined as the: 
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`process of reflection that researchers using qualitative methods go through so as to 
document how the research process in general and often themselves in particular construct 
the object of research. 247 
In other words, my ability to step back and look objectively at something I have a strong 
vested interest in protecting. Being reflexive and acknowledging the influence of one's 
own subjective political and cultural standpoint in interpreting observations is now 
`comfortable convention' within social anthropology. 248 Many texts have raised the 
problem of how their participation in the group/culture studied influenced their 
understanding and interpretation of that culture. In my case I was already a participant 
in the study before I began to observe, in other words, I was required to observe my 
own work. As an outsider (as in a `standard' anthropological study) I would have had 
no status within the team. However, as a study participant I already had roles, 
responsibilities and interests as a junior researcher that conflicted with my ability to 
evaluate the study in an objective manner. 
In addition I found that this type of participant observation presented challenges for 
critiquing the work of my colleagues and supervisors. Although the study group was 
large in the context of a single research project, it was still small in absolute numbers. 
Thus it was relatively easy for members within the team (and possibly externally) to 
identify the thoughts and actions of other team members when reported as a descriptive 
account (for example there is only one trial coordinator and only one principal 
investigator). Even if quotations or descriptions were anonymised it still poses ethical 
challenges and problems for confidentiality. Being a work colleague allowed me a 
privileged position, making it easy to gain the trust of colleagues at an early stage. This 
may have encouraged participants to reveal thoughts or actions, which they would not 
routinely have disclosed had I not also been a team member. All team members were 
aware of the evaluation and my role as evaluator from the start of the study. But, being a 
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work colleague may have made me less 'visible, 9245 such that trial team members no 
longer realised that their disclosures could be made public. 
The status of the core investigators in the study is also likely to have had an influence 
on my data collection and interpretation. No matter how objective I may have wished to 
be, the core investigators had the ultimate decision over how Stop Stroke events are 
analysed and published. It was not in any of our interests to present findings that reflect 
badly on them, the intervention, the trial, or me. 
The ethical dilemmas listed above presented ongoing challenges throughout the course 
of the study; the details of which (together with my solutions) are discussed further in 
the subsequent chapters. 
4.5. Methods for evaluating application of The Framework in evaluation 
In Chapter 8,1 continue presenting findings from the process evaluation, this time 
focusing on the conduct of the trial and intervention implementation after the trial 
started on 2ls` July 2003. The process evaluation and data collection will be ongoing to 
the end of the trial but for the purposes of this PhD, analysis focuses on the first two 
years to the end of July 2005. 
4.5.1. Data collection and analysis 
I continued to collect and organise data using the chronological diary method outlined 
in the previous section, recording minutes of meetings, field notes on discussions with 
the investigators and trial staff, collating documents and correspondence related to the 
study and recording my own thoughts on trial progress. However, my role as the 
participant/onlooker changed over the two years. According to the trial investigators, I 
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was no longer responsible for aspects of trial process. I also went abroad at the start of 
the trial for nine months and so was unable to see first-hand how the trial was operating. 
To investigate the trial operations and clarify observations from the point of view of the 
key staff, I conducted in-depth interviews with the trial coordinator (TC) and trial 
researcher (RA) at three time points: July 2003, just after the start of the trial; August 
2004 one year into the trial and September 2005 two years into the trial. As with the 
patient interviews I had conducted for Chapter 5, a topic guide was used to investigate 
trial process (Appendix 4). Topics included the researchers' roles and responsibilities, 
their understanding of the intervention, their understanding of trial process, their 
experiences of conducting the trial, any problems that had arisen and how these 
problems had been resolved. 
During year one of the trial (while I was abroad) the TC and RA were also asked to 
keep their own diaries of trial processes (Appendix 5). Diary format was slightly 
different from my own trial diary, consisting of one-page sheets with headings under 
which trial staff could record details of progress, raise issues, or list problems 
encountered and subsequent solutions. The headings included recruitment issues, data 
collection problems, trial process issues, computer programme failures and any other 
issues. The coordinator and researcher agreed to complete the diaries on a weekly basis 
and to email them to me overseas. I encouraged the trialists to write down anything they 
felt important. The diaries were also emailed to one of the core investigators in the 
study. 
As in Chapter 7, findings from evaluation of the first two years of the trial were 
organised chronologically; trialists' diaries and interview findings were incorporated 
alongside my own diary records. Evaluation data were analysed for themes as in 
Chapter 7. 
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In addition to diary and interview data, for this part of the process evaluation I also used 
data from the SLSR and trial monitoring data to investigate trial recruitment and 
intervention delivery. 
4.5.1.1. Identifying potential trial patients 
The SLSR was used to identify patients who would potentially be eligible for the trial. 
The SLSR uses 12 overlapping sources of notification to identify potential first-in-a- 
lifetime stroke patients. The most common sources of notification are: hospital wards, 
death certificates and hospital medical staff. '7 Once identified each potential stroke 
patient is assessed by a trained researcher, to ascertain whether or not they have had a 
first stroke. Stroke is defined using the World Health Organisation classification 
described in Chapter 1.10 If they are found to fulfil the eligibility criteria for the SLSR 
the researcher approaches them to participate. The researcher also assesses whether or 
not the patient is eligible for the Stop Stroke Trial. This process and the eligibility 
criteria for inclusion in the trial are discussed in more detail in Chapter 8. 
4.5.1.2. Trial recruitment and intervention delivery rates 
Trial recruitment was measured using SLSR data and data from a separate trial 
monitoring database. Recruited patients were those who fulfilled the trial eligibility 
criteria, gave consent to participate and who were successfully randomised into either 
the control or intervention arms. Monthly recruitment rates were estimated based on the 
number of recruited patients over the number of potentially eligible patients within a 
given month. 
Intervention delivery was recorded using the trial monitoring database. The database 
contained information on each patient's SLSR identification number and the arm of the 
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trial to which the patient had been allocated. For those in the intervention arm, trial staff 
recorded the dates when intervention components were delivered, or if not delivered, 
details of the reasons why not. 
Changes in monthly rates of recruitment and intervention delivery were investigated 
using x2 tests for association. 
4.5.1.3. Follow-up rates 
Follow-up of trial patients was also recorded in the trial monitoring database. To 
estimate trial follow-up, monitoring data were merged with SLSR data. Follow-up rates 
were calculated based on the proportion of patients who received a one-year follow-up 
visit by the SLSR team to collect outcome data for the trial. 
4.5.2. Ethical and methodological challenges 
In practice although the trialists' diaries were useful to a certain extent in documenting 
events during the trial, in most cases the researchers did not document issues as they 
arose. The trial researcher in particular would go for weeks without completing and 
sending her diary and was regularly chased by investigator one and me. When her 
diaries did arrive they were usually left blank or stated `no problems'. A retrospective 
analysis showed that problems did arise but the diaries were not used to record them. In 
the interviews conducted in 2004 1 asked both participants whether there had been 
problems with the diaries. They both indicated that they felt that the diaries were being 
used as a method of surveillance rather than as a research tool or a place to document 
worries or problems. The diaries also took extra time adding to their workload. 
Although I had gained their confidence in reporting trial problems verbally, this did not 
apply to written statements as this comment from the TC illustrates. 
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It was more like a reporting. I couldn't let loose on the diary if you know what I mean. I 
will let loose on a conversation or an appropriate forum but I'm not going to write -I don't 
have the space, I don't really have the time and space to write down all the little different 
rubbish that happens [TC 20041 
Written statements present a more formal account of the individual's thoughts or 
actions. Both the RA and the TC felt that the interviews were a safer environment for 
them to discuss trial concerns. In September 2004 after I had returned to the team I 
asked that the diaries be stopped. 
As in the previous section, other methodological and ethical issues arose from using 
participant observation to investigate a study in which I had a vested interest. The 
diaries themselves presented one such problem in that when I did uncover problems 
with the trial (through diary or interview) I found it very difficult not to intervene to 
improve the trial process. Burr presents a detailed discussion of a similar ethical 
dilemma arising from participant observation conducted with street children and 
orphans in Vietnam. 249 In her work, she uncovered evidence that the children in her 
study were infected with HIV and were unknowingly spreading the virus amongst their 
peers. HIV transmission was not the focus of her own study but she felt it unethical not 
to attempt to intervene to prevent infection. In the Stop Stroke Trial the consequences of 
intervening or not intervening were not so life or health threatening as in the Vietnam 
study but the dilemma was the same. I had evidence that the trial staff did not fully 
understand aspects of the intervention or trial that might potentially prevent the 
intervention from working. I also had evidence that trial staff were unhappy with the 
support they were receiving. I felt that I was able to resolve these problems and found it 
difficult to ignore `cries for help' when they were expressed. If the trial process or 
intervention delivery were inadequate this might influence intervention success, have a 
detrimental impact on the trial patients themselves and consequently our ability to 
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publish findings. I did not feel that methodological `purity' was a sufficient excuse not 
to intervene. These challenges may illustrate the limitations of conducting participant 
observation as an insider, or alternatively illustrate the potential benefits of using 
participant observation alongside a RCT. Which answer is right depends on the research 
context and one's epistemological standpoint. These issues are discussed in more detail 
in Chapters 8 and 10. 
4.5.3. Validation of findings 
My role as both observer and participant also raises challenges for validation of 
findings. Respondent validation is perhaps particularly important in this context, since 
as discussed above, the findings pose ethical challenges and the data may have a 
negative impact on the investigators. However, feedback to trial staff while the trial is in 
progress may also influence trial process, or intervention delivery in a similar way to 
reporting interim findings. 65 In this case, findings from the research have been fed back 
to the core investigators (the principal investigator and investigator one) who are not 
responsible for intervention delivery. Their comments have been incorporated into the 
discussion and findings will be fed back to other team members once intervention 
delivery is complete. 
4.6. Methods for evaluating the impact of the Stop Stroke intervention. 
Data for the final results chapter are also drawn from in-depth interviews with stroke 
patients and carers, this time to explore the impact of the intervention on the 
mechanisms influencing intervention success or failure. 
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4.6.1. Sampling 
As for the interview sampling methods reported in section 4.2.1., the SLSR was also 
used to identify patients for this in-depth study. However, for these interviews, I 
purposefully selected 20 patients in the intervention arm. SLSR data were similarly used 
to identify patients with particular socio-demographic and risk factor characteristics for 
inclusion to create maximum variation in characteristics of the group selected. 218 There 
have been a number of recently published articles outlining challenges and guidance on 
the conduct of this kind of qualitative process evaluation' 15,117 250 and there is debate 
over the appropriateness of conducting research which interferes with trial process. For 
this part of the process evaluation, patients were deliberately sampled once they had had 
their one-year follow-up interview for the SLSR (to collect trial outcome data) so as not 
to interfere with the main trial (I will return to this discussion in Chapter 10). 
Thus the patients included in this part of the study were those who were first recruited 
to the trial. It is possible that patients recruited later into the trial may have had a 
slightly different experience since the intervention appeared to become more 'tine 
tuned' as it went along (see Chapter 8). Interviewing those patients who had received a 
one-year SLSR follow-up also excluded those who could not be traced by the SLSR. 
These patients are likely to include those less engaged with services and possibly those 
who have poorer secondary prevention management. 
4.6.2. Consent 
Patient and carer consent to participate in the process evaluation was collected at the 
time of stroke as part of the Stop Stroke Trial. However, many of the patients 
participating in the trial did not remember that they had agreed to take part in an 
interview and some did not remember that they had taken part in a trial. For many 
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patients, research activities since the stroke including the SLSR visits appeared 
indistinguishable from usual care. Thus prior to the interviews I reminded patients that 
they had taken part in a research study to test the efficacy of a new package for stroke 
patients and their doctors. I explained in simple terms what the trial had involved and 
that I was conducting the interviews to find out what patients thought of the intervention 
and what actions they had taken as a result of receiving it. Although all interviewees 
were in the intervention arm, I did not reveal to the patient whether or not they were 
supposed to have been sent a package (disclosed the trial arm) until they themselves 
indicated whether or not they had received one. 
4.6.3. Data collection and analysis 
To answer the first question (how was the intervention implemented'? ) copies of all 
plans sent to patients and professionals were collated with the data collection forms 
(initial SLSR questionnaires, 3 month and 6 month follow-up questionnaires). Each plan 
was compared with the original forms to check for errors. The patient and professional 
plans were also checked against each other for consistency and the content checked for 
formatting and typographic errors. A list of errors for each patient and each plan was 
created together with notes on the sources of error. 
For the second question (how did the plans influence secondary prevention'? ) in-depth 
interviews were conducted with patients and their carers in their own homes. A topic 
guide was used, based on one developed for investigating secondary prevention 
management in Chapter 5. This topic guide also incorporated specific questions about 
the intervention, whether patients had received anything and if so what they had 
received, their views of the intervention, how they had used it and its impact on stroke 
secondary prevention (Appendix 6). As in Chapter 5, interviews were audio taped and 
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transcribed (except for two interviews; one where the patient refused to be taped and 
one in which the tape recorder failed and detailed field notes were taken instead). 
Transcripts were then also analysed for emerging themes (see section 4.2.3). 
4.7. Summary 
In this chapter I have outlined the methods for the ethnographic study of how the MRC 
Framework was used in developing and evaluating the Stop Stroke intervention. 
Different methods were used to investigate specific phases of The Framework including 
those which are standard within public health such as in-depth interviews and 
qualitative observational methods and those with are less common within this context 
such as participant observation. In this chapter I have outlined some of the 
methodological and ethical challenges arising from using these methods; the 
implications of these for interpreting findings and enhancing RCTs will be discussed in 
more detail in the discussion sections presented in each individual chapter and in 
Chapter 10. 
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Chapter 5. Patients' experiences of secondary prevention 
5.1. Introduction 
This chapter presents findings from the first part of the research conducted in the 
theoretical phase of intervention development to investigate patients' perspectives on 
secondary prevention. The aim of the theoretical phase was to investigate barriers to and 
facilitators of secondary prevention in order to design an intervention that would be 
grounded in research evidence. The research presented in this chapter followed SLSR 
analyses of patterns of secondary prevention management (outlined in Chapter 1 and 
presented in Appendix 1) and a review of interventions to improve secondary 
prevention in vascular chronic diseases. 
5.1.1 Optimal secondary prevention 
In the context of health policy for older people and stroke management, secondary 
prevention can be seen as a specific clinical concept involving the design of strategies to 
prevent future strokes. 26.2' At the time this research was conducted, recommended 
guidelines on secondary prevention management such as the RCP recommendations 
outlined in Chapter 1 were not yet published. More recently, clinical and policy 
documents have been published outlining strategies to prevent further strokes. These 
include: monitoring of body processes including blood pressure, cholesterol and body 
weight to ensure they are kept within clinically defined `safe limits'; controlling blood 
sugar levels in people with diabetes; prescribing medications such as antihypertensives 
or statins to assist in this; and prescribing antithrombotic medications to prevent blood 
clots from forming. Health professionals are encouraged to provide their patients with 
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advice on giving up smoking, moderating alcohol consumption, eating a low fat-low 
salt diet and taking physical exercise. 27 
As discussed in Chapter 1, SLSR analyses prior to the Stop Stroke study and those 
conducted to inform intervention development, demonstrated inadequacies in secondary 
prevention management, including low rates of health service follow-up after stroke, 215 
under-use of medications post stroke34 and inadequacies in behavioural risk factor 
management. 214 Investigation of the relationship between socio-demographic 
characteristics and management revealed that ethnicity and disability were 
independently associated with aspects of risk factor control: Black Caribbean and 
African stroke patients were more likely to have received district nurse support, more 
likely to be prescribed antihypertensive medication and more likely to quit smoking but 
were less likely to lose weight if they were obese. Patients with more severe disabilities 
were less likely be followed up in outpatient clinics, less likely to be prescribed 
anticoagulant medication but more likely to quit smoking post stroke. 34'2 14'2 i5I lowever, 
these analyses provided little guidance on the best way to improve secondary 
prevention. 
At the time this research was planned (September 1999) there were few published 
intervention studies specifically targeting stroke secondary prevention (only one 
intervention was identified and this targeted hospital inpatients with 'teaching 
brochures' on stroke 148). Therefore the study team drew on evidence of the success or 
failure of previous interventions from studies on intervention in primary prevention of 
stroke disease 152,153,156,158,161,165 and interventions to improve secondary prevention in 
similar chronic diseases including coronary heart disease. `51 253 Interventions could be 
divided into three types: those aimed at educating patients about secondary prevention 
(to improve knowledge or change attitudes or beliefs about secondary prevention); those 
targeting professionals, to improve the communication of secondary prevention advice; 
and those aimed at improving the coordination of care. However, these previous 
interventions had had limited success in reducing recurrence or improving key risk 
factor outcomes such as blood pressure control and smoking cessation. Since these 
interventions were all evaluated using only traditional RCT methods, it was difficult to 
explain the reason for their success or failure. 
5.1.2. Mechanisms for achieving 'optimal' risk management 
While there is no defined `best way' to achieve public health goals, recent health policy 
has suggested that personalised healthcare can be used to `empower' patients to take 
control of their own health, particularly in relation to chronic disease. 254 254,255 There is 
considerable debate over what constitutes personalised or 'patient-centred' care. 256.257 
Most models of patient-centred care highlight the importance of patient participation, of 
sharing decisions about treatment and of attention to the doctor-patient relationship (see 
Brown, Mead and Bower, Lewin et al., Ong et al. for a full discussion of the 
components of patient-centred care and their relation to health outcomes). 258.26 
Although not clearly defined, the concept of patient-centred care has been described as 
care `closely congruent with and responsive to patients' wants, needs and 
preferences'. 262 Calls for a more patient centred approach have coincided with a shift in 
the past decade from a traditional `compliance' model of treatment, in which patients 
are expected to follow doctors' orders, to a `concordance' model. Although not 
necessarily understood or practiced as intended, 263'264 the concordance model implies 
prescribing based on negotiation and mutual agreement between doctor and patient. 265 It 
is compatible with a patient-centred approach since it is often assumed that patient- 
centred consulting is synonymous with patient centred care. The research team 
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hypothesised that one reason for poor secondary prevention management and a reason 
why previous interventions had failed may have been the lack of attention to the 
individual patient experience. 
5.1.3. Stroke secondary prevention and the patient 's experience 
Sociological and psychological studies of prevention have highlighted differences 
between `official understandings' of chronic disease and risk management and the lay 
person's understandings of their illness and prevention, 266 27° hypothesising that many 
public health interventions often fail because their aims are `out of step with popular 
culture'. 267 At the time the research was conducted, little was known about the stroke 
patient's understanding of secondary prevention but studies of the lived experience of 
stroke had highlighted the importance of social and cultural factors, such as views about 
aging, which influence understanding and management of stroke disease. " Thus the 
primary aim of this part of the theoretical phase was to identify social, cultural or 
political influences on `optimal' management. It was anticipated that investigating 
patients' experiences of secondary prevention would lead to a clearer conceptual 
understanding of what secondary prevention means to patients. 
An outline of the methods for this chapter is presented in Chapter 4, section 4.2. All 
extracts presented here and in subsequent chapters are verbatim quotes unless otherwise 
stated. Patient and carer names have been changed to numbers in the text to protect their 
identities. Some patients had strong accents or difficulties with speech and the text in 
square brackets has been added to enhance the understanding of the reader. 
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5.2. Participants 
Participants were 20 people (SLSR patients) aged between 38 and 85 (average age 70 
years) all previously diagnosed with acute stroke. Table 9 illustrates the socio- 
demographic characteristics of those interviewed. 
Thirteen patients were women and seven were from Black Caribbean ethnic groups. Six 
patients were classified as `independent' in activities of daily living (having a Barthel 
Index of 20 at three months post stroke) and 14 were moderately disabled (Barthel 
Index between 10 and 19). However, the ceiling effects in using the Barthel Index as a 
measure of disability after stroke (particularly for those with mild strokes or living in 
the community) are well reported. 271'272 Of those considered either independent or only 
mildly disabled, many described being housebound or were limited in their ability to get 
out and about and perform household tasks. Fourteen patients were from manual 
occupational groups although none of these patients were working. All patients were 
interviewed between one and four years after their stroke. 
According to the epidemiological data collected by the stroke register, three patients had 
controlled all stroke risk factors one-year post stroke, eleven had controlled some of 
their risk factors (but not others) and two patients had controlled no risk factors. 
5.3. Factors influencing secondary prevention 
Four key factors emerged as having influenced patients and carers experiences of 
secondary prevention management. These were health service management of 
secondary prevention; understanding of the causes of stroke (whether it is preventable), 
priorities after stroke and the way stroke is conceptualised temporally as an acute event 
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5.3.1. Health service management 
From patients' accounts three categories of health service management of secondary 
prevention emerged: opportunistic management, organised management and lay 
management. 
5.3.1.1. Opportunistic management 
When questioned about health service monitoring of risk factors and delivery of 
secondary prevention, the picture described by most patients was a haphazard or 
`opportunistic' approach. For example, some patients described having their blood 
pressure checked if they happened to visit their GP but also explained that they did not 
routinely see their GP. 
JR: And do they [the doctors] ever check your blood pressure? 
Patient 3's husband: They do when you go round, although you ain't been round there 
lately but when you go round there, yes. 
Alternatively, others described seeing their doctors frequently but did not necessarily 
get their risk factors monitored when they were seen: 
JR: Does he [the patient] ever get his blood pressure checked? 
Daughter 7: When you go into the hospital you get your blood pressure checked don't you? 
Patient 7's wife: He hasn't had it done for ages. 
Patient 7: I've had a lot of blood checks. 
Patient 7's daughter: No blood pressure? 
Patient 7: Not that I know of. 
Patient 7's daughter: Not when you go to the doctor you know the machine that they wrap 
round your arm? 
Patient 7: No. 
In some interviews it was difficult to identify just how often the patient actually saw 
their GP or other health professionals. Definitions of what 'regular' meant in relation to 
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having regular check-ups were diverse. For some, seeing the doctor every few months 
was thought to be `regular', for others a fortnightly check-up was infrequent. Patients 
might go to the GP surgery on a frequent basis but it was not clear whether such check- 
ups included secondary prevention. 
JR: Do they check your blood pressure regularly? 
Patient 6: Not regularly, no. 
JR: And how often do you go to your doctor, is this your GP? 
Patient 6: Yes my GP, haven't been to him very often. I went there 2 weeks ago for this flu 
jab. So I haven't seen him now for a while, he came once. 
Patients on repeat prescriptions collected their medication without seeing a professional. 
These automated systems for making appointments and collecting prescriptions may 
have facilitated access to medication for some patients but at the same time appeared to 
act as a barrier to accessing clinical advice. The organisation of GP care may have 
prevented patients from accessing advice on secondary prevention since it would have 
meant making a specific appointment to do so. Patients appeared to see the GP as 
someone who was responsible for them when they were sick and having had a stroke in 
the past did not necessarily constitute being currently sick. One patient had not seen his 
GP for over three years since the stroke. He explained that he only visited the GP if he 
thought there was something seriously wrong with him. 
Oh yeah I mean if I really felt ill of course I'd go down and see him. Like the eye when I 
realised it wasn't opening like it should have done, I thought there was something wrong 
with it, you know, that's when I went down. (Patient 20) 
Some patients described their GPs as being `too busy' and they would not make an 
appointment unless they had an emergency (they were sick) or needed a specific 
procedure such as a flu injection. Practically, seeing the doctor appeared to be 
discouraged: 
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JR: So do you go to your GP regularly? 
Patient 7's wife: No 
Patient: Only to get my prescriptions and that and then I only see the receptionists. I don't 
get to see the doctor 
Patient 7's wife: He doesn't ask, you have to ask to see the doctor, which is very hard to do. 
JR: Why is that? 
Patient 7's wife: They put you off... 
Patient 7: When you go over there you're sitting there for hours before you see the doctor. 
You can even make an appointment time but it makes no difference its still 2 or 3 hours 
before you go and see a doctor. That's what puts me off. But then if you imagine you can 
make an appointment for the afternoon and it might take about a month before you get that 
appointment. That's what puts me off. 
5.3.1.2. Organised secondary prevention 
However, despite the overwhelming sense that health service organisation of secondary 
prevention was haphazard, some patients did describe seeing hospital or GP services on 
a frequent basis. These patients were categorised as having organised secondary 
prevention management. Patients in this category had been provided with advice about 
ways to help prevent further strokes and had routine monitoring of risk markers such as 
blood pressure or diabetes. 
JR: You said you go to a doctor quite a lot. How often do you go to your doctor? 
Patient 2: About twice a week, check the blood pressure and check the diabetic (sic[. I see 
the doctor very often and check the blood pressure very often and the diabetic [sic] very 
often. 
However, 
not all patients in this category were receiving their care specifically in 
relation to their stroke. Some patients were receiving regular monitoring of risk factors 
as pan of their care for a concurrent disease and organised through another specialty 
(such as cardiology or diabetes care). In fact it was almost as if the only people who 
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received ongoing organised management were those who had this organised through a 
separate specialty. There appeared to be no specific specialised ongoing follow-up for 
stroke. One patient did state that he had attended the stroke clinic on a regular basis but 
it was difficult to tell whether the focus of these visits was on stroke recovery or 
whether it was to check up on his smoking and alcohol use. Certainly from the patient's 
point of view these visits were not about helping him to prevent future strokes. 
JR: And have you been back to the hospital at all? 
Patient 12: Oh yes, I go back every month, I go back and the last time I went they said I got 
to go back every 3 months. 
JR: And is that to see people about your stroke or is that...? 
Patient 12: [interrupts] Awful, they don't do nothing. 
[later in the interview] 
JR: And when you actually get to see the doctor what happens? 
Patient 12: give up drink and smoking they say... They've got a great job them doctors, 
sitting down there, two of them.... They do nothing. 
Since the patient's understanding of stroke focused on physical symptoms and the 
residual disability resulting from the stroke, services that focused on secondary 
prevention issues even if delivered in a specialist environment, were not seen as stroke 
specific by the patient. 
5.3.1.3. Lay management 
Stroke specific services appeared to be short lived, being restricted to hospital rather 
than community services. Some patients were angry, feeling that their stroke monitoring 
had been terminated before their stroke problems had been resolved. 
I'm very bitter [with named hospital], they just don't care, there's no care in society, care in 
society has just gone out the window. They stitch you up put you on a train and send you 
home and that's it. Nobody... you don't get after care. (Patient 9) 
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Without organised stroke follow-up and given the haphazard nature of routine 
monitoring, some patients appeared to rely heavily on `lay support' from friends and 
relatives to assist them in their secondary prevention management. 
When she first came home she refused to take her medicine her tablets so I can't remember 
whether I did or not, anyway we must have gone over and told the doctor she wasn't taking 
them. So she sent a district nurse from the [named] centre, [named] estate. Do you know 
the [named] estate up there in [named town] they've got a big sort of health centre. She [the 
nurse] came here and she said she [the patient] must take them. And it was her and the 
doctor said that she must take them...! thought she [the nurse] was gonna come back and 
see that she took them but she only ever came the once she never came no more. But 
anyway, we got round to making her take them and she's taken them ever since.... she takes 
them alright now. Mind you you've gotta be after her. Because you know my brother leaves 
them there he puts them in the cup, 2 in the little egg cup for her morning ones. And then 
half way through the morning he says to her you haven't taken your tablets. She says yes I 
have he says you haven't they're still here, oh alright! You would think she'd help to look 
after herself. If we weren't here I dare say she would be up the wall. (Patient 7's sister) 
This haphazard approach to routine secondary prevention delivery appeared to influence 
not only the delivery of secondary prevention monitoring but also the uptake of health 
promotion messages. Some patients could recall being given advice in hospital or by 
their GP (such as stroke education, information leaflets or an opportunity to ask 
questions of a health professional) that satisfied them at the time but on leaving hospital 
the advice could not always be recalled, perhaps due to the time of delivery. Ley's 
model of behaviour change demonstrates the importance of information recall in 
influencing health behaviour. 274 Shortly after the stroke, patients and their carers may 
have been more concerned with recovery and getting home than on secondary 
prevention. In one interview the discussion turned to provision of written information. 
The patient and her daughter described how they had not been given any written advice 
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on stroke management and had had to seek it out themselves. However, later on, the 
patient said that she had read something about stroke in a leaflet in hospital. The 
daughter described how the nurses in the hospital had informed her about the stroke and 
given her the opportunity to ask questions but at the time she had not been that 
interested 
Well I've got to be honest, the nurses when she was in [named hospital], on the ward she 
was in, we weren't bothered because we was really worried, we nearly lost it. (Patient 4's 
daughter) 
She went on to explain how the nurses had taken her aside into a private room and spent 
about half an hour with her answering her questions. Unfortunately as she put it but 
that was in hospital' and on returning home she and her mother had been forced to rely 
on their own initiative. 
JR: And what about information since you left hospital? 
Patient 4's daughter: We've done it yourself really, we've done it ourselves 
Once in the community, some patients felt that the information they had received was 
not relevant. 
JR: Have you ever had any written information about your stroke like this (JR shows the 
patient a selection of leaflets]? 
Patient 1I: I got one at the hospital... 
JR: And did you find it useful? 
Patient 11: Not really, it's mostly for older people. It was a shock to me. I didn't know that 
a young person could have a stroke. 
There appeared to be little opportunity for secondary prevention messages to be 
reinforced once patients had been discharged from hospital. It was difficult to ascertain 
whether the low levels of information provision reported in stroke studies 275-277 were 
because secondary prevention advice had not been provided or whether it was simply 
not salient. When questioned about secondary prevention advice and information, many 
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patients referred to information they had received about other aspects of their stroke 
rather than about secondary prevention. 
However, even when patients did recall receiving secondary prevention advice post 
stroke (from information leaflets or their GP), some patients' interpretations of the 
advice appeared at odds with current secondary prevention recommendations, 
suggesting that there was no mechanism to ensure that secondary prevention messages 
were understood. One patient described his interpretation of his GP's dietary 
recommendations: 
Patient 8:... the doctor, the GP give me some of those [information leaflets], to help with 
eating and doing your food and whether you want fish or drink anything, vinegar or 
anything like. Oh give you advice about what is good for you. Oh they're very good over 
there 
JR: So did you find the leaflets quite useful? 
Patient 8: Well I did and I didn't actually. Because I don't go crazy like with certain food I 
just do a normal, like chips or something. I don't have any of that fancy stuff. I thought if I 
did want any of the fancy stuff I wouldn't be able to eat it. No it's been good advice like the 
drinking and sort of thing. If you want a beer or something that's OK provided you don't go 
crazy with spirits. Which he did tell me once - he said do you drink spirits? I says no, a 
weak beer. He says no beer's all right. You can have 2-3 of them, no problems. 
Although he had been informed of the need to eat a healthy diet, his interpretation of 
healthy food appears to be food that is `not fussy' rather than foods low in fat and salt as 
described in health promotion and stroke literature. 27'278 
5.3.2. Beliefs about stroke and models ofprevention. 
Perhaps because of the way stroke is conceptualised and the way services are organised 
(more as an acute event than a chronic disease), it was not easy to engage patients in 
discussion about preventive action for the future. When initially contacted about the 
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study, a number of patients had commented that it was too late to be talking to them 
about stroke prevention. There appeared to them, to be little relevance in focusing on 
preventive strategies if the stroke had already happened and was now something of the 
past. Given the lack of information provision described by patients, they may have been 
unaware that they could have subsequent strokes. However, lack of knowledge could 
not explain the lack of concern expressed by some patients, since they had been 
explicitly told by health professionals that they could have more acute events in the 
future. 
JR: You said that the doctor said to you that you could have another stroke. Do you worry 
about that? 
Patient 8: Well you do to a certain extent but I think to myself well I don't know. If you've 
already had the stroke you've just got to you know [make the best of it]. But I've been 
lucky and touch wood, I haven't had the [problems with] movements [disability]. I mean 
I've seen people in the markets there - young people you know. Really they're in a position 
where they [should] be going to a church, you know. 
It is often assumed in the literature that risk management will be more relevant to those 
who already have a disease than to the general population, 28'29 since it is hypothesised 
that those who have already experienced the symptoms of an illness and are thought to 
be at high risk, will be more fearful of the future. This hypothesis did appear to be 
partially supported in the interviews since some patients talked of the fear they 
experienced in relation to their acute event. 
lt is frightening when suddenly it comes and for two days it don't feel at night, I couldn't 
sleep. It hurt, it hurt (until somebody gave me something)... but I really suffering (sicj, 
especially the stairs up till now. I don't recover that still yet. Still have a problem with the 
stairs - can't get to my room you know, the balance, I stay down here - you should see the 
way I walk, because I'm scared I'm down here. It is bad. (Patient 6) 
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However, fear surrounding the acute event did not necessarily translate into worry about 
preventing strokes in the future. Fear for the future appeared to be heightened 
immediately after the acute event. A year on, patients learned to focus on other things. 
While this may not have been helpful for secondary prevention management, it may 
have been a coping strategy to consider the stroke as something in the past. 266 
Well, it got to the stage, after having one, I used to wake up in the morning, I used to 
worry. I keep trying to quote my old army number, 23.9829 and if I could do that, I knew I 
was all right. You know, when you first woke up, 23.9829, oh yeah, that's all right. But 
apart from that, no, it's not a problem, I don't even think about it now one way or another. I 
keep myself busy out in the garden. (Patient 5) 
Psychological theories have highlighted the importance of beliefs or representations of 
illness in influencing illness behaviours 200,279"282 and it had been in the original proposal 
for the study to investigate patients' beliefs about stroke causation and prevention. It 
was anticipated that where risk factors were well managed, patients would have a 
clearer understanding of stroke aetiology as defined in epidemiological and clinical 
studies. 
In the interviews there did appear to be a relationship between patients' understandings 
of prevention and their interpretations of what had caused their initial acute event. Some 
patients explained that there was little they could do in trying to prevent a future stroke 
since strokes were random events that could not be prevented. For others, the stroke 
simply could not yet be explained scientifically and current secondary prevention 
strategies were not perceived as being advanced enough to make a difference 
Patient 7's daughter: I tried to talk to the doctor that was standing in there and she more or 
less said well you can't really do much about it. So I said what the hell are we doing here? 
JR: Did she not explain it? 
Patient 7's daughter: Not really I got the impression she could say a lot of things but it 
wouldn't really make much difference. It's just a question of he'd continue to have mild 
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strokes. Each time he had one it would get a bit worse, he wouldn't recover every time as 
much.. . that's 
just about it. 
JR: But she didn't explain anything to you about what you could do to help stop this 
happening? 
Patient 7's daughter: No I got the impression you couldn't do anything. That's the 
impression I got.... Wait till they get these gene things sorted out because when they can 
pinpoint which genes do this that and the other it'll solve all the problems. It's just a 
question of waiting. Perhaps when it's my time you'll just be able to take a tablet and 
probably when you're my age you probably won't have any of these problems at all. 
Those who did think there was something that could be done described different models 
of prevention. Three models emerged. Firstly, a medical model in line with public 
health theory on secondary prevention, where modifying risk factors could prevent a 
stroke 
JR: Do you think the medication that you're taking could stop you having another stroke? 
Patient 4: 1 hope so that why I take it. Aspirin, I definitely worry about taking it. 
Secondly, a stress model in which patients suggested that stress or anxiety had 
contributed to the stroke and so taking it easy or removing that stress would prevent a 
recurrence. Some patients discussed a particularly stressful event which they thought 
had triggered the stroke including death of a spouse, problems at work or problems with 
housing, while others talked more generally about the problems of stressful lives, 
building up and contributing to poor health over time. 
JR: Do you think anything like smoking, or diet, or alcohol, are related to strokes? 
Patient 5: Well, I, I mean, anything you take to excess, you're asking for trouble, ain't you? 
If you do it in moderation, I can't see any...! think one of the worst things is blood pressure 
and stress, I think, especially, today, I mean it's all bloody stress, everybody's fighting for 
their job, or fighting to be a bit better than the next one and all that. I think that's the main 
cause of it, as I say, it's better to be doing, to be one notch under what you're capable of, 
than one notch above it, cos one notch above you're in trouble. 
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Thirdly, a spiritual model was described where patients felt that God had caused their 
stroke and so praying would help prevent further strokes. However, alternative models 
of prevention such as stress or spiritual beliefs did not necessarily translate to fatalistic 
views about the future (see Davison et al. for a discussion of the limitations of 
psychological theories of illness attribution 283) since these models were not mutually 
exclusive. Patients could at the same time believe it was important to control blood 
pressure (medical model) and reduce stress (stress model). Holding a spiritual model 
would not necessarily negate the need to take medicine to prevent further strokes, the 
two models might even complement each other. 
Well I pray over my medicine. Because the doctor can give you medicine but it is God that 
do the healing. We pray over our-just as you pray over your food that is the same that you 
prey over your medicine and God will remove the side effect. You see some people just 
take medicine and drink it but I pray over the medicine. (Patient 1) 
What was not clear from questioning patients about their understanding of stroke 
causation and preventability of future stroke was the extent to which these models 
actually influenced the patient's behaviour. When questioned about the importance of 
engaging in specific preventive behaviours, patients talked more about their priorities, 
than their understanding of stroke causation. 
5.3.3. Priorities after the stroke 
Previous studies have highlighted the importance of individual context in influencing 
lay understanding of prevention. 267 This is perhaps particularly relevant in the context of 
stroke, which affects mainly older people and can lead to long-term physical or 
psychological difficulties. In this study, patients talked about clinical secondary 
prevention strategies in terms of their priorities, using a type of economic cost-benefit 
approach. 267 The benefits of managing risk factors appeared to be weighed up against 
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the costs of having to engage in risk controlling behaviours (giving up smoking, cutting 
down on alcohol, losing weight or taking tablets). 
Whether these models were used to inform cognitive decisions about risk management 
or whether patients presented them in interviews as an afterthought, to justify why they 
were/were not engaging in specific secondary prevention activities, was not clear. 
However, in some cases the stroke appeared to have had a significant impact on the 
patient's ability to fulfil social roles or participate in activities. Specific risk factor 
behaviours such as smoking or drinking were some of the few pleasurable distractions 
patients had left as illustrated by one young woman's experience. She had a stroke at 
the age of 34 and now four years on described still being restricted in leaving the house 
due to problems with incontinence since the stroke. In such cases decisions not to 
engage in risk factor control appeared quite rational. 
JR: And you said they told you to cut down on drinking as well, do you drink a lot? 
Patient 11: yes, too much 
JR: And did you try to cut down on that? 
Patient 11: Yes, I seem to have got worse over the years. Because there's nothing for you to 
do, you get bored and the only source of comfort is drinking booze and cigarettes, it's a bad 
cycle. 
Yet while it may have been helpful for patients to prioritise health promoting 
behaviours specifically for the purpose of stroke prevention, it was not a necessity for 
patients to see a direct cause and effect relationship. Some patients felt that behaviours 
(such as exercise) that might help prevent future strokes were important, not because 
they could prevent a further stroke but because they brought general health benefits. 
Well to me I feel exercise makes you became more fitter. But I don't think the exercise, you 
understand me, if you haven't got the stroke, you take your exercise, your body feel more 
fitter. But I don't think, if you've got a stroke, don't matter what exercise you take and no 
matter what you do, you're still going to have it. (Patient 19) 
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Equally for some, engaging in risk controlling behaviours appeared to be more of a 
routine, or a reaction to medical advice, than the result of decisions about preventing 
stroke. Some patients suggested that they were happy to engage in secondary prevention 
behaviours (such as tablet taking) without any understanding of the aims of doing so. 
I take it because that is what they gave me at the hospital. I don't know what it is doing. 
(Patient 14) 
5.3.4. Health and social factors influencing priorities 
Patients' priorities after stroke and their ability to engage in secondary prevention 
appeared to be heavily influenced by their health and social circumstances, either as a 
result of the stroke or from a pre-existing problem. Approximately one third of stroke 
survivors are estimated to experience some form of residual physical or cognitive 
disability after stroke25 and this appeared to have an important influence on secondary 
prevention management. Cognitive problems influenced medication use, since some 
patients who were happy to take their medication had difficulty remembering it. The 
husband of one patient described how his wife's cognitive problems made her 
dependent on him for aspects of secondary prevention management. At the start of the 
interview he had told me that his wife had problems remembering things that had 
happened since the stroke. This was not obviously apparent at the start of the interview 
but after about half an hour she started to repeat things she had discussed earlier. It 
became clear that without her husband's assistance the patient would not have 
remembered to take her medication. 
Interviewer: Did they put you on any medication or anything when you came out [of 
hospital]? 
Patient 3's husband: Well, she's got loads of medication actually but, you know.... these 
blood pressure pills and aspirin I should think... 1 know that you were put on aspirin. 
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JR: And, and how often do you have to take them? 
Patient 3's husband: Daily. 
Patient 3: What do I do with those aspirins, two a day, three a day? 
Patient 3's husband: Daily, two, two a day, two a day. 
Patient 3: Yeah, you lay 'em out on the table don't you? 
Patient 3's husband: Yeah, otherwise if I don't get it, get them, she won't bother, if you 
know what I mean. 
JR: And do you, do you have any problems at all about taking them or do you not mind 
taking them? 
Patient 3: No 
Patient 3's husband: Provided I put 'em there she'll take 'em and if I don't put 'em there 
she won't. 
Physical problems also appeared to act as a barrier to secondary prevention even if 
secondary prevention was seen as a priority. Some patients, despite being aware that 
exercise was important for their health, had stopped taking exercise since the stroke 
because they felt fatigued or were physically unable to be active, making them reliant 
on family or friends to collect their prescriptions or to help them get out and about. 
JR: And do you ever get out at all? 
Patient 10: Not unless my daughter, I couldn't climb the stairs, I had to have a shower put 
in because I couldn't get in the bath. 
JR: And was that after the stroke? 
Patient 10: Yes...! don't go out because I can't walk anyway and my daughter does 
everything for me. 
Social, environmental and economic limitations were also discussed in relation to risk 
factor management. Some patients talked of the financial difficulties they experienced 
and while financial constraints might have assisted in some aspects of secondary 
prevention management (one patient talked about cutting down on smoking and alcohol 
to save money), having financial difficulties also appeared to prevent patients from 
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accessing services. None of the patients interviewed had access to a car for getting to 
and from hospital or their GP surgery and some patients talked of the difficulty they had 
in walking to their local surgery and getting to hospital or using public transport. 
I don't do much walking because you know, because I is scared of falling. I don't go out 
any more. (Patient 14) 
Some patients stated that they were afraid to go out alone in the local neighbourhood. 
This might, as Bandura suggested, be due to lack of self-efficacy (or self confidence) in 
going out alone. 279 However, many patients talked of practical difficulties negotiating 
the environment since the stroke. Patient 4 described how her shoes fell off while she 
was walking because she could no longer bend her foot and was unable to bend down 
and put them back on. Others talked of difficulty going up and down steps or problems 
negotiating traffic. 
JR: And would you if you had any questions be able to ask your GP? 
Patient 13: 1 couldn't go there on my own. 
JR: Is your doctors quite a long way away? 
Patient 13: You've got to cross too many roads. 
JR: And you couldn't use public transport? 
Patient 13: No. 
Others still, described their local area as being too dangerous and felt that since the 
stroke they had become vulnerable to being mugged or attacked (their local Boroughs 
falling into some of the most deprived boroughs in England). 284 
5.3.5. Stroke as an acute event or chronic disease 
The clinical concern for management of risk factors to prevent recurrence implies 
construction of stroke as a chronic condition. By contrast patients described their stroke 
largely in relation to the acute event. At the start of each interview participants were 
first asked to talk a bit about the stroke and to describe what had happened to them. 
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Almost without exception, this question initiated a history of events focusing on the 
acute stroke experience, including descriptions of what patients had been doing at the 
time, who they were with and whether they had contacted their doctor or called an 
ambulance. The symptoms they had experienced during the acute onset were 
particularly vivid in patients' descriptions, such as loss of consciousness, weakness in 
their limbs and problems with speech or coordination. 
I just went to bed normal, I wasn't reading. I mean I might go to bed at ten o'clock some 
nights, half past ten. But I read until about twelve o'clock, half past twelve, in bed like, I 
like reading. And I just woke up, me eyes was closed, this one was closed, just closed, you 
know, no pain with it. I looked in the mirror like and I thought, you know, it seemed as 
though it was stuck, you know, when you over sleep sometimes like. Anyway it never went 
away after three or four days and I rang up the GP and he turned round and said, "Oh I 
think you've had a slight stroke". (Patient 20) 
Thus, from the outset, it appeared that `the stroke' referred specifically to the acute 
event itself, the symptoms relating to it and the events that happened, rather than to any 
pre-existing health concerns or underlying unseen bodily damage. 
Lawton has discussed the importance of `embodiment' in relation to cardiovascular 
prevention, suggesting that those who experienced symptoms of cardiovascular disease 
would be more likely to seek out and relate to strategies for prevention. 239 In these 
interviews, experience of stroke and subsequent residual disability appeared to play 
similar roles in helping patients to understand their illness. If patients still experienced 
symptoms and saw themselves as still recovering or improving, then this helped in 
conceptualising the stroke as an ongoing disease. However, if patients did not 
experience symptoms, or could no longer see any change in their symptoms or 
disability, then the stroke was viewed as a thing of the past: 
JR: So, so do you feel like you've recovered from your stroke now, do you feel like it's, 
you're, you're over it? 
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Patient 3: [it's a couple of years now] finit, a couple of years. 
Patient 3's husband: Well it's over and done now I suppose. 
Patient 3: Once you, once you feel alright, you pull yourself round, you don't harbour on it, 
you forget it don't [you], you try to push it away 
However, while symptoms were clearly influential in shaping patients' understandings 
of the stroke, their experiences also appeared to be linked to ongoing monitoring of risk 
factors. Even if the symptoms had disappeared, the stroke could still be seen as a current 
health problem if continuously monitored by health services. 
JR: Do you feel now then, that you've recovered from your stroke, completely, or...? 
Patient 4: I've got, I've always been careful, well, you know, I do really, yeah. 'Cos I know 
I can keep on with what I'm doing, you know, the tablets get checked every three months 
and the blood six and oh yeah, I've got every confidence in them, ... the treatment I'm 
getting, is bloody marvellous, you know. 
Although in the above example the patient described receiving ongoing monitoring, this 
was not the pattern of service provision described by most of those interviewed. Instead, 
organisation of stroke services focused mostly on the acute event with few patients 
describing any ongoing stroke monitoring in the months or years following the stroke. 
Patients did not necessarily view the sort of care that the research team had considered 
to be part of secondary prevention management (diabetes management, hypertension 
monitoring, attendance at warfarin clinics) as being related to the stroke. For example, 
in some cases patients described seeing health professionals for risk factor management 
prior to the stroke (visiting the diabetes clinic or cardiologist) and so continuation of 
these practices was not viewed as being part of stroke care. Since most patients 
appeared to relate the stroke to specific physical or psychological symptoms it was only 
the services that targeted these symptoms (such as physiotherapy) that were seen as 
being stroke specific services and in some cases patients were unaware that the risk 
factor monitoring they received was related to their stroke. 
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JR: So it's just the people at the Warfarin clinic that see you? 
Patient 17's sister: Yes that's the only people and all we do is you go over there you go in, 
you put your card in, being a wheelchair patients she's one of the first to be seen too. They 
prick her finger on a bit of thing shove it in the machine. He tells her whether it was all 
right or not and you come out - everybody does this. And you go up to another room and 
whether he's a doctor or what he is he tells you, you know, that it was alright or what and 
gives you your next appointment and tells you he'll see you again in 6 weeks time. And 
then you're out. You're in and out in well not long so... Well no one sees her about the 
stroke. 
Thus while stroke is conceptualised within epidemiology as a chronic disease, this is not 
necessarily the case for those experiencing the stroke. While health service management 
may have the potential to influence the patient's embodied experience, current health 
service management does not encourage this view. 
5.4. Discussion 
This study used in-depth qualitative interviews to explore the experiences and 
understanding of patients and their carers in order to identify factors influencing 
secondary prevention management. In particular it aimed to identify barriers to 
secondary prevention that could be targeted by the new intervention to improve 
management. 
From the outset, it became clear that achieving `optimal' management was a complex 
process involving many different individual, social and environmental factors. Patients 
were often required to manage multiple risk factors involving taking both 
pharmaceutical therapies and modifying a range of behaviours. Having one risk factor 
controlled was not necessarily an indication that all risk factors would be well managed 
and assumptions that patients could be neatly classified into those with optimal or sub- 
optimal management were misplaced. Whether or not a patient's risk factors were 
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controlled appeared to be influenced by an interaction between health service input 
(specialist stroke services, attendance at primary care or community services for other 
concurrent health problems); social support; individual understanding of stroke disease 
and prevention; and a range of other physical, cognitive, economic and psychosocial 
factors including individual priorities following stroke. 
5.4.1. Organisation of services 
Evidence from these interviews suggests that stroke services are organised around the 
acute event, focusing primarily on the physical aspects of stroke recovery and being 
available for a limited time period only. From examining patients' experiences, ongoing 
organised stroke secondary prevention did not appear to exist and risk factor 
surveillance was limited to other disease groups such as heart disease or diabetes. Most 
other secondary prevention monitoring appeared to occur through opportunistic health 
service contacts. Patients might receive monitoring if they happened to contact their GP 
but there was no automatic mechanism for recalling patients to guarantee either that 
patients would routinely visit their GP, or that visiting the surgery would lead to 
secondary prevention monitoring. The organisation of appointments and management of 
medication using repeat prescription may have created the perception that seeing a 
doctor was for emergencies only and discouraged patients from contacting busy health 
professionals specifically to discuss secondary prevention. Where patients did not 
receive ongoing monitoring through concurrent disease management, there was no 
alternative and patients were dependent on existing social support networks for ongoing 
management. 
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5.4.2. Knowledge, education and beliefs about secondary prevention 
Knowledge or education is often thought to be a prerequisite for adherence to health 
promoting behaviours or medication274 and is a feature of many previous interventions 
targeting cardiovascular disease secondary prevention. 251,252 This perhaps stems from 
the assumption that sub-optimal secondary prevention management is the result of 
patients' erroneous or irrational beliefs about health and illness and that education can 
be used to manipulate these beliefs in order to improve health behaviour outcomes (see 
Sheeran and Abraham285 on the origins of the Health Belief Model and other cognitive 
theories of illness behaviour). However, in this study there appeared to be no clear 
association between knowledge of secondary prevention practices or health beliefs and 
secondary prevention management. A recent qualitative study into patients' causal 
attributions after myocardial infarction concluded that patients may have multiple 
models of illness causation and that certain (perceived to be inappropriate) beliefs about 
causation (such as bad luck) were not necessarily the result of lack of knowledge but a 
coping mechanism for justifying responsibility after the event. 266 In this study some 
patients appeared to be able to achieve `optimal' management without any knowledge 
of stroke or stroke prevention. Whilst it could be argued that knowledge probably is a 
prerequisite for making educated decisions about secondary prevention management, 
there should be no expectation that an increase in stroke knowledge would necessarily 
lead to improvements in risk management outcomes. 
The models of stroke causation and prevention identified in this study appeared to be 
used by patients to explain what had happened and, in some cases, in discussing health 
behaviour choices for preventing future strokes. However, it was not clear whether these 
models were used to inform health behaviour choices prior to engaging in health 
behaviours, whether they had been constructed after the event to explain current 
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preferences for risk management, or whether the models were voiced simply for the 
benefit of the interview. 
5.4.3. The individual context, prioritising secondary prevention 
As Davison et al. suggest, in order to understand the reasons for successful or 
unsuccessful risk factor management, it is necessary to understand how decisions to 
engage in health promoting behaviours are rationalised and prioritised according to the 
individual context of the patient. 267 These interviews demonstrate how failure to engage 
in a particular stroke secondary prevention practice, such as visiting the doctor for a 
blood pressure check appears almost inevitable if a person has problems with mobility 
and is unable to leave the house alone. Such decisions are not necessarily due to lacking 
in self efficacy as many psychological models suggest, 279 but might be due to physical 
disability or practical difficulties getting out and about. Likewise a decision to prioritise 
smoking over stroke prevention might appear quite rational if the person is no longer 
able to participate in social activities they previously enjoyed prior to the stroke. 
Physical and cognitive ability, social support, social and environmental circumstances 
may be particularly important in influencing patients' priorities in the case of stroke 
where such a high proportion of patients experience some form of residual disability. It 
is perhaps not surprising then that education or coordination interventions alone have 
had limited influence on improving risk factor management. 
5.4.4. Summary 
In the introduction for this chapter, I discussed previous attempts to improve risk factor 
management in coronary heart disease and stroke, focusing on patient education, service 
coordination and training of health professionals. The limitations of these particular 
137 
interventions cannot be explained by this study but these interviews do suggest that 
while education, coordination and training are all likely to be important in risk factor 
management, secondary prevention cannot be taken out of context of the stroke 
experience as a whole. Novel ways need to be found to overcome the physical, 
cognitive and social difficulties commonly experienced by patients after stroke. For 
example, retraining hospital specialists to attend to patients' information needs in 
hospital is unlikely to have an impact if secondary prevention is not a priority for the 
patient or their carers during the hospital episode. Introducing a nurse coordinator to 
improve patient access to services is unlikely to have an impact if current services are 
designed around the acute event rather than chronic disease management. While patients 
may appreciate and benefit from more structured secondary prevention education after 
stroke, it should not be assumed that making educated choices and making choices 
compatible with current public health goals are necessarily one and the same. 
The research for this part of the theoretical phase may not be able to address all the gaps 
in our understanding of secondary prevention practice but it does provide some 
explanation of the multiple social, psychological and cultural processes influencing 
patients' experiences of secondary prevention management. Any intervention based on 
these findings would need to consider these in its design and evaluation. 
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Chapter 6. Secondary prevention in the stroke clinic 
This chapter presents further findings from the research to inform intervention 
development. The research used qualitative observational methods to investigate the 
delivery of secondary prevention strategies by healthcare professionals in the stroke 
outpatient clinic. 
6.1. Introduction 
As we have seen, previous studies of interventions to improve secondary prevention 
targeting multiple risk factors have hypothesised that poor management was either the 
result of poor communication by health professionals or poor coordination of care. 251,252 
Members of the research team (and in particular the lead stroke clinician) felt that 
communication style was likely to be particularly important in explaining poor 
secondary prevention management. Roter et al. have conducted considerable research 
aimed at identifying and measuring attributes of particular communication `styles' that 
promote patient adherence. 286,287 Yet, while there is some evidence that particular 
attributes are associated with patient satisfaction and even patient recall, there is little 
evidence to support the hypothesis that communication style influences other outcomes 
such as adherence to medication and clinical advice, or subjective measures of health 
outcome. 261 Thus, this investigation was not limited solely to exploring communication 
style. 
In this chapter I draw on two theoretical frameworks to understand delivery of 
secondary prevention in the stroke clinics: (i) current theories of the social context of 
risk were explored to understand how professionals practise risk construction and 
represent risk to patients: (ii) the concept of a patient-centred approach to care (outlined 
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in Chapter 5) was used to understand organisational barriers to achieving public health 
goals for `optimal' risk management in the stroke clinic. A brief discussion of theses 
concepts and how they relate to stroke risk management is presented below. 
6.1.1. The social context of risk 
Social scientists have theorised the notion of `risk management' in a number of different 
ways, including risk management as a tool for controlling future uncertainty; 288'289 as a 
means of categorising individuals into social groups; 290 for allocating responsibility and 
apportioning blame; 269,291 and as a mechanism for surveillance and socio-political 
control. 292 Although there have been numerous studies focusing on risk management in 
chronic disease (see Lupton, for an overview), 269 to date, the literature has tended to 
focus on investigating the notion of risk in people without disease and how these 
representations are used to manage particular categories of people. For example the HIV 
literature has demonstrated how risk has been used to control already marginalized 
groups such as homosexuals and drug users. 293 Little is known about the significance of 
the risk concept amongst those for whom the risks have already been realised, that is, 
people with disease. 
In Chapter 5,1 demonstrated how individual patient and social factors including 
individual priorities and service organisation, influenced patients' understandings of 
risk management and the activities they engaged in after stroke. Other studies of stroke 
survivors' experiences have suggested that understanding of stroke and stroke 
management are shaped by cultural, social and political structures. `20-222 294 In this 
chapter I focus on social and political influences on professionals' practice in relation to 
management of risk after stroke. Little is known about how professionals understand 
and manage risk in this context, although the complexities of constructing medical 
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knowledge have long been recognised. 295'296 For example Jackson et al. emphasise the 
non-rational and subjective ways in which professionals use evidence-based medicine in 
managing cardiac risk, with trust in specialist knowledge and personal experience in 
some cases overriding `evidence based' risk reduction recommendations. 295 
In the context of secondary prevention management `risk' refers both to risk factors 
(characteristics of the individual patient's body or behaviour making them `at-risk') and 
the probability of having a subsequent stroke. Strategies to prevent further strokes (such 
as those outlined in the previous chapter) can be seen as strategies to manage risk. 
6.1.2. Organisational influences on 'optimal' risk management 
I have already outlined a definition of `optimal' risk management in Chapter 5. One of 
the findings from the SLSR analysis presented in Appendix 1 was that a substantial 
proportion of patients do not receive adequate health service follow-up after stroke. `15 
Follow-up was significantly associated with provision of certain risk controlling 
strategies such as medication prescribing. However, as the findings from Chapter 5 
suggest, even when patients do access health services, secondary prevention issues are 
not always addressed. These findings illustrated how health service organisation 
influenced both patients' understandings of secondary prevention and access to 
appropriate management strategies. 
Other studies of stroke survivors' experiences of stroke have also demonstrated the 
importance of `system' influences on patients' experiences of stroke for example in 
relation to stroke recovery. Hart illustrated how problems within a health system, 
particularly interactions with health and social services at transitional time points, may 
lead to `setbacks' for patients which consequently have a negative impact on 
recovery. 81,297 The primary aim of this part of the theoretical phase was to identify 
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social, cultural or political influences (facilitators and barriers) on delivering optimal 
secondary prevention management in the stroke clinic. 
An outline of the observational methods used to collect and analyse data is presented in 
Chapter 4 (section 4.3). Extracts presented have been selected to illustrate the emerging 
themes and are verbatim quotes unless otherwise stated. Each quotation or extract is 
identified by the clinic number (Clinic I or 2) and the consultation number. 
6.2. Clinics and Participants 
The study participants included two hospital specialists, a consultant physician and a 
consultant neurologist both with an interest in stroke medicine, four specialist registrars 
and one specialist stroke nurse. Both clinics focused on stroke disease but neither was 
dedicated specifically to providing secondary prevention, each consultation also 
covering a range of clinical, psychological and social topics related to stroke. 
At Clinic 1, the consultant (Cl) saw most of the patients himself, although, if the clinic 
was busy he was assisted by a specialist registrar (trainee who was not observed). 
Consultations with 35 patients (eight women) aged between 45 and 92 were observed 
during the study period at clinic one. Most attended for a follow-up consultation after a 
period of treatment in hospital or a previous outpatient clinic visit. Seven were newly 
referred (by a GP or other hospital professional). Consultations focused largely on 
stroke recovery, providing an opportunity for the doctors to monitor patient progress 
since the stroke. 
At Clinic 2, the consultant (C2) was assisted by a team of trainee doctors and a 
specialist stroke nurse. Each week at least one of the trainee doctors conducted blood 
tests for research purposes alongside the stroke clinic but was not involved in providing 
clinical care. All newly referred patients were seen by one of the trainee doctors to gain 
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experience in diagnosing stroke. The trainees reported back to the consultant, who, in 
almost all consultations had a brief consultation with the patient before final clinical 
decisions were made. Most patients returning for a follow-up appointment, were seen 
by the consultant alone. Trainees alternated over the study period: junior doctor one 
(JD1) left the team and was replaced with junior doctor five (JD5, who was not 
observed). C2, junior doctor two (JD2) and the specialist nurse were observed twice; 
junior doctors one (JD1) three (JD3) and four (JD4) were observed once. All the junior 
doctors observed were at least specialist registrar or clinical research fellow level. The 
specialist nurse was the only female member of the clinical team at either clinic (one of 
the research doctors at clinic two was also female but she did not provide clinical care 
during the study period). The nurse had a particular interest in nutrition and saw patients 
referred to her by the clinic doctors for secondary prevention advice and follow-up. She 
also saw patients whom she had identified as needing additional nursing follow-up from 
her ward visits'iii. 
Although observations were conducted over a similar number of visits at each clinic, in 
total, fewer consultations were observed at clinic two (reflecting a lower throughput of 
patients per doctor). At clinic two, consultations were slightly longer on average, with 
junior doctors nearly always having to wait to confer with the consultant before 
finishing the consultation. Consultations with 26 patients (10 women) were observed at 
clinic two. As anticipated, clinic two specifically targeted people suspected of having a 
TIA or mini stroke. Consequently these patients were slightly younger (aged 24 to 70 
years) than those attending clinic one. Just under half (10/26) had never been admitted 
to hospital since they had `mild' symptoms and were referred for specialist opinion by 
""' The role of the specialist stroke nurse is not clearly defined but may include aspects of health 
promotion, health education and coordination including secondary prevention. 29 
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another doctor. These patients also had had less severe physical consequences and 
tended to be more mobile than those attending clinic one. 
6.3. Social influences on secondary prevention management 
In the next section I discuss the main findings from the research. Although the aim was 
to identify both barriers and facilitators of `good' risk management, in practice it was 
easier to identify barriers since well managed patients tended to be discharged as soon 
as their specialist stroke concerns were resolved. Equally, the literature to support the 
emerging themes largely focused on the negative rather than the positive aspects of 
professional practice. The themes presented here should be taken to represent social 
influences on the way secondary prevention is practiced rather than errors in practice 
made by individual clinicians. 
Three types of social influences on secondary prevention management emerged from 
the data, (i) those relating to medical authority, its constraints on the consultation 
process, influence on the way in which notions of secondary prevention management 
were constructed and patient involvement in that process; (ii) structural barriers 
influencing continuity in service provision; and (iii) expectations of the roles of patients 
and problems addressing the needs of those who deviated from that role. 
6.3.1. Medical authority 
The first theme, `medical authority' refers to the way in which social hierarchies (the 
status, training and responsibilities of health professionals) influence the delivery of 
care in the stroke clinic. Medical authority influenced the content and sequence of 
consultations; patient participation, particularly in relation to decision-making 
processes; and the professionals' ability (and requirement) to share information with 
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patients. Depending on how `optimal' secondary prevention is defined, medical 
authority acted either as a barrier to or a facilitator of `optimal' management. 
6.3.1.1. The consultation process 
Consultations generally followed a common sequence of events beginning with a brief 
introduction and a chance for the professional to summarise existing information about 
the patient. Professionals then tried to open up the consultation by asking `And how 
have you been? ' Patients responded with details of current and past symptoms, 
problems they were experiencing (physical, psychological or social), or progress since 
the stroke or last consultation. In some cases this might include progress in managing 
secondary prevention such as success in quitting smoking. Then followed a sequence of 
detective work with professionals gathering and processing `evidence' in order to 
construct a `profile' of the patient, in terms of their health more generally but 
specifically in terms of `risk factors' for stroke (a risk factor profile). Evidence for the 
profile was gathered from a number of sources including statements from the patient; 
from accompanying relatives ('witness statements'); and professional statements from 
GPs or hospital professionals provided in the referral letter. The patient's body itself 
was also used as evidence, with heart rate, blood, blood pressure and cholesterol all 
representing measurable sources of data, as well as the patient's sensory body, its 
appearance and smell (for example being from an ethnic minority group, being 
overweight, smelling of tobacco smoke or alcohol). Smelling of smoke or alcohol might 
indicate that a patient was at risk from smoking and drinking, whilst looking overweight 
or being from an ethnic minority group might indicate that the patient's diet put them at 
risk of high blood pressure or high cholesterol. 
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Professionals asked patients to relate the events that took place during and since the 
stroke. Patients provided descriptions about their families, occupation, interests and 
activities, medication use, smoking and alcohol consumption. The professionals 
directed these narratives, circumscribing what information was admissible, ensuring it 
was relevant to their clinical purpose (their own construction of risk). Statements from 
friends and relatives were used to `corroborate' the evidence provided by the patient 
themselves, or as a surrogate for the patient's statement in cases where patients had 
difficulty communicating. Questions about symptoms, risk factors, tests results and 
investigations were asked in a set order. Although no physical protocol or checklist was 
used, the order was standardised across consultations. At the neurology clinic, the 
trainee doctors reported the evidence they had gathered to the consultant, so that he 
could assess whether their detective work was adequate. 
JD2: She is 56, a Caribbean woman, has a history of left numbness since 1996. She 
complains of waking at night with left leg numb and similar symptoms. [He goes on to 
discuss the symptoms]. She has had cardiac problems, hypertension which is checked by 
the GP, she is on drugs for high cholesterol. She is on aspirin, has a family history of 
diabetes and hypertension. Her blood pressure was 98/62; she has had dopplers and a CT 
scan. 
Clinic 2-1; professional discussion outside the consultation 
This standardisation helped professionals to ensure that they did not forget to ask 
anything important, since the information gathered had implications for interpreting 
what had happened and in making treatment decisions. Once all the evidence had been 
collated the professional assembled it into a risk profile of the patient. Professionals 
used the risk profile both to explain what had happened to the patient and to define an 
appropriate future course of action or treatment. For newly referred patients it was used 
in making a diagnosis. 
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Assembling the profile was a complex process, evidence collected from one source 
often contradicted that from another and professionals were required to judge which 
type of evidence was more accurate. Evidence from the patient's body (sensory signs 
and test results) tended to take priority over the patient's own account in defining the 
profile, as in the case of this patient who initially reported that he only smoked two 
cigarettes and drank two glasses of wine a day. 
Cl: 'I don't believe you, you are very heavily nicotine stained and smell of smoke and 
alcohol. ' 
Clinic 1-8; consultation 30 
Different types of evidence had different value. At the top of the hierarchy were 
relatively uncommon pathologies generally diagnosed using technologically 
sophisticated tests or investigations needing particular expertise to interpret (such as 
rare neurological diseases and heart disease). Treatment usually involved surgical 
procedures or medical therapy. In the middle of the hierarchy were more common 
pathologies (high blood pressure, diabetes and high cholesterol) requiring tests to 
diagnose but more commonly tested and needing less expertise than those at the top of 
the hierarchy (possibly because they were less difficult to administer or interpret, less 
costly or more common place). Results from these tests were also commonly interpreted 
and discussed by the nurse, whilst those at the top of the hierarchy were not. At the 
bottom of the hierarchy were risky behaviours diagnosed from the patient's account and 
examination of their appearance. These included alcohol use, diet and exercise. These 
behaviours were not treatable with medical or surgical procedures and were less 
commonly used to define future risk. Every attempt appeared to be made to explore the 
risks at the top of the hierarchy before using those at the bottom to explain what had 
happened: 
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JD3: We need to check it's not cholesterol or diabetes and then we need to address other 
things such as lifestyle. The main thing [regarding lifestyle] is your smoking. I know that 
its difficult but it could cause another stroke. We'll try and find other things which might 
have caused it... 
Clinic 2-3; consultation 50 
In some consultations, professionals talked about 'clinical evidence' to justify their risk 
evaluations. It was as though professionals needed to demonstrate their authority or 
expertise to the patient in discussing risk; 'evidence' was something restricted to the 
domain of professionals, as one doctor explained when evaluating the relative risks of 
surgery versus future stroke from narrowed arteries. 
JD4: the narrowing on the left artery is 50% and the evidence that we have.... by 'we' I 
mean the medical fraternity has... you wouldn't normally operate on that level. 
Clinic 2-7; consultation 61 
The use of the term `evidence' implies some sort of tangible proof but in practice the 
interpretation of patients' bodily signs and epidemiological statistics was more 
subjective, differing between different professionals. Some models of patient-centred 
consulting recommend that professionals' subjectivity be acknowledged '2 
but this 
appeared to conflict with the need for professionals to maintain their authority as 
experts and to uphold the notion that clinical evaluations are 'scientific'. 
6.3.1.2. Patient participation 
The rigid structure of consultations may have facilitated optimal secondary prevention 
management through ensuring standardised coverage of risk topics. However, it may 
also have acted as a barrier to patient participation. For example standardised formats of 
questioning may also have prevented professionals from tailoring consultations to the 
individual patient, or discouraged them from attending to the other aspects of the stroke 
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(such as recovery or social re-integration) and prevented patients from participating in 
the decision-making about treatment. 
Once the risk factor profile had been assembled it was used both in understanding what 
had happened to the patient and in deciding on strategies for prevention or treatment. 
For certain risks, a range of treatment options was available, including medication and 
surgery. For others, professionals could only offer 'lifestyle' advice or refer patients 
elsewhere for such advice (to GPs, nurses, or specialist clinics). In general it was the 
professional who made decisions about treatment options based on the patient's risk 
profile and their own interpretation of best practice. I lowever, such decisions were also 
influenced by a number of individual and social factors. For example, different 
treatment decisions reflected the status and expertise of the professional, with 
prevention strategies that required particular skills or qualifications (such as prescribing 
medication) being utilised by those at the top of the medical hierarchy (the hospital 
doctors) and the less technical aspects of prevention (such as providing lifestyle advice) 
being covered by lower status health professionals (nurses). Utilisation of particular 
prevention strategies was also influenced by personal interest. For example the nurse, 
who had a particular interest in nutrition dedicated much of her consultation to 
discussing diet, encouraging patients to eat less salt, more fruit and vegetables and cut 
down on foods high in saturated fat. The doctors rarely discussed such strategies, 
possibly because they were less skilled in doing so but also possibly because they were 
less interested in such areas. 300 One doctor justified his decision not to give diet advice 
suggesting that the net gain in terms of stroke prevention was not worth the costs to 
patient's happiness. 
'Sometimes I don't really know what to say to people [about diet]... I don't believe in 
making people's life a misery ... they should 
be able to enjoy things in life, like pork chops 
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which won't do them that much harm.... maybe I should be strict but I don't think it is 
fair. ' (Comment made to JR at the end of clinic 1-8). 
Thus in some consultations patient happiness appeared to be a priority over and above 
risk control. Such allowances may represent the importance of medical authority in 
allowing professionals to be able to tailor secondary prevention management to the 
individual patient. However, it does conflict with population health goals, which do not 
allow for individual `happiness' to be taken into account in providing treatment advice. 
Standardised turn-taking rules may also have discouraging patients from voicing their 
concerns. Patients sometimes initiated conversation but rarely asked direct questions of 
the doctor (on average three questions per consultation). By contrast, health 
professionals asked seventeen questions per consultation on average (ranging from I- 
69). These were mainly related to the patients' history, or formed part of examinations 
such as `ten quick questions' to test cognitive recovery. When patients did ask questions 
this was generally towards the end of the consultation after the diagnosis had been made 
and in response to information provided by professionals about diagnosis, explanations 
for what had happened and treatment instructions. In some cases the opportunity was 
used to request further investigations or a second opinion. However, patients tended to 
ask only about issues already broached by the professionals themselves. Where patients 
did attempt to discuss issues out of the usual sequence, professionals were quick to 
regain control of the consultation, redirecting it back on course. For example in 
consultation 47, the patient's wife tried to start the consultation by asking the consultant 
a question about the social services her husband had received. The consultant responded 
by saying Can I just go through things first and then you can ask questions at the end'. 
Although this approach to questioning does not in itself mean that secondary prevention 
was delivered in a `sub-optimal' way, it does support previous studies suggesting that 
patients find it difficult to participate in consultations that are governed by professional 
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routines. 301 It also demonstrates the difficulty faced by doctors in reconciling their 
professional obligation to take an accurate and detailed history, with the `patient- 
centred' need to encourage patients to become more involved in consultations. 302 
However, even when patients did manage to express a preference for a particular type of 




We ought to reduce the cholesterol a bit. 
Patient: I did come off the medication, I wanted to try and get it down with these 
margarines but... 
C2: [interrupts] No the medication actually reduces the risk 
(clinic 2-5; consultant supervision of consultation with JD3) 
In this consultation even though the patient expressed a preference to try non- 
pharmacological strategies to lower his cholesterol, medical authority ensured that that 
the professional's opinion took preference and medication was subsequently prescribed. 
6.3.1.3. Information sharing 
While it may be a policy goal for patients to take responsibility for their secondary 
prevention management, 254 professionals did not routinely appear to share information 
with patients that would enable them to understand how to prevent a recurrence. This 
may have been because professionals were desensitised to patients' needs regarding 
advice about secondary prevention management (such as informing them of operational 
aspects of health service management) and consequently did not think it necessary to 
provide such information. Alternatively it may have been as DiGiacomo suggested that 
they did not want their patients to be too `expert' since expert patients may challenge 
professional authority. 303 Blood pressure results were mentioned in passing rather than 
relayed as important information needing to be understood and retained for future use, 
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the only exception to this rule being one patient who had clinical training (clinic 1-9; 
consultation 3). Actual blood pressure readings were only discussed in half (35/68) of 
the consultations and in most cases interpretation of measurements was not given (only 
10/35). In some cases (13/68) blood pressure was not measured at all. After having her 
blood pressure checked by a doctor, one patient could not recall the result of the check 
in a consultation with the specialist nurse almost immediately afterwards. 
Nurse: what is it [blood pressure] now? 
Patient: They didn't say, they said it was higher but they didn't say 
(clinic 2-8; consultation 65) 
The patient went on to estimate that the measurement was `Between 150 and 200 over 
something? ' suggesting that the result had been provided but not necessarily 
understood. 
By contrast, the nurse may have been less constrained by medical authority when 
sharing information. She did attempt to discuss strategies to help patients to take 
responsibility for their risk management, encouraging them to ask questions about their 
blood pressure. She recommended that they find out the blood pressure measurement 
and remember it so that they could inform other health professionals who might need to 
know. She also advised some patients that they should make their own decisions about 
control and even query the doctor's judgement if it conflicted with recognised 
guidelines. 
What we recommend, the ideal blood pressure reading is no more than 145/85 whatever 
your age [she writes it on one of her secondary prevention leaflets] and sometimes you need 
to know that. This is new information, sometimes you get GPs who are old fashioned. He 
might say `that's fine' but you need to say `well I'm not happy about it! ' (clinic 2-9; 
consultation 67) 
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Encouraging patients to query medical advice might have been an appropriate strategy 
had patients been able to voice their concerns but, if GP consultation processes are as 
influenced by medical authority, it is unlikely to be feasible in practice. 
Although doctors seemed aware that newly referred patients had a lot of stroke related 
information to absorb, assumptions were made about the patient's knowledge of health 
service processes. Including about how to take tests, how to arrange appointments and 
how to gain prescriptions: 
Patient: My tablet has run out. 
Cl: You didn't think to get any more from your doctor? 
Patient: I had three tablets missing, I don't know how it works. 
Cl: I'm sorry I didn't explain it properly.... (Clinic 1-7; consultation 25) 
Medical authority may have also created language barriers to information sharing since 
professionals used technical language when giving instructions, which some patients did 
not understand. 
One such example was information provided to two patients who were required to have 
blood tests conducted in order to assess control of high cholesterol and diabetes. In 
order to interpret the results of the blood tests, the patients had needed to `fast' (not eat 
or drink anything except water for a specified period prior to the test, for example 12 
hours prior). However, when each of these patients returned for follow-up appointments 
it was clear that the instruction to `fast' prior to the test had not been understood. Since 
the patients had not fasted, they had to have blood tests repeated. In other examples the 
misunderstandings were over less technical instructions; for example the following 
patient did not realise that blood tests were conducted at a walk in clinic: 
C2:... we need the blood tests. [addresses the junior doctor] Has he had any done? 
Patient: I had lots of papers. 
C2: That was the blood tests. They're not appointments. 
(clinic 2-3; consultation 52) 
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Since he had either not been told or not understood that he should go to a specific clinic 
the patient went home to wait for an appointment. 
One possible explanation for the observed lack of information sharing is that 
professionals in their positions of authority were unaware of what information patients 
needed, how much information to provide and at what level the information needed to 
be pitched. Due to the consultation structure they had difficulty eliciting such details 
from patients themselves. 
Professionals may also have had difficulty communicating their own concepts of risk to 
the patient in a meaningful way. In the clinical literature concepts of risk tend to be 
discussed in terms of statistical probability or chance, which may be difficult to 
translate to a lay audience. 304,305 Some professionals were more comfortable discussing 
risk profiles than others, so information sharing appeared to be an individual skill. As 
with the descriptions of tests results, doctors mostly described future risks as `high' or 
`low' but sometimes backed up their predictions with statistical values or estimates of 
risk to stress the point. Such information was sometimes confusing for patients and 
when they queried what doctors meant by their explanations of risk, the explanations 
became increasingly unclear. While it may have been relatively simple to provide a 
probability estimate of population risk, it appeared to be more difficult to interpret and 
communicate such estimates in a meaningful way for the patient. 
Patient: Can you say what the risk is of having another one? 
JD4: I can't personally give you an estimate... your risk of stroke doesn't turn back to the 
same risk as before, for several years. But I can't give you a likelihood figure but it's higher 
than for the general population. If you said `do you think I will have another stroke in my 
life, or in the next 5 years' I would probably say not. But statistically you could. 
(Clinic 2-7; consultation 61) 
154 
Risk was rarely presented to patients in an `objective' fashion but instead used as a tool 
to persuade patients to engage in secondary prevention strategies or to legitimise the 
message the professional wanted to get across. In the above extract, risk discourse was 
used as negative reinforcement to frighten the patient into complying with the doctor's 
wishes. However, discussion of risk was also used as a means of providing positive 
reinforcement: 
Patient: If it carries on like this, I could have another one [stroke] tomorrow, there're no 
guarantees? 
JD2: I wouldn't say - with all these things controlled [your risk is] much reduced. You 
were smoking [quite a lot] at the time weren't you? Twenty-five a day is quite heavy. 
Patient: I know it hasn't cured the risk but it's reduced the risks? 
JD2: Oh much reduced. 
(Clinic 2-6; consultation 56) 
One mechanism for sharing information with patients is written information. There was 
a clear difference between the clinics on their policy for providing written information 
during the consultation. Professionals at Clinic 2 routinely handed out an information 
leaflet on stroke secondary prevention to their patients (published by a national stroke 
charity) but similar information was never issued during consultations at Clinic 1. It is 
difficult to explain why the policies at the two clinics differed other than that at Clinic 1, 
since more patients had been seen previously on the ward, written information may 
have been distributed at that time rather than in the outpatient clinic. However, eight 
patients attending Clinic I were newly referred and would not have received 
information previously. 
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6.3.2. Structural influences on continuity of care 
The second theme `structural influences' refers to the influence of health service 
organisation on the ability of patients and professionals to carry out recommended 
secondary prevention activities. Similar to the `system induced setbacks' identified by 
Hart, 297 many of the emerging barriers to delivering secondary prevention related to 
problems of continuity between health and social services. Three key problems 
emerged, those related to assumptions about health care as a `seamless service', those 
related to the way the specialists delivered secondary prevention advice as a `one off 
dose' and those related to the problem of multiple providers being involved in patient 
care. 
6.3.2. I. A seamless service 
Although not explicitly stated, strategies for delivering secondary prevention 
management are based on the assumption that health care is provided in a seamless 
system, with tidy overlap between different sectors. For example, in prescribing 
medication professionals reassured patients that information was shared across hospital 
and community services: 
Cl: Your blood pressure is much too high, it's not surprising as you haven't been taking 
[your tablets]. You mustn't run out. 
Patient: How do I not run out? 
C 1: Go to your own doctor. 
Patient: Does he know about it? 
Cl: Yes he does 
... 
(Clinic 1-7, consultation 25) 
Both professionals and patients discussed health care services as if continuity was 
expected. However, in some cases their experiences of care suggested that assumptions 
were misplaced. For instance information sent to other providers did not necessarily 
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lead to action, as in the case of this patient who had been referred to the addiction clinic 
to aid smoking cessation 
JD4: Are you still on cigarettes? 
Patient: Yes I am. I was supposed to be seen in the addiction clinic but they didn't send me 
an appointment (Clinic 2-7 consultation 59) 
In rare cases professionals explicitly acknowledged that there were problems with 
continuity in service provision, sometimes compensating for problems with other 
services by changing their own practice. One doctor explained (to me) that he would 
retain a patient for additional monitoring at the clinic if he felt the GP would not 
monitor them properly (Clinic 1-1). 
However, the extent to which professionals were able to compensate for poor continuity 
in services was limited by the type of problem experienced by the patient and the 
structure of services. Problems with social services were more difficult for professionals 
to address. For example, one patient who had experienced difficulty getting the steps 
outside his house adapted to enable him to get to and from his home more easily 
(influencing his ability to get prescriptions or engage in exercise to prevent stroke 
recurrence) could not be helped by the clinic professional. Since health service 
structures place housing issues outside the remit of health professionals it was not 
possible in this case for the professional to address the secondary prevention needs of 
the patient. Thus the structure of services had the ability to act as a barrier to optimal 
care, limiting professionals' abilities to address population health goals and in allowing 
them to delivered patient-centred secondary prevention. 
6.3.2.2. Multiple providers 
People with stroke often have multiple illnesses and may be cared for by different health 
care specialists. This gave professionals the opportunity to defer responsibility for 
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secondary prevention management to others. In some cases, aspects of secondary 
prevention were neglected, professionals indicating that secondary prevention would be 
addressed elsewhere. Even when patients made it clear that the advice they had received 
elsewhere was not satisfactory, their queries were not always addressed. In one 
consultation a patient previously prescribed Amlodipine (a calcium channel blocker 
which can be used to lower blood pressure or as a treatment for angina) by a 
cardiologist requested additional information about the medication. The doctor appeared 
unwilling to answer the patient's questions, saying `I don't want to get involved in the 
treatment' (Clinic 2-5). In other cases there seemed to have been an assumption that 
advice would be better provided elsewhere: 
JD I: A couple of things: you have to try and stop smoking. 
Patient: It's awful hard. 
JD I: I know but... you have had a stroke at 48. It's your only chance to stop what happened 
to your mother. If you think you want more help, talk to your GP. 
Patient: [laughs] 
Patient's wife: We'll get you a new GP. 
JDI : It's more in their realm - if you need patches or support groups. 
(Clinic 2-6, consultation 56) 
6.3.2.3. A single-dose approach 
Professionals also appeared to view secondary prevention as cumulative, being 
delivered over time in different consultations and by different professionals. If a 
particular issue was not covered in one consultation, it was assumed that the issue 
would be addressed in subsequent consultations. One doctor explained (to me) that he 
did not see providing too much or too little information as a problem since patients 
could be recalled for subsequent visits to cover aspects of secondary prevention not 
previously understood. In practice, secondary prevention advice delivered in the initial 
158 
consultation was not repeated unless the patient expressed concern that something was 
wrong. In one consultation the specialist stated upfront to the patient (and to me) that he 
did not intend to cover secondary prevention in the current consultation because he had 
covered it in their last meeting and this consultation was about a recent fall she had had. 
C 1: We went over everything last time about your stroke and what we need to do to avoid 
[another one]. (Clinic 1-3, consultation 7) 
In other words, despite the physical opportunity to make secondary prevention ongoing, 
there appeared to be an assumption that a single transfer of advice in a consultation was 
sufficient. Only if problems with management were explicitly raised would subsequent 
`doses' of advice be provided. The nurse explained how organisational structures 
promoted this single dose approach. She said that in conducting her ward consultations, 
she was required to make a record in the patient's notes if she had discussed secondary 
prevention with the patient. Having `ticked the box', the patient would not then be re- 
referred for additional advice at the stroke clinic, since it was assumed that their 
secondary prevention needs had been met in this one-off consultation. She was 
concerned that this structured referral system prevented her from ensuring her patients 
had properly understood the messages she had delivered and recounted an example of a 
patient whom she later saw regarding an unrelated matter who could not recall ever 
being given secondary prevention advice by her. 
6.3.3. Expectations of the patient role 
The third category of social influences on secondary prevention delivery relates to 
expectations of the patient role and the reactions to those who deviate from the expected 
role. In particular, expectations influenced how risk profiles were represented to 
patients, which may have helped or limited the patient's ability to engage in secondary 
prevention activities. 
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6.3.3.1. Being a good patient 
Consultations entailed the classification of patients into those who were `good' and 
those who were not. A number of studies have defined `good' patients in terms of their 
ability to act out what Parsons defined as the `sick' role. 303,306-308 Lorber defined good 
patients as those with the ability to comply with doctors' orders, 308 whilst for Jeffery 
they were those who were clinically interesting and not socially deviant. 307 DiGiacomo 
reflected on her experience of cancer treatment and suggested that being a good patient 
also involved remaining ignorant of clinical practice and not challenging professional 
judgements. 303 In the stroke clinic consultations classification was not always explicit 
but could be discerned from compliance related discourse. 
Although the shift from a compliance model of prescribing to a concordance model 
suggests mutual agreement in decision-making, 265 stroke professionals did not 
distinguish between the two concepts. Concordance was discussed as if it was just the 
latest word for compliance, as one doctor commented `I know your compliance is not 
good, I mean your concordance! ' If the doctor had felt that the patient's tablet taking 
behaviour was related to mutual agreement, then presumably he would have used the 
phrase `our concordance' rather than using the phrase `your concordance' which 
suggests that tablet taking (or lack of it) was the patient's responsibility alone. In some 
cases patients were reprimanded if they failed to comply with advice or treatment such 
as taking tablets: 
Patient's son: She doesn't take her tablets because she has had diarrhoea. She was on 
dipyridamole and Lisinopril but she wasn't taking them 
C 1: What about aspirin? 
Patient's son: The way I understood it aspirin was not recommended because of her 
stomach problem. 
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Cl: Because she was taking aspirin at the time of the attack, that is why I put her on 
dipyridamole and Lisinopril. She needs to be on a platelet drug. 
The conversation continued until the doctor came to a decision 
Cl: I think what I will do is put you back on aspirin now. If you have any more attacks or 
loss of speech come back and we will put you on other tablets. We are trying to prevent you 
having a major stroke where you can't speak ever again. You have to take it seriously - it's 
not a joke. 
(Clinic 1-6; consultation 20) 
Such reprimands are reminiscent of psychological theories of behaviour change through 
operant conditioning, 309 whereby good behaviour is reinforced with praise and bad 
behaviour chastised or punished. Some patients and their carers highlighted how 
compliant they were to the doctor, stressing their own good behaviour suggesting that 
this 'reinforcement' may have encouraged patients to follow the doctor's advice, thus 
facilitating optimal secondary prevention. 
However, there is much in the psychological literature about the limitations of 
punishment as a means to achieving behaviour change and in these consultations 
reprimands may have ultimately acted as a barrier to optimal secondary prevention since 
some patients may have deliberately withheld information from professionals for fear of 
judgement or reprimand. This was illustrated in one consultation, where a patient tried 
to withhold information about the amount he smoked and drank. Initially he reported 
that he smoked only two cigarettes and drank two cans of Guinness a day. He justified 
his apparent changed lifestyle by saying that he could no longer afford to drink or 
smoke the amount he had done previously. However, later in the consultation he 
admitted smoking and drinking more than he had earlier stated. 
Cl: Are you really only smoking 2a day with yellow nails like that? 
Patient: It was a lot worse 
C 1: How much have you had to drink today? 
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Patient: One glass of red wine today at about 12.30. 
C 1: How much wine are you drinking? 
Patient: I small bottle, only 3 glasses. 
C 1: In addition to the Guinness? 
Patient: No. 
C 1: How many cigarettes have you had today? 
Patient: Five or six. 
(clinic 1-8; consultation 30) 
Professionals expressed their frustration with patients whom they later exposed as 
having hidden information from them, through their manner and what they said. In the 
case presented above the patient's fear of reprimand was justified since the professional 
subsequently accused him of telling lies and warned him that his life would be in danger 
if he did not make more of an effort to stop smoking and drinking. 
6.3.3.2. Commitment to secondary prevention 
In addition to apportioning blame, judgements about patients' behaviour were used in 
making decisions about providing information or services, defined by Lorber as 
professional `labelling' of patients. 308 In the outpatient consultations, management 
decisions appeared to be based on assumptions about patient commitment. If the patient 
did not demonstrate enough commitment to stroke prevention then professionals were 
able to withhold further services (such as further follow-up or referral to other specialist 
services including the addiction clinic). 
Doctor: Is it was worth making another appointment for me to see you again knowing that 
you'll have to see me if you haven't given up smoking? 
Patient: yes. 
Doctor: I'll see you in 2 months. You must have given up smoking for at least a month by 
then. 
(clinic 1-5, consultation 14) 
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Whilst professionals routinely stressed the importance of stroke secondary prevention, 
some patients queried aspects of their medical care, resisting the clinician's advice or 
treatment. One patient queried being hospitalised for stroke prevention investigations 
given his family commitments and given it had taken four months to get an appointment 
at the stroke clinic: 
Patient: As far as the medication goes, I had the stroke in January and haven't been seen 
until now. I would have thought [if it was urgent] I would have been dealt with more 
quickly. I'm sorry but the urgency has gone out of the situation. 
(clinic 2-7; consultation 57) 
These differences reflect what has been described as differences between the medical- 
world view and the patient's experience310 and again highlight the conflict between 
patients' needs, wants and preferences and optimal secondary prevention practice to 
achieve public health goals. `Good' patients were happy to conceptualise their stroke 
using the medical-world view. By contrast, `difficult' patients were those who resisted 
taking on the expected role and the responsibilities associated with being a stroke 
patient (such as taking medication). Tensions appeared to exist when there was a 
mismatch in the way patients and professionals viewed the stroke experience. Previous 
researchers have suggested that patients may determine the impact of the stroke by 
evaluating it in relation to what their life was like before the stroke rather than against 
some objective measure of functioning. 119 In this study some patients found it difficult 
to come to terms with what had happened to them, even if they were relatively 
independent. 
Patient: Don't get me wrong I'm not looking for miracles, I just thought something else 
could be done. 
Cl: You can almost certainly have an aspirin tablet every day so get onto that as soon as 
possible. 
Patient: As well as the cholesterol [tablet]? 
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C 1: It doesn't matter what size or shape. 
Patient: Until now I've never taken a tablet in my life. 
Cl: [dismissively] Well I'm sorry about that. 
(Clinic 1-7; consultation 23) 
Ultimately tensions between patients and professionals may have been detrimental both 
in terms of delivering patient-centred care and in relation to optimal secondary 
prevention management. Although patients had little opportunity to voice their 
concerns, they were able to express their dissatisfaction with doctor's decisions through 
other means, including not taking their treatment. Patients might stop taking their 
medication if they felt that the drugs were potentially harmful, if they were experiencing 
unpleasant side effects from the drugs, or if they feared being stigmatised by them. 
Patient: At the moment I'm taking them [antiplatelet tablets] every day. Is it really 
necessary? ... 
It looks bad on the medical record or if you tell people'. 
(clinic 2-9; consultation 55) 
In the case of this younger patient (age 24), medication represented being ill and she 
was not happy to be defined in terms of her stroke. 
6.3.3.3. Ability to conform to the patient role 
For Lorber, a good patient is one who follows doctors' orders. 308 However, fulfilling the 
sick role in relation to secondary prevention management also meant being informed 
about stroke risk factor control. `Good' patients had developed strategies to demonstrate 
their ability to assist the doctor in developing their risk profiles such as bringing along 
their current medication in a carrier bag (clinic 1-2; consultation 5) or producing 
printouts from home blood pressure kits (clinic 1-9; consultation 34). They were used to 
the medical system, understood the `ceremonial order' of consultations, 311 including 
knowing what to do, when to speak and what to say. 
CI: How have you been keeping? 
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Patient: Fine [patient hands over some test results to the doctor] 
C 1: well your cholesterol is up a bit, I haven't chased you about that. 
Patient: It was up originally, I was allergic to statins, the GP tried 2 or 3 times and came to 
the conclusion that I couldn't successfully take statins. I can't afford to have mal-absorption 
of anti-hypertensive drugs. Since Christmas I've taken a drug called Propanolol and take an 
anti-hypertensive at 5 o' clock... 
(clinic 1-9; consultation 34) 
One reason why some patients had difficulty adopting the sick role may have been that 
they did not understand enough about health service processes, secondary prevention, or 
clinical terminology. For instance, some patients were not used to the methods of 
questioning used in consultations, making it hard for professionals to elicit the 
information they needed: 
C 1: do you take your tablets? 
Patient: yes. 
C 1: how often do you forget them? 
Patient: the tablets give me constipation. 
C 1: so you don't take them? 
Patient: I have to take them but I can't help it if [I have constipation] there's nothing I can 
do. 
Cl: that's not necessarily the case but I need to know if you aren't taking them because 
there is no point prescribing more if you don't take them most of the time. 
(Clinic 1-3; consultation 8) 
Lack of patient competencies may be explained by the lack of technical expertise that 
patients had. For example, one patient on seeing the result of the CT scan of her brain 
displayed on the wall (showing a cross-sectional image of her brain) commented, 
`You'd have to be very clever to understand that', to which the doctor replied `not 
really'. However, technical expertise was not necessarily a requirement for being a good 
patient. Some patients participated in discussions of secondary prevention without 
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referring to technical terms, using their own words to describe the drugs they were 
taking and what they were for: 
C1: Your blood pressure is the same as last time so if [the tablet is] causing you side effects 
you may as well stop it and try something else. 
Patient: the triangular ones? 
C 1: No, the other ones. 
Patient: No, I only take the triangular ones. 
(clinic 1-6; consultation 18) 
6.4. Discussion 
In this chapter I have presented research conducted as part of the theoretical phase of 
the Stop Stroke study, to investigate the delivery of secondary prevention strategies in 
the stroke clinic. Although the aim of the research was to uncover barriers and solutions 
to the problem of delivering `optimal' secondary prevention management, this was 
difficult to do through observation alone. For example it was not possible to know what 
impact the clinic activities had on risk factor control once the patient had left the 
consultation. Equally, it was not so easy to draw out recommendations for `optimal' 
management, since in some ways `optimal' patient-centred practices seemed to conflict 
with `optimal' best practice recommendations. However, if the stroke clinic is a place 
for delivering secondary prevention strategies then three types of social influences were 
identified which may act as barriers to achieving optimal care (however defined): those 
related to medical authority and the way this shapes consultations; structural barriers 
resulting from current organisation of services; and expectations of the patient role. 
Incorporating the patient's experience of illness into the consultation is a common 
characteristic of models of patient-centred care . 
258,260,299 However, this appeared 
problematic in the context of the stroke clinic where the key purpose of the clinics 
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appeared to be to provide specialists with an opportunity to form risk factor profiles of 
their patients. These were used both in understanding what had happened to the patient, 
in making decisions about the patient's future and in persuading patients of the 
importance of engaging in particular secondary prevention strategies. To ensure that 
clinically important evidence was not missed, consultations were directed in a 
standardised way with the focus being largely on the biological (rather than the 
psychological or social) aspects of stroke risk management. However, while this may 
have facilitated the profiling process it may also have limited the professionals' ability 
to incorporate the patient's illness perspective since standardisation discouraged patients 
from participating in consultations. If patients are unable to express their point of view, 
or when they do it is ignored, then this clearly presents problems for achieving patient- 
centred management. However, excluding patients' views may ultimately limit the 
professionals' ability to choose strategies appropriate for a particular patient. 
Kleinman et al., proposed a process of `negotiation' to uncover the patient's concerns in 
relation to their illness experience and mediate between the different viewpoints of 
patients and professionals. 312 However, to deviate from the standardised consultation 
format might have comprised the professional's ability to form a comprehensive risk 
profile upon which all other clinic decisions were based. Deviation from the 
professionals' area of expertise may also have presented challenges to medical status 
since on uncovering psychological or social health concerns (such as problems with 
access to community services to aid risk factor management), professionals were unable 
or unwilling to try to resolve them. 
The ability of individual health professionals to overcome the constraints of medical 
authority is likely to be limited. In this study, professionals did try to ask patients if they 
had any concerns they wished to discuss but patients rarely responded and where they 
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did, medical authority ensured the prioritisation of measurable physical or psychological 
outcomes over other aspects of health and well-being. Since even those not related to 
the health system such as researchers can have problems uncovering patient concerns 
and preferences, 313 it is not surprising that health professionals find it particularly 
difficult operating within positions of authority and would continue to find it difficult 
even if they as individuals tried to adopt a more patient-centred `style' of consulting. If 
clinicians are to identify with patients' experiences of risk management then social and 
cultural barriers need to be removed: either differences in authority between patients 
and health professionals need to be reconciled; or new ways of eliciting patient 
preferences outside of current clinical format need to be found. 
Medical authority also had an impact on the patient's ability to share in decision-making 
processes (another important component of many patient-centred care models). Even 
when patients did indicate their preferences for specific treatment options, professionals 
appeared to make few attempts to incorporate them into the decision-making process. 
The difference between compliance and concordance appeared not to be properly 
understood by professionals, who seemed to encourage patients to agree with their own 
preferences rather than to find a mutual understanding that suited both parties 
(something Jones defines as a `gift wrapped' version of compliance 264). If a shared 
consulting style encompasses recognising patient autonomy260 then the stroke clinic 
practices do not fit the patient-centred care model. Here autonomy was only supported if 
patient decisions concurred with clinical preferences. There appeared to be an implicit 
expectation that patients do what they are told, conform to a sick role and demonstrate 
commitment to secondary prevention. Yet this appeared to be at odds with the notion of 
a shared approach to decision making. Neither did professionals routinely provide 
information that would enable patients to share in decisions (the written information 
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provided by professionals at clinic two included only general facts about stroke rather 
than detailed advice to allow patients to participate in choices). Similar contradictions 
can be identified in the rhetoric of the recent UK government initiative to develop 
`expert patients'. 314 Whilst the initiative claims to be about improving the lives of 
patients with chronic disease and not about compliance, the discourse on its vision 
includes achieving public health goals, for instance encouraging patients to `use health 
promoting strategies (improving diet, exercise and weight control)' as well as using 
fewer services. Rather than being a problem of consulting style, lack of negotiation in 
consultations may reflect tensions between the concept of patient-centredness and the 
goals of risk management. In order to incorporate patient preferences, professionals 
would need to prioritise patients' concerns over and above population and professional 
priorities (including risk management), regardless of the impact of doing so on 
traditional health outcomes. 
In the outpatient setting, the relationships between the professionals and most of the 
patients were of relatively short duration making it difficult for them to develop in a 
way that could promote personalised care. Most patients were seen only once by the 
professional during the course of the study and one-off appointments such as these may 
not have been enough to develop the relationships necessary to facilitate effective 
ongoing risk management. The purpose of the consultation appeared to be to address all 
the patient's stroke needs and then discharge them elsewhere (to a GP or other 
specialist) and consequently there was little continuity, secondary prevention being 
provided by many different professionals. Although the clinic provided a centralised 
place for the identification of issues for disease management after stroke, it did not 
provide a forum for continued care or for tackling non disease-related aspects of health. 
This in turn prevented professionals from providing aspects of patient-centred care and 
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monitoring risk factors over the longer term. Patients were subsequently prevented from 
being able to successfully negotiate health services, receive appropriate risk factor 
advice and participate in decisions about their care. 
6.4.1. Summary 
The findings presented in this chapter demonstrate how qualitative observational 
methods can be used to investigate health service delivery and generate hypotheses for 
use in intervention development. This `formative' research in the stroke clinics was 
conducted to provide a better understanding of the process of delivering secondary 
prevention strategies, highlighting problems with medical authority, service structures 
and expectations of patients implicit within current practice. Depending on how 
`optimal management' is defined these processes may act as barriers to public health 
goals for optimal risk factor control or barriers to patient-centred care. Exactly how 
these findings influenced the development of the Stop Stroke intervention will be 
investigated in subsequent chapters. 
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Chapter 7. The MRC Framework in Intervention Development 
In this chapter I present a description of the Stop Stroke intervention package and its 
development (the modelling and exploratory trial phases outlined in the MRC 
Framework). The focus of the chapter is on understanding how the concept of the 
intervention and its components were developed. We have already seen the findings 
from some of the theoretical work conducted to inform intervention development and in 
this chapter I explore the extent to which the intervention was theoretically grounded. 
This in turn provides an insight into factors and processes that might influence the 
eventual success or failure of the intervention. 
7.1. Introduction 
Development of the intervention began in 1999 when the protocol for the study was 
accepted for funding and continued until July 2003 when the main RCT started. 
Development during this time period is presented in this chapter. Funding for 
intervention development was provided by a UK national charity, The Stroke 
Association, in the form of the first five years of a 10-year programme grant, totalling 
£251,271. This covered funding for a junior research associate (JR for the first three 
years) and research costs. The first two years of funding were allocated for theoretical 
work and intervention development; the remaining three were allocated for the main 
RCT evaluation, although in practice, the RCT did not start until year four. 
The methods for this chapter are presented in Chapter 4, section 4.4. To summarise, 
participant observation was conducted from the start of the development phase with 
detailed field notes taken on interactions between staff, correspondence and meeting 
minutes collated and analysed thematically. The results are divided into four sections: 
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development of the intervention concept; development of the intervention components; 
the exploratory trial; and a discussion of the development process. 
7.2. Participants 
A multi-disciplinary group was involved in the development of the intervention with 
diversity in discipline and skill mix. They included a core group involved throughout 
the four years of development, with others participating in an ad-hoc manner at different 
stages of the development process (Table 10). 
7.2.1. The core investigators 
The core group of investigators included the principal investigator, a clinically trained 
senior researcher in public health medicine with a special interest in stroke (PI); two 
other key investigators: a social researcher with a background in social anthropology 
and an interest in stroke illness (II); a senior stroke physician (12); and a junior 
statistician (later promoted to senior level SS 1). All had previous experience of working 
on at least one complex RCT study. Although I was not one of the original 
investigators, I feel that I was still part of the core group since I was involved in the 
study almost from its conception and was involved throughout the first four years of 
theoretical phase research and intervention development. I had an MSc in health 
psychology and several years' research experience but no practical experience of 
complex intervention development or RCT evaluation. 
7.2.2. Advisors during the theoretical phase 
During the first two years of development the core investigators were supported by a 
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support was provided by a steering group. This included two senior nursing researchers 
(NI, N2), two clinical professors of stroke medicine (PSI and PS2), a GP (GPI), a 
senior statistician (SS2) and a clinical public health specialist (PHSI). The steering 
group met on two occasions, once after a year of the study in August 2000 and a second 
meeting when the shape of intervention was proposed in April 2001. 
7.2.3. Advisors during the latter stages of intervention development 
Once the intervention had been designed, a second steering group was formed. This 
steering group was responsible for advising on matters relating to the main RCT 
evaluation but also had some input into intervention design (at the steering group 
meeting held in 2003 before the start of the trial). This group included the senior 
statistician from the previous steering group (SS2); two GPs, one who was head of one 
of the local primary care trusts (GP2) and one who had a particular interest in stroke 
(GP3); an expert in speech and language difficulties (SL); and a senior clinical public 
health specialist (PHS2). 
7.2.4. Investigators involved in the modelling and exploratory trial phases 
During the modelling phase additional people became involved in the intervention 
design. A public health trainee was employed with responsibility for evaluating written 
materials produced for part of the intervention and for conducting the exploratory trial 
(PHT). Two staff, a trial coordinator (TC) and a research assistant (RA) were employed 
to work on the main RCT but also contributed in the development phases: the TC was 
involved in administrative aspects of setting up the trial; the RA was involved in 
evaluating patient information literature. Neither the TC nor the RA had any previous 
experience of working on a RCT. The TC had previously worked as a programme 
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coordinator at a London business school. The RA had no previous research experience 
but had received research methods training from her MSc in health psychology. 
The remaining staff involved in intervention development all worked on other projects 
within the stroke team. These included two statisticians (JS3 and JS4), five junior 
doctors (SPRI, SPR2, SPR3, SPR4, SPR5) and three non-clinical staff (NC1, Adminl 
and FUPI). A third statistician who was not a member of the stroke team (US) also 
provided advice during the modelling phase. He had special expertise in cluster RCT 
methods. Table 10 summarises the staff participating in intervention development. 
7.3. Developing the intervention concept 
According to the MRC Framework, the design of the intervention should have emerged 
from theoretical phase findings. But while theoretical phase findings did guide aspects 
of intervention development, in practice, design was also influenced by other factors. It 
was clear from the timeline of events that the key investigators already had ideas about 
the shape of the intervention even prior to the start of the theoretical phase, meaning that 
intervention development was not strictly an `inductive' process. 315 
7.3.1 Synthesising theoretical phase findings 
The first part of the theoretical phase involved conducting a literature review to 
investigate previous multiple risk factor interventions in chronic disease, 124 but it was 
decided at the outset of the study, that the intervention would not involve placing 
another individual (such as a nurse or support worker) into the health system. Recent 
published studies of such interventions suggested that they had limited efficacy 251,252,316 
and there was no evidence that placing additional health professionals into the system 
would necessarily solve the problems of coordination between primary and secondary 
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care, or reach those patients who did not currently access services. Creating an 
intervention based on one individual also had resource implications for rolling out the 
intervention if it proved successful. 
The theoretical phase of intervention development was conducted between March 1999 
and April 2001. In addition to the theoretical work already discussed (literature review, 
qualitative investigations and SLSR analyses), 34,214,215 an investigation of patient 
information literature was conducted (unpublished). At this stage, analysis of qualitative 
data was limited by time and cost. Since only one year's funding had been allocated for 
completion of all four components of the theoretical phase, it was not possible to 
conduct a thorough theoretical analysis prior to the development of the intervention 
itself. Instead a rapid assessment was conducted. 317 As the researcher on the project, it 
was my responsibility to collate findings from each part of the research phase and to 
compile a list of facilitators and barriers to secondary prevention. For each barrier I 
suggested a number of potential solutions, which were then presented to the other key 
investigators for consideration. Our aim was to define a potential intervention, which 
could tackle the multiple barriers to secondary prevention. 
Although data collection was still ongoing, initial findings suggested that barriers to 
secondary prevention were multiple (see Chapters 5 and 6) relating to individual factors 
(patient and professional conceptualisation of stroke secondary prevention and poor 
communication of secondary prevention advice); and organisational factors 
(organisation of stroke services, lack of coordination between primary and secondary 
care). Preliminary theoretical phase findings suggested that an intervention focusing on 
one specific problem such as the coordination of care would be insufficient. To improve 
risk factor management for all stroke patients the findings suggested that an intervention 
with multiple components was required, one that would promote an understanding of 
178 
stroke as a chronic disease and be tailored to account for each individual patient's 
secondary prevention needs and experiences. 
7.3.2. Using the SLSR as a tool for intervention 
The decision to make use of the SLSR, 17 the team's ongoing population register of first 
in a lifetime strokes, as a tool for intervention was made early on in the intervention 
development process. The initial suggestion was presented by the PI at the first steering 
group meeting in April 2000 mid-way into the theoretical phase. Although the 
theoretical phase did not drive the decision, since the SLSR was an ongoing resource for 
identifying stroke patients and following them up at multiple time-points, the core 
investigators felt that it could potentially be adapted as a mechanism for delivering 
secondary prevention. 
In March 2001 an experimental phase started. I began to design an outline of a 
secondary prevention plan for patients that could contain individualised risk factor 
information from the SLSR. The design was a single sided A4 sheet listing the 
individual patient's risk factors. The list included those risk factors that the clinicians 
considered to be most important for preventing a future stroke. At the same time, 
collaborative talks were conducted with a team in another academic department who 
had created software to provide similar information for GPs about their patient's 
diabetes (Diabeta-3). 318 The possibility of linking with Diabeta-3 was discussed but it 
was decided that the Stop Stroke intervention should stand alone since there had been 
problems of uptake of the Diabeta-3 computer software in GP practices. In the case of 
stroke where each GP only saw 1-2 patients per year, the software appeared impractical. 
At the second Stop Stroke Programme steering group in June 2001 the collated findings 
from the theoretical phase were presented together with a proposal for the intervention 
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itself drafted by the key investigators and me. It was agreed at the meeting that the 
intervention would `dovetail' with the SLSR and target both patients and professionals. 
Tailored secondary prevention plans (derived from SLSR data) would be produced and 
delivered to patients and carers. In addition, the patient's GP would receive a plan 
tailored to their patient, together with academic visits from expert clinicians319 (the lead 
stroke physician and the PI) providing information on the intervention and local stroke 
issues. Data collected by the register (clinical, socio-demographic and service data 
related to the stroke) would be transformed to provide an individualised secondary 
prevention package for patients, carers and health care professionals at three time points 
post stroke. The aims of the intervention were four-fold: i) to make the screening of risk 
factors and delivery of secondary prevention advice ongoing, encouraging patients and 
professionals to conceptualise stroke as a chronic disease rather than an acute event; ii) 
to standardise the delivery of secondary prevention advice to ensure that all patients 
have access to secondary prevention treatment and advice and that it is provided at a 
time when it is likely to be salient; iii) to standardise the content of secondary 
prevention advice so that it is evidence-based and less influenced by professional 
preferences or priorities; iv) to tailor the amount of advice provided to the patient and 
individualise the content so that it is personalised and relevant to the individual. The 
intervention not only fitted with the skills and priorities of the research team but also 
with current public health priorities targeting stroke and with recommendations in the 
new GP contract that general practices should keep chronic disease registers for their 
patients. 320 Figure 3 presents a diagram of the intervention process. 
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Figure 3. The intervention process. 
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Patients & Carers Primary care team 
1 
Distribution of manaqement plans and information sheets 
The intervention process involves five key stages: (i) recruitment to the SLSR; (ii) data 
entry; (iii) transformation of data to intervention plans; (iv) distribution; (v) follow-up. 
Stage (i) involves identification of potential stroke patients through phoning 
`notification sources', assessment by a clinical researcher to ascertain stroke diagnosis 
and collection of data on clinical, socio-demographic and health service factors relating 
to the stroke. Stage (ii) involves manually checking SLSR data collection forms for 
errors, entering SLSR data onto the computer and using computer processes to further 
crosscheck data for errors. Stage (iii) involves using computer algorithms to transform 
the SLSR data into individualised secondary prevention plans for patients, carers and 
the primary care team. The plans included details of the individual patient's risk factors, 
together with evidence-based advice on appropriate management. Patient plans include 
instructions on what to do to improve secondary prevention and detailed advice on their 
own specific risk factors and treatments. GP plans included individualised information 
on their patients' risk factors and the relevant RCP guidelines on best practice. 
Examples of patient and professional plans are presented in Appendix 7. In stage (iv) 
plans are distributed to patients and carers and the primary care team. In stage (v) 
patients are followed up at three and six months post stroke by the SLSR team to collect 
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additional data, develop and distribute new intervention plans to reinforce the messages 
delivered in the initial plan. 
7.3.4. Time and place for intervention delivery 
Ideally, to meet the recommendations of the theoretical phase, the intervention needed 
to be delivered at the time point most relevant to patients. Currently, secondary 
prevention appeared to be delivered when the patient was in hospital (at a time point 
close to when the acute event had occurred) but evidence from the theoretical phase 
suggested that this was not necessarily the most appropriate time or place". As 
discussed in Chapter 5, patients may have had other priorities at this time such as 
focusing on recovery and getting home. However, since the intervention was to be 
designed using the SLSR and the SLSR used designated (academic and practical) time 
points to collect information, it was not possible to collect data or deliver the 
intervention at a time point dictated by each individual patient. 
The theoretical phase findings (from the literature review, patient interviews and clinic 
observations) also suggested that the time when such information was likely to be 
relevant to most patients was after discharge from hospital. While patients were in 
hospital they and their community health professionals had little control over secondary 
prevention strategies but on discharge, responsibility was shifted to the individual 
patient and to community services. It was hypothesised that if the intervention was 
delivered at multiple time points after discharge then one of these time points would 
hopefully be a relevant time for patients to focus on secondary prevention and to receive 
the information. Again, ideally to meet the recommendations of the theoretical phase, 
"` My own preliminary analysis of SLSR data suggested that only approximately 14% of patients reported receiving written advice about their stroke either because it had not been provided, or they could not remember receiving it, indicating that current methods of delivery were inadequate. 
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the intervention would have been designed to deliver secondary prevention plans on 
discharge and then at three months and six months post discharge. However, since the 
SLSR collected information at time points `post stroke' rather than `post discharge', the 
ideal delivery time points were modified so that the intervention was delivered at three 
and six months post stroke. 
There was considerable debate within the Stop Stroke team about the most appropriate 
place to deliver the patient component of the intervention, whether to deliver it to the 
patient in hospital or to send a package to the patient's discharge address. The lead 
stroke clinician was keen that the intervention be delivered to patients in hospital so that 
health professionals could explain any information provided in the secondary 
prevention pack. He felt that this would add weight and credibility to any advice 
provided as well as allowing the professionals to monitor what advice their patients 
were being given. However, as an investigator I raised a number of concerns about 
hospital professionals being involved. Delivering the intervention in hospital conflicted 
with my own analysis from the theoretical phase, which suggested that any advice 
would be better provided after the patient had returned home. Equally, the intervention 
was to be evaluated in a RCT and I was concerned that since hospital staff would be 
treating patients in both arms of the trial, there was possibility for contamination of the 
control arm. I was also concerned that hospitalised patients in the intervention arm 
would receive a slightly different intervention: both a written package and counselling 
from health professionals; whilst non-admitted patients would receive only the written 
package. This did not seem consistent with RCT methods and might make it difficult to 
define the replicable components of the intervention. These concerns were discussed 
amongst the team who concluded that different methods of delivering the intervention 
should be investigated further in the exploratory trial. 
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The two alternative methods for delivering the intervention (in hospital versus postal 
delivery) were tested by the PHT responsible for the exploratory trial. Her testing 
revealed a number of practical problems in providing the intervention to patients in 
hospital. Firstly, it was difficult to predict exactly when patients were to be discharged 
from hospital, making it problematic to obtain the necessary information and deliver the 
intervention before the patient left. Some of the information such as ongoing medication 
was not prescribed until the point of discharge. For a combination of reasons, 
theoretical, methodological (relating to the RCT) and practical, the PHT recommended 
that all plans would be sent to the patient at their discharge address. 
The influence of RCT methods had a further impact on the theoretical grounding of the 
intervention in March 2003 when the decision not to deliver the intervention to patients 
in hospital was reversed by the Pl. With the current protocol, patients who had not been 
discharged from hospital at a given time point would not be eligible to receive the 
intervention package meaning that some patients would receive different `doses' 
compared to others (if the patient had not been discharged at 6 weeks post stroke they 
and their GP would receive only two `doses' of the intervention; if they had not been 
discharged by 3-months they would receive only one dose of the intervention and if 
they were still an inpatient at 6-months they would receive nothing). The PI felt that if 
some patients did not receive all three doses they would essentially be receiving a 
different intervention and thus it would be difficult to identify the active components 
when generalising the intervention elsewhere. To make the intervention more robust, he 
decided that it was necessary to deliver the intervention both to those still in hospital 
and those who had been discharged. In consultation with the SLSR field workers 
(clinical and non clinical) and statisticians, the core investigators decided on a six-week 
cut-off time point for intervention delivery, that is if the patient had not been discharged 
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from hospital within six weeks of their stroke, the intervention would be delivered to 
them in hospital. The six-week time point was chosen since the SLSR field workers felt 
that of those discharged from hospital, the majority were discharged within this time 
period. 
7.4. Developing intervention components 
Having decided on the intervention concept, the next stage involved developing 
individual components (data collection and data management methods, computerised 
system for transforming data into secondary prevention advice, patient and professional 
information, method of delivery). As noted in Chapter 1, in 2000 the RCP published 
evidence-based guidelines on best practice in stroke management. 27'33 The guidelines 
included a section on secondary prevention outlining the key risk factors and treatments 
for those risk factors. The guidelines were primarily targeted at health professionals but 
also included a `lay' section designed for patients. The PI suggested that these should be 
used to guide the different aspects of patient and GP intervention components, that is to 
guide decisions about what constitutes appropriate secondary prevention and what 
advice should be provided to patients and professionals. 
Three main tasks were required in designing the intervention components: i) 
development of computer algorithms to evaluate individual patient data and define 
appropriate steps for management, ii) adaptation of the SLSR to collect and process 
data, iii) development of patient and professional information literature. 
In the original proposal, in addition to the secondary prevention plans, academic 
detailing visits by stroke experts had been included as one of the intervention 
components. There was some evidence from the literature that education provided by 
clinical specialists could influence GP prescribing behaviour, particularly when coupled 
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with social marketing strategies. 319 The nature of these visits was not clearly defined but 
academic detailing has been defined in the literature as educational outreach visits to 
providers in their own setting (for example the GP practice). 319 In the Stop Stroke 
intervention the detailing component involved a member of the team (the PI, lead stroke 
physician or junior doctor) visiting GP practices in the intervention arm. These visits 
were used for multiple purposes including: introducing the intervention; introducing the 
new RCP guidelines; providing information about the SLSR; and about local stroke 
services including the recently developed neurovascular (or TIA) clinic. 
7.4.1. Developing a computerised method of transforming SLSR data into individualised 
advice 
As previously discussed, initially the investigators considered linking in the current 
intervention with previous attempts at `computerising' chronic disease management 
such as Diabeta-3318 (a new computer software package for GPs to enable them to 
monitor diabetes risk factors). However, since the SLSR and most GP practices were 
already computerised we (the investigators) felt that the computerised system for Stop 
Stroke needed to utilise these existing systems rather than create new ones. I proposed 
using current data and analysis software for the SLSR (Epidata, Microsoft Excel and 
STATA) to input patient data and evaluate patient's secondary prevention. This would 
then be linked to a word processing package such as Microsoft word), which would be 
used to produce patient and professional secondary prevention plans using the `mail 
merge' facility. 
In July 2001 I drafted a proposal for the development of a computer system to turn 
SLSR data into hard/electronic copy secondary prevention plans (Appendix 8). 1 had 
experimented with the SLSR dataset used previously to examine socio-demographic 
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patterns in behavioural risk factor management in the theoretical phase and found a 
method of combining SLSR data with a cover letter (using the word processing mail 
merge facility) to produce an individualised plan. My initial estimated timeframe for 
development was four months. In practice, although this initial design was completed 
within the time frame, the final computer system for the intervention took a further year 
and a half to complete and needed ongoing refining once the intervention was 
implemented. 
The computer system used SLSR data exported from Epidata (a data entry software 
package) and read into STATA (a statistical package) for analysis. A series of data 
checks were designed to take place before the analysis started. These included checking 
serial numbers, dates of birth and dates of stroke from different files, to ensure that data 
from each file were merged for the correct patient. Commands were also designed to 
conduct preliminary data cleaning (to check dates and ages to ensure they were within 
range; to recode missing data). Finally when all the data were `clean' the computer 
system used a series of algorithms to define and analyse the patient's risk factors, to 
produce statements about their current secondary prevention management and to 
generate instructions for patients on how to improve management. The algorithms 
worked by sequentially examining SLSR data for each risk factor and each patient to 
calculate whether the patient had the risk factor and if so how well it was being 
controlled. Initially a decision was made to focus on the patient's three most important 
risk factors. The lead stroke physician suggested that patients might become over- 
burdened with information if they were given information on more than three risk 
factors and certain risk factors (high blood pressure, diabetes) were felt to be more 
important than others (lack of exercise, diet). However, once testing of the intervention 
started, it became clear that many patients had more than three risk factors for which 
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they were receiving treatment. I was concerned that patients might become confused if 
references to stroke medication did not include all their treatments. By limiting the 
advice to only three risk factors some important risk factors might be excluded (for 
instance a patient might have atrial fibrillation, diabetes and hypertension in which case 
their smoking behaviour would not be discussed). The investigators agreed and 
subsequently the algorithms were redesigned to produce information on all risk factors. 
The computer algorithms were designed using the RCP evidence based guidelines and 
expert consensus. The definitions of risk factors derived from these sources are 
presented in Table 11. 
Patient information on stroke type and risk factors was designed to provide a definition 
of the risk factor and an explanation of the relationship between having the risk factor 
and strokes. For those without clinically defined high levels of blood pressure or 
cholesterol, alternative information was designed explaining relationships between 
blood pressure or cholesterol and stroke. 
7.4.2. Defining appropriate management and instructions for patients 
The aim of treatment advice was to provide patients with statements on management 
relevant to their own risk factors but standardised across patients with the same risk 
factors. Although evidence based guidelines were used to help define appropriate risk 
factor control, guidelines alone were not sufficient to define patient instruction. In some 
cases recommendations were too ambiguous or were unable to answer the questions 
patients had raised as being important to them (for example failing to define terms such 
as `heavy' drinking or `healthy' diets). There was a lack of consensus amongst authors 
of different guidelines as to which risk factors needed to be targeted for optimal 
secondary prevention (not all included alcohol use as a risk factor and different 
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Table 11. Risk factor definitions used in computer algorithms. 
Risk Factor Diagnosis 
Hypertension: Patients were considered hypertensive if they had a diagnosis of hypertension 
prior to stroke, if they had a previously recorded blood pressure of > 140/85, if 
they were diagnosed with hypertension in the 6 months post stroke or if their 
blood pressure measured at 3 months and 6 months post stroke was > 160/85. 
Patients not diagnosed as hypertensive were considered to have `normal' blood 
pressure even if they were prescribed blood pressure lowering medication. 
Atrial Atrial fibrillation was diagnosed if an ECG confirmed that they were in atrial 
Fibrillation: fibrillation at the time of stroke or if they had a diagnosis of atrial fibrillation in 
the first 6 months post stroke 
Diabetes: Patients were diagnosed as diabetic if they had a recorded history of diabetes 
prior to the stroke or were subsequently diagnosed with diabetes whilst in 
hospital or within the first 6 months of stroke 
High Patients were diagnosed with high cholesterol if they had a recorded cholesterol 
cholesterol: of>5mmL prior to stroke or a previous history of high cholesterol, or if they 
were diagnosed in the first 6 months post stroke. Patients not defined as having 
high cholesterol were considered to have `normal' cholesterol even if they were 
prescribed cholesterol-lowering medication. 
Smoking: Patients were diagnosed as smokers if they were smokers at the time of stroke or 
reported smoking any tobacco, cigarettes or cigars within 6 months of the stroke 
Heavy alcohol Patients were diagnosed as drinking heavily if their total weekly alcohol 
use: consumption at the time of stroke or in the first 6 months post stroke was greater 
than 28 units or alcohol a week for men or 21 units a week for women. 
Obesity: Patients were diagnosed as being obese if their body mass index (BMI) was 
greater than 30 at the time of stroke or within the first 3 months post stroke. 
Stroke type: The patient's stroke type was confirmed by a CT scan at the time of stroke. 
Patients were divided into two types, ischaemic and haemorrhagic strokes. 
guidelines included different levels of blood pressure requiring treatment). Some of the 
evidence underpinning the recommendations came from studies of primary stroke 
prevention rather than secondary prevention33 and it was assumed that the findings 
could be transferred (for example that exercise, diet, weight loss, smoking cessation and 
reduction of added salt would be beneficial even after a stroke to prevent a recurrence). 
Recommendations also changed quite dramatically in the early stages of development 
with new evidence emerging on the appropriateness of different medications (in 
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particular HOPE, PROGRESS and The Heart protection Study looking at the efficacy of 
antihypertensive and lipid lowering drugs for those without particularly high levels of 
blood pressure or cholesterol321 323) 
Table 12 lists the different risk factors prioritised in four different guidelines: The 
RCP; 33 the European Stroke Initiative Guidelines (ESI); the National Service 
Framework for Older People (NSF)26 and the British Hypertension Society Guidelines 
(BHS). 324 
Table 12. Risk Factors Prioritised in 4 different Evidence Based Guidelines. 
Risk factors included Guidelines 
Antiplatelet therapy 








RCP ESI NSF 
RCP ESI NSF 








RCP: Royal College of Physicians 
ESI: European Stroke Initiative 
NSF: National Service Framework for Older People 
















In order to clarify these inconsistencies, I gave a short questionnaire to six clinicians 
with a special interest in stroke to gain a consensus of opinion. Questions included: how 
should appropriateness for medications be defined and what are the contraindications 
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for medication? How should hypertension and high cholesterol be defined? Are 
pipe/cigar smoking risk factors? How should alcohol use be measured and how is heavy 
drinking defined? How should obesity, poor diet and physical activity/inactivity be 
defined and what advice should people with these risk factors be given? Their answers 
were varied and there was no clear consensus over what advice should be provided to 
help patients with diet, exercise or losing weight. For example, one doctor simply 
suggested "eat less and do more exercise" to lose weight. Where no clear consensus was 
achieved, I developed definitions in consultation with 11 using a combination of the 
clinicians' responses, published evidence, health promotion advice and government 
recommendations. 
Risk factor treatment was categorised into three types, surgical, medicinal and lifestyle. 
Some risk factors such as hypertension could be treated either with medication or 
through lifestyle intervention (such as dietary change) or using a combination of both. 
Surgical interventions were not included, the focus being on the main lifestyle and 
medicinal interventions (blood pressure lowering, cholesterol lowering, smoking 
cessation, diabetes management, alcohol moderation, use of antithrombotics, diet and 
exercise). Definitions of those appropriate for the intervention and appropriate advice 
are given in Tables 13 and 14. 
In developing instructions for patients, as an intervention developer, I felt that it was 
important to allow for the possibility that the information collected was incomplete or 
inaccurate. The algorithms were designed to standardise patient information but certain 
patients might be unusual and not fit the appropriateness criteria. Therefore statements 
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treatment regime unless problems were identified, in which case they were 
recommended to visit their doctor for a check up. Patients were not recommended to 
stop their treatment even if (according to the algorithms) the treatments appeared to be 
inappropriate. In such cases the primary care plan would alert the GP if medication was 
thought to be contraindicated. 
Having defined patients' risk factors and produced statements on appropriate 
management, computer programmes were designed to merge the SLSR data with 
patients' names and addresses. Prior to merging, patients' personal details such as name 
and address were stored separately from clinical data at all times and only merged with 
the clinical data to produce the hard copy plans. This ensured data protection 
requirements were fulfilled. The merged data were then imported into a Microsoft Word 
mail merge letter template. Each exported variable formed a `field' in the letter template 
or was used to create a text statement giving particular instructions. Thus individual 
patient data was slotted into standard letters and tables. 
With the system for producing individualised secondary prevention plans now 
computerised, in theory intervention distribution needed only administrative skills to 
enter the data, process the algorithms, print off the finished plans and post/deliver them 
to patients and professionals. 
7.5 Adaptation of the SLSR 
The original aim of the SLSR was to collect stroke incidence data in a defined area of 
south London and to collect clinical, socio-demographic and health service data for 
clinical and social research studies within the team. However, for the purposes of the 
intervention some of the SLSR processes were not sufficient. Additional questions 
needed to be designed to enable collection of specific risk factor data (for example 
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questions on behavioural risk factors such as smoking, alcohol use and diet needed to be 
added). A completely new data collection time point (the six-month follow-up) needed 
to be put in place and the procedures for collecting and managing data needed to be 
revised, all without impacting on the existing data collection for the SLSR since it and 
its dependent projects were research studies in their own right. 
One of the key challenges for adapting the SLSR was addressing the timeframe for data 
collection and analysis. Existing time frames were relatively flexible (for example data 
did not need to be entered onto the computer until it was needed for analysis at a later 
date and a batch system was in operation for doing this). However, for the purposes of 
the intervention, data collection and analysis processes needed to be `real-time'. In the 
first stages of development, the intervention was designed using a separate data entry 
system. The intervention needed to use only a fraction of the total data collected by the 
SLSR and having a separate data entry system speeded up data processing and made 
data cleaning a simpler task. It was this system that was tested in the exploratory trial 
phase described in the next section. However, in January 2003 the PI proposed that data 
entry and processing should be carried out using existing SLSR data entry processes. He 
felt that a separate intervention data entry system was not practical (since some SLSR 
processes such as data entry would be duplicated) and that using existing processes 
would make the intervention more generalisable to other chronic disease registers. 
I held discussions with the SLSR statistician and the TC to investigate the possibility of 
using the SLSR data entry system. The conclusion was that making SLSR data entry 
`real time' was not possible. The SLSR protocols and practices had developed over 
nearly eight years and the team met proposals to change established practices with 
resistance. As the sole person responsible for creating the computerised component of 
the intervention, I also resisted this decision. The programmes already developed would 
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need to be considerably changed to operate with an alternative data entry system but this 
aside, changing the system meant that responsibility and control over the data would be 
passed from the smaller Stop Stroke research team to all those involved in data 
collection and processing for the SLSR. This increased the potential for error. To 
illustrate the advantages and disadvantages associated with each method I made a list 
with the aim of convincing the investigators and the SLSR staff that that the 
disadvantages of merging data collection outweighed the advantages (Table 15). 
Table 15. Advantages and disadvantages of using established SLSR protocols to 
process data. 
Advantages: 
Separate data entry 
Tidy and less room for error. 
Ready to implement. 
Is independent of future changes made 
to SLSR systems. 
Does not require stats support. 
Combined data entry 
Speeds up the SLSR data entry system 
- improvements for other studies. 
Does not require specific data entry 
person for Stop Stroke 
Disadvantages: Data are entered twice. 
Some SLSR data required for the 
intervention were not currently entered 
onto the SLSR. 
Requires a person on the SLSR to take 
specific responsibility for Stop Stroke. 
Requires a dedicated real-time data 
entry person. 
If a backlog of data entry occurs the 
intervention will fail. 
Data will need to be entered at many 
time points. 
Data entry is "messy" - more room for 
error. 
Stop Stroke programmes need to be 
re-written. 
Three systems were proposed: system one involved separating data entry for the SLSR 
and for the intervention; system two involved combining data entry for the two systems; 
and system three involved a combination of separate data entry for the initial time point 
(when turnaround is most urgent) and combined data entry for the follow-up time 
points. The main advantages of the combined system appeared to be the overall 
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improvements this would have for studies linked to the SLSR and the lack of replication 
in duties between studies. The main disadvantages were the potential for loss of 
ownership, lack of clarity of responsibilities for different studies and problems with 
existing systems such as the current backlog in data entry. In reflecting on my own 
agenda, it is also important to note that having developed a functioning intervention, I 
felt protective over Stop Stroke and did not want to lose ownership or see the problems 
associated with managing larger SLSR processes affecting the efficacy of the 
intervention. However, at the next meeting in February 2003 the decision to use only 
the SLSR data entry system had been finalised by the PI and other SLSR members and I 
never found the opportunity for proposing the alternatives. 
To address some of the difficulties in adapting existing data management processes to 
meet the needs of the intervention, JS2 proposed splitting the data collection form for 
the initial data collection (the most difficult form to complete and return in the 
designated time frame) into four sections so that the data needed for the trial (in the first 
three sections of the form) could be prioritised and so that data which were difficult to 
collect quickly (such as test results not relevant to the intervention) would not delay 
data processing. 
7.6. Developing patient and professional information literature 
7.6.1. Professional information literature 
Although the professional secondary prevention plan was sent to the patient's GP, the 
aim was for the information to be made available to all members of the primary care 
team (since many practice nurse or other practitioners involved in health promotion 
might take responsibility for secondary prevention). The trial steering group stressed the 
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importance of focusing on the team as a whole and not just the GP. A covering letter 
accompanied the intervention package explaining what the pack included and who it 
was for. It encouraged GPs to file the patient information with practice data on the 
patient. The professional intervention (Appendix 7) consisted of a single page plan with 
a table listing stroke type and the six main risk factors for stroke (hypertension, atrial 
fibrillation, diabetes, high cholesterol, smoking, heavy alcohol use and obesity). At each 
time point the individual patient's risk factor status, test results and pharmaceutical 
management were inserted together with any contraindications to treatment and 
patients' reported attempts to change risk factors (such as attempts to lose weight or 
give up smoking). Individual patient data were located next to the relevant RCP 
guidelines on stroke secondary prevention (for example patient's hypertension status, 
last recorded blood pressure result and antihypertensive medication prescribed were 
positioned next to the guideline on managing blood pressure). The PI had met with a 
manager at the local PCT who had recommended we incorporate GP read codes (codes 
compatible with diagnosis used in current practice software) into the package so that 
GPs could easily transfer the information to their own computerised databases. Where 
appropriate, GP read codes were inserted next to risk factors and treatments. For non- 
computerised practices the single sided sheet was designed so that it could be folded 
and stored in the patient's notes. Both patient and professional plans were printed on 
coloured paper, yellow at the initial time point, green for the three-month time point and 
peach for the six-month time point. This was so that the plans would stand out, also 
hopefully to encourage recipients to see that each plan was different. 
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7.6 2. Patient information literature 
The patient information literature was developed by II and me, drawing on findings 
from the theoretical phase and the RCP professional guidelines (in practice the RCP lay 
guidelines were not detailed enough to develop information literature). The aim was to 
develop information that would be evidence based but also, would: a) address the needs 
of patients; b) be tailored to the individual patient; and c) be accessible. Development of 
the patient plans was more complicated than the professional plan since it was expected 
that there would be more diversity in patients' baseline understanding of stroke 
secondary prevention. The intervention needed to provide enough information to satisfy 
those who wanted to know about their risk factors in detail but without being too 
technical for a non-clinical person to understand. 
Il and I decided that in order to provide enough detailed information, patient advice 
would be provided in two parts, an individualised part (single page letter containing a 
table detailing the individual patients' risk factors, Appendix 7) and a standardised part 
(a series of numbered information sheets containing more detailed information on 
specific risk factors and management strategies, Appendix 9). However, even with the 
standardised information, each patient would receive only the sheets relevant to their 
individual risk factors. 
Content of the individualised plan included diagnosis of risk factors, test results, 
summary of previous and current management and tailored instructions on how to 
improve preventive management. The plan also referenced the relevant information 
sheet numbers so that patients would know where to find additional information. 
Twenty-one standardised information sheets were developed in total covering stroke 
type and the six main risk factors and their management. With changing evidence on the 
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appropriateness of pharmacological treatments the system needed to be able to adapt to 
changes in best practice (for example sheets on blood pressure and cholesterol for those 
without hypertension or hypercholesterolaemia were introduced just prior to the start of 
the trial). Five sheets focused on the pharmacological management of future stroke risk: 
aspirin; dipyridamole and clopidogrel; warfarin; blood pressure lowing medication; and 
cholesterol lowering medication. Six sheets were designed focusing on lifestyle 
management: diet for non-diabetics; diet for diabetics; exercise; smoking cessation; and 
separate alcohol use sheets for men and women. We aimed to make each sheet a 
maximum of two sides of A5, which would be laminated to protect it from wear and 
tear and to encourage patients not to throw it away. Readability of patient information 
literature was an important consideration in the design of the sheets. It was hypothesised 
that readability would be influenced by a number of factors including format, layout, 
organization, font size and use of graphics. 325 Guidelines were followed to design the 
format and style of the information incorporating pictures, using text boxes and 
headings to break up the text. 326 Since the average age of stroke patients is 70 years and 
many older people have difficulties with sight, attention was focused on text size. 
Consequently, all sheets were designed with text no smaller than Arial size 16 so that 
even those with some sight difficulty would be able to see the text. 
The reading level of the patient information was tested using a SMOG test (simple 
measure of gobbledygook 327) by the public health trainee (PHT). The test focused on 
sentence length and number of syllables per word to calculate the average reading age at 
which the information is pitched. Having tested the literature, 11 and I subsequently re- 
worded sections to decrease the reading level to a maximum reading age of an 11 year- 
old. We found it particularly difficult to discuss clinical risk factors such as atrial 
fibrillation and hypertension, which have many syllables without increasing the reading 
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level of the information. However, we felt it important that these technical terms were 
explained. All information sheets were checked by the lead stroke clinician before being 
distributed to patients in the exploratory trial. 
7.7. The Exploratory trial and revising the intervention. 
The MRC Framework is quite flexible about what the exploratory trial should entail but 
in the case of the Stop Stroke intervention this phase was not clearly demarcated from 
the modelling phase. However, testing of the intervention components was conducted 
by the PHT and involved 25 patients recruited to the SLSR and their GPs. Patients were 
not randomised and the focus was on testing trial procedures and gaining feedback on 
the patient and professional information literature rather than trial outcomes. To test the 
intervention using the main trial outcomes would have required a further year of data 
collection, delaying the start of the trial further. Instead a qualitative evaluation was 
conducted. 
The MRC framework emphasises that qualitative methods can be used in the modelling 
phases but qualitative methods are not discussed in relation to the other phases of 
development. However, Patton argues for the use of qualitative methods at all stages of 
programme development, particularly during implementation. 95 In the Stop Stroke 
exploratory trial, patients and their primary care professionals were interviewed two 
weeks after the intervention was delivered to find out whether they had received the 
intervention, what they had understood from the advice provided and what actions they 
had taken as a result of the advice. GPs and other health professionals were very 
positive about the intervention but a number of problems were identified with the 
patient information literature. One of the key aims of the intervention package had been 
to try to make the approach to secondary prevention delivery more representative of a 
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chronic disease rather than an acute event. Another was to make secondary prevention 
messages more relevant to the individual. However, it was clear from the pilot that in its 
current format the intervention might fail at the first hurdle since patients were not clear 
that advice was individualised and subsequently disregarded it. The `packaging' of the 
intervention needed additional input and it was decided to present the intervention to 
patients in a plastic wallet with a sticker on the front identifying the patient. This was 
designed to encourage patients to keep their package and return to it if they had 
questions about secondary prevention in the future. 
In November 2002, feedback was also sought from the South London Stroke Patient 
Forum, a group the stroke team were trying to form to provide patient input on stroke 
research. However, only three patients attended the meeting. The RA gained additional 
feedback from patients after presenting the packs during her routine SLSR visits. In 
some cases changes recommended by professionals (such as removing the numbering 
system to link statements on risk factor management in the individualised plan to the 
more detailed standardised advice sheets) conflicted with patients' suggestions or 
requests for information identified in the theoretical phase. In such cases patient 
feedback rather than professional feedback was used to inform design. 
Having revised the sheets it was decided that they would be presented to the entire 
stroke team at the team's journal club meeting (March 2003) for a final chance for 
members of the team to give feedback. The meeting started with the lead stroke 
clinician (who had previously approved the sheets) disagreeing with content and asking 
whether he had ever seen the sheets before. The sheets had changed since his original 
viewing but not substantially and he had also been through the content in great detail at 
the patient forum four months previously. Lack of consensus again emerged between 
different health professionals over the most appropriate way to define risks and provide 
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explanations (12 and SPR4). It also appeared to be difficult to reconcile differences 
between the patients' perspective (answering their questions and acknowledging their 
experiences) and the need to provide information that the clinicians felt was clinically 
accurate. For example, 12 was unhappy about acknowledging that patients might 
experience symptoms of high blood pressure arguing that there was no clear evidence of 
symptoms in the clinical literature. In addition, there was tension between 
recommendations in the literature to provide an honest account of what is and what is 
not clinically well understood (for example acknowledging where epidemiological 
evidence is lacking)328 and the professional need to maintain their status as experts. 12 
also queried the statement `no one knows why you had your stroke' (which was aimed 
at acknowledging that few strokes have a direct cause or event that led to their stroke on 
a particular day or time). He argued that in most cases clinicians did know why the 
patients had had a stroke and that the statement might encourage a view that health 
professionals don't know what they are talking about. 
The patient information sheets were revised again and the final stage of development 
was to present them at the steering group in April 2003 prior to the start of the trial. The 
steering group was positive about the intervention and the processes leading to its 
development but had concerns about patients with literacy problems, or those with 
speech and language difficulties. It was suggested that a question could be added to the 
SLSR to establish the patient's literacy level. If the patient had difficulty with reading 
then it was suggested that the information could be provided in an alternative form such 
as a video. However, the core investigators and I were unhappy with this suggestion 
since it was not something previously considered and would have involved considerable 
additional development and testing. Instead the team proposed that the SLSR 
researchers ask the patient to nominate a carer to whom the information could be sent if 
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the patient had communication difficulties. It was felt that those with language 
difficulties would most likely be reliant on a person (such as a friend or relative) who 
did not have language difficulties. The speech and language specialist felt that more 
could be done to design the information sheets for people with speech and language 
difficulties and offered to discuss them with her team. Unfortunately due to time 
constraints her team did not get involved in revising the sheets. Instead, ideas from the 
UK Connect" website were incorporated, for example highlighting key words in the text 
so that the main messages could be understood through key words and diagrams without 
having to read a full paragraph. No further evaluation was conducted prior to the start of 
the trial in July 2003. 
7.8. Discussion 
As Patton stresses "Once in operation, innovative programs are often changed as 
practitioners learn what works and what does not, as they experiment and as they 
develop and change their priorities" (p19). 95 Analysis of the development of the Stop 
Stroke intervention illustrates how a protocol to design a theoretically driven 
intervention changed and evolved during the development process. 
On numerous occasions the MRC Framework has been cited as having guided Stop 
Stroke intervention development but these data suggest that this was not strictly the 
case, since the research process for developing and evaluating Stop Stroke development 
were defined before The Framework was published. However, in many ways the 
multiple-stage research and development process outlined by the researchers in the 
original protocol does follow the recommendations for intervention development 
" UK Connect is a charity for people with speech and language difficulties. A number of staff working for 
UK Connect have particular experience in developing tools for communicating. 
205 
outlined in The Framework (use of literature review and empirical study to understand 
intervention process). Thus Stop Stroke intervention development can be regarded as an 
example of its application even if the theoretical phase research and evaluation design 
were not specifically guided by it. 
7.8.1. Putting theory into practice 
Although the MRC Framework suggests that demarcating a distinct theoretical phase, 
will lead to a more theoretically grounded intervention (and therefore a more efficacious 
intervention), in practice the theoretical phase of intervention development was used as 
much to justify research team ideas, as it was to guide them. Since the final intervention 
was only partially influenced by theory it raises questions about the ability of models 
such as The Framework to influence the theoretical grounding of interventions. 
It was certainly our intention as investigators to develop a theoretically driven 
intervention and the theoretical phase findings did contribute in some ways to 
intervention design. However, in order to be truly theoretically grounded, the 
intervention would have needed to be based on a full analysis of the theoretical phase 
data. In the context of Stop Stroke this was not possible given the time and resource 
limitations but it is also questionable whether a lengthy theoretical phase would be 
appropriate. In the Stop Stroke study, the iterative process of progressing from 
theoretical to definitive RCT phases took approximately four years, requiring multiple 
sources of funding. Yet, even if a full analysis had been conducted, the intervention 
might still have reflected the research interests of the team over and above any 
theoretical recommendations. To ensure that interventions are theoretically grounded, 
Eccles et al., have recently published recommendations for choosing the most 
appropriate theory in intervention development. 329'330 However, like the Framework, 
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including such recommendations assumes that interventions can and should be 
influenced solely by theory. They do not allow for the practicalities of research or the 
`interference' of extraneous factors such as resources, time, or investigator priorities. 
Such factors had an important impact in Stop Stroke intervention development. 
In the case of Stop Stroke, designing an intervention that fitted in with the ongoing 
SLSR was probably the most important influence on intervention design. Given the 
expertise in the stroke team, the intervention was never going to be designed to tackle 
particular aspects of secondary prevention, such as the social problems of secondary 
prevention management highlighted in the theoretical phase findings (for example fear 
of crime or poverty). Designing an intervention to utilise the SLSR would not only 
potentially support ongoing research projects but would also fit with broader academic 
requirements to develop an area of expertise for academic assessment and to attract 
funding. Thus intervention design was also influenced by the broader political academic 
context within which health and social care research is situated. 
Having defined the intervention concept, the actual components were further influenced 
by practical and resource issues. Since the SLSR was already established, redesigning it 
so that assessments would fit in with service changes rather than the natural history of 
stroke would have required additional resources. In some cases the intervention design 
also appeared to be influenced by medical hierarchies and authority. Clinicians and 
other investigators (members of the advisory group) made or requested changes to 
intervention components to support their own agendas and maintain their authority as 
experts despite the intervention being based on evidence from patient interviews. 
I have termed such influence `interference', in other words things which interfere with 
theoretical purity. When I first presented these findings (at the Society for Social 
Medicine and to the PI) I was criticised for using the term interference, since it was 
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argued that these findings simply reflect the difficulties of real life research and thus are 
of little interest. However, I would argue that such criticisms support rather than negate 
the argument. In the case of Stop Stroke, despite attempts to base the intervention on 
qualitative research evidence, the intervention was not theoretically pure. If such 
interference is an inevitable part of the process in developing complex interventions (in 
other words it is not possible to operatationalise theoretical recommendations 33 1'332) 
then MRC Framework recommendations to develop theoretically based interventions 
using extensive theoretical phases seem unrealistic. Others have reported similar 
conflicts in multi-disciplinary research and similar challenges for integrating 
ethnographic or qualitative research findings in generating knowledge of health and 
health services. 82,89 In the case of Stop Stroke, interference in the form of political, 
practical and resource influences may be as important as the underlying theoretical work 
in understanding the success or failure of the intervention. ' 00,333 
7.8.2. Challenges of the exploratory trial phase 
The MRC Framework also recommends the use of an exploratory trial to pilot the 
intervention prior to the main RCT. However, it is not clear in the context of complex 
interventions how this phase should be operationalised. The Framework is not intended 
to be prescriptive but does suggest questions to be addressed in this phase including 
investigating variations in the intervention components and methods of delivery, 
ensuring that intervention delivery is standardised, investigating the comparative arm 
and investigating sample size. ' In the Stop Stroke pilot evaluation, only one of these 
questions, variations in intervention delivery was investigated. The phase was used for 
testing the feasibility of delivering the intervention rather than for testing outcomes and 
the impact of the intervention was tested using qualitative methods, something not 
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recommended by The Framework. The pilot evaluation resulted in substantial revisions 
to the intervention. However, following these revisions a second pilot was not 
conducted, so that the intervention in its current form was not tested prior to 
implementation. It is not possible to ascertain whether the interpretation of the 
exploratory trial used in the Stop Stroke study has had an influence on intervention 
efficacy, since complex interventions by nature are likely to be difficult to evaluate 
because the whole is often greater than the sum of the components. 7' 334 The Stop Stroke 
intervention needed to be able to change over time; it also needed to be reactive to new 
research findings and therefore it was not be possible to pre-test all aspects of the 
intervention prior to implementation. The exploratory trial phase in The Framework 
appears to isolate the intervention components from the context within which they are 
delivered. Thus it ignores the difficulties of piloting complex interventions, assuming 
that the environment and components remain static once tested. This was not the case, 
nor could it have been for the Stop Stroke intervention, which was designed to be both 
tailored to the individual and able to accommodate changing best practice guidelines. 
7.8.3. The influence of RCT design 
Finally, intervention design also appeared to be influenced by the chosen evaluation 
methods. Since the MRC Framework required that the intervention be evaluated for 
efficacy in a RCT, it needed to be a concept or entity, which could be subjected to the 
rules of RCT design. In some ways these rules (or our interpretation of the rules) 
restricted the intervention design. In particular, the assumption that all patients should 
receive an identical intervention interfered with the intervention design. While the 
theoretical and exploratory trial phases suggested that it would be difficult to implement 
an intervention delivered to patients in hospital and these patients might be less likely to 
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benefit from it, at the last minute, decisions were made to deliver the intervention to 
these patients. Equally, concerns about randomisation and contamination of trial arms 
may have limited the intervention in a way that could influence its future uptake. 
These findings also raise broader questions about the nature of scientific evidence for 
complex interventions. If intervention choice is influenced by interference from the 
research team or by evaluation design then this may also limit the sorts of intervention 
that will be developed. For example, it may encourage development of interventions 
which are more easily evaluated using RCT methods, or those that fit within a given 
research budget but have little chance of influencing health outcomes. 
7.8.4 Implications for understanding trial outcomes 
One of the key assumptions of the MRC Framework is that if the intervention is 
informed by theoretical work, then it will help in interpreting eventual trial outcomes 
(whether positive or negative) and will thus help when generalising the intervention 
outside of the trial context. However, if social, economic and political forces interfere 
with the theoretical purity of intervention design then it makes it more difficult to 
interpret trial outcomes. For example, if the intervention is unsuccessful it will be 
difficult to untangle whether this is due to failed theory, inappropriate use of theory or 
interference from elsewhere. This in turn makes it difficult for others to learn from and 
build on trial findings. 
The implications of these findings for complex intervention development are discussed 
further in Chapter 10. In the next two chapters I investigate intervention delivery in the 
Stop Stroke Trial itself, how the intervention is implemented and the impact it has on 
patients' experiences of secondary prevention. 
210 
Chapter 8. The Stop Stroke Trial. 
Following on from the previous chapter, in this chapter I present findings from the 
process evaluation of the Stop Stroke definitive RCT. The chapter focuses on 
implementation of the intervention within the RCT setting. The process evaluation was 
embedded within the RCT to help in understanding the eventual success or failure of the 
intervention. 
8.1. Good practice in conducting RCTs 
While there is some guidance on the best way to develop complex health interventions, 
as argued in Chapter 2, there is less published guidance on the best way to conduct a 
RCT of such interventions. However, there are recommendations for good practice in 
conducting clinical trials of pharmacological interventions that cover organisation, 
planning and monitoring. Such recommendations include details of the responsibilities 
of the host institution, the principal investigator, other investigators and those of 
independent committees (steering committee, data monitoring committee). 65,335-337 
Common recommendations include: that the study has a clearly defined protocol; that 
staff understand the requirements of the protocol; and that staff ensure that participants 
have given informed consent. It is recommended that a trial coordinator be nominated 
and that staff have sufficient expertise to carry out their duties. The recommendations 
outline the responsibilities of independent committees including ensuring the trial sticks 
to the original protocol, ensuring recruitment is sufficient and that the intervention is 
safe to use. However, these recommendations were developed for more traditional 
clinical trials and little is known about their application to trials of complex 
interventions. 
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8.2. Evaluating the Stop Stroke Trial 
As in the previous chapter, I used an ethnographic approach to explore intervention 
implementation. I used a range of quantitative and qualitative methods to record data 
and analyse trial processes (see Chapter 4, section 4.5 for a detailed description of the 
methods). The analysis presented in this chapter covers the first two years of the trial, 
which started on 21 S` July 2003. Data used to illustrate the problems of trial conduct and 
intervention implementation are verbatim quotes from research staff and extracts from 
my own trial diary unless otherwise stated. Details that might identify staff have been 
changed to protect their identities. 
8.3. The evaluation team 
Participants in the RCT included many of those involved in the development of the 
intervention (Chapter 7) but also included new staff to assist in administration, 
monitoring and evaluation (research staff, administrative support staff, the trial advisory 
committee and me as researcher/evaluator). Research staff included those specifically 
employed to work on the study (trial staff), those who had designed the study and were 
responsible for overall management (core investigators) and other staff members 
involved in the SLSR. Details of staff roles and experience are outlined below. 
8.3.1. Trial staff 
As discussed in Chapter 7, a designated trial coordinator was employed on the study 
appointed at a junior level (TC), and a designated trial research assistant (RA). These 
research administrators had been involved in the modelling and exploratory trial phases 
of intervention development since November 2002 and January 2003 respectively (see 
Chapter 7 for a description of their skills and experience). During the RCT, the TC was 
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responsible for overseeing trial administration and intervention delivery; the RA was 
responsible for data collection, administration and research tasks including giving 
presentations on the study at academic meetings. Part of the RA's role involved 
organising data collection for the trial that would not otherwise have been collected by 
the SLSR including taking blood samples from patients to measure one year outcomes. 
For this she received training in phlebotomy during year one. 
The core investigators involved in intervention development remained as core 
investigators during the trial (see Chapter 7). The PI had responsibility for overall 
management of the trial but was also involved in some technical aspects of the SLSR, 
including checking data collection forms for quality prior to being entered onto the 
computer. The PI and 12 were also involved in delivering intervention components 
(academic detailing visits at the local practices) until this responsibility was handed 
over to the junior doctors later in the study. 
8.3.2 SLSR staff 
Although not specifically employed to work on the trial, since the trial used data from 
the SLSR, all SLSR researchers/fieldworkers also contributed to intervention delivery 
and trial data collection. In July 2003 three researchers were employed to collect data on 
newly identified strokes for the SLSR (SPR4 a specialist registrar with an interest in 
stroke, SPR5 a junior doctor training to be a GP and NCI a non-clinical research 
associate with an MSc in Health Promotion). One research administrator (FUP 1) was 
employed to coordinate a team of nine student field workers (all training as medical 
students) to collect SLSR follow-up data used in the intervention and to assess 
outcomes. The SLSR staff were assisted by a non-clinical research associate with a 
background in health promotion who was involved in some aspects of data collection 
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(NC2). At the start of the trial a research administrator was also employed on the SLSR 
to conduct administrative tasks some of which had a direct influence on the trial 
including identifying new stroke patients and entering data (Adminl). 
8.3.3. Statistical support 
The trial had a nominated senior statistician (SS 1) responsible for advising on statistical 
aspects including providing power estimates for the main outcomes, advising on 
randomisation and analysis. The statistician was based off-site and was on maternity 
leave at the start of the trial, which meant that most statistical support was provided by 
junior statisticians (JS2, US and JS3). US had expertise in statistical methods for cluster 
RCTs but was not employed to work either on Stop Stroke or the SLSR. 
8.3.4. My role as researcher evaluator 
Although I had considered myself a core investigator during the development phase of 
the intervention, initially I did not consider myself to be a core investigator during the 
RCT. Since I was to be evaluating the study, we (the core investigators and I) felt that it 
would be better if I were not involved in management, technical or administrative 
processes (I would be unable to evaluate my own work). I went overseas from October 
to June during the first year of the trial but despite my physical absence, I still provided 
technical and advisory support throughout the trial. 
8.3.5. Advisory group 
As with intervention development, the trial was overseen by a steering group who met 
yearly in August (see Chapter 7 for a list of advisory group members for the main trial). 
Trial staff and statisticians but not the SLSR team attended advisory group meetings. 
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Attendance was generally good although GPI only attended the first meeting of the 
group and SS2 declined to attend any of the meetings. SSI also did not attend any 
meetings (due to an administrative error she was not invited to the first meeting and did 
not subsequently attend the second or third meetings). 
Each year at the meeting I gave a brief presentation on the study covering the MRC 
requirements for conducting RCTs (including eligibility, recruitment, follow-up, 
missing data and a chance to raise any problems). The group then discussed trial 
progress and made recommendations for the way forward. The minutes were taken by 
one of the research administrators and distributed to the group. 
8.4. Conduct of the Stop Stroke Trial 
Prior to the start of the trial, efforts were made by the study team to ensure that 
recommendations for good practice were followed. 336 In addition to appointing the TC 
and an advisory group, the core investigators produced a detailed study protocol, 
conducted staff training and considered issues of ethics and consent. Each of these 
processes is outlined below. 
8.4.1. Study protocol 
The study's detailed protocol was developed to gain funding for the study in 2002. The 
protocol outlined details of how the intervention components worked, trial process 
including randomisation methods, details of outcome measures and estimation of 
statistical power. The intervention itself comprised two main components: academic 
detailing visits to GP practices; and production and delivery of individualised secondary 
prevention plans to patients, carers and professionals (see Chapter 7). 
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The protocol specified that the intervention would be tested in a cluster RCT in which 
participants would be allocated to one of two groups, the intervention arm or control 
arm. General practices in the SLSR area were randomised to one arm or the other and 
then all subsequent SLSR patients at a given practice would receive either the 
intervention or `usual care'. This method of cluster randomisation was utilised to 
prevent `contamination' of the control group, in other words to ensure that participants 
in the control arm would not be able to access the intervention. Randomisation was 
stratified by practice type (whether single or multiple-handed) and practice size. It is 
debatable whether such factors have a significant impact on patient care. 338 339 However, 
stratification aimed to ensure that different types of practice and those with very large 
list sizes were roughly evenly distributed between the two arms. 
Key outcome measures included prevalence of uncontrolled risk factors (use of 
antihypertensives, aspirin and smoking cessation). The study also aimed to influence a 
number of secondary risk factor control outcomes including control of cholesterol, 
diabetes, atrial fibrillation, obesity and heavy drinking. 
A power calculation was estimated to identify how many participants were required to 
give the study enough statistical power to investigate the impact of the intervention on 
the key outcomes. The calculation was based on existing SLSR recruitment figures and 
suggested that if at least two-thirds of SLSR patients took part in the study over a three- 
year recruitment period, enough patients (315 in total) would be recruited, giving 
moderate power (80%) to detect a 21% increase in antihypertensive use, a 29% increase 
in smoking cessation and a 17% increase in aspirin use. The estimation assumed that the 
SLSR recruits 225 patients per year and that outcome data would be collected on at least 
70% of those agreeing to take part. 
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The protocol also outlined recommendations for `blinding' trial staff and participants. 
`Blinding' refers to the process for preventing those involved in the trial from knowing 
which arms of the trial participants have been allocated. Blinding can occur at a number 
of different levels: recipients of the intervention may be blind as to whether they have 
received the intervention or the control; health care providers may be blind as to 
whether the recipient has received the intervention or not; those administering the 
intervention may be blind as to whether they are administering the intervention or a 
control (alternative intervention or placebo); those collecting data or those conducting 
analysis can also be blind as to which of the two groups is intervention or control. 65,340 
Blinding aims to limit bias in the way trial participants are treated. In the Stop Stroke 
protocol all trial and SLSR staff responsible for collecting data were `blind'. This meant 
that at the start of the trial, these staff did not know to which arm of the trial patients, 
GPs and practices had been allocated. GPs and patients themselves could not be `blind' 
because the investigators thought that it would be obvious to them during the trial 
whether they were receiving the intervention or not. Similar problems of `blinding' have 
been reported in relation to other types of complex intervention including in RCTs of 
alternative therapies such as hypnotherapy and Ayurvaedic medicine. 341,342 
In addition to the protocol a separate manual was produced (by me) outlining step-by- 
step instructions on how to produce secondary prevention plans. The manual included a 
list of `trouble-shooting' tips on how to deal with anticipated problems in producing 
plans (such as what to do if particular error messages appeared when executing the 
computer files, or what to do if new drugs were developed and new coding needed to be 
added). The manual also listed a number of quality control checks to be conducted by 
the research administrators before plans were distributed to patients. These aimed to 
ensure data and advice provided were accurate and `safe'. They included checking the 
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advice provided on medication and contraindications for medication, checking for 
spelling mistakes and stylistic problems. 
8.4.2. Ethics and consent 
Ethics approval was obtained from two local hospital research ethics committees. Prior 
to the start of the trial all GPs at practices within the recruitment area were sent a letter 
outlining the study and providing a description of the intervention. GPs were informed 
that participation was voluntary but if they chose not to participate, they needed to `opt 
out' of the study by contacting the study team rather than `opt in'. GPs were informed 
that individual patients would be asked for consent to participate prior to inclusion in 
the study. At this stage, no GPs opted out. 
The procedures for gaining consent from patients were informed by existing SLSR 
process. It was the research administrators' responsibility to ensure informed consent 
was properly sought and that consent forms were signed. All consent forms were stored 
in a folder in the trial office. The computerised mechanism for producing the 
intervention ensured that patients and professionals were unable to receive a secondary 
prevention intervention plan without the researcher specifically indicating on the SLSR 
forms that the patient had consented to participate. 
8.4.3. Expertise and training 
All core investigators and trial staff had worked on the study for at least six months 
prior to the start of the trial and all had been involved in the development of the 
intervention at various stages (Chapter 7). All staff were given copies of the protocol 
and the trial manual and were familiar with the SLSR. All staff had been involved in 
discussions of eligibility criteria prior to the start of recruitment and one of the research 
218 
administrators and I had been involved in the randomisation process with the PI, SS2 
and US. The research administrators were given specific training sessions (by me) on 
using the computer system to produce the secondary prevention plans and on how to 
monitor trial recruitment. 
Lines of responsibility were established for addressing unanticipated problems with trial 
process not outlined in the protocol, should they emerge during the trial; if the research 
administrators had queries regarding eligibility or problems with trial process they 
would present them to the Pl. If they had problems with technical issues related to the 
computerised component of the intervention they would email their queries to me. 
The advisory group decided prior to the start of the trial that it would not be necessary 
to have an additional data-monitoring group to check for adverse events since there 
were no anticipated adverse `side effects'. Instead, recruitment was monitored at 
fortnightly meetings of the trial staff and the Pl. Recruitment figures were also 
presented at a quarterly local independent research group meeting by the research 
administrators and to the trial advisory group on a yearly basis by me. 
8.5. Trial process 
The main processes took place on a weekly rather than a daily cycle. In any given week 
the following procedures were initiated, although exactly which procedures took place 
differed during the course of the trial (for example outcome data collection did not start 
until year two). 
8.5.1. Identifying eligible patients 
The first stage of the trial process involved identifying patients eligible for inclusion 
into the trial. The process was integrated into the SLSR routines for identifying incident 
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strokes. Twice a week a research administrator would phone specific hospital wards and 
community contacts ('notification sources') to identify potential stroke patients. Once a 
week, an administrator would also go in person to key wards at the hospital to identify 
potential stroke patients. '7 The information gained about potential recruits was 
transferred into a `notification book' and onto a computer database for use by all SLSR 
staff. Those responsible for trial and SLSR recruitment then checked each patient 
against those already recruited and visited any new patients (or at least looked through 
the patient's hospital notes) to decide whether they had had a stroke and if so, whether 
they were eligible for any of the SLSR research studies (including the trial). 
8.5.2. Obtaining consent 
The second stage of the trial process involved gaining informed consent from 
participating patients. If the patient was eligible for the trial, the researcher responsible 
for completing the initial SLSR questionnaire explained about the intervention and the 
trial and asked the patient for consent to take part. For patients unable to give informed 
consent themselves their next of kin was asked for `assent', that is consent on the 
patient's behalf. In some cases, the researchers were unable to see the patient (or next of 
kin) in person, in which case he or she phoned to explain the study and then sent a copy 
of the consent form, together with a pre-paid envelope so they could sign and return the 
form if they wished to take part. 
8.5.3. Collecting patient data 
Once informed consent was given, the researchers started to collect data using the SLSR 
questionnaires. The questionnaires were divided into four parts specifically for trial 
purposes. Only parts one to three included questions to collect data relevant to the trial. 
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Part one was used to collect data that were relatively easy to access but the form could 
not be completed until after two weeks post stroke since it included information on the 
patient's state at two weeks (although this data was not relevant to the trial). Part two 
collected data which the staff found more difficult to collect such as body mass index 
and diagnoses of risk factors since the stroke, which required waiting for test results that 
might take longer than two weeks to process (including diagnosis of diabetes, atrial 
fibrillation, high cholesterol). Part three collected data relating to discharge information 
such as medications prescribed on discharge that could only be collected once the 
patient's discharge summary had been completed. 
Meanwhile the SLSR follow-up team conducted interviews with patients (or carers) to 
collect follow-up data, some of which was used in the three and six month follow-up 
plans. These interviews were conducted in the patient's place of residence (own home, 
nursing home or in hospital if patient had not yet been discharged). Student field 
workers assisted with data collection at the follow-up time points and each student was 
allocated responsibility for a batch of interviews one month before the follow-up was 
due (i. e. a three month follow-up interview was allocated to the field worker two 
months post stroke). When a batch of interviews had been completed, the field workers 
returned the forms to the office for data entry. The field workers were instructed to 
conduct the interview on or as close to the follow-up date as possible. If the field worker 
had difficulty identifying the patient or conducting the interview the SLSR follow-up 
team took over the responsibility for chasing up the patient. This `chasing up' process 
involved phoning on a number of occasions to arrange a visit; sending a letter to the 
patient to arrange an interview date; and as a last resort, conducting a `cold call' at the 
patient's address if no response was obtained. If the research administrators had 
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problems identifying the address at the follow-up date then they contacted the patient's 
GP to try to track the patient down. 
8.5.4. Data processing 
Completed data collection forms were returned to the office and checked for errors 
(cleaned) by the Pl. Forms were then passed to the research administrators who entered 
the data onto the SLSR computer database. Each form was entered twice into separate 
files and then the files validated against each other to check for errors (a process known 
as double entry). 337"343 The administrators checked through the forms to identify patients 
eligible for the trial and entered their details onto a trial specific database. The team 
used the database to keep track of who had been recruited and to highlight when various 
intervention components were due for delivery. It was the research administrators' 
responsibility to coordinate between different trial and SLSR staff and to remind those 
collecting data of the deadlines for returning forms. The timing of data processing was 
crucial to intervention quality. If the forms were not returned within the specified 
deadlines of 6 weeks, 4 months and 7 months post stroke (later extended to 10 weeks, 5 
months and 8 months post stroke) then the patient and GP intervention plans could not 
be produced. If only parts of the form were returned then the plan would contain little 
advice or information for the patients, carers and primary care team. 
8.5.5. Producing intervention plans 
Plans were not always produced on a weekly basis (since this was subject to trial 
recruitment) but if a plan was due, one of the research administrators initiated the plan 
production process, exporting the data from the SLSR database so that it could be used 
in the trial programmes (see Chapter 7 for a detailed description of the process). If the 
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computer programmes identified errors then the administrator had to go back to the 
original forms to check the source of the error (for example if the wrong date of birth 
had been typed onto the SLSR database this would result in an error and the process of 
producing plans would be halted). If the administrator could not resolve the problem he 
or she would check with the other administrators, one of the team's statisticians or me 
to identify a solution. In some cases this process took a number of days. Once all the 
safety checks had been passed, the intervention plans were produced and printed out in 
hard copy form. The administrator then hand checked the plans against the checklist 
provided in the manual. If further errors were found these needed to be resolved and 
new plans produced. The administrator made a hard copy of each plan as a record of 
what had been produced. The originals were then sent out by post or delivered to the 
patient in hospital by the administrator, who then finally updated the computer database 
to record that a plan had been sent. 
8.5.6. Organising and conducting GP Practice visits 
In addition to producing the secondary prevention plans the intervention also involved 
academic detailing visits from stroke specialists (the PI and 12) at practices allocated to 
the intervention arm. The administrators were responsible for identifying and liaising 
with practice staff and organising each visit, which was conducted either as part of an 
existing practice meeting or as a stand-alone visit from the specialists. The specialists 
provided information on the SLSR, the trial, the recently published RCP guidelines on 
best practice in stroke care, as well as details of local stroke services (the newly 
developed TIA clinic) and components of the local Modernisation Initiative focusing on 
stroke service development. 
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8.5.7. Outcome data collection 
The final piece of data collection (trial follow-up) was also integrated into the SLSR 
data collection process. All trial patients also needed to have blood tests conducted. The 
RA and research administrators were responsible for finding out which patients needed 
specific tests, organising the tests and analysis of the results. Tests included HbA Ic for 
those previously diagnosed with diabetes; cholesterol level for all patients and cotinine 
level for those patients who had reported smoking at any time point either at the time of 
stroke or since. As with the other follow-ups, these interviews were conducted in the 
patients' own home. The information was collected using the standard SLSR 
questionnaire and entered by the researcher responsible for data collection. 
8.6. Problems with trial process and intervention implementation 
According to published recommendations, the study fulfilled criteria for `ideal' trial 
conduct. However, despite being an ideal study in theory, in practice, a number of 
problems related to trial conduct and intervention delivery emerged during the course of 
study. These may have impacted on intervention efficacy. They related to four broad 
themes (i) those related to the study protocol including unrealistic expectations of trial 
process; (ii) those related to staff understanding, communication and motivation leading 
to protocol deviations (iii) limitations of the pilot work (modelling and exploratory trial 
phases) and (iv) wider problems related to the trial environment. 
8.6.1. Inadequacies of the Protocol 
Although a detailed protocol was produced at the start of the trial, problems emerged 
during the course of the trial as a result of the complexity of the intervention, which had 
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not been anticipated prior to the start of the trial and were not covered in the protocol. 
These are outlined below. 
8.6.1.1. Inadequate recruitment estimates 
Although a detailed power calculation was presented in the protocol, by the end of year 
one it became clear that the recruitment estimates had been over optimistic. By August 
2004 figures suggested that the trial was under recruiting (9.4 patients per month instead 
of the 12.5 patients per month anticipated). The power calculation and recruitment 
estimates had been determined using `real' data. However, they had been based on 
yearly incidence figures for the number of patients surviving to three-months post 
stroke and not on the number of stroke survivors identified within a relatively short time 
period since the stroke (for the purposes of the trial, within six weeks of the stroke). 
SLSR staff informed me that both very mild and very severe strokes were often notified 
late to the SLSR and this had not been taken into account. For patients who died very 
quickly from their strokes this would have little relevance to trial process since even if 
they were identified quickly the patients would still not have met our eligibility criteria. 
By contrast the mild strokes would have been eligible had they been identified more 
quickly and potentially would have been those most likely to benefit from the 
intervention. 
The problem of under-recruitment was discussed at the second steering group meeting 
and as a result the PI proposed extending the study area to increase recruitment. The 
area was extended in November 2004, with an extra 10 practices recruited and 
randomised. By July 2005, the extension was starting to have an impact on recruitment 
meaning that recruitment estimates were now over the 150 patients per year estimated in 
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the protocol. Figure 4 shows the numbers of patients eligible for inclusion in the trial 
and those actually recruited over the first two years of the study. 
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Within the first two years of the trial 466 stroke patients who were potentially eligible 
for the trial were identified by the SLSR team. Of these, 12 were not registered with a 
GP practice and nine were registered with a practice not included in the original 
randomisation lists. Two practices were subsequently recruited to the study and 
randomised; the remaining seven were not. Thus in total 444 patients were eligible for 
inclusion in the trial, of whom, 382 gave consent to participate and were randomised 
into the study. 
The proportion of potentially eligible stroke patients identified by the SLSR and the 
proportion of patients recruited to the study did not increase at the same rate. The mean 
difference between rate of eligible patients and recruitment rates significantly increased 
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after the extension in November 2004 (9.5 patients per month) compared to before the 
extension (5.1), raising questions about the types of patients recruited and the 
generalisability of the findings to the stroke population as a whole (two sample t-test 
with pooled variance, t=3.82; p=<0.0001). 
At the steering group meeting in 2005 yearly follow-up rates were presented for the first 
time. There had not been enough data to explore follow-up until this point and follow- 
up had not been investigated in the pilot evaluation. The estimates showed a drop out 
rate of 40%, 10% higher than anticipated in the power calculation. As with trial 
recruitment, one possible explanation is that the original estimates were made based on 
SLSR data not necessarily collected at the appropriate time point for the trial (in 
practice, one year follow-up data could be collected at any time after one year post 
stroke). Alternatively, since recruitment estimates in the protocol had been based on 
patients surviving until three-months post stroke and in practice the trial was recruiting 
anyone surviving to six-weeks post stroke it is possible that those recruited had a higher 
death rate than anticipated in the original estimate. 
8.6.1.2. Lack of consensus about patient eligibility 
At the start of the study it was agreed that all patients on the SLSR registered with a 
participating practice would be eligible for inclusion in the trial. However, explicit 
eligibility criteria were not outlined in the protocol. Confusion over eligibility began 
even within the first two weeks of the start of the trial. The research administrators were 
unsure about the designated start date and whether starting on 21S` July 2003 meant that 
all patients would be recruited who had had their strokes since 21 S' July, or whether all 
SLSR patients currently on the stroke wards would be included. To clarify things, I 
recommended that we should take all patients whose stroke had occurred after 21 S` July. 
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However, a week into the trial no patients had been recruited and the PI recommended 
that all newly recruited SLSR patients should be included regardless of stroke date. 
The decision raised further questions about eligibility that had not previously been 
considered. It also raised questions about what exactly the intervention components 
were. The theoretical phase findings had suggested we needed to deliver the 
intervention at multiple time points relevant to the patient and so the original aim had 
been to send patients three consecutive secondary prevention plans (see Chapter 7, 
section 7.3.4). In order to do this, patients needed to be identified as soon as possible 
after the stroke. To include all newly identified patients regardless of stroke date meant 
including those for whom it was already `too late' to deliver the first part of the 
intervention. Thus some patients could potentially receive all three `doses' of the 
intervention whilst others would receive only one or two. 
Since the original power calculation and funding had been based on all surviving SLSR 
patients being eligible, I (as a member of the trial team) proposed that we would include 
all patients notified to us within 6 months of their stroke (that is, they were eligible to 
receive at least one `dose' of the intervention). Otherwise it would have been impossible 
to hit the required recruitment estimate of 150 patients per year. This decision was 
approved by the PI and 11. At the same time, I also clarified the eligibility criteria for 
receiving each specific dose of the intervention; patients eligible for the initial plan must 
have been recruited to the trial within six weeks of stroke. Patients eligible for 
subsequent doses must have been recruited to the trial by three months and six months 
respectively. Plans must then be sent to patients and professionals by eight weeks, four 
months and seven months respectively. These decisions satisfied the ethical requirement 
that we should be able to recruit sufficient numbers to detect statistically significant 
differences. However, in doing so we had been forced to change the intervention itself. 
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Of those recruited in the first two years of the trial, only 27.7% (54) were sent all three 
intervention plans; 30.3% (59) were sent two plans; 26.2% (51) were sent only one 
plan; and 15.9% (31) were not sent any intervention plans at all. In other words 
satisfying RCT requirements (the need to recruit sufficient numbers within a given time 
frame) had forced us to compromise the theoretical grounding of the intervention. 
Questions over eligibility continued to arise during the course of the trial in relation to 
other problems such as what to do if a patient moved GP during the trial or what to do if 
the patient did not have a GP at the start of the trial but subsequently registered with a 
GP during the course of the trial. Pocock argues that trial protocols need to provide 
comprehensive details of trial operations including requirements for patient entry, 
treatment and evaluation. 65 However, some of the research administrators reported that 
when they tried to raise questions in advance about what they should do in different 
potential scenarios they were told that this was a `pragmatic trial' and therefore 
problems would be addressed as they arose. In some instances it was felt that decisions 
could have been made earlier, such as decisions on what would happen in the patient 
moved GP practice during the trial: 
I know everyone kind of says it's a pragmatic trial but there are some things, probably, I 
think we could have easily sort of sat down and sorted out at the beginning, like for 
example, if somebody has a certain GP when they have their stroke and they swap GPs 
because they're may be out of area [sic], or that someone is in the control arm and they 
swap to a GP and is in the intervention, that type of thing. (Research administrator, 2004). 
SLSR analyses revealed that in practice only a small minority of patients changed GP 
during the first two years (6,1.5%). Thus lack of clarity over practice changes may 
prove to have little impact on trial outcomes. However, this seemingly insignificant 
problem may have had broader implications in terms of staff understanding and morale. 
At each yearly interview the research administrators discussed confusion and frustration 
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resulting from lack of detail in the protocol (and particularly in relation to what they 
should do if a patient changed GP during the trial). Lack of detail affected confidence, 
particularly at the beginning of the study: 
I think in the beginning I used to feel like a nan [sic] because I always used to have to go in 
to ask questions, because I didn't know. There was nothing written for me. (Research 
administrator, 2005). 
The same administrator went on to explain that even though she now felt that she 
understood the appropriate procedure for dealing with patients who changed GP, she 
still found it frustrating that such issues had not been clarified at the start of the trial: 
Well I know what the procedure is now. But what I'm saying is, that wasn't a hard thing to 
develop from the start and stick with, if you get what I'm saying. It could have been said 
from before and written down. (Research administrator, 2005). 
Clarifying the specifics of trial process may be particularly difficult in the case of a 
complex intervention trial where potential deviations from the norm are numerous and 
solutions cannot always be identified prior to the start of the trial. However, the impact 
of detail about seemingly insignificant numbers of patients (in this case what to do 
about patients with new GP practices or those whose GP moves during the trial) may be 
important in influencing trial operations. 
8.6.1.3. Limitations of quality control measures 
Although quality control procedures had been put in place at the start of the trial, it 
became clear during the course of the trial that they were insufficient. In March 2004, 
one of the research administrators wrote in her process evaluation diary that a patient 
she had visited had shown her a copy of an intervention plan that had suggested that he 
was not taking his blood pressure tablets appropriately when he felt that he had been. 
She checked what had been sent to the patient and it emerged that there was a 
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programming error that meant that patients taking antihypertensives were being 
provided with inappropriate advice. The issue had only emerged because the patient 
himself had alerted the team to the problem. She wrote in her diary: 
As I enter the six-month forms and [another administrator] just produces them there is no 
real checking process... I have discussed this procedure in the light of the current problem 
and [one of the administrators] will now go through the questionnaire and management 
plan together to ensure no incorrect information is sent out. 
(Research administrator, 12/03/04) 
The PI had been under the impression that the research administrators checked the 
advice in each plan in detail against the original SLSR forms to make sure all data were 
accurate. However, none of the administrators were clinically trained and it would have 
been difficult for any of them to ascertain from original SLSR forms what `accurate' 
secondary prevention advice should be. Prior to the start of the trial as an intervention 
developer, I was under the impression that they would check the items listed in the 
checklist provided in the manual (checking that medications were not contraindicated, 
that spellings and style were correct). The administrators thought that the programmes 
had been sufficiently tested and no checking at all was required. However, with the 
problem highlighted through the process evaluation, the team were able to intervene to 
improve quality control; I was able to modify inaccurate computer programming and 
the PI asked for all future plans to be checked against original forms. 
8.6.2. Staff understanding, training and support 
In addition to being given copies of the protocol, all staff had been given training in trial 
process prior to the start of the trial. However, when I interviewed trial staff a year into 
the trial, I found little understanding of trial process including aspects of trial 
recruitment and data collection outlined in the protocol. 
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8.6.2.1. Understanding the protocol 
Lack of understanding of the trial protocol may have influenced who was being 
recruited (or not recruited) into the trial. One of the researchers responsible for 
recruiting patients described how she had been confused about the inclusion criteria and 
had been recruiting patients who she was later told were not eligible: 
in terms of the inclusion and the exclusion of people in the trial, I know we - at the 
beginning it was kind of decided that we weren't going to exclude anybody, everybody was 
going to be included but obviously if they died, if they passed away before their six week 
point... However, when I was kind of in the process of this, [the PI] checks through all the 
forms and I'd just written on one the forms that, I think I'd written at the top, I think 'poor 
prognosis' or something like that, along the lines of that, that this person was very poorly. 
And then he came to me and said, `Why have we included this person in the trial then? ' 
And then I sort of said, `That's what I thought we were meant to be doing. ' But then [the 
P1] said, `But that's actually something, when someone's got a really, really poor 
prognosis, then we're not going to be including them in the trial. ' 
(Researcher responsible for recruitment, 2004). 
Members of the research team were aware that there were some areas of the trial that 
they did not properly understand. In particular they found the lack of defined solutions 
for potential problems difficult to deal with on a day-to-day basis and blamed protocol 
deficiencies. 
Research administrator: We deal with it as and when it comes up. It's on the ball problems 
solving kind of, you know. But, it's not a consistent thing, I don't think, because I just think 
that every time something comes up, you could have a similar situation that came up six 
months ago and the same decision would not be made. That's what I think because I just 
know that people forget what they've said and things just get awry which is why I think -I 
think even for a pragmatic trial, there should be some ground rules where you could be 
flexible on some things but not everything. You must have some sort of- this is our ... 
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JR: A protocol. 
Research administrator: Yes and not just a protocol to give the Steering Committee ... 
but a 
protocol that when we're on the ground working, we can use it to assist us and problem 
solving our everyday problems that we don't have to come and ask you every time, `Oh this 
happened, what do I do? ' We just know, we have it written there, refer to it. 
(Research administrator, 2004). 
Such details were not presented in the trial protocol but some of the concerns expressed 
were issues that had been discussed prior to the start of the trial (such as what to do if a 
patient changed GP during the trial). The problem here was that different team members 
did not agree on the solutions to different problems. The administrators felt that the root 
of the problem was that they did not have a written record of such decisions. However, 
neither did they feel that it was their responsibility to make note of what had been 
discussed at meetings. 
People tend to forget what they've said, or the agreements they've made ... 
I don't really 
have the presence of mind to be writing down everything that you've just said. We have to 
make certain assumptions. If I tell you you told me something, [then] you told me 
something to do. So don't come back and say, `Oh why are we doing this? ' Now, 'write it 
down, let us agree, so whatever happens we can say that on this day, we had this meeting 
and we agreed to ten points as to what we would do. ' (Research administrator, 2004). 
Although the trial team were aware of some of the problems they were experiencing, 
other implementation problems were not recognised and only emerged as a result of the 
process evaluation itself. For example, misunderstandings emerged in relation to the 
recruitment figures. Recruitment figures had been reported to the PI roughly on a 
fortnightly basis throughout the first year but those doing the reporting did not fully 
understand the figures they were presenting. The administrators had been unaware that 
they were under recruiting and had informed the PI that recruitment was on track. They 
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had been under the impression that the trial need only recruit 315 patients in total (100 
patients per year) rather than the 450 outlined in the proposal. 
8.6.2.2. Training and support 
The research administrators also seemed uncomfortable with the backup systems in 
place for dealing with queries on an ongoing basis (going to the PI or emailing me). 
They felt they needed training and support to understand trial problems rather than 
instructions on what to do to resolve a particular problem. 
We kind of felt just a bit, sometimes just a bit like, 'okay we don't really know what to do, ' 
and to go to the PI, you do need to go with a solution, you can't go with, 'Argh, I've got all 
these problems and we just don't know what to do about them. ' And I do think it is good to 
think through yourself about what the kind of solutions are. But sometimes when you just 
get to the point where you've kind of been thinking about it, thinking about it... but you just 
don't have any idea really of what you're doing. And you just feel really lost going, 'Oh my 
God, this is all going really wrong. ' And you kind of go to someone and they say, 'Oh ring 
this person, ' and you ring this person and they're of no help whatsoever. And you go back 
and they say, 'Well didn't you ring the person? ' And you say, 'Well yes but they were of 
no help. ' (Research administrator, 2004). 
Pocock (2004) recommends that regular meetings are held with all trial participants for 
communication and feedback on trial progress and to `air any problems'. 65 During year 
one, meetings had been held roughly fortnightly with the PI, the RA and the TC but I 1, 
12, the other research administrators and SLSR data collection staff had not been present 
and I had been abroad. When the problems with trial recruitment emerged, 11 and I set 
up new fortnightly meetings together with the PI, the research administrators and JS2 
focusing on trial recruitment and management problems. At first, these meetings proved 
useful in that they ensured routine monitoring and also shared responsibility for trial 
problems: 
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it doesn't feel quite so formal. I think sometimes when we go to [the PI], it's very much 
like... you have to go with a kind of the solution bit. I sometimes just like with this whole 
blood taking thing, I was just like, `Argh, I just don't know what to do. ' And sometimes it's 
quite good just to maybe brainstorm things or get an idea of what other people think, rather 
than have to have a solution to everything. And so, yes, I think they are very useful, really 
useful. (Research administrator, 2004). 
However, the continued identification of problems and feedback from the process 
evaluation may also have had a detrimental impact on staff morale. A year later the 
administrators saw the meetings as just another routine that did not help in resolving the 
trial problems. 
Sometimes it always feels a bit of like a blaming, `Why hasn't this been done, what's going 
on here? ' (Research administrator, 2005). 
This started to be reflected in attendance at the meetings which went from all trial team 
and core investigators (except 12) attending regularly in 2004, to at least one member 
being absent from every meeting by 2005, as illustrated in my own diary entry in July 
2005. 
I am feeling quite down about the trial again today .... at the 
last Stop Stroke meeting [the 
PI] did not attend. He said that it was not in his diary. I am not sure how to take this since 
every Tuesday that there is a SLSR meeting there is also a Stop Stroke meeting... II also 
missed the last meeting and came into my office to say happily that he had [another] 
meeting and so wouldn't be able to attend. It is part joking but I feel there is a real element 
of dread about these meeting[s] now.. . they symbolise something negative. 
(JR diary 
23/06/05). 
The meetings were also limited in that some of the problems affecting the trial were 
broader resource, staffing and management issues related to the SLSR (which 
influenced trial recruitment, follow-up and intervention delivery). 
I think probably one of the main things that's been difficult is the fact that often a lot of the 
register, things that were maybe not working quite so well in the register, lap over to Stop 
235 
Strokes, they sort of get mentioned in the register and we try to mention them in the register 
meeting and we try to sort them out there. ... 
For example, the fact that, ... 
1 need some 
more help with initialling, is it something then to come in to Stop Stroke meeting ... 
I don't 
know. It can't really be resolved. (Research administrator, 2005). 
Since the SLSR team were not present at the Stop Stroke meeting and those present did 
not have the power to instigate change it was impossible to address broader SLSR 
concerns within this forum. 
8.6.3. Limitations of the pilot evaluation (exploratory trial) 
Although a pilot evaluation had been conducted prior to the start of the trial (see 
Chapter 7) some of the problems emerging during the course of the trial may have 
resulted from limitations of that evaluation, in particular those discussed previously in 
relation to trial recruitment, follow-up and intervention delivery. 
8.6.3.1. Lack of testing of recruitment and data collection processes 
Data collection systems for the SLSR had been in place for eight years prior to the start 
of the trial. However, some aspects of the data collection process were changed to fit 
with trial requirements and these changes had not been tested in the pilot. One of the 
research administrators felt that some of these changes, in particular the identification 
and registration of stroke patients within the time frame required for intervention 
delivery, did not work. 
... we were running on such a 
kind of `full steam ahead' that if one little thing goes wrong, 
then it's just like, right and then it's just going to be a bit of backlog and a bit of backlog. 
But I think again that's the way the register has always been run. There's always been a 
backlog built up... and I suppose that just doesn't fit with Stop Stroke ... 1 suppose with 
Stop 
Stroke, it's just like, we really can't have a backlog because we need everyone we can have 
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within the sort of 6 weeks. I suppose that's one of the things how Stop Stroke and the 
register have maybe clashed a bit. (Research administrator, 2005). 
In the pilot study the data collection processes had been conducted and processed with 
additional assistance from a public health trainee and were only collected on a small 
group of 25 patients (see Chapter 7). Processing had involved only small amounts of 
data relevant to the trial rather than all data collected by the SLSR, thus problems with 
backlog had not emerged. One of the research administrators explained how the broad 
inclusion criteria for the main trial made it particularly difficult to gain patient consent 
within the first six weeks of stroke since some patients were difficult to see in person or 
had other health or psychological problems and could not sign consent forms 
themselves. 
Getting consent in the time period needed has definitely been something that's been tricky, 
because if the person - it's alright if they're in hospital and they're kind of with it, so you 
can get consent. But I think the problem mainly comes when they get discharged and you 
speak to them on the phone and you explain everything, you ask all the questions you need 
to process the initial form and you send off the consent forms in the post and you don't get 
them back, that can be tricky. (Research administrator, 2005). 
Similar difficulties emerged in gaining carer consent. Involving carers in secondary 
prevention management through sending plans to nominated main carers was an 
important component of the intervention (Chapter 7). Two years into the trial only 
7/382 patients had given consent to contact a nominated carer. Difficulty gaining 
consent caused delays for trial recruitment. 
Despite attempts to reduce delays as a result of the pilot work (which had led to splitting 
the initial SLSR form), delays also existed in the data collection process. Getting the 
patient's height (or demi-span) and weight and their behavioural risk factors prior to 
stroke (alcohol use and smoking) proved difficult since these data were not always 
recorded in the patient's notes. In the pilot evaluation all included patients had been 
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seen by the researcher in person to collect data. However, in the main trial some patients 
were not seen in person at the time of stroke and it was not possible to gain consent or 
collect risk factor data in time to produce the intervention plans. 
One of the data collection team also noted that data on secondary prevention 
medications were particularly difficult to collect and return to the office in time to be 
processed for the intervention. The process of data collection was further complicated if 
the patient had not yet been discharged from hospital. 
I think it would just be so much easier just to really keep on top of ... 
if all we had to do was 
focus on a person and [think] `right, they've been discharged'- instantly... get the discharge 
summary (Researcher responsible for data collection, 2005). 
Problems collecting medication data prior to discharge had been identified in the pilot 
evaluation but recommendations to only deliver the intervention to patients on discharge 
had not been taken up. At the time the PI had felt that it was important to create a neat 
trial environment in which all patients would receive the same components at the same 
time points. Thus in the main trial, the data collection staff had to make judgements 
about when to conduct the data collection and what data to include to meet the 
requirements of intervention delivery. They then had to go back after the prevention 
plans had been produced to collect further information (when the patient was eventually 
discharged from hospital) to be used for the SLSR and subsequent intervention plans. 
One of the researchers responsible for data collection explained her thought process in 
this scenario: 
'have they been discharged? T 'Oh right, okay but it's, you know, five weeks [so there is still 
time left to collect further data]. ' `Oh they haven't been discharged yet, but we're at six 
weeks [the time at which the data is due]. ' And it can get really complicated. 
(Researcher responsible for data collection, 2005). 
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This complicated system made it difficult to collect and enter data within the given 
timeframe for the trial but also suggested that these problems would remain outside of 
the trial if it were rolled out in routine practice. 
The research administrators and data collection team felt that there were fewer problems 
with follow-up data collection (at three and six months) than at the time of stroke. 
However, analysis of SLSR data revealed that only 80% of patients who had entered the 
trial completed a three month or six month follow-up visit and of these 10% received 
their three month visit more than five months post stroke (that is, not in time for the data 
to be used for the three month plans). 
For those patients who had completed a follow-up visit, problems also emerged in 
ensuring data were complete. One particular problem related to the collection of blood 
samples at one year. The one-year follow-up interviews had started late and in her 
interview in 2004 one of the researchers responsible for data collection stated that she 
felt to blame for the delays explaining that she had not started thinking about how blood 
samples would be stored and analysed until one month before the tests needed to start 
and this was too late to arrange storage space. 
I've kind of had quite a few problems with the whole blood thing. And I do think it is my 
fault because I should have started sorting it out a lot sooner than I did, the whole kind of 
process. And I didn't really realise it was going to be as complicated to sort out as what it 
is. And there's kind of other things that factor in that kind of in terms of getting equipment 
for the blood taking stuff. (Researcher responsible for one year data collection, 2004). 
In a subsequent interview in 2005 she went on to explain that she also had a confidence 
problem about collecting blood samples from patients in their own homes despite 
having had additional practice with clinical supervision in the hospital. This had further 
delayed the start of data collection. 
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I think the feeling, the actual doing the training was fine, that was really smooth and quick 
and was perfect. I did that at [Hospital X] and they were brilliant there. And I think then it 
was the, sort of having the confidence of going out into the community on my own, so I 
needed a bit of practice within the hospital. 
(Researcher responsible for one year data collection, 2005). 
These delays meant that the one-year follow-up data collection started at the same time 
that patient recruitment expanded to the whole of Southwark and Lambeth placing 
considerable demands on staff time. Since SLSR recruitment and initial data collection 
had been prioritised, the one-year follow-up interviews were compromised. 
8.6.3.2. Lack of testing of intervention components 
Problems also emerged for delivering intervention components themselves, both for 
conducting GP practice visits and in delivering secondary prevention plans. 
At the start of the trial the administrators were given the task of organising GP practice 
visits for practices in the intervention arm. They were instructed to start with the largest 
practices first since it was thought that these practices were likely to yield most patients. 
To begin with, the administrators were highly motivated in delivering this component of 
the intervention despite it requiring considerable effort. The task involved making 
multiple telephone calls, sending emails, letter and faxes to practice managers and GPs, 
as well as juggling diary commitments: 
you need to call them at least once a week. Just have a block time because I mean ... 
I've 
tried every trick in the book recently. I've started calling them, I've got their emails, I email 
them. [then I send] just general letters. After letters, I fax them... And after all these 
different methods I got responses, a trickle. I reached a point of ... 
I said, Wright, I'm 
going to sit down with the diaries and see what dates are available. ' I did this proposal 
meeting, with a sheet, where they could just - simple, date, time, box to tick, yes/no. And I 
asked for two or more dates, because even though times were free in their diary, [the PI and 
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12's] diaries, any time, anything could happen, so I needed to have an alternative as well 
because they might not be able to make it on the days or something. You know, you just 
need to have more than one option. And I put a prepaid envelope in it. And faxed it. So I 
posted and faxed it. That was probably the best thing because I think people like just having 
to tick it and fax it back... 
... 
But it's a lot of hard work... it is an exercise that you have to put time into, you have to 
call, you have to follow-up, they're not going to follow you up, you have to follow them 
up. (Research administrator, 2004). 
But within five months the administrators started to experience problems coordinating 
the diaries of two senior staff members and the busy GP practice meetings. On average 
only one practice per week was visited. Some practices indicated that they did not have 
time for a practice visit or felt that since the visiting specialists were linked to Hospital 
A and they did not routinely send patients to Hospital A it was not relevant to their 
patients. The task of visiting the practices was passed on to the junior doctors in the 
team, raising questions about their ability to act as unbiased data collectors. If they were 
also delivering the intervention they would become `unblind' as to which practices were 
in the intervention arm. Despite the handover, the diary problems remained. Equally, 
although it was part of the protocol, those doing the visits were not committed or not 
able to prioritise the time needed to conduct the visits. Visits were sometimes cancelled 
or rescheduled at short notice: 
I'll never forget, I did - this woman, basically she agreed for a date and a time and I emailed 
[one of the specialists] ... 
[the P1] couldn't make it. [Then on the day of the visit] I saw him 
[the specialist] there and I said, `How was the meeting? ' `What meeting? ' 'Your practice 
meeting today. ' And he said, `Oh I didn't, I don't have it. ' Oh my God, I ran upstairs to call 
to apologise because these GPs are there, they have collated their diaries for this half an 
hour, after basically coaxing them for so long, you can't afford to miss a meeting with these 
practices, you're not going to give a good impression ... 
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So, the second time, they gave me another time and [one of the SLSR clinical researchers], 
I booked [one of the SLSR clinical researchers] in. And she as well -I said to [her], `It's 
very important that you attend this meeting, because we've cancelled on them before and it 
would look really horrible if we don't go again. ' And she was like `No problem I'll go, ' but 
she ended up cancelling again. And the thing that pisses me off is that they don't have to 
call them and tell them that they can't make it. I have to call them and tell them. And that 
just grates, because it's like, `Oh I'm really sorry but' and at the time I had all good 
intentions. Everybody was free, it should have been done. (Research administrator, 2004). 
The process of organising and conducting GP practice visits was another part of the trial 
which had not been pilot tested prior to the main RCT. In the end only 15/28 
intervention practices in the original area received a visit and 6/10 practices in the 
extended area. 
Problems also emerged for delivery of secondary prevention plans (which had been 
tested in the pilot study). As described earlier, once all the data were entered, statistical 
software (STATA) programmes were executed to produce the intervention plans. 
Despite testing some of the computer programmes for the pilot study, not all aspects of 
the programming had been fully tested. For example, six-month data collection was not 
fully integrated into the SLSR until September 2003 (after the trial had already started). 
Consequently there had been insufficient `real' patient data to fully test the six-month 
computer programmes. 
Programming errors emerged throughout the first two years of the study, with errors 
delaying production and distribution of the intervention. Errors included mismatches 
between the patient's control of risk factors and the advice presented; problems dealing 
with data on alcohol use; wrongly numbered additional sheets; and missing test results. 
Although most problems were minor typographical issues, one problem that could have 
led to inappropriate advice being provided to the patient, was not picked up through 
quality control checks. In May 2004 one of the data collection staff visited a patient for 
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a six-month follow-up interview and the patient revealed to her that he had received the 
intervention. He told the researcher that he had had a gastro-intestinal bleed, a 
contraindication to aspirin. However, when the patient's next intervention plan was 
produced, it advised the patient to ask his GP whether he needed to take aspirin. The 
problem had resulted from a programming error in one of the computer algorithms (I 
had omitted gastro-intestinal bleed as a contraindication for aspirin). Although a manual 
had been produced and disseminated outlining the content of the programmes, the 
mistake had not been identified. For this patient, the plan was modified manually and 
the programmes changed. 
One of the administrators felt that if there had been a few months more lead-time before 
the start of the trial then many of the problems including those related to programming 
errors would have been resolved. 
And I don't know whether, I suppose we could have rushed in a little bit but I don't think, 
by sort of starting it now, I think, we could have quite easily started it maybe, I don't know, 
we started in July, probably by Christmas I think we really knew all the issues... but then 
obviously, in terms of money and stuff, with a trial like that, you can't have a pilot. 
(Research administrator 2004) 
Whether in practice a few extra months would have made a difference is debatable since 
SLSR forms and processes were continuously being modified meaning that new 
technical problems continued to emerge throughout the study. For example, in June 
2004 the RCP published updated guidance on risk management which led to changes in 
the advice provided to patients; in June 2005 new versions of the initial SLSR form 
were produced for a European study the trial team were conducting, causing delays in 
data entry processes and subsequent delays for producing secondary prevention plans. 
As one of the other administrators argued, after two years many of the initial problems 
had been resolved but new problems continued to emerge. However, some form of 
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`lead-in' phase for the main trial might have provided staff with a better opportunity for 
consolidating trial processes, in turn improving staff understanding and motivation. In 
2005 one of the administrators reflected on how trial processes had improved during the 
course of the study: 
The trial is now on its feet, it's now - you know, to me, in another year, or probably 
another two years, you will really get what you need to get, because it's not a point where 
everything is on point - everything is working you know ... 
I never thought I would be able 
to say it but it is! It is smooth right now. And that gives me motivation in a sense, because I 
can finally see - kind of like being rewarded. It's not finished 
but you're still seeing the 
fruit of your work, in a sense. It feels good and I think that's also the motivation for me to 
try and do these entries as well, so that we can run the figures and see the difference. So I 
can run them, I suppose and think, `Right, figures are improving, that is part of my, you 
know, little joy. ' It's not much but it gets me going. (Research administrator, 2005). 
Delays in recruiting patients and producing the intervention resulted in a large 
proportion of patients eligible to receive intervention components not receiving them. 
One year into the trial, only 46% of patients and professionals eligible to receive the 
initial plan were sent plans; 67% of those eligible to receive the three month 
intervention component were sent plans; and 64% of those eligible for the six month 
intervention were sent plans. Of the three patients in the intervention arm who had given 
consent for a carer plan to be sent and were eligible to receive the intervention, none 
were sent the intervention at any time point. The administrators had forgotten to 
monitor plan production and delivery for these patients. 
8.7. The trial environment 
In addition to problems of trial process, the environment within which the intervention 
was delivered may also have had an impact on outcomes. An `ideal' experimental 
environment would be one in which all factors other than the one of interest (the 
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intervention) are held constant so as not to confound the relationship between the 
intervention and outcome. 62 In the case of clinical/pragmatic trials this is not usually 
possible since the interaction takes place in a real life environment where change cannot 
be controlled62 unlike in a laboratory setting. While randomisation and control may 
overcome some of the problems of a changing research environment, a number of extra 
safeguards are usually put in place to ensure that effects can be attributed to the 
intervention including `blinding' of those involved in the trial. 340 Although all data 
collection staff were initially blind as to which arm the patient had been allocated, all 
were `unblind' to at least some patients or practices by the second year. I have already 
discussed how time commitments of the stroke specialists led to SLSR clinical 
researchers becoming `un-blind' (section 8.6.3.2). However, the trial environment also 
led to other staff becoming aware of the trial arm for particular practices and patients. 
Due to resource and practical constraints the administrators were located in an office 
with the data collection staff. This meant that when intervention plans were produced 
and practiced visits organised conversations could be overheard and names of those 
receiving the intervention plans observed by all other SLSR data collection staff 
including the student field workers. On a number of occasions I witnessed an 
administrator discussing the arm of trial to which practices or particular patients had 
been allocated, with or in front of SLSR staff. 
There were also a number of environmental factors, which changed throughout the 
course of the trial, which although not biasing the trial, may have had an impact on 
intervention delivery and on the effect size of the intervention. These are now discussed. 
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8.7.1. Development of local services 
The first type of environmental change involved development of local health services 
during the trial. A new neurovascular clinic was developed in one of the hospitals in the 
study area, which had not existed when the theoretical phase research had been carried 
out. The clinic had a particular focus on preventing stroke after a TIA but also provided 
follow-up for people after a stroke. Clinic staff included a doctor specialising in stroke 
medicine and a specialist stroke nurse. The clinic may have increased patient access to 
secondary prevention advice and specialist management limiting the potential impact of 
the intervention. The clinic also influenced trial recruitment since it affected the way 
patients were identified to the SLSR. Throughout the first year of the trial there had 
been problems with data collection at the TIA clinic (due to staffing problems and 
workload issues). This had resulted in a backlog of patients who were recruited late to 
the trial and therefore had less chance of receiving all intervention components. 
Protocols for disseminating information from hospital to primary care also changed 
during the course of the study. At one of the hospitals in the study area a standardised 
discharge summary sheet was developed for recording stroke secondary prevention 
information. The sheet aimed to improve continuity between hospital clinicians and 
primary care teams. If this system worked then professionals may have had less need for 
the professional component of the intervention. 
Thirdly, as part of the local Modernisation Initiative (a three-year programme to 
improve local health care including stroke services235), a stroke patient group was set up 
to help develop local services. Some trial participants were also members of this group 
and as part of the groups' activities, fed details of intervention components they had 
received as part of the trial to other stroke patients and service developers. One service 
developer subsequently decided to design his own similar intervention (an 
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individualised secondary prevention workbook) for stroke patients, which he aimed to 
implement before the trial had finished. His decision to develop such an intervention 
may not have been influenced by the stroke patient group but the patient feedback and 
the subsequent intervention were nevertheless potential contaminators of the trial. In 
this case, the plans for intervention development were uncovered by the process 
evaluation and fed back to the PI who consequently stopped the intervention from going 
ahead. 
8.7.2. Distribution of intervention components outside of the trial environment 
In addition to environmental changes outside the control of the investigators a number 
of environmental changes also occurred as a result of the actions of the study team, 
included distribution of intervention components outside of the trial environment. The 
patient information sheets developed as part of the intervention were distributed to a 
local GP in the trial (whose practice was allocated to the intervention arm). The same 
information sheets were also distributed to another research team (outside the study 
area) who aimed to place them on a national website to be accessed by anyone with an 
interest in stroke (patients, professionals, researchers). Distribution of the sheets to the 
GP could have improved their use within that particular practice. However, it could also 
have led to contamination if the GP then distributed the sheets to other GPs or practices 
in the control arm. Publication of sheets on a website could have contaminated patients 
or professionals in the control arm who could theoretically have access to them. In this 
case I intervened asking the PI to consider the impact of distribution of the intervention 
outside the trial context. Both 11 and I felt that according to the principles of RCTs it 
was not appropriate to distribute the intervention when it had not yet been evaluated but 
the PI and 12 argued that in this case it did not matter. They argued that distribution was 
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unlikely to lead to contamination of the trial since they felt that few trial patients or 
practitioners would access the website. They argued that it did not matter that 
intervention components had not been sufficiently evaluated since this was not a drug 
trial and patient safety was not an issue. The PI also argued that patient information was 
not the intervention per se but simply one of the components and thus it could not 
potentially contaminate the trial. In addition 12 was concerned about improving 
collaborative links with the other research team, which he felt took priority over 
adhering to trial recommendations in this case. He challenged my stance ('interference') 
suggesting that I was being unsupportive of sharing research expertise. 
In hindsight, while it is unlikely that the environmental changes described above would 
have a large impact on trial outcomes, distribution of the intervention outside of the trial 
did nevertheless have the potential to influence outcomes. For example, distribution of 
intervention components to another research team had the potential to influence the 
effect size of the intervention, which might have been lessened if those in the control 
arm had started to receive secondary prevention advice not routinely received prior to 
the start of the trial. Equally, we know that if patients had received an intervention 
similar to the Stop Stroke intervention which they felt was not relevant (such as routine 
information leaflets) then this may have prevented uptake of subsequent individualised, 
more appropriate advice. 270 
8.7.3. Staff changes 
During the trial there were also a number of staff changes (Figure 5), which may have 
had an impact on intervention delivery and trial process. A total of 19 staff members 
worked on the trial during the first two years, plus nine student field workers. At the 



















vý co00ov c) v 
° o(Z 
ce n '- ?; v' 
vv ice. Z ice. 'j» uö ý5 
o^A 
oy 
io ý, ýýývvýüüüüc=ccý 
oA o ýý., 
Q [i C. 4 [i. [i. ý"ý ca co ý "v GN 
ca `ý 
.C .ý .C .GýUv 
>Vccüüüüüüüüv, N u. l 
"-° 
v° Ev c_ c_ c_ c_ cGcc ro-- y 







-ZUH V) H /) Vý C/) C)V: V c/) V c/) 
- 
-ý -ý- LLB 
rl 0. 
d 














based off-site and provided input by telephone or email only - 12 and SSI ). During the 
first year this had dropped to 10 staff (one off-site) and in some cases the turnaround 
dates for staff changes allowed little time for training about SLSR or trial process (liar 
example SPR4 leaving and SPR6 starting). 
Staff changes and their subsequent impact on workload and support mechanisms were 
sources of tension amongst the team. For example one of the research administrators 
explained how her morale had fallen as a result of staff leaving in year one. By the end 
of the second year she felt that she was a changed person and that this was a direct 
consequence of her increased workload: 
I think everybody is just so stretched... - somebody said to me, 'name), you were so 
different when you first started, you were so happy, you were so - your personality, it's just 
a totally different personality. ' And that really affected me. I was like, well something has 
to happen. It happened gradually but it happened... and I think it's because you just feel as 
if, you know, nothing you do is good enough. (Research administrator, 2005). 
Pocock warns that if staff motivation is not maintained this has consequences for all 
aspects of the trial: 
"Without this sense of enthusiasm, there is a real danger that the trial will deteriorate: 
protocol deviations, missing data or a fall rate in the rate of patient entry may occur" 
(p35). o5 
The Stop Stroke intervention was built onto a research tool with changing priorities and 
as research priorities changed so the numbers of staff changed, increasing the workload 
for trial staff (for example the amount of data to be collected increased) 
.... after everybody was phased out, then 
it was predominantly ISPR31 and I doing the 
initials, which, I think for a while, was fine. But I know ISPR3 has] got a lot of other things 
on and stuff. And I think and I know kind of, I think it was around Christmas time, just 
before or just after Christmas, she was going on it lot of foreign trips... for the I Furopean 
study] stuff. And that didn't help, I don't think, at all. And then I suppose with [one ot'the 
administrators] going, that kind of didn't help either, because we all kind of got other bits 
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put on us. And I mean you can quite easily say, 'Okay I've got to prioritise this, this and 
this, ' then it gets to the point where, if you don't - and then you've got this to do as well 
and if you don't start prioritising that, then it can be like two months and v ou haven't done 
it and you are meant to do it every week. 
(Researcher responsible for data collection, 2004). 
One of the administrators felt that her increased workload had had a detrimental impact 
on the quality of her work. She explained that as her workload increased, some 
responsibilities were compromised including aspects of the trial. 
lt takes away from your attention really, because you have to pay attention to so man, 
different things. So many different bits, you have to try and kind of manage, in a sense. But 
something always suffers, that's the thing. Something always - when you have too much 
on, things suffer. It's not that you don't want to do it, I mean, it's just that you can't do 
everything. (Research administrator, 2004). 
8.8. Discussion 
In this chapter I have presented findings from a process evaluation embedded %ýitliill tile 
Stop Stroke Trial. There is little guidance on the use of process evaluation in this 
context but in the Stop Stroke study the process evaluation was used both to highlight 
problems of intervention implementation and to provide ongoing feedback to trial stall 
to improve protocol adherence. 
The Stop Stroke Trial followed both the recommendations Cor development outlined in 
the MRC Framework for complex interventions and the MRC guidelines liar good 
practice in clinical trials. Yet problems of intervention delivery and trial conduct still 
emerged. The evaluation highlighted problems with trial process, which could he 
attributed to limitations of the protocol, problems with statu understanding, support and 
motivation, limitations of the pilot study and changes to the trial env ironnment. 1'hesc 
problems may have had an important influence on intervention deli\ery, which 
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subsequently could impact on trial outcomes. The study therefore raises questions about 
whether existing guidelines for evaluation are sufficient or appropriate when applied to 
complex interventions. 
It would be easy to criticise the Stop Stroke team (including me) for not producing a 
more defined protocol, not hiring more experienced staff, providing better training, or 
for not continuing the pilot until all intervention components and outcomes had been 
tested. However, the findings suggest that there are a number of issues specific to 
complex intervention implementation and evaluation that make complex trials 
problematic. These include the influence of RCT methods on intervention design and its 
subsequent impact on the implementation process; and the relevance of the pilot 
evaluation in an environment where resources are limited and where routine practice, 
trial environment and even trial process changes over time. 
8.8.1. Improving the study protocol 
The study protocol used in the trial could have been more detailed with more clearly 
defined eligibility criteria and a more accurate power calculation at the outset. The term 
`pragmatic trial' appeared to be used too readily, possibly to avoid addressing complex 
technical issues or `grey areas' such as potential future problems in defining eligibility 
criteria. Clinical practice guidelines simply state that the protocol must be detailed and 
clear and do not encourage investigators to acknowledge `grey areas' or prepare 
strategies for dealing with potential problems which are not yet fully understood. This 
possibly reflects the fact that lack of clarity in protocol decisions is thought to challenge 
trial integrity. 
One protocol issue that could potentially have been improved prior to the start of the 
study was the inadequacies of the power calculation. Compared to previous complex 
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intervention studies (Chapter 3), Stop Stroke power calculations were more detailed 
than most since they were based on `real' data appropriate to the population. 
Estimations were also calculated for each key outcome but these were still over 
optimistic. One explanation for this is that since the intervention components were 
dependent on the SLSR, the power calculation was limited by SLSR throughput. 
Starting with a base of 225 SLSR patients per year, the statistician calculated what 
would be possible to achieve within three years of funding. Unfortunately the yearly 
estimates of 225 patients per year were not sophisticated enough for the trial, since not 
all 225 patients were ultimately eligible for inclusion. In the case of Stop Stroke, these 
inadequacies were picked up within a year via the process evaluation and it was possible 
to compensate for under recruitment by widening the recruitment area and increasing 
the number of GP practices. The process evaluation provided the opportunity for the 
investigators to find novel ways to overcome challenges. However, given that most 
RCTs of complex trials are underpowered, as shown in Chapter 3, it might have helped 
to have had detailed strategies for monitoring recruitment and considered ways of 
addressing possible under-recruitment in the protocol. 
8.8.2. Improving the pilot 
In the case of Stop Stroke, most of the protocol problems only really emerged once 
recruitment had started but in a standard clinical trial it is not considered good practice 
to adjust the protocol once the trial is underway. Conducting any pilot study is unusual 
within a complex trial environment (see Chapter 3). However, resolving all protocol 
issues that subsequently emerged would have required an extended pilot study and there 
would have been no guarantee that an extension of the existing pilot would have 
unearthed or resolved protocol problems. Some issues such as the difficulty of 
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delivering the intervention to patients prior to discharge from hospital had emerged 
during the pilot but the solutions (to wait until all patients had been discharged) were 
not taken up in the interests of preserving a neat trial and ensuring that all participants 
received the same intervention regardless of hospitalisation status. In practice patients 
did not end up receiving the same intervention since it would have been impossible to 
recruit sufficient numbers if the trial had been restricted to patients identified within six 
weeks of their stroke. The trial methods had both defined the intervention and limited 
the uptake of pilot findings at the outset. 
RCT processes and intervention quality may have benefited from a `run in' phase in the 
first year. This might have helped resolve problems such as programming errors, 
allowed staff to gain experience in running trials and allowed them to develop a better 
understanding of the intervention and their roles in delivering and evaluating it. 
However, it is not clear where the extra funding for such a phase could have come from. 
It is unlikely that funding bodies would provide additional resources for a post-pilot 
`run-in' phase prior to a definitive RCT. 
Equally, because the environment, the `real life laboratory' within which the 
intervention was delivered, was continuously changing, new problems continued to 
emerge throughout the study. Lack of continuity in staffing over the three years 
combined with the complexity of understanding the SLSR, the Stop Stroke intervention 
and trial process meant that solutions to problems that had emerged in the pilot phase 
were insufficient to address problems emerging later on in the main trial. An ongoing 
recruitment and training programme would have been needed to ensure that staff 
turnover did not have a negative impact on trial process or outcomes, something not 
possible within the limited resources. 
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8.8.3. Improving staff understanding and motivation 
A second problem that could theoretically have been avoided, concerned staff 
understanding and experience particularly in relation to recruitment practices. The 
administrators were hired on the basis that the intervention did not require technical 
expertise to deliver. However, their lack of clinical trial expertise may have contributed 
to poor understanding of trial methods (such as the importance of concealing from the 
data collection staff to which arms of the trial patients and practices had been allocated, 
or methods for rigorous monitoring). Complex trials often aim to influence outcomes 
87 over a longer period of time than in a clinical trial (over one or more years). Thus in 
order to gain sufficient power, the recruitment and follow-up also take a long time (in 
the case of Stop Stroke three years plus one year follow-up). It would not have been 
possible to hire an experienced trial manager over this four-year period within the 
limited budget. In clinical trials it is possible to overcome such problems by conducting 
trials on multiple sites (multi-centre). However, while theoretically possible, conducting 
a multi-centre trial of a complex intervention such as the Stop Stroke intervention may 
have been even more difficult to operationalise. There have been few publish examples 
of multi-centre complex intervention trials in the literature. For example, in the review 
presented in Chapter 3 only one complex trial was a multi-centre study. 161 
My role as process evaluator had an important impact on trial process and intervention 
implementation since it enabled me to uncover problems as they arose and to intervene 
to resolve them. It was not written into the protocol that it was my role to monitor 
recruitment or to provide support for staff and there is little guidance on the 
appropriateness of using process evaluation data in this way. Some researchers have 
acknowledged the benefits of participant observers making `practical contributions' to 
the research environment, 216.244 and it is generally accepted that when using interpretive 
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approaches the researcher will have an impact on the research, a Hawthorne effect, 216 
and is expected to acknowledge this through reflexivity. 247 However, there may be 
conflict when practical contributions are used within a study using a positivist research 
paradigm such as a clinical trial. ' 17.250 Clinical trials have strict rules governing the 
influence of the research process on trial outcomes, for example rules about the conduct 
of data monitoring and interim analysis while the trial is ongoing. 65 It is thought such 
monitoring/analysis may interfere with intervention delivery in such as way as to 
compromise trial integrity. Process evaluation findings may be just as powerful as 
interim outcome analysis in influencing trial staff (for example feedback about the 
patient's experiences of the intervention might increase or decrease staff motivation and 
disturb equipoise for those responsible for delivering the intervention '05"06) Clearer 
guidance is needed on the conduct of process evaluation within the RCT context. ' 17 In 
the case of Stop Stroke, the process evaluation proved useful in ensuring that trial 
protocols were adhered to but this may also have had a detrimental affect on staff 
morale and motivation. 
8.8.4. Summary and limitations 
This analysis is limited in that it only reports on trial process during the first two years 
of the trial and it is possible that further issues will arise before the trial is completed. 
The interpretation of findings may also be limited by the methods used to collect data. 
This ethnographic approach incorporated the views of investigators with different levels 
of involvement in trial conduct and intervention delivery, those from differing academic 
backgrounds and with differing status within the academic setting. However, in-depth 
interviews were conducted only with junior staff since they were most closely involved 
with trial process. Interviews with other trial staff (for example the core group) might 
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have revealed other explanations for trial process. Differing interpretations of trial 
problems were identified in subsequent feedback. In particular, the PI and 12 both 
indicated that the analysis was quite negative. Although the investigation aimed to 
provide a balanced account of trial process, the findings may appear threatening to the 
study team, since some of the problems exposed may be interpreted as having been 
avoidable. However, I would reiterate that the investigators followed recommendations 
for the conduct of clinical trials and that the problems encountered were largely a 
consequence of applying RCT methods to a complex intervention rather than 
attributable to individuals. 
The problems of interpreting these data have already been acknowledged in Chapter 4. 
However, despite these limitations, this analysis presents a novel insight into the 
problems of conducting a complex trial and the potential of process evaluation for 
uncovering such problems and in resolving them. The use of qualitative methods 
embedded within RCTs is discussed further in Chapter 10. In the next chapter, I discuss 
the impact of the intervention on patients' understanding and experiences of secondary 
prevention. 
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Chapter 9. Understanding how the intervention works 
In this chapter I investigate the use of qualitative methods alongside RCTs, using in- 
depth interviews with stroke patients to understand how the intervention might 
potentially influence outcomes. 
9.1. Introduction. 
Stop Stroke aimed to improve secondary prevention of stroke by influencing patient 
management in multiple ways. These included improving patients' awareness of 
secondary prevention and through encouraging the idea that stroke is a chronic disease. 
To achieve the first aim, it was hypothesised that advice needed to be evidence-based 
but also, targeted to the individual patient. To achieve the second aim, it was 
hypothesised that multiple strategies were needed. These included explaining the links 
between stroke and the individual's underlying risk factors; providing continuity 
between hospital and community providers; and providing secondary prevention advice 
in an ongoing manner at a number of time points. Thus intervention design was at least 
partially influenced by theoretical ideas generated from qualitative and quantitative 
research . 
34,124,214,215,344 However, in Chapters 6 and 7, I demonstrated that intervention 
development and delivery were also influenced by social, political and economic factors 
leading to deviations from original theoretical ideas and protocols. What has not yet 
been explored is whether these deviations have had any influence on trial outcomes. 
In Chapters 5 and 6, I suggested that patients' experiences of secondary prevention were 
influenced by a number of factors including the organisation of secondary prevention 
services, their understanding of stroke secondary prevention, personal priorities and 
physical, psychological, economic and social barriers. In this chapter I consider how the 
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intervention influenced these (or not) and the subsequent implications for understanding 
outcomes. 
9.2. Methods and participants 
A detailed investigation was conducted with a purposefully selected sample of 20 
patients in the intervention arm of the trial. See Chapter 4, section 4.6 for a full 
description of the methods. The investigation included documentary analysis of what 
was actually sent to patients and professionals, linked with in-depth qualitative 
interviews with stroke patients and/or their carers to explore what patients received and 
the impact of this on secondary prevention. 
Table 16 lists the characteristics of participants for this detailed investigation. Patients 
included those with a range of different risk factors and maximum variation of age at 
the time of stroke (below 65,65-79 and 80+), gender, socio-economic (SE) group at the 
time of stroke, ethnic group and stroke subtype (haemorrhage or ischaemic). Patients 
were interviewed after their one-year follow-up interview for the SLSR so as not to 
interfere with the measurement of trial outcomes. For all those interviewed this was at 
least one year after the acute stroke event and at least eight months since the last `dose' 
of the intervention plans had been sent. 
It was already reported in Chapter 8, that not all patients were sent all three doses of the 
intervention and this was incorporated into the sampling frame so that dose response 
could be explored. For this sample, a total of 47 patient and 47 professional plans were 
sent out. Three patients/professionals were sent only one plan each; seven were sent two 
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9.3. What patients received and the impact of this on patients' experiences 
At the start of each interview I introduced myself to the patient (and/or carer) and 
reminded them that they had been participants in a research study of a special 
intervention aimed at preventing stroke recurrence. Not all patients recalled that they 
were involved in the research. In these cases I provided more detailed explanations, 
including describing the purposes of the study, informing them that some people had 
been given special advice about preventing further strokes and others had not. I 
explained that they themselves might not have been aware of whether they had received 
anything special. At the time of the interview I knew the arm of the trial to which 
patients had been allocated but I did not specifically reveal this information at the start 
of the interview, unless the interviewee themselves indicated that they had received the 
intervention package. 
9.3.1. Patients for whom the intervention had no impact 
One of the commonly accepted assumptions of RCTs is that analysis should be based on 
`intention to treat' (Rothman, p525), 68 that is, when conducting analysis, all those 
completing follow-up assessments should be analysed according to the arm of the trial 
to which they were originally allocated at the time of recruitment. This should be the 
case regardless of whether the participant changed arms during the trial (for example 
whether a control participant started taking the active treatment in a drug trial) or 
whether or not those in the intervention arm actually received the intervention. In the 
Stop Stroke Trial this intention meant that in analysis all those in the intervention arm 
had to be treated as if they and their GP had received the intervention plans and GP 
visits as outlined in the original protocol. I already demonstrated in the previous chapter 
that in implementing the intervention the trial team had difficulty adhering to the 
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protocol, that less than half of patients and GPs were sent all three doses of the 
intervention plans and that only just over half of GP practices in the intervention arm 
were visited by specialists. However, even when the intervention was sent to the patient 
(that is, the team did adhere to the protocol) it became clear from the interviews that 
some patients could not have benefited at all from the intervention. For three patients 
interviewed the intervention appeared to have had no impact on their experience of 
secondary prevention (patients 1,18 and 22). 
It was not always easy to establish whether patients had actually received the 
intervention since for most patients the intervention acted in subtle ways rather than 
having a life changing impact on their experiences. However, for at least one of the 
twenty patients interviewed no intervention packages reached the recipient. Since the 
intervention was delivered by post to the patient's home address there was an 
underlying requirement that a stable address could be identified. It is estimated that a 
substantial proportion of stroke survivors require ongoing care after stroke either 
through `formal' support from health care services (just over a fifth from my analysis of 
trial monitoring data) or `informal support' from friends and relatives. 
224 For many of 
those patients, accessing support may also involve changing place of residence. 
345 Place 
of residence appeared to have an important influence on intervention impact. By the 
time some patients had become settled (had a stable address) the period for delivering 
the intervention had already passed. For Patient 22, the intervention had no impact 
because she did not return home to her usual address after discharge from hospital, 
instead spending some months deciding on a choice of nursing home whilst living in 
hospital. The Stop Stroke team had sent her sole dose of the intervention (6-month plan) 
to the nursing home address she had provided to the SLSR at the 6-month follow-up 
263 
interview [Nursing home A]. However, Patient 22 had never taken up residence at this 
home and the plan was never forwarded on: 
JR: You haven't received anything. You haven't had anything through the post like a pack 
about strokes? 
Patient 22: No, unless it's gone to me home. It might have gone to me address when I 
wasn't there [sic]. 
JR: Your previous address. So you were in hospital for three weeks and you came here 
straight away after? 
Patient 22: No, not straight away. I come and visit [Nursing Home A] first. And I didn't 
like it, I wouldn't go there, so I went back to [Hospital C]. And then ... 
[Nursing Home B] 
had a vacancy so I come and see them and they said to fetch me and show me and they did. 
And they showed me this room and everything and I said, `Yes I like it, ' so I was accepted 
in and I've been here ever since. 
JR: So it took a bit of time going backwards and forwards from [Hospital C]? 
Patient 22: That's right. 
For other patients, receipt of the intervention was more difficult to establish. Despite 
considerable probing (about packages sent through the post, advice about stroke, advice 
from the hospital and information leaflets received from health professionals or other 
sources where patients had learned about their stroke) three patients reported having not 
received the intervention, with no obvious explanation for not receiving it. Nor was 
there a clear dose-response explanation since one of these patients (Patient 24) was sent 
only one plan, one patient (Patient 18) was sent two plans and the other (Patient 1) was 
sent all three. For Patient 18 the impact of the intervention may have been 
`contaminated' by another research study he was involved in. He was taking medication 
for diabetes, hypertension and high cholesterol but was also taking part in the 
`PROFESS' Trial, a pharmaceutical industry trial of a combined antiplatelet drug for 
stroke secondary prevention. 346 This trial involved Patient 18 having regular check-up 
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visits with his GP and taking a specific medication that he had been informed was to 
prevent further strokes. The following extract from field notes written up after the 
interview demonstrates how the PROFESS Trial had influenced his understanding of his 
medication: 
He [Patient 18] was taking 7 different tablets plus some medication for the PROFESS Trial, 
which he described as his stroke prevention medication. This consisted of three tablets, one 
to be taken before breakfast, one after breakfast and one in the evening. He didn't think the 
other medication was for his stroke since he had been told this [the trial medication] was 
specifically to prevent him having further strokes. He showed me the special leaflet that 
came with it, with pictures of the different tablets and instructions on when to take them in 
large bold letters. This was not the normal drug advice that came with a tablet. His other 
tablets included Gliclizide for his diabetes, Ramipril to lower blood pressure and 
Simvastatin. He said he didn't have high blood pressure and hadn't ever heard of 
cholesterol. He hadn't been told what these medications were for and hadn't been given any 
advice about his stroke or his medicines either in hospital or since. 
The procedures and marketing of the PROFESS medication as the `stroke medication' 
had a strong impact on Patient 18's experience of secondary prevention and may have 
made all other attempts at secondary prevention including the Stop Stroke package 
seem negligible by comparison. 
In three further interviews patients stated that they had not received the intervention but 
went on to describe having received information which they had received, that 
resembled advice provided by the intervention plan but which they were unable to 
produce when asked (Patients 5,13 and 24). 
9.3.2. The intervention as a source of information about stroke 
Despite evidence that the intervention had failed to influence some patients' experiences 
at all, for most, it appeared to have had at least some impact. The packs were most 
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commonly discussed as a source of information for helping patients to learn about the 
stroke event or stroke risk factors. However, the importance of different aspects of the 
advice varied from patient to patient. Advice about diet and physical exercise were most 
frequently recalled, possibly reflecting inadequacies of information sources on these 
risk factors through routine services. 275'276 Patients for whom the intervention had 
provided information discussed how it had informed them about what a stroke is, the 
tablets they had been prescribed for stroke, their risk factors (atrial fibrillation, blood 
pressure and cholesterol) and the limits within which their physiological markers of risk 
should be maintained. As anticipated, the information was deemed useful for different 
reasons. For Patient 23, the intervention plans were the first and only source of 
information about stroke that she had received: 
Well I didn't know anything about strokes... . So really, they 
did enlighten you as to what a 
stroke was and how it comes about, you know. (Patient 23) 
For Patient 11, the information was not new but had helped to reinforce the advice 
given from health professionals at the hospital or from the GP: 
JR: Did you get a package or anything, when you - after your stroke, that had sort of 
information about strokes? 
P 11: Oh yes, yes. 
JR: You did. 
P 11: Yes. 
JR: And what did you think of it? 
P11: 1 read through it all, it was very informative, yes. You know, basically that sort of 
backed up what they verbally told me anyway in the hospital, in the outpatients. 
For patient 10, the packs were useful not only in providing facts about stroke but also in 
providing guidance on prevention management. 
JR: And did you find it [the intervention packs] helpful? 
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P10: Well you get to know things about yourself and what you should do and what you 
shouldn't do. And they explain the details of the stroke ... 
how the cholesterol works, they 
have graphs in there somewhere haven't they [patient shows JR his plan]. The blood 
pressures and all, they explain. ... with the arteries and the 
blood pressures, there you are. 
That's, they tell you what the different tablets you take. 
Although some patients seemed to have little interest in secondary prevention and stated 
that they would not necessarily wish to receive any more information, none of the 
patients indicated that they were unhappy with what they had received, even in cases 
where they felt that the information was incorrect. It is well known that measures of 
satisfaction often have ceiling effects or reflect other patient characteristics rather than 
the ability of the intervention to meet patients' needs or expectations . 
347-349 Thus, it is 
difficult to interpret whether patients' non-critical responses to questions about how 
useful the intervention was, represented satisfaction or simply reflected a ceiling effect 
on this type of questioning. 
Some patients identified errors in the plans. For example Patient 16 identified 
typographical errors: 
P16: They've spelt my name wrong on that one. 
JR: Oh have they? 
P 16: They've put an E ... 
JR: Is it right on the next one? 
P16: No. 
JR: No. Still the same, okay. 
P 16: And they've put the wrong postcode on. 
Spelling mistakes were not the only errors identified and patients also pointed out 
problems with the test results presented in the plans. Documentary analysis of what 
exactly had been sent to patients revealed that only 5/20 patients were sent interventions 
with no errors at all (patients 10,11,17,24 and 25). All other patients were sent at least 
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one plan containing errors. Errors included: simple formatting problems such as poor 
presentation of test data (6.0000001 mmol/L instead of 6. Ommol/L), bits of text 
highlighted in grey, or medications miss-spelt; misdiagnoses of risk factors or 
contraindications for medication; omitted medications; advice that was confusing or 
inappropriate. Inappropriate advice included: misdiagnosing the patient as a heavy 
drinker (when SLSR data indicated that the patients' alcohol use was unknown); telling 
the patient to visit their doctor to check they were on the right medication (when SLSR 
data indicated that the medication was appropriate); or not telling the patient to take the 
aspirin they had been prescribed (because the SLSR question diagnosing stroke sub- 
type had not been completed). 
While the above problems primarily related to technical issues in intervention 
production and delivery, some patients also identified problems with advice not 
provided in error. For example some patients disagreed with the advice they had 
received about their risk factor management, such as recommending that patients should 
change aspects of their diet (cutting down on salt or fat). These patients argued that the 
advice was not applicable to them since they did not usually eat much salt or fat. 
P17: It says here, `You haven't cut down on salt or salty foods. ' Well I don't take much salt 
anyway... 
JR: So some of the things in here don't seem to be quite right? 
P17: No 
However, these disagreements and errors did not seem to have a large impact on 
whether or not patients found the plans helpful. Patient 17 said that she had read 
through the pack couple of times and that it had provided her with information about 
blood pressure and cholesterol and diet, despite her highlighting that she felt that the 
advice on diet was inappropriate. Wiles argues that trust plays an important role in the 
efficacy of prevention advice and patients did not necessarily lose trust in the 
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information provided even when they disagreed with what it said. 276 Patient 10 
explained that since he understood that the intervention had come from the hospital he 
felt that the information provided was more credible and reliable than other similar 
sources that he might have been able to seek out himself (such as in magazines or 
newspapers). Thus some patients may have appreciated being given information about 
their strokes even if it did not tell them anything new and even when they felt that the 
information was not wholly accurate. 
However, despite providing information and advice on a range of stroke secondary 
prevention topics, there were some factual aspects of stroke care that patients felt that 
the packs were unable to address. In particular they could not explain how or why the 
stroke had happened. For patient 23 there had been no definite diagnosis so she was still 
unsure as to exactly what had happened: 
P23: So I mean, the unanswered question is, what happened to me? Just probably like a 
dizzy spell. And nobody could answer that because it didn't leave me with anything to go 
on, did it, really for them. I mean they give you a brain scan. And they can tell from that. 
But that was all fine. 
Even when a stroke diagnosis had been made, for some patients, explanations of the 
mechanisms between the risk factors and development of the blood clot that caused the 
stroke were still not sufficiently clear. 
P19: Well yes, the first thing is, do they definitely know, it's too late now, what caused it in 
the first place? What caused the stroke in the first place? Well they do, they say a clot of 
blood through the scan, there that's caused the trouble. But where did it come from? How 
did it come about? 
The plans had attempted to address patients' queries about stroke causation through 
explaining that the acute event was linked to underlying risk factors and through 
providing tailored advice on risk factor control relevant to the individual. However, for 
some patients (including patients 19 and 23) who did not have any of the usual risk 
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factors (including hypertension, atrial fibrillation or diabetes), the plans were 
insufficient in helping them to understand why the acute event had happened. 
9.3.3. Encouraging continuity 
A second key aim of the intervention was to try to create a sense of stroke as a chronic 
disease requiring ongoing monitoring and management. One of the strategies for 
achieving this was through providing the intervention at multiple time points. I have 
already demonstrated that due to trial requirements, only a minority of patients 
(approximately a third) were actually sent the intervention at multiple time points (in 
Chapter 8). Thus it might be expected that this component would fail to have had any 
impact. However, for some of those who did receive all intervention components (as 
originally intended) the intervention did appear to influence their understanding of 
secondary prevention. For example, Patient 23 discussed the intervention as something 
that was ongoing: 
JR: Has anyone ever given you any written information since the stroke, about your stroke 
or about? 
P23: I've got all the literature... yes, they send it often, don't they... what to do to prevent it 
and how to avoid it and what to do. 
JR: Was it like a pack that you received? 
P23: Yes it's a pack isn't it, in a plastic cover like. 
JR: That's right yes. 
P23: Yes. I've had two of them. They do send them at regular intervals I think, don't they? 
There was evidence that the strategy to deliver advice in a more personalised way also 
encouraged the idea that care was ongoing. Personalised advice may have reassured 
patients that there were no aspects of care that they had missed out on or that needed to 
be improved. The plans provided reassurance for some patients even if the patient did 
not agree with the advice provided. For example, Patient 16 identified mistakes in the 
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plans he had received but explained, "It's very satisfying when I know people have 
some interest in me". This contrasted with the routine care he expected to receive from 
his GP: 
Patient 16: The doctor, I go, I bet if I go in next month, as he asked me to, there will be a 
different doctor there. That's the trouble. No continuity. Not that I've seen anything but 
good treatment but it doesn't help the doctor. You know, I mean, he sees maybe 50 or 60 
patients a day. 
JR: Yes. 
Patient 16: And he's got to look up all their records. 
JR: Yes. Each time. 
Patient 16: Each time. 
It seemed to be that patients felt that receiving some advice (even if not perceived as 
being completely accurate) was better than the usual care alternative (in other words, 
receiving nothing). Thus some patients appreciated the intervention even if the packs 
did not appear to have had a life-changing impact on secondary prevention 
JR: Did the package say anything about anything else apart from what you eat? 
P14: Well it probably did but I can't remember. 
JR: You can't remember? 
P14: No, that's one of ... the head don't retain. As I say, 
it don't hold things long, you 
know. 
JR: Do you remember whether you found it useful? 
P14: Yes, I thought it was quite good really. I thought it was quite good because I thought it 
gives you an insight into something because people don't tell you nothing. You know, 
when you go to these hospitals, they don't tell you... 
However, despite these examples of the intervention working as anticipated, the 
findings cannot be generalised to all patients. Patient 17 did not believe the intervention 
was personalised, while Patient 23 did not feel that the advice was relevant or 
personalised to her: 
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JR: Did this contain any information that was specifically about you, or was it just general 
advice? 
P17: Well I think it was probably general. Although it says here, `Personal Plan. ' 
JR: Did you, the information that they sent you, did you find it useful? 
P23: Well I did read through it. And if it was necessary, if it applied to me, I would have - 
but not much applied to me because I wasn't, you know, damaged from the stroke, was I? 
To a certain extent the influence of the plans may reflect the strengths and limitations of 
the SLSR as an intervention tool. Patient 23's stroke had been coded by the SLSR as 
`unclassified' and all her risk factors had been controlled at the time of stroke. Thus it 
was difficult to provide explanations for what had happened to her, or to provide advice 
on how best to prevent further strokes. Equally, the packs included test results showing 
how the patient was progressing but tests were not conducted specifically for the plans 
at each time point and instead were based on patients' reports and existing tests. If a 
new test had not been done since the last SLSR interview then the same information 
would be provided at multiple time points. Without updated information the plans may 
have had limited influence. 
JR: Do you think that this sort of thing [the intervention] can help, that it's important to 
have something like this? 
P19: Yes but that [three-month plan] is the same as that [six-month plan]. 
JR: Right. 
P19: There's no point in people giving you the same thing. But if the cholesterol had been 
taken and that had been done and everything had been tested, and then you see if it's made 
any difference, then you would know. 
Simply providing the same advice time and again was not necessarily enough to 
persuade patients that monitoring was ongoing. Equally, the plans were only provided 
to patients over a maximum of the first eight months post stroke and this may not have 
been long enough to promote the idea of continuity. For most of those interviewed, 
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contact with specialist stroke services ended within a year of the stroke. The termination 
of intervention delivery coincided with this, possibly reinforcing the idea that stroke 
care had finished. 
Patient 10: I've had one [a plan] now for a long time, I think I had two, I may even have 
had three. But that's long ago, back a long way, a long way ago... 1 didn't have any last 
year, I finished with Mr X [at the hospital] last year. 
JR: Yes. 
Patient 10: 1 think April or something, or May or something was my last visit to Mr [X]. He 
said, `there is no point in coming back, you're okay. ' 
However, continuity in secondary prevention management was encouraged if patients 
had other ongoing activities, which reminded them of the stroke and the need for 
secondary prevention. A number of patients went to stroke groups run by voluntary 
sector agencies such as Age Concern, Time and Talents, other research projects and the 
patient-involvement group set up by the local stroke Modernisation Initiative described 
in the previous chapter. 235 These contacts may have unintentionally interacted with the 
intervention to influence secondary prevention. Patient 19 described how his 
participation in the patient-involvement group had encouraged him to revisit his stroke 
intervention pack and to continue watching his risk factor management, which he would 
not otherwise have done. The Stop Stroke intervention had been discussed by another 
participant at the group as an example of something positive which had been provided 
after the stroke. The meeting had encouraged him to take another look at the packs and 
to take note of the secondary prevention advice. 
JR: So did you come back and look at this? 
P19: Because I was involved with the unit [user involvement group]... I've been paying a 
little bit more attention ... 
JR: So you came back after this group and had a look at? 
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P19: Well yes, yes. I got them out and thought, 'Oh I'd better read what those 'Keeping 
Well Personal Plans, ' are for. 
Patient 19 discussed how after reading the packs, he had realised the importance of 
cholesterol control in preventing further strokes and consequently had started to take 
more notice of risk factor control strategies. 
P19: When I got this `Keeping Well After Your Stroke Personal Plan, ' up to now I haven't 
taken a lot of notice of it but when I did read about the - where are we - the cholesterol 
tablets, these [patient shows JR the cholesterol advice sheet]. 
JR: This one here, the cholesterol. 
P19: Yes, the cholesterol ones, I didn't really understand what they actually did but they're 
just as important, more than some of the others I take. 
It was the interaction between the packs and the user involvement group that appeared 
to encourage continuity in risk factor management rather than the intervention alone. 
Without the user involvement group meeting and without the intervention having been 
discussed at that meeting the plans might not have been used. 
9.3.4. Patient empowerment 
The final theme that emerged from the interviews concerning the influence of the 
intervention on patients' experiences of secondary prevention, I have termed 'patient 
empowerment'. 'i In this analysis I use the term in relation to responsibility and control 
and refer to the patient's ability to take responsibility for their own secondary 
prevention management. Thus the impact of the intervention on patients' choices, 
behaviours or actions related to secondary prevention is explored. 
' Empowerment is a contested construct and has been used differentially over the past decades in relation 
to a range of social and political agendas. Historically it was used to refer to financial resources, but more 
recently has been used in relation to consumer choice. 350 Within consumerist models of healthcare, 
empowerment is often used to refer to user oriented services, responsive to users' needs . 
351 Recent health 
policy is based on the principle that poor health is a consequence of individuals being 'dis-empowered', 
the assumption being that they can subsequently be `empowered' through individual or social 
intervention, to enable them to take responsibility for their own health concerns. 254,255 
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It was difficult to establish through interview whether the intervention had had any kind 
of direct impact on patients' choices, behaviours, or actions in relation to risk 
management strategies. In most cases patients did not, or could not distinguish whether 
the advice that had triggered their actions was provided by the intervention plans or by 
other sources. This was further complicated by the fact that most patients saw the plans 
as having come from the hospital and did not distinguish between the impact of the 
intervention and that of other health services or activities they were engaged in. 
However, there were examples of patients developing new strategies since the stroke 
that fitted with recommendations for optimal secondary prevention and there were some 
patients who related their actions to the intervention. Such strategies included 
developing new exercise routines or making alterations to diet: cutting down on sugar or 
salt or eating substitutes for these; drinking less coffee, less alcohol or more water; 
eating foods marketed as cholesterol lowering; cutting down on saturated fat from red 
meat; or buying low-fat dairy products. Since diet and exercise awareness were most 
strongly attributed to the plans it is possible that they also had an influence in 
encouraging patients to take responsibility for risk factor management in these areas: 
JR: With this information that you've had, did you, did it make you do anything different 
after you'd read it? 
P2: Oh yes. It make me exercise and drink more. 
JR: Really? That's good. 
P2: I drink a lot of water. 
JR: Is that drinking water or is that drinking alcohol? 
P2: Water. I never smoke and I don't drink... about the stroke, I mean about the 
diabetic.. 
. 
but I'm never interested in that and since I know it don't agree with me, I don't 
do it. And... I just keep away from that. 
JR: Yes, that's the best thing, I think. 
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P2: My drink is water and tea and I drink the diabetic drink but sometimes it tastes sweet, 
Coke and those, you know. I drink the diabetic drinks. And, what do they call it? Keep fit 
yoghurt. 
In the interviews presented in Chapter 5, the local environment and fear of crime were 
found to be barriers to patients leaving the home either to exercise or to access health 
services. The environment was also identified as a barrier to secondary prevention in 
these interviews but some patients with disabilities had developed novel strategies to 
overcome these barriers. These included, walking around the home or up and down the 
corridor outside of the flat to exercise, or in the case of Patient 25, climbing the stairs in 
her block of flats by the rubbish chute which did not require her to cross busy roads. 
Other examples of patients taking responsibility for their own risk factor control 
included monitoring body processes. Two patients kept records of their own blood 
pressure, one of whom had bought his own device which he demonstrated to me during 
the interview. He explained how he used it to monitor his own blood pressure: 
Patient 10: 1 check it myself, I take it regularly. 
JR: Oh right. 
Patient 10: It's a little one you put on your wrist, you know what I mean... 1 check it every 
day. 
JR: You check it every day, do you? 
Patient 10: 1 check most days, most days, yes. 
JR: Right. 
Patient 10: Well it varies, as you know, the blood pressure goes up and down doesn't it? 
JR: Yes. 
Patient 10: One day it's high, next day it's down... that's how it goes. But when they expect 
it high, then it's low. 
JR: So you checked it today did you? 
Patient 10: 1 haven't checked it today. I usually check about 4 o'clock in the afternoon, at 
the same time every day. 
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Checking one's own blood pressure was one of the suggestions in the blood pressure 
advice sheets but Patient 10 was unclear as to what had prompted him to buy a machine 
or start his own monitoring. When asked about the level at which he was aiming to keep 
his blood pressure he explained that his GP had recommended less than 150 (systolic 
blood pressure) but he had also been told 140 (as it stated in the plan). However, he 
attributed this advice to the doctors at the hospital and not the plan specifically. 
The plans themselves were also used as a means of monitoring blood pressure, a record 
that patients could use if questioned about how they were progressing. 
JR: And you're on tablets for your blood pressure as well. Do you know what your blood 
pressure is? 
P19: Wait a minute, it's in one of these [intervention plans] and it's accurate. I think I used 
to keep - in here. No I can't remember now. [the patient gets out one of his secondary 
prevention plans. ] It was 136 - no but this is months ago. 
JR: that was your blood pressure in June last year? 
P19: Yes. Oh crumbs. Because when I was going regular, I used to write it down on 
me... but they said it was alright. 
JR: It was okay, was it? 
P19: Yes. 
However, the plans only seemed to encourage patients to take responsibility for risk 
factor control in areas where they did not need to seek contact with medical services. 
There were a number of different scenarios in which the intervention plans advised 
patients to seek medical advice (see Chapter 7, Tables 13 and 14). Twelve patients were 
advised to seek medical consultation from their doctor in their three-month intervention 
plan, including for advice about their medication or for cholesterol monitoring. Fourteen 
patients were advised to seek medical consultation for the same reasons in their six- 
month plan. However, only one of the 20 patients interviewed indicated that (s)he had 
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sought medical advice as a result of the plans"'. One explanation for patients not 
discussing the plans with their GP may have been that they perceived that the GP would 
already know of any problems with their health and thus would contact them directly 
for a consultation if necessary, or would automatically raise any problems should the 
patient routinely visit the surgery. 
JR: You haven't ever taken it [the plan], you haven't ever shown your doctor or anything 
like that? 
P25: No. If he asks when he comes over, it's there for him to look at. 
In Chapter 6, I demonstrated how both patients and professionals assume continuity of 
information between primary and secondary services, despite gaps in service provision. 
I also demonstrated how `medical authority' can prevent patients from challenging 
professional decisions. Such influences may have had an impact on patients' 
interpretations of recommendations to seek medical advice provided in the plans. 
The one patient who did seek medical advice about his tablets (Patient 16) may have 
been different from the others. He was both highly motivated to take responsibility for 
his own risk factors (changing his diet, cutting out alcohol and walking at least a mile 
daily) and had atrial fibrillation (an ongoing heart condition for which specialist clinic 
follow-up is provided, unlike other stroke risk factors, see Chapter 5). According to the 
RCP guidelines Patient 16 should have been prescribed warfarin since the register data 
indicated that he had no contraindications for the drug. The intervention informed him 
that he was not taking any secondary prevention medication for his atria] fibrillation and 
encouraged him to check with his GP. Patient 16 used the plan as a reason to question 
his GP about the treatment he was taking. 
In a study of advice to seek cholesterol testing for heart disease, a letter to patients achieved a check up 
rate with GPs of 81 %. 352 
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P16:... they wrote on it, `You're receiving no medicine for your heart. Go to your doctor ... 
for your heart condition, ' you see. So I thought I can't go to my doctor and say that, `you're 
not treating me right. ' So anyway...! showed him and he said, 'What's this? ' And I said, 
`It's from [Hospital X], it's a record of my illness and it shows that I'm not getting anything 
for my heart. ' 
However, he explained that his GP had informed him that his medication was 
appropriate. Yet according to SLSR data, by the six-month follow-up visit the patient 
had been prescribed warfarin (the RCP optimal treatment). Although this is an isolated 
case it does suggest that the plans may have some capacity to `empower' patients to 
challenge medical authority and this may in turn have influenced risk factor 
management. 
One of the key aims of the intervention was to provide secondary prevention advice to 
those who were less mobile as a result of the stroke and would not routinely receive it 
from health services. Thus the intervention was designed to be used by carers as well as 
patients. For Patient 20, this strategy appeared to work since her daughter who had 
some clinical training, was able to use the intervention to explain to her about secondary 
prevention: 
JR: So, you didn't receive any packs that were specifically for you and about stroke? 
P20: Yes, I received a packet when I've just come out, yes. 
JR: Oh okay. 
P20: I did receive one. And it show you everything like your heart rate and everything. I 
don't know, I think it must be somewhere upstairs. This is the last one I get a couple of 
weeks ago. So I did receive a big package. 
JR: That was shortly after your stroke, was it? 
P20: Yes, yes. And it showing that - like my blood pressure should be checked quite often 
and things like that, you see. 
JR: Was it useful? Do you remember? 
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P20: It was useful to me because I could see - my daughter was, she's a nurse too, you see, 
my daughter but she has so many different job that she don't know which one to keep. So 
she also explain it to me. 
There were some patients for whom the intervention had little chance of `empowering' 
them to take responsibility for risk factor management. Patients with severe disabilities 
who were living in residential care (Patient 13) and those who had full time carers at 
home (Patients 21 and 24) were dependent on their carers for secondary prevention 
management. For these patients the ability of the intervention to influence secondary 
prevention strategies depended on the carer prioritising secondary prevention, which did 
not always happen. For example, Patient 13 had psychiatric problems and was 
dependent on her nursing home staff to organise monitoring of blood pressure and 
cholesterol, provision of food and administration of medication. She was also bed- 
bound and thus unable to engage in even light forms of physical exercise for prevention. 
The nursing staff explained that only experienced psychiatry specialists could deal with 
her health concerns. At the time of visiting her, the manager of the nursing home 
explained that in the context of her psychiatric illness she felt that stroke secondary 
prevention was relatively unimportant. 
Similarly Patient 21, who was cared for by a friend, also had little individual power to 
influence his own secondary prevention management. He had been a heavy smoker and 
an alcoholic at the time of stroke and was homeless, living either in the park near his 
friend's house or in hostels. The stroke had left him severely physically disabled and 
unable to speak. On discharge from hospital he had moved in with his friend and now 
lived on a bed in the living room (he was in bed at the time of interview). This interview 
was not recorded but the following extract from field notes taken during the interview 
illustrates the lack of `power' the patient had over aspects of his secondary prevention 
management. 
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I asked [the carer] whether [Patient 211 smoked. Throughout the interview [the carer] had 
chain smoked, in fact the room was so smoky at one point my voice started to go and my 
eyes started watering as I tried to suppress a cough. I can still feel it in my throat an hour 
later! [The Carer] said that [Patient 211 used to smoke before the stroke but since the stroke 
he [the carer] had refused to give [Patient 21] any cigarettes, like with the alcohol. He said 
[Patient 21] would look over and see him smoking and would sometimes gesture for a 
cigarette but [the carer] always refused. He said [Patient 21 ] had given up for a year now 
and he didn't want to let him start again. I asked [the carer] if I could speak to [Patient 21 ] 
about it. I went over to the bed and asked [Patient 21 ] whether it was OK that he wasn't 
allowed to smoke anymore. He gestured `thumbs up'. I asked if it was OK not drinking so 
much and [the carer] said you feel better not drinking and smoking don't you" [Patient 
21 ] gave the thumbs up. 
Although the plans may have helped the carer of Patient 21 to take responsibility for 
aspects of the patient's secondary prevention management (through informing him of 
the medication he needed and encouraging him to prevent his friend from smoking), it 
had done little to empower Patient 21 himself to make choices about alternative 
treatments, to take control of his own management or to prevent him being at risk from 
passive smoking. 353,354 
For those who had less severe physical disabilities but no carer assistance the plans also 
appeared to have limited use in the context of empowerment. Patient 12 had less severe 
disabilities (as measured by the Barthel Index) but was not only housebound but also 
unable to make phone calls since he could not afford credit for his mobile phone and the 
landline had been disconnected. He had fallen out with his family and had no way of 
contacting his GP practice to explain why he was unable to come for a check up. When 
I asked him about the intervention package he explained that he had read the 
information but had not found it helpful since he felt that he needed personal contact 
from health services. 
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JR: So do you feel a bit that the information is not that helpful because you can't get to see 
the doctors anyway? 
P12: No, the question yes is that, the most knowledge you told people about their various 
type of illness, they should - either the patient to see them, or their doctors should make 
sure that they see to the needs of these people, how they could improve their condition 
... 
Now, the follow-up should come from the proficient people like the doctors, the 
specialist and so forth and they should then provide adequate means or contact, you see. 
Although he had appreciated that the intervention was designed to help him manage his 
own secondary prevention, he did not feel that this was an adequate substitute for the 
clinical care that he could not access. Consequently he did not find it helpful. 
9.4. Discussion 
In this chapter I have presented findings from analysis of patients' experiences of using 
the Stop Stroke intervention. These findings, together with those from Chapters 7 and 8 
on intervention development and implementation will help in understanding the 
eventual success or limitations of the intervention in influencing outcomes. 
However, before I discuss the possible influences of the intervention on patients' 
experiences of secondary prevention and on trial outcomes, it is important to consider 
the context in which these interviews took place. The interviews were solely with 
patients (and carers) and so interpretation of how health professionals had used or 
responded to the advice provided cannot be investigated (except where patients reported 
it had influenced their own experience). The timing of the interviews may also have 
limited my ability to investigate links between the intervention and subsequent patient 
actions. These interviews were more of a snapshot of patients' and carers' 
understanding of secondary prevention, which may change over time (as their 
symptoms change and as patients and carers are exposed to different services and 
282 
information sources). Since the interviews could not be conducted until the outcome 
data had been collected (to prevent contamination of trial outcomes), all interviews took 
place at least eight months after the date at which the last intervention plan had been 
sent. In this time patients may have taken up advice provided by the intervention but 
may not have been able to recall doing so. Certainly there were some patients (Patients 
1,5,13,18 and 24) for whom it was difficult to establish whether or not they had 
received the intervention at all. Memory and cognitive problems resulting from the 
stroke exacerbated difficulties with recall. Thus it is possible that the intervention had a 
smaller, greater or different impact on secondary prevention experience than could be 
uncovered through these interviews. 
9.4.1. How the intervention influenced patient experience 
Understanding the impact of the intervention is complex since risk management itself is 
complex and the intervention was not delivered within a vacuum. Although the aim was 
to identify `themes' that might help understand intervention process and consequently 
trial outcomes, patients' experiences varied according to the health and social context of 
individual lives. I have presented case examples of how individuals discussed the 
intervention and their secondary prevention management, which provide an insight into 
the processes by which the intervention influenced outcomes. The intervention had a 
subtle impact and thus it was difficult to disentangle experiences influenced by the 
intervention from those influenced by routine health services, other voluntary services 
and research studies. However, three key mechanisms emerged by which the 
intervention potentially influenced patients' experiences of secondary prevention: 
through providing information about the stroke, underlying risk factors and treatment; 
through providing a sense of continuity in service provision, reassuring patients that 
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they were being looked after; and through encouraging or `empowering' patients to take 
responsibility for secondary prevention. 
It is well known in the literature that educational or information-based interventions are 
most likely to improve knowledge212 and thus it is reasonable to speculate that for those 
who used the intervention as a source of information, it contributed to increased 
awareness of optimal secondary prevention strategies. Both patients and carers 
discussed how the plans had provided them with information that they had either not 
known before, or that reinforced information that they had received elsewhere. Poor 
information provision for patients after stroke has been consistently reported in the 
literature 275'276 and the intervention may go some way to filling this need. 
However, it is also known that education based interventions are less likely to have an 
impact on other types of health outcome (such as adherence to medication, uptake of 
preventive behaviours or changes in bodily process). 212'355 This intervention tried to be 
more than just an educational package. It also aimed to encourage the notion that stroke 
is a chronic disease, through targeting primary care practitioners and improving 
continuity in service provision. The observation that some patients appreciated the 
intervention despite finding factual or typographical errors suggests that the information 
component was only one of a number ways in which it influenced patient experience. 
Previous studies have consistently documented that stroke patients have unmet needs 
and may feel abandoned with poor service provision once discharged to the 
community. 356 Yet few interventions to improve social support during this transition 
phase have had success (see the literature review Chapter 3). Providing systematic risk 
factor advice in the longer term may only have a subtle influence but may be better than 
opportunistic follow-up (usual care) in reassuring patients in this uncertain time. 
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Linking the intervention to a respected source (such as the hospital) seemed enough to 
ensure that patients did not lose trust in advice even when mistakes were obvious. 
There was evidence from at least some patients that the intervention also had an 
influence on risk factor control through encouraging them to become more actively 
involved in their own risk factor management. Although some might argue that it is 
impossible to `empower' people solely through education targeted at individuals, 83,357 
individual patients discussed how the intervention had assisted or prompted them to 
take responsibility for aspects of risk factor management. There were enough individual 
examples of patients changing aspects of secondary prevention (their food or exercise 
routines, checking bodily process or even asking questions of GPs) to suggest that for 
some patients the intervention had some influence on their notions of responsibility and 
control, possibly through increasing awareness of what was considered optimal 
management or through increasing self-confidence (or self efficacy279) in their own 
abilities. 
9,4.2. Limitations of the intervention 
In Chapter 8, I identified a number of problems with intervention implementation 
(environmental changes, deviations from the protocol and the impact of the trial on 
theoretical development), which may influence the power of the intervention to 
influence outcomes, or the power of the study to detect differences in outcome. These 
problems had some obvious consequences. For example, not all patients were sent plans 
as intended and even when plans were sent, they did not necessarily reach the intended 
recipient. Problems of intervention delivery could have been overcome if time of 
discharge and place of residence had been taken into account (as recommended in 
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theoretical phase findings, Chapter 7) but may have been impractical in the context of 
this RCT (Chapter 8). 
However, not all of the limitations associated with the intervention were necessarily the 
result of poor implementation. In Chapter 5, I discussed how the nature of stroke as a 
disease and organisation of services promote an experience of stroke, which focuses on 
the acute event. The intervention aimed to assist patients and primary care professionals 
in re-conceptualising stroke as a chronic disease through providing a more organised, 
personalised approach to the provision of secondary prevention advice, which it was 
hoped would encourage continuity. Despite the examples presented earlier, patients 
were not homogenous in their responses to the intervention and the interviews 
uncovered a number of social, health and service related factors that may have impacted 
on the ability of the intervention to achieve its aims. 
Firstly, although for some patients the intervention provided reassurance that health care 
needs were being monitored, the process of producing intervention plans was 
computerised and there was no mechanism for `active' intervention if inadequacies in 
management were reported. Patients' GPs were also sent risk factor information (via the 
professional plan) but there was no guarantee that they would take action if the 
information they received identified problems with patient management. Thus the 
intervention may have created an illusion of continuity for patients without influencing 
provider practice at all. The interviews uncovered one example of the intervention 
having had an influence on treatment prescribing. However, further investigation with 
GPs themselves would be required to gain a better understanding of the impact of the 
intervention on GP practice. To prevent contamination of the trial, this investigation is 
being withheld until trial outcome data collection has been completed (as discussed in 
Chapter 4). 
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Secondly, the `embodied' experience of illness is complex and is influenced by a range 
of processes located both within the body (such as symptoms) and externally (such as 
health service intervention). 239 In the case of stroke, symptoms tend to be associated 
with the acute event and residual pain or explicit disability rather than underlying bodily 
process (such as high blood pressure or damaged arteries) which are hidden and thought 
to be symptom free (see Chapter 5). Despite attempts to make visible the links between 
the acute event and underlying bodily processes, the intervention had little power to 
change certain aspects of the embodied experience, such as the individual experience of 
symptoms. The intervention also had little power to influence stroke specialist service 
provision for treating such symptoms since it was targeted solely at primary care teams. 
Since intervention delivery finished roughly around six months post stroke, for some 
patients the intervention may have reinforced the experience of stroke as an acute event, 
rather than counterbalancing discontinuity in stroke services in the longer term. 
Where the intervention did interact with health services, voluntary projects or other 
research studies it seemed to have a stronger impact. However, the patients who interact 
with these services may already have better access to secondary prevention 
management. Previous epidemiological analysis of the SLSR has demonstrated that 
patients who fit into health service `systems' at an early stage are those most likely to 
benefit from services in the longer term. 358 Interviews with professionals have also 
revealed that healthcare professionals streamline patients through suitable services and 
that those who do not fit existing service templates may have reduced access to care. 359 
One of the aims of the intervention was to close the gaps in service provision for such 
patients. It was felt that those who do not benefit from existing service `templates' 
might benefit most from the intervention. However, these interview findings suggest 
that the problems of intervention implementation identified in Chapter 8 may have 
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exaggerated rather than closed such gaps with those missing out on existing secondary 
prevention strategies also falling `through the net' of intervention provision. 
The one group for whom the intervention had clear limitations were those with severe 
physical and psychological disabilities. This does not mean that the intervention did not 
have the potential to influence patient experiences at all, since it could have been used 
by the patient's carer. Other carer focused interventions have demonstrated improved 
patient outcomes. 185 If the Stop Stroke intervention improved continuity and awareness 
of risk management strategies for carers then this may have translated into subsequent 
management. However, we know from analysis of trial process (presented in Chapter 8) 
that no carer plans were sent in the first two years of the trial. Equally in the research 
presented in this chapter, none of the three carers of severely disabled patients 
interviewed, viewed secondary prevention as a priority in the context of the patients' 
other health concerns. Thus the intervention was unable to `re-prioritise' stroke risk 
management. 
It is perhaps not surprising that the intervention had less influence for patients with 
severe disabilities given that theoretically it was not designed with these patients in 
mind (see theoretical development Chapter 7). Subgroup analysis of trial impact for 
those with different levels of disability could explore these issues further. The 
challenges of theoretical development and the influence of RCT design will be 
addressed more fully in the discussion presented in Chapter 10. 
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Chapter 10. Discussion and implications for complex intervention 
development 
10.1. Introduction 
This thesis has provided a novel insight into the methodological challenges of applying 
`gold standard' RCT methods of evaluation to Stop Stroke, an intervention to improve 
stroke secondary prevention. A number of questions were investigated including: the 
use of The MRC Framework as a measure of quality in intervention development and as 
a practical tool for guiding research; how qualitative methods embedded within a RCT 
can be used to improve our understanding of complex interventions; and how social, 
economic and political processes influence the construction of medical knowledge in 
the context of a complex public health intervention. 
The work used a range of qualitative methods that are standard within public health 
research but also used one, ethnography that is much less common. Ethnographic 
accounts have been used to understand the production of scientific knowledge in other 
areas of science, for example in the laboratory 360 and in medicine 361 but there has been 
relatively little investigation of the construction of knowledge within the context of 
public health. Ethnographic studies of public health interventions have focused mainly 
on understanding the outcome of interventions rather than the production of knowledge 
per se. 113,116 This investigation was not straightforward and took approximately five 
years to complete, reflecting the lengthy and complex processes involved in the 
development of public health knowledge. 
The research has raised a number of questions for complex intervention development, 
including questions about the benefits and limitations of the MRC Framework as a 
research tool; the social and political implications of adopting The Framework as a 
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measure of quality or research tool; the nature of scientific evidence more broadly; and 
the use of qualitative methods in intervention development and evaluation. In this final 
chapter, I discuss these issues and implications for future research and complex 
intervention development. 
10.2. Application of The MRC Framework 
In Chapter 1,1 described how I became interested in The Framework as a result of its 
popularity and at the time I had hypothesised that this was because it was a 
groundbreaking tool, a methodological `revolution'. 93 1 had assumed that it would 
transform the way research studies were designed and in the process improve our 
understanding of the workings and outcomes of complex interventions. However, as the 
thesis has evolved, the practical uses of The Framework have become less clear, leading 
to questions about its revolutionary status and its ability to enhance our understanding 
of complex interventions. I now discuss The Framework, firstly, in relation to the 
practical benefits and limitations of using it as a research tool; and secondly, in relation 
to the broader social and political consequences of its publication. 
10.2.1. Benefits and limitations of the MRC Framework as a research tool 
In this thesis The Framework was used as a research tool in two contexts: i) as a tool for 
defining and improving quality in intervention development; and ii) as a practical tool 
for guiding intervention development. The benefits and limitations of using The 
Framework in these ways are now discussed. 
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10.2.1.1 Defining and improving quality in intervention development. 
In Chapter 3, I attempted to investigate the relationships between theoretical 
development, methods of evaluation and study outcomes. The MRC Framework was 
used both to guide search strategy and to devise quality criteria to evaluate theoretical 
and methodological quality. I used The Framework as a tool for evaluating a range of 
complex intervention studies for which current critical appraisal tools might be 
insufficient (since most studies would have failed to fulfil appropriate criteria). It was 
certainly possible to categorise interventions according to the development strategy 
adopted, as well as the evaluation strategy (more usual in critical appraisal), albeit not 
strictly into the four developmental phases outlined in The Framework. Thus the quality 
criteria developed may prove useful in defining and categorising interventions 
according to the theoretical assumptions used. It would then be possible for critical 
appraisal guidelines to incorporate such criteria into their recommendations for complex 
intervention evaluation. Since so few of the studies were classified as being 
theoretically and methodologically `well developed' when judged against these quality 
criteria, it is possible that the observed lack of success of studies to demonstrate efficacy 
results from poor theoretical or methodological rigour. By defining standards for 
development, The Framework could enhance the outcomes of future research studies. 
However, the MRC Framework has a number of potential limitations if used as a 
measure of quality in complex intervention development. Firstly, the definition of 
complex intervention is vague. Therefore it is not clear which sorts of intervention 
should be judged using these quality criteria. In the literature search presented in 
Chapter 3 (that based search criteria on MRC definitions), most of the interventions 
identified were not relevant to HSR or public health. I have already discussed how 
health promotion specialists have argued that the nature of complexity stems not from 
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the disease group or intervention components but from the ideology underpinning the 
intervention (Chapter 2). While I would not limit the definition of complexity to one or 
the other, I would argue that many different layers of complexity exist and that a clear 
understanding of these layers and how they relate to the intervention of interest is 
needed before recommendations can be made about appropriate evaluation strategies. 
Failure of the MRC Framework to at least consider the different challenges posed by 
different layers, or multiple layers of complexity before defining good practice (quality) 
in intervention development and evaluation must be seen as a limitation. 
It is also debatable whether the MRC recommendations for intervention development 
and evaluation are the most appropriate indicators of quality. Findings from the 
systematic review suggest that even when RCTs are more rigorously developed 
(according to MRC phases), there is no apparent association with outcomes. The only 
significant findings suggested that: a) excluding non-RCT designs excludes most 
prevention and community-based studies; and b) if a RCT is conducted, the study has 
less chance of demonstrating success. Contrarily this finding supports previous 
arguments that RCT methods are inappropriate for evaluating certain types of complex 
intervention. 8,88 
The need for better theoretical grounding of interventions is particularly controversial 
within HSR, since it is a discipline which has typically been thought of as 
atheoretical. 'o3,362 While those from psychological or sociological disciplines might 
think it essential and intuitive that research (and intervention studies in particular) are 
strongly grounded in established theory, 42,329,362,363 others argue that understanding 
process is neither necessary nor appropriate. 332 It has been argued that until there is 
evidence that theoretically driven interventions are superior to a theoretical 
interventions, theoretical grounding should not be used as a marker of quality . 
331 The 
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lack of association between theoretical development and outcomes of the 67 studies 
included in the systematic review may provide support for this argument. 
While demarcating explicit modelling and exploratory phases may bring some benefits 
in terms of planning and obtaining funding, attempting to demarcate these phases may 
be problematic as a measure of quality. Both in the published studies (Chapter 3) and in 
the development of Stop Stroke (Chapters 5 and 6), it was difficult in practice to draw 
distinctions between the theoretical, modelling and exploratory trial phases. In terms of 
the intervention studies already published, this may reflect the fact that authors or 
publishers do not recognise (or have not in the past recognised) the importance of 
describing developmental work. A recent survey of pre-trial testing for complex 
intervention trials concluded that many trial investigators do conduct preparatory work 
including exploratory trials but simply do not report it. 213 In the context of Stop Stroke 
the first three phases were not distinct. Progression through the phases was cyclical 
rather than linear, with different phases overlapping and one phase merging into the 
next. It was also very difficult to implement a meaningful exploratory trial phase given 
time, resources and the nature of the intervention (Chapter 7). 
To summarise, the MRC phases were a useful guide for investigating and critically 
appraising studies of psychosocial interventions in stroke care, particularly since other 
critical appraisal frameworks might not have be appropriate. 125' 340 However, given the 
lack of clarity in defining complex interventions, current publication priorities and the 
difficulty of operationalising distinct phases of development, the limitations of using 
The Framework phases in defining quality need to be recognised. 
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10.2.1.2 Guiding intervention development 
My original hypothesis about the agenda of The Framework was that it was designed to 
help in guiding the development of new interventions. In the first publication of The 
Framework, ' the authors stress that it is designed for those who are considering 
evaluating complex interventions. They go on to state that the main purpose of The 
Framework is to identify the unique challenges of complex intervention development 
and to `suggest some strategies for addressing these issues' (pl). ' Since its publication, 
there have been a number of studies that have reportedly used The Framework in this 
way (to guide development). 3,121,364 Two of these reported that The Framework was 
`helpful', although neither study has completed its evaluation so the impact on 
intervention success or interpretation of outcomes is not yet known. ' 21,364 
The MRC Framework was also reportedly used to guide development and evaluation of 
the Stop Stroke intervention, 365,366 yet findings presented in Chapters 5,6 and 7, suggest 
that this was not strictly true. In practice, it provided little guidance. Firstly, as noted in 
Chapters 1 and 7, design of study methods for developing and evaluating Stop Stroke 
pre-dated publication of The Framework. The Framework did not assist in guiding 
choice of methods in this phase (the team had already decided to use a mixed methods 
approach), nor did it provide any guidance on how to interpret `theory' in the modelling 
phase of development. Eccles et al. have recently produced guidance on how to choose 
the most appropriate theory in intervention development (in other words practical 
guidance for the modelling phase)329'367 but such guidance is not included in the MRC 
Framework. ' Thus although The Framework could be said to have refined Stop Stroke 
development methods or provided post-hoc justification for the approach, it could not 
be described as having guided them. 
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It is not clear whether our team's decision to conduct a pilot evaluation was guided by 
MRC recommendations for an exploratory phase. A pilot evaluation was not explicitly 
outlined in the original research protocol for Stop Stroke, suggesting that The 
Framework may have influenced the decision to include this phase. The PI also 
confirmed that The Framework was influential in the exploratory trial phase in his 
feedback on the research findings. However, whether influencing the decision to include 
an exploratory trial constitutes `guidance' is questionable, particularly since the pilot 
evaluation did not meet many of the recommendations for the exploratory trial included 
in The Framework. In the Stop Stroke pilot evaluation, possible variations in 
intervention delivery were tested (as recommended in The Framework) but qualitative 
methods were used to evaluate the impact of these variations rather than testing the 
main trial outcomes (Chapter 7). Other recommendations of The Framework such as 
ensuring that intervention delivery is standardised, investigating the comparative arm, 
or investigating sample size were not tested in the pilot phase. 
Nor did The Framework assist in addressing the difficulties of applying RCT methods 
to complex interventions in the definitive RCT phase. Although the authors identify 
challenges for RCT evaluation (recruitment, consent, blinding, statistical power and 
choice of outcomes), The Framework does not provide guidance on how to address 
these challenges. Nor does it provide guidance on how to address challenges related to 
funding, staff continuity, protocol deviations and data monitoring (which in Chapter 8 
were shown to have a significant impact on the potential of the intervention to influence 
outcomes). Complex intervention studies continually report under-recruitment in 
trials233 yet no criticisms of current methods for producing power calculations or 
recommendations for strategies to obtain additional funds to extend recruitment are 
presented. There was an underlying assumption that the exploratory trial phase would 
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have uncovered all such challenges and that they would be addressed prior to embarking 
on the main RCT. In practice, The Framework provided little guidance for evaluation, 
simply outlining standard RCT evaluation rules. 
10.2.2 Social and Political implications of using The Framework 
Beyond whatever practical value The Framework may have, adopting it as a measure of 
quality, or tool for guiding intervention development is likely to have broader social and 
political implications. Two potential consequences are discussed below: i) 
consequences for the development of knowledge relating to non-pharmacological 
interventions; and ii) consequences for researchers using mixed methods approaches in 
medical research. 
10.2.2.1 Consequences for the development of knowledge relating to non- 
pharmacological interventions 
Adopting the MRC Framework as a research tool addresses calls for more RCT 
evidence to support the use of non-pharmacological interventions (for example, in 
rehabilitation research). 57,73,75,79 Given the dominance of the evidence based medicine 
paradigm, policy makers and providers require an evidence base to recommend and 
fund complex interventions. By encouraging developers of complex interventions to use 
RCT methods in evaluation it could be argued that an aim of the authors of the MRC 
Framework is to increase the evidence base (as defined by RCTs) for these types of 
intervention. 
The Framework is novel in its contribution to the evidence-based medicine debate in 
that it explicitly attempts to address the problem of interpreting clinical trial findings. 
Such problems are well recognised in the literature. 42,60,368-370 By setting out the 
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theoretical and modelling phases, the MRC Framework not only acknowledges that 
interpretation of findings can be difficult (whether the intervention is successful or not) 
but also recommends methods for overcoming such difficulties. The Framework 
proposes that a better understanding of theoretical process (in other words the 
mechanisms by which the intervention is intended to work) will facilitate interpretation 
of RCT evidence (p7)'. Analysis of the development of the Stop Stroke intervention 
suggests that although theoretical and modelling work were undertaken, the choice of 
intervention was not dictated by the results of this work. The modelling phase was used 
to identify how the intervention components could potentially influence outcomes (as 
recommended by The Framework) but in practice the intervention was not delivered as 
intended. Having a theoretical understanding of how the intervention could potentially 
work is not the same as understanding how it works in practice. The challenges for 
translating theoretical ideas into practice were also demonstrated in the `Dutch heroin 
experiment'. ' 13 This intervention sought to reduce rates of heroin addiction and was 
based on theoretical work and a pilot evaluation prior to its evaluation in a RCT. This 
work suggested that prescribed heroin could be a suitable treatment for users. However, 
the RCT failed to demonstrate any impact of the intervention on outcomes. Findings 
from the theoretical and pilot phase work were only partially able to explain the 
intervention's failure. By contrast, an ethnographic process evaluation of 
implementation in the main RCT revealed that users' attitudes to the prescribed heroin 
programme changed after the pilot study, creating recruitment and adherence problems 
that doomed the trial to failure. In this study it was the process evaluation rather than the 
initial theoretical or pilot work that helped to explain outcomes. As noted in Chapter 2, 
social scientists, including those who are proponents of RCT methods, have frequently 
argued for use of process evaluation to enhance interpretation of 
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findings, 82,113'' 15,1 "'371'372 something not included in the MRC Framework (an issue I 
return to later). 
The MRC recommendation that complex interventions are evaluated using RCT 
methods also raises broader questions about what constitutes evidence in public health 
and HSR. This recommendation assumes that it is necessary to define particular 
methods to further medical knowledge. By contrast, Feyerabend argues that no single 
method or theory can be used to define what is or is not `scientific' since this would 
inhibit scientific progress. 373 Unlike Kuhn, he suggests that scientific innovation is often 
accidental and thus argues for theoretical and methodological `anarchy' (pl 1). 373 There 
has been considerable debate within the literature about existing hierarchies of evidence 
which place RCTs at the top of the hierarchy and define other methods either as 
producing `lower level' evidence or discount them altogether. 100,333,341,342 As noted in 
Chapter 1, there are two versions of The Framework, one in which the authors specify 
that it is for guiding those embarking on RCT evaluations of complex interventions' and 
the other in which the authors do not distinguish the types of complex intervention 
study to which it should be applied. 6 Thus it is not wholly clear whether the authors 
intend The Framework to be applied to all complex interventions or only those for 
which RCT evaluation is considered to be appropriate. If The Framework is to be 
applied only to interventions for which RCTs are considered appropriate (for example 
medical, behavioural or educational models of intervention) then it would be unfair to 
criticise the authors for focusing on RCTs. However, if the authors intend The 
Framework to be applied to all complex interventions then focusing on the RCT as the 
sole method of evaluation may be problematic. The novel aspects of The Framework 
(theoretical and modelling phase guidance) do not help to address the criticisms of those 
who argue that it is inappropriate to apply RCT methods in evaluating complex 
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interventions. For example, The Framework does not give guidance on: how to include 
marginalised groups into intervention studies; how to address the problem of 
randomisation when no suitable control group can be found; or how to maintain a trial 
over a long period of time so that appropriate outcomes can be measured. If complex 
intervention evaluations are to be restricted to RCT evaluation, then this is likely to 
restrict both the types of interventions that are developed and the evidence that is 
subsequently produced. 8'9'88 ""3,374,375 As previously noted, dependence on the RCT 
method to define evidence does ultimately restrict the types of intervention that can be 
transformed into evidence. 45,210 If it is more difficult to conduct RCTs of population and 
preventive interventions, then a consequence of following the recommendations of The 
Framework could be that funds are re-directed towards those interventions which are 
situated within more easily defined communities (such as hospital departments), or 
those targeted at individuals (and consequently those which are `trialable'). 
Proponents of RCT methods have argued that such criticisms are due to 
`misconceptions' about RCTs and cite history of experimentation in social science to 
defend their preferences. 73.74°76 However, in the context of scientific innovation, 
Feyerabend argues the opposite: historically it is only when scientists diverge from 
existing theories or methods that science can progress. 373 Enforcing one specific method 
such as the RCT or specific phases of development (as in the MRC Framework phases) 
may stifle rather than enhance progress and consequently inhibit our understanding of 
complex interventions. 
10.2.2.2 Consequences for researchers using mixed methods approaches 
If the MRC Framework did not provide guidance for Stop Stroke intervention 
development or evaluation, it begs the question, why do we (the Stop Stroke team) 
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stress that it did? I propose that this is because adopting The Framework has social and 
economic consequences for those using mixed methods, in other words, that it in some 
way encourages or legitimises the work of these researchers. 
As outlined in Chapter 3, part of the appeal of The Framework amongst social scientists 
is that it is perceived to support a mixed methods approach. The Framework was not 
developed specifically for qualitative researchers but, since its publication, has been 
embraced by some researchers who use qualitative or mixed methods. Just as alternative 
medicine practitioners may seek evidence for their practices in order to "bolster their 
case" for funding, 84 so MRC support for using qualitative methods in intervention 
development may be perceived by qualitative researchers to enhance the appeal of 
qualitative methods to those who fund medical research. Having access to medical 
funds may be a particularly attractive prospect for qualitative researchers, since this 
research attracts far more funding than is available from more usual sources (the MRC 
research spend was just under £475 million in 2005 compared to the ESRC research 
budget of £77 million). 376,377 
Those who use qualitative methods may also view The Framework as having the power 
to enhance their authority as researchers working within a medically dominated 
discipline such as HSR. An example of the need for social scientists to bolster their 
social, rather than economic position is described by Balshem in her study of Project 
CAN-DO. 378 Project CAN-DO was a health education programme focusing on cancer 
prevention. The project was situated in a working class neighbourhood of an 
industrialised city in the USA and involved health educators giving community-based 
talks and providing leaflets to encourage people to change `unhealthy' behaviours. 
Balshem worked on the study both as an anthropologist employed to gain an 
understanding of community resistance to health education and as a practitioner 
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delivering health education messages to the community. She describes how, when she 
first joined the study, the symbols of authority within her own discipline (a doctoral 
degree in anthropology) counted for little within a medical discipline. She explains how 
as an anthropologist working in an environment where only science was valued, she 
yearned `to be seen as professionally competent' (p126-128). 378 
As we know, The Framework does not explicitly call for a mixed methods approach to 
either intervention development or evaluation but acknowledgement by the MRC that 
qualitative methods may be useful in the theoretical and modelling phases of 
development, may be seen to legitimise the researchers and research of those who use 
mixed methods. 
10.2.3. Summary 
The MRC Framework was put forward as a research tool to improve complex 
intervention development and enhance our understanding of outcomes. This thesis has 
demonstrated that in practice it provided little practical guidance. However, if The 
Framework is adopted as a research tool, it may have broader social, political and 
economic implications. For example, if The Framework shapes the way clinical 
knowledge is constructed and restricts the type of knowledge developed, it may have 
implications for clinical practice, health policy and ultimately patient care. The 
Framework may also have broader implications for those who conduct research by 
legitimising a mixed methods approach that apparently bolsters the case for qualitative 
research and gives authority to the researchers themselves. 
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10.3. Embedding qualitative methods within RCTs 
A second aim of this thesis was to investigate the potential uses of qualitative methods 
in intervention development and evaluation. As noted earlier, calls for the use of 
qualitative methods alongside or embedded within RCTs to inform intervention 
development (formative research) and to enhance understanding of outcomes (process 
evaluation) are becoming increasingly common. 
82'87'95,102,106,113,1I5,117,250.3I6,371,372,379-383 
In the Stop Stroke study, an ethnographic approach was used throughout development 
and in evaluation. However, while proponents of qualitative methods usually outline the 
potential strengths of conducting such research, few have questioned the limitations of 
using qualitative methods in this way, or investigated the impact of qualitative research 
in influencing intervention development or clinical trial evaluation. I now turn my 
attention to these issues in the context of developing and evaluating the Stop Stroke 
intervention. 
10.3.1. Using qualitative methods to inform intervention development 
In this study, qualitative methods were used to investigate current secondary prevention 
practice to identify barriers to and facilitators of `optimal secondary prevention' 
(Chapters 5 and 6). Important considerations for intervention development were 
uncovered. For example, findings from the in-depth interviews with patients 
demonstrated that the concept of secondary prevention itself had little meaning for 
patients (Chapter 5). These findings were essential in challenging a priori assumptions 
of the team about categories of good and bad patient, of `belief systems' and 
communication `styles' which subsequently proved to be of little use in understanding 
secondary prevention in practice. However, it was difficult through interview alone to 
establish the reasons why current services were insufficient, patients having limited 
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insight into the organisational and social mechanisms influencing secondary prevention 
delivery. Observational methods were helpful in developing an understanding of the 
process of secondary prevention delivery in the stroke clinic (Chapter 6) but it was not 
practically possible to observe consultations in general practice, the forum where 
secondary prevention advice and monitoring is most likely to be provided in the longer 
term. Thus if interventions are to be developed using qualitative methods, it is important 
to be explicit about the limitations of the specific methods used and generalisability of 
the findings collated. 
Perhaps the biggest challenge for using qualitative methods to inform Stop Stroke 
intervention development was that qualitative findings were limited in influencing 
intervention choice (Chapter 7). This may have happened for a number of reasons 
including restrictions of time and funding (the one year allotted for the development 
phase was insufficient to collect and analyse data) but may also have reflected the lack 
of weight that qualitative findings have in influencing research decisions. Firstly, 
findings from the research phase of development were used to back up rather than 
inform intervention development. Secondly, recommendations for intervention design 
emerging from work in the theoretical, modelling and exploratory trial phases were not 
taken up, in the interests of preserving a methodologically pure trial (Chapter 7). The 
tensions between researchers from different disciplines using different epistemological 
approaches or research methods have also been reported elsewhere. 82'89,378 For example, 
in Balshem's analysis of Project CAN-DO, she discusses how authority and in 
particular, medical authority influenced the conduct and uptake of her anthropological 
work378. Balshem described how she found it difficult to reconcile the conflict of 
loyalties she experienced. On the one hand she wanted to develop an effective 
programme to improve people's health (the education programme). On the other, 
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conducting anthropological research that would subsequently be used by those in 
authority (health professionals) to exert this authority over others conflicted with her 
epistemological loyalties (p128). 378 Thus, it appears that the same social hierarchies and 
political agendas that influence whether qualitative research findings can be defined as 
`evidence' for clinical practice also influence uptake of qualitative research findings in 
intervention development. 
Researchers from disciplines supportive of qualitative methods have promised a great 
deal in terms of being able to improve our understanding of health services. 82'102 There 
is now pressure for them to deliver. However, such promises may have contributed to 
misunderstandings regarding the purpose of qualitative research. 89 For example, it may 
be assumed that qualitative investigations should be used simply as an add-on to more 
traditional methods for investigating health services or to fill in the gaps in our 
understanding that cannot be answered within a positivist paradigm. In practice, 
exploratory investigations, particularly those incorporating mixed methods, often result 
in posing more questions than they answer. 216 As others have demonstrated, there are 
challenges for conducting mixed methods investigations including difficulty 
synthesising findings obtained using different methodological or epistemological 
approaches. 89 In the case of Stop Stroke development, while the qualitative studies 
highlighted issues for current secondary prevention management they did not 
specifically define what the intervention should look like. Perhaps because of this, the 
influence of the qualitative findings in defining the intervention was further limited by 
broader social, political and economic influences (research priorities, expertise, 
resources, requirements of RCT design) and it is important to keep this in mind when 
interpreting outcomes. If the intervention fails to deliver, there is a danger that this will 
be attributed to the qualitative research failing to identify the `real' problems and best 
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solutions. Such an attribution would require disregard for the ethnographic evidence 
reported here, which suggests that the impact of such evidence on intervention design is 
limited by social and economic factors which I have terms `interference'. 
This research is a case study and without other such in depth studies it is difficult as yet 
to generalise too widely. In the current scientific climate qualitative research still has 
relatively low `status' in the evidence hierarchy. Presumably any status changes will 
take time and it will be interesting to see whether The Framework can have more of an 
impact in the longer term. 
10.3.2. Using qualitative methods in intervention evaluation 
A second use of qualitative methods in this thesis was in evaluating the intervention and 
the trial process through an ethnographic investigation embedded within the main RCT 
design. Qualitative methods are increasingly being recommended to enhance different 
aspects of trial evaluation, including to enhance trial recruitment, to improve participant 
understanding of trial process, to improve trial implementation and to understand 
outcomes. 106,107,112,115,119 However, what is less often considered is the influence of 
process evaluation on the trial itself. In a recent process evaluation of a school peer-led 
smoking intervention, Audrey et al. concluded that there was a Hawthorne effect, that 
is, that the evaluation interfered with the intervention. "' Audrey et al. justified their 
methods by saying that the data obtained from the process evaluation provided a rich 
insight into the workings of the intervention; in other words they assumed that the end 
(having rich data) justified the means (conducting processes evaluation), even if the 
process evaluation ultimately contaminated the main trial. They argued that interference 
with the trial was acceptable since it would be easy to incorporate the interventional 
aspect of the process evaluation (a simple questionnaire) into the intervention, should it 
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prove successful. However, attaching aspects of process evaluation onto the intervention 
might not be so practical or appropriate for all complex interventions or all process 
evaluations. It is also perhaps nave to assume that all process evaluations are either 
easy to implement or cost-free. 
In the case of Stop Stroke, the process evaluation was specifically designed so as not to 
interfere with the RCT outcomes: patient interviews were conducted after outcome data 
had been collected and interviews with GPs will only be conducted at the end of the 
study. However, this does not mean that the process evaluation had no impact. In the 
Stop Stroke Trial the process evaluation appeared to have both positive and negative 
effects. While it helped ensure that the study investigators adhered to the protocol, it 
may also have demoralised staff or created problems where none previously existed. 
Others have also demonstrated the powerful impact that qualitative process evaluations 
can have in influencing trial process. ' 18,123 In a RCT of a patient decision aid for 
prescribing of anti-thrombotic medication for atrial fibrillation, Thompson et al. ceased 
one arm of a three arm trial in which qualitative data had demonstrated that patients 
were experiencing distress as a result of the intervention. 118 Although qualitative 
findings may have limited weight in influencing the decisions of investigators regarding 
intervention design, potentially they could have a powerful impact on research practice. 
Riley et al. recently argued that monitoring committees should monitor and guide 
decisions relating to ethics and the influence of qualitative research on community 
intervention trials. '23 
Findings from the Stop Stroke study experience also raise particular questions about the 
application of ethnographic methods. I have already outlined in Chapters 4 and 8 some 
of the problems I experienced as a result of being both participant and observer in the 
same study. While being a participant allowed me to uncover trial limitations that might 
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not have been accessible to an outsider, it also raised questions about contamination, 
ethics and presented conflicts of interest. These ethical and methodological challenges 
are well recognised within the ethnographic literature216 and recommendations have 
been made to ensure that participants are not exploited. These challenges apply equally 
within the context of a RCT. 
10.4. Implications and directions for future research 
Issues relating to the potential uses of the MRC Framework and the strengths and 
limitations of using qualitative methods in intervention development have some 
important implications for future research and practice. 
One aspect of conducting lengthy developmental work and of incorporating mixed 
methods in intervention development and evaluation rarely considered, is the 
implication for funding complex intervention development. The authors of The 
Framework draw an analogy between development of complex interventions in public 
health/HSR and the pharmaceutical industry. However, I would argue that in practice 
there are few similarities between the two processes. Historically the phases of 
pharmaceutical trials were developed by the Food and Drug Agency (FDA) in the US 
and the European Agency for Evaluation of Medicinal products (EMA) in Europe to 
protect patient safety. 7° By contrast there is no explicit or implicit reference to patient 
safety within the MRC Framework. New drug therapies are also developed to make 
financial profit for the pharmaceutical industry, while complex interventions are often 
less marketable. Both differences have important implications for funding. Stop Stroke 
development benefited from multiple sources of funding and in the context of complex 
intervention development was relatively well funded. However, the true costs of 
intervention development and trial evaluation are likely to have been considerably 
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higher than the amount funded, particularly considering the number of staff involved 
throughout these phases and the dependence of the intervention on other research 
studies including the SLSR. The average cost of developing a new pharmaceutical 
therapy may be considerably more than for a complex intervention but so is the 
available funding (the average cost of developing a new drug is estimated to be over US 
$800 million not including pre-clinical work). 91'384 Thus if future intervention studies 
wish to include multiple developmental phases, with or without the additional costs of 
process evaluation and process monitoring committees then increased funding will be 
imperative. 
A second difference between pharmacological and complex interventions is the 
environment within which interventions are developed and delivered. Some types of 
complex intervention reflect social, political and environmental trends (as demonstrated 
by changes to the clinical environment during the Stop Stroke development and 
evaluation). Thus a long developmental `phase' that might be feasible within the context 
of drug development is not necessarily appropriate for complex intervention 
development. The only way to shorten the developmental process would be to increase 
research turnover (for all phases) or to consider multi-centre evaluations of complex 
interventions. There has been limited work on exploring the application of multi-centre 
methods to complex interventions. Again, unless funding for the development of these 
types of intervention increases, it is impractical, if not impossible, to expect the methods 
for drug development to be relevant in the context of complex intervention 
development. 
The findings also have implications for publication of research on complex 
interventions. I have already noted that developmental work, important for 
understanding intervention choice and interpretation of outcomes, is not always reported 
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in publications. 213 Without such information it is often difficult to understand how 
intervention components are chosen, how such components work in influencing 
outcomes, or how such interventions should be implemented if rolled out into practice. 
If our understanding of complex interventions is to change, a `cognitive shift' is 
necessary in relation to the requirements for publication of findings from such 
studies. 84,34 1 There is a greater need for investigators to acknowledge the challenges 
emerging in the development of such interventions in order that the findings can be 
generalised and translated into practice. Unlike Eccles, 329 I do not think this requires set 
guidelines on how to choose theory. Rather, I would argue for more reflexivity by 
researchers in acknowledging how decisions about intervention choice are made and the 
motivations behind such choices. One way to achieve this might be through new 
standards for critical appraisal of complex intervention studies requiring authors to 
acknowledge and explain the theoretical work conducted and how this relates to 
intervention choice. Such guidelines could also provide recommendations for recording 
of intervention implementation so that future investigators or providers can see where 
the challenges lie and not repeat the same mistakes. 
There is also a need to move beyond discussion of whether RCTs constitute the only 
appropriate research evidence and to realise that different types of complexity present 
different challenges. Rather than classifying all non-pharmacological interventions as 
`complex' or `social', it is important to consider what it is about the intervention that 
presents a challenge for evaluation. Strategies could then be designed to meet or 
compensate for such challenges, through conducting process evaluation for example, or 
through accepting that other types of evaluation are necessary to understand particular 
types of intervention (quasi-experimental, observational or qualitative designs). Arguing 
that non-randomised studies are inadequate on the basis of bias is an insufficient 
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exclusion criterion. It is clear from this thesis that choosing the RCT method can also 
bias the knowledge we have about complex interventions. 
The MRC Framework was presented as a guide for addressing the challenges of 
applying RCT methods to complex intervention evaluation. However, through this 
thesis I have demonstrated that it provides limited practical guidance and may be more 
useful in legitimising than defining methodological choice. If RCTs are to be accepted 
as the appropriate method for evaluating complex interventions then further practical 
guidance is needed to enable researchers to prepare for potential problems, which might 
compromise study findings (such as problems with recruitment, staffing and data 
monitoring). Further guidance is also needed on how to incorporate process evaluation 
within the RCT context. Oakley et al have made some recommendations but these are 
limited to the context of educational interventions and were not applicable in the Stop 
Stroke context. ' 15 Ethnographic process evaluation, or experimental ethnography may 
provide enhanced benefits (in terms of understanding implementation and outcomes). 
104,113,123'371 Process evaluation monitoring committees may provide the answer to 
difficult ethical and methodological challenges but further investigation is needed in this 
area. 123 
One further area of research that may prove fruitful is in the area of non-complex or 
regular RCT evaluation. I have assumed throughout that the challenges presented in the 
Stop Stroke study are applicable only in the context of complex intervention evaluation. 
However, it may be that regular drug trials present similar challenges and would also 
benefit from process evaluation or mixed methods approaches. 
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Appendix 1. SLSR analysis informing Stop Stroke development. 
This appendix includes the two published papers covering the SLSR analysis of patterns 
in management of stroke risk factors after stroke. These analyses also formed part of the 
theoretical phase research contributing to intervention development. 
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Behavioral Risk Factor Prevalence and Lifestyle 
Change After Stroke 
A Prospective Study 
Judith Redfern, MSc; Chris McKevitt, PhD; Ruth Dundas, MSc; 
Anthony G. Rudd, FRCP; Charles D. A. Wolfe, FFPHM 
Background and Purpose-Stroke patients have a 15-fold increased risk of recurrent stroke, and those with >_ I risk factor 
have a further increased risk of recurrence. Previous work found management of physiological risk factors after stroke 
to be unsatisfactory, but there is little information on behavioral risks within the stroke population. This study estimates 
behavioral risk factor prevalence after stroke and explores lifestyle change. 
Methods-The study used data from the population-based South London Stroke Register, collected prospectively between 
1995 and 1998. Main measures included smoking status, alcohol use, and obesity. Logistic regression was used to 
determine sociodemographic differences in these measures. 
Results-At 1 year after stroke, 22% of patients still smoked, 36% of patients were obese, and 4% drank excessively. 
Younger patients, whites, and men were more likely to smoke, and younger whites were more likely to drink 
excessively. Women and nonwhites were more likely to be obese. Those living in hospital, nursing home, or residential 
care and nonwhites were more likely to give up smoking, but there were no other associations between lifestyle change 
and the sociodemographic characteristics of patients. 
Conclusions-Different behavioral risk factors were associated with specific sociodemographic groups within the stroke 
population. After stroke, high-risk groups should continue to be targeted to prevent stroke recurrence. However, the 
relationship between sociodemographic characteristics and lifestyle change remains unclear; more research is needed into the 
process of change to find out how best to intervene to improve secondary prevention. (Stroke. 2000; 31: 1877-1881. ) 
Key Words: lifestyle   risk factors u stroke prevention 
n the United Kingdom, Our Healthier Nation targets aim to I 
reduce mortality from stroke by a third by 2010. ' Stroke 
survivors have a 15-fold increased risk of stroke recurrence 
compared with the general population2 and represent an 
important group to focus on if targets are to be achieved. 
Reducing recurrent stroke and death from recurrence is also 
recognized as a European priority, with targets set out in the 
Helsingborg Declaration. ' 
Patients with >_ 1 clinical or behavioral risk factor have a 
further increased risk of stroke recurrence, and appropriate 
management of risk factors has been shown to be important for 
secondary prevention. ' Recent work focusing on management of 
physiological risk factors in an inner-city multiethnic population 
found secondary prevention to be inadequate with high rates of 
nontreatment in patients for whom antihypertensive and anti- 
thrombotic therapies are appropriate. 5 Few data are available on 
behavioral risk factors within the stroke population. 
One reason for focusing on clinical rather than behavioral 
risks is that lifestyle change is commonly assumed to be 
difficult to achieve, and secondary prevention interventions 
often have limited success in reducing behavioral risk fac- 
tors . 
6-d However, randomized controlled trials have shown 
that interventions to modify specific behaviors, such as 
physicians' advice to give up smoking`' and excessive drink- 
ing, 10 can be successful, and the assumption that patients 
(elderly patients in particular) are unwilling to engage in 
health promoting behavior is not justified. " 
Our Healthier Nation emphasizes the importance of em- 
powering patients to make educated decisions regarding 
health and lifestyle and the importance of identifying high- 
risk groups to provide high-quality services. If stroke second- 
ary prevention is to be successful, more information is needed 
about current management of such risk factors. This study 
aims to answer 2 key questions: What is the prevalence of 
behavioral risk factors following stroke, and what factors are 
associated with reduced risk? 
Subjects and Methods 
The study used data from the South London Stroke Register, a 
population-based register that since 1995 has been collecting data 
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prospectively on first-in-a-lifetime strokes in patients of all age 
groups. Twelve overlapping referral sources are used to attain 
complete notification of such strokes in the study area, which 
comprises 22 wards of the Lambeth, Southwark and Lewisham 
Health Authority, with a population of 234 533. The total population 
is 72% white, 21% black (11% African Caribbean, 7.5% West 
African, and 2.5% black mixed), and 3% Asian, Bangladeshi, and 
Pakistani. The methodology has been described in detail elsewhere. 12 
Data were collected on patients' sociodemographic characteristics, 
including age, sex, ethnic group, social class, and place of residence. 
Face-to-face consultations with patients were conducted at 3 months 
and 1 year after stroke to collect data on functional ability and risk 
factors. Functional ability after stroke was measured with the Barthel 
Index. Data on physiological risk factors (atrial fibrillation, hyper- 
tension, and diabetes) were collected at the time of stroke and after 
3 months and l year. Diagnoses were based on patients' reported 
history and general practitioner and hospital records. A detailed 
description of the classification of physiological risk factors is 
presented elsewhere. 5 
Behavioral risk factor measures for alcohol consumption (units per 
week) and smoking status were based on standardized questions. 14.1 
"Sensible" drinking limits were based on current published guide- 
lines and defined as 14 U/wk for women and 21 U/wk for men, 16 Ix 
where I unit is approximately equivalent to half a pint of beer, lager, 
or cider; a single measure of spirits; I glass of wine; or I small glass 
of fortified wine. Waist and hip circumferences were measured, and 
waist-to-hip ratio (WHR) was calculated. Obesity is defined as WHR 
>0.98 for men and >0.88 for women. 19.20 Change in smoking status 
is indicated by the patient giving up smoking or reducing the amount 
smoked compared with the amount smoked before the stroke. 
Measures of smoking status and alcohol use were taken at the time 
of stroke and at the 3-month and 1-year follow-ups. Obesity was 
measured at the time of stroke and 1-year follow-up only. Questions 
concerning obesity and reduction in the amount smoked were asked 
only of patients registered until July 1997. 
Bivariate associations between patient characteristics and behav- 
ioral risk factors were analyzed with X' tests. Multiple logistic 
regression was used to analyze associations between age, sex, ethnic 




Between January 1,1995, and December 31,1998,1139 
patients were registered with first-in-a-lifetime stroke. Of 
these, 377 (33.1%) died within the first 3 months after stroke, 
and of the survivors, 45 (5.9%) did not complete a 3-month 
follow-up questionnaire. Data at 1 year after stroke were 
available for all patients who registered before July1997 
(769). Of these, 311 died within the first year, and of the 
survivors, 36 (7.9%) were lost at 1-year follow-up. For the 
purposes of this study, 717 of 1139 patients are included for 
analysis at 3 months and 422 of 769 patients are included for 
analysis at 1 year after stroke. 
Characteristics of Stroke Patients 
At the time of stroke, the average age of patients was 72 
years. Just over half of the patients (593) were women. Most 
patients were white (905,79.6%), but a relatively large 
minority were nonwhite, most of whom were black African or 
black Caribbean (181,15.9%), with only 35 (3.1%) Asian, 
Bangladeshi, or Pakistani and 16 (1.4%) coming from other 
ethnic groups. 
Three hundred fifty-eight patients (32.2%) were smokers at 
the time of stroke; 138 (13.2%) drank more than the weekly 
limit of alcohol; and 471 (56.3%) were obese. 
Prevalence of Behavioral Risk Factors 
After Stroke 
At 3 months after stroke, 150 patients (22.2%) smoked, and 
33 (4.9%) drank more than the weekly limit. At I year, the 
prevalence rates had changed very little: 89 (22.4%) were still 
smoking, and 15 (3.6%) were drinking excessively. One 
hundred thirty-two patients (36.1%) were still obese at I year. 
Table I shows the prevalence of behavioral risk factors at 3 
months after stroke for smoking and alcohol use and at I year 
for obesity, identifying groups at high risk. Logistic regres- 
sion analyses of associations between behavioral risk factors 
and sociodemographic and physiological risk factors are 
presented in Table 2. 
Age, sex, and ethnicity were associated with behavioral risks 
in younger patients, with men and whites more likely to smoke 
at 3 months after stroke. Younger patients and whites were also 
more likely to be heavy drinkers at 3 months after stroke. 
Women and nonwhites were more likely to have a high WHR at 
1 year. Patients still in hospital, nursing homes, or residential 
care at 3 months were also less likely to smoke, and none of 
these 149 patients were heavy drinkers. Fewer patients with 
physiological risk factors (atrial fibrillation, diabetes, and hyper- 
tension) reported being smokers, and the confidence intervals 
suggest that this association remained even after controlling for 
sociodemographic factors and stroke severity. There was no 
association between physiological risk factors and heavy drink- 
ing at 3 months or obesity at 1 year. 
Risk Factor Change 
Of those at risk prior to their stroke, a large minority of 
smokers (82,34.8%) reported giving up completely 3 months 
later. One hundred sixty-nine patients who smoked before 
their stroke were registered before July 1997; of these, 61 
(36.1%) had given up completely and another 44 (26.0%) 
reported having reduced the amount smoked. Seventy-five 
(72.1%) of those who drank heavily before their stroke no 
longer drank more than the weekly limit. 
Analysis of change within the first year suggests that for 
smoking and alcohol use, most patients who made lifestyle 
changes did so within the first 3 months after stroke. Of the 
151 smokers before stroke who were still alive at I year, 62 
(41.1%) gave up smoking, 53 of whom gave up within the 
first 3 months and only an additional 9 gave up between 3 
months and 1 year. Seventy-three excessive alcohol users 
survived to 1 year, of whom 62 reduced their drinking to less 
than the weekly limits. Fifty-five of these did so within the 
first 3 months, and only 7 did so between 3 months and I 
year. Of those who were obese before stroke, 72 (41.1%) 
were no longer obese 1 year later. 
A minority of patients without behavioral risk factors at the 
time of stroke had increased their risks factors afterward. 
Four patients who were not heavy drinkers before stroke 
drank more than the weekly limit 3 months later, and 30 
patients (16.4%) who were not obese at the time of stroke 
were obese at 1 year. Data on smoking status after stroke 
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TABLE 1. Prevalence of Behavioral Risk Factors After Stroke 
Drinking More Than Weekly Limit 
Smoking (n=675) (n=678) High WHR' (n=364) 
Total n (%) P Total n (%) P Total n (%) P 
All patients 675 150 (22.2) 678 33(4.9) 364 132 (36.3) 
Age, y 
<65 199 73 (36.7) <0.001 205 18(8.8) <0.001 119 41 (34.5) 0.88 
65-79 321 65 (20.3) 328 13(4.0) 170 63 (37.1) 
80+ 155 12(7.7) 145 2(1.4) 75 28 (37.3) 
Sex 
M 349 98 (28.1) <0.001 356 24(6.7) <0.001 299 62 (31.2) 0.03 
F 326 52 (16.0) 322 9(2.8) 165 70 (42.4) 
Ethnicity 
White 518 131 (25.3) <0.001 517 31 (6.0) <0.001 282 95 (33.7) 0.06 
Black or other 157 19 (12.1) 161 2(1.2) 82 37 (45.1) 
Physical functioningt 
Independent 251 74 (29.5) <0.001 257 23(9.0) <0.001 146 42 (28.8) 0.03 
Moderate disability 301 63 (20.9) 294 8(2.7) 177 70 (39.6) 
Severe disability 123 13 (10.6) 127 2(1.6) 41 20 (48.8) 
Social class# 
Manual 452 105 (20.6) 0.61 454 20(4.4) 0.05 243 92 (32.1) 0.56 
Nonmanual 199 41 (23.2) 196 13(6.6) 106 34 (37.9) 
Not known 24 4(16.7) 28 0(0.0) 15 6(40.0) 
Hospitalisation 
In hospital, nursing home, or 145 13(9.0) <0.001 151 0(0.0) <0.001 63 29(46-0) 0.08 
residential care 
Not in residential care 530 137 (25.9) 527 33(6.3) 300 103 (34.3) 
Physiological risk factors 
Atrial fibrillation 98 11 (11.2) 0.01 96 3(3.1) 0.07 58 25 (43.1) 0.24 
No atrial fibrillation 577 139 (24.1) 582 30(5.2) 306 107 (35.0) 
Diabetes 124 14 (11.3) <0.001 123 4(3.3) 0.48 57 22 (35.8) 0.69 
No diabetes 551 136 (24.7) 555 29(5.2) 307 110 (38.6) 
Hypertension 434 85 (19.6) 0.03 439 20(4.6) 0.70 257 90 (35.0) 0.44 
No hypertension 241 65 (27.0) 239 13(5.4) 107 42(39.3) 
*Smoking and alcohol use were measured at 3 months after stroke; obesity, at 1 year. 
tPhysical functioning was measured at 3 months and 1 year with the Barthel Index (BI). Physical functioning categories are defined 
as follows: independent, BI=20; moderate, BI 10-19; severe, BI <10. 
Social class was not known for 24 (3.6%). Of these, 19 described themselves as retired or permanently sick. 
were available only for patients who were already smokers at 
the time of stroke. Factors associated with behavior change 
are presented in Table 3. 
Giving up smoking at 3 months was associated with being 
nonwhite (black African, Caribbean, or other nonwhite ethnic 
group). Twenty patients (51.3%) from black ethnic groups did so 
compared with 62 (31.6%) of white patients. Living in institution- 
alized care was also associated with smoking cessation: 26 patients 
(66.7%) living in hospital, nursing home, or residential care had 
given up smoking compared with only 56 (28.4%) of those living in 
the community. All 16 patients living in hospital, nursing home, or 
residential care who previously drank more than the weekly limit 
had reduced their drinking at 3 months; therefore, place of residence 
could not be included in the logistic regression model for alcohol 
use. 
Discussion 
Previous work has discussed the appropriateness of physio- 
logical risk factor management after stroke, ' but no research 
to date has focused on behavioral risk factors. This study 
investigated 2 key issues: the prevalence of behavioral risk 
factors after stroke and whether specific problem groups 
could be identified. We also aimed to identify characteristics 
about those who change risk factors after stroke to help 
understand what factors help or hinder risk factor change. 
Younger patients, whites, men, and those living in the 
community (as opposed to residential hospital or nursing 
home care) were more likely to be smokers, and these groups 
could be targeted with interventions to promote smoking 
cessation tailored to meet their needs. Younger patients and 
whites were also more likely to be at risk from excessive 
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TABLE 2. Association Between Behavioral Risk Factors and Sociodemographics, Physical Functioning, and 
Physiological Risk Factors After Stroke 
OR 
Smoking 
95% Cl P 
Drinking More Than Weekly 
Limit 
OR 95% Cl P OR 
High WHR' 
95% Cl P 
Age, y 
<65 1 <0.001 1 0.02 1 0.71 
65-79 0.40 0.26-0.63 0.42 0.19-0.93 1.16 0.69-1.95 
80+ 0.13 0.06-0.27 0.17 0.04-0.84 0.93 0.47-1.82 
Women 0.65 0.43-0.99 0.05 0.59 0.26-1.35 0.21 1.67 1.06-2.63 0.03 
Nonwhite ethnicity 0.28 0.16-0.50 <0.001 0.17 0.04-0.73 0.02 1.70 0.98-2.96 0.06 
Physical functioningt 
Independent 1 0.81 1 0.19 1 0.31 
Moderate disability 1.15 0.74-1.79 0.50 0.21-1.18 1.34 0.82-2.18 
Severe disability 1.00 0.42-2.40 1.44 0.29-7.18 1.85 0.77-4.42 
Social classt 
Manual 1 0.82 1 0.19 1 0.51 
Nonmanual 1.15 0.73-1.80 0.60 0.28-1.29 1.29 0.78-2.13 
Not known 1.15 0.34-3.92 ... ... 1.62 
0.54-4.91 
Living in residential care, 0.38 0.17-0.84 0.02 ... ... ... 1.15 0.59-2.28 0.68 
hospital, or nursing home 
Physiological risk factors 
Atrial fibrillation 0.54 0.27-1.08 0.08 1.03 0.29-3.71 0.96 1.33 0.73-2.41 0.35 
Diabetes 0.46 0.24-0.88 0.02 0.90 0.29-2.81 0.85 0.91 0.49-1.72 0.78 
Hypertension 0.70 0.46-1.05 0.08 0.94 0.44-2.01 0.88 0.80 0.49-1.29 0.36 
OR indicates odds ratio. 
'Smoking and alcohol use were measured at 3 months after stroke, obesity, at 1 year. 
tPhysical functioning was measured at 3 months and 1 year with the Barthel Index (BI). Physical functioning categories are defined 
as follows: independent, BI=20; moderate, BI 10-19; severe, BI <10. 
Social class was not known for 24 (3.6%). Of these, 19 described themselves as retired or permanently sick. 
drinking; nonwhites and women were more likely to be 
obese. These groups could also be targeted with appropriate 
interventions to reduce their risk of second stroke. 
A large minority of those with risk factors did modify their 
lifestyles after stroke; in particular, most excessive drinkers 
reduced their alcohol consumption within the first year. 
However, despite some successes, not all patients managed to 
change their risk factors. Half of those who still smoked at 3 
months had reduced the amount they smoked, suggesting that 
they were willing to change their risk factors but might have 
needed further support to give up completely. A minority 
continued to drink more than the weekly limit, and most 
obese patients did not reduce their WHR. 
Apart from living in institutionalized care (hospitals, 
nursing homes, or residential care), there were no partic- 
ular patient characteristics associated with behavioral 
change, although nonwhites were more likely to give up 
smoking. Older patients were no less likely than their 
younger counterparts to change any behavioral risk factors 
after stroke, and this finding supports previous research1° 
emphasizing that older people should not be excluded from 
secondary prevention care because they are equally willing 
to change. 
Of those who stopped smoking or cut down on alcohol use, 
most did so in the first 3 months, suggesting that smoking and 
alcohol use might be more amenable to change during this 
time. An alternative interpretation might be that health 
professionals offer secondary prevention advice only in the 
first 3 months, failing to deliver appropriate information in 
the longer term. However, further investigation is needed to 
determine whether this is the case. 
These findings are based on a limited number of questions 
about patient characteristics and behavioral risk factors and as 
such can provide only an outline of the relationships between 
them. If the problems of inadequate management of behav- 
ioral risk factors are to be addressed, more research is needed 
into the actual process of change to find out why some 
patients change their risk factors while others do not. Trials of 
interventions to promote behavior change have shown posi- 
tive results, 9"1° but we do not know whether these interven- 
tions work for patients with stroke. Little is known about 
current health service management of behavioral risk factors, 
what secondary prevention interventions are used in practice, 
and which patients are being targeted. 
We are currently conducting further research to gain a 
better understanding of risk factor management and the 
process of change, including interviews with stroke patients 
about their experiences of risk factor change and observa- 
tional work to explore the role of health services in promoting 
secondary prevention or stroke. 
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TABLE 3. Association Between Change In Behavioral Risk and Soclodemographics, Physical Functioning, 
Physiological Risk Factors, and Health Service Use After Stroke 
Reduce Drinking to Less 
Give up smoking Than Weekly Limit Reduce to Nonobese' 
OR 95% Cl P OR 95% Cl P OR 95% Cl p 
Age, y 
<65 1 0.84 1 0.63 1 0.62 
65-79 1.09 0.57 -2.07 1.02 0.36 -2.91 0.66 0.25 -1.77 
80+ 0.78 0.21 -2.86 2.87 0.28-29.62 1.00 0.26 -3.82 
Women 1.24 0.64 -2.40 0.32 0.48 0.13 -1.84 0.29 0.72 0.29 -1.76 0.27 
Nonwhite ethnicity 2.21 1.01 -4.82 0.03 1.73 0.32 -9.43 0.53 0.53 0.18 -1.62 0.73 
Physical functioningt 
Independent 1 0.19 1 0.12 1 0.93 
Moderate/mild disability 1.11 0.56 -2.21 3.17 0.98-10.30 0.90 0.35 -2.28 
Severe disability 2.01 0.65 -6.18 0.82 0.10 -7.02 0.74 0.14 -3.80 
Social class$ 
Manual 1 0.23 1 0.51 1 0.08 
Nonmanual 2.09 0.90 -5.57 1.42 0.50 -4.08 0.41 0.14 -1.67 
Not known 2.18 0.42-11.44 ... ... ... 
Living in residential care, 3.16 1.20 -8.35 0.02 ... ... 0.45 0.12 -1.67 0.23 hospital, or nursing home 
Physiological risk factors 
Atrial fibrillation 1.69 0.62 -4.59 0.31 0.86 0.12 -6.18 0.89 0.56 0.20 -1.63 0.29 
Diabetes 1.22 0.48 -3.09 0.67 1.28 0.29 -5.70 0.74 3.13 0.59-16.66 0.18 
Hypertension 1.61 0.87 -2.97 0.13 0.69 0.24 -1.95 0.48 2.09 0.89 -4.89 0.09 
OR indicates odds ratio. 
*Smoking and alcohol use were measured at 3 months after stroke; obesity, at 1 year. 
tPhysical functioning was measured at 3 months and 1 year with the Barthel Index (BI). Physical functioning categories are defined 
as follows: independent, BI=20; moderate, BI 10 -19; severe, BI <10. 
#Social class was not known for 24 (3.6%). Of these, 19 described themselves as retired or permanently sick. 
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Background. Stroke patients have a 15-fold increased risk of a recurrence, but management of 
risk factors following stroke has been found to be unsatisfactory. Little is known about health 
service follow-up of patients after stroke or, consequently, the opportunities for providing 
secondary prevention to patients. 
Objective. The aim of the present study was to investigate the relationship between health 
service follow-up and management of risk factors after stroke. 
Methods. The study used data from the population-based South London Stroke Register, 
collected prospectively between 1995 and 1998. Main measures included risk factor change and 
follow-up by hospital physicians, GPs and district nurses. Logistic regression was used to deter- 
mine relationships between these measures. 
Results. Seven hundred and seventeen stroke survivors were registered with first stroke 
between 1995 and 1998. Most patients were followed-up on at least one occasion by at least one 
service within the first 3 months after stroke: 51% saw a hospital specialist; 72% saw a GP; and 
14% saw a community nurse. However, 14% of patients did not see a doctor at all. Disabled 
patients were less likely to see a doctor, only 17% of severely disabled patients seeing a hospital 
specialist [odds ratio (OR) 0.17; 95% confidence interval (CI) 0.07-0.411. Doctor-led follow-up was 
related to treatment of physiological risk factors (e. g. 73% of hypertensive patients who had 
seen a GP were treated compared with 59% who had seen only a hospital specialist and 47% 
who had seen neither). Contact with health services was not associated with behavioural risk 
factor change. 
Conclusions. Opportunities for delivering secondary prevention existed through a range of 
services, but problems of continuity and effectiveness of care are evident. Further investigation 
is needed to determine how best to intervene to address these issues. In other words, whether 
interventions should concentrate on improving access and availability of current services, or 
whether the focus should be on making current strategies more effective. 
Keywords. Prevention, risk factors, stroke. 
Introduction 
Stroke survivors, who have a 15-fold increased risk 
of further vascular events compared with the general 
population, 1 are an important group to target if mortality 
rates are to be reduced. 
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Secondary prevention requires appropriate manage- 
ment of risk factors, but our previous research indicates that 
risk factor management in the stroke population is poor 
(e. g. 30% of patients with hypertension were not treated 
3 months after stroke). 2'3 In this paper, we now investigate 
health service opportunities for secondary prevention. 
In the UK, as in many other areas of Europe, oppor- 
tunities for secondary prevention arise through a range 
of services. These include follow-up by a specialist phys- 
ician in hospital out-patient clinics, or by a primary care 
doctor (GP) in a community surgery or in the patient's 
own home. Other primary care professionals who 
may provide secondary prevention include the 'practice 
nurse' (whose other duties include providing chronic 
disease management in partnership with the GP), or a 
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community-based `district nurse' (whose main respon- 
sibilities include nursing care, health promotion and 
preventive activities). ' 
Research on primary prevention identified failures 
of follow-up, advice and monitoring as avoidable 
contributory factors to death from stroke and hyper- 
tension. 5 Evidence-based guidelines for the delivery of 
secondary prevention have been produced, 6-8 but little is 
known about current practice. This paper focuses on the 
following questions: what factors influence patient 
contact with health professionals? Is contact associated 
with risk factor management? 
Methods 
The study used data from the population-based South 
London Stroke Register, which, since 1995 prospectively 
collects data on first ever strokes in patients of all age 
groups. Twelve overlapping referral sources are used to 
attain complete notification in the study area comprising 
22 wards of the Lambeth, Southwark and Lewisham 
Health Authority (LSLHA), with a population of 234 533. 
The methodology has been described in detail elsewhere. 9 
Data were collected on patients' socio-demographic 
characteristics and risk factors at the time of stroke. 
Patients were seen by a trained interviewer 3 months 
after stroke and data collected on: place of residence and 
functional ability (Barthel Index); physiological risk 
factors (hypertension, atrial fibrillation, diabetes and 
coronary heart disease); and behavioural risk factors 
(smoking, heavy drinking and obesity). Risk factor man- 
agement 3 months after stroke was defined as treatment 
with anticoagulant, antiplatelet or antihypertensive 
medication, smoking cessation and reduction in drink- 
ing. Detailed descriptions of patients' risk factors are 
presented elsewhere .23 
Data on health service follow-up 
within 3 months after stroke included: one or more visits 
to a hospital out-patient clinic or GP surgery, or a home 
visit from a GP or district nurse. 
Data were analysed using chi-square tests and multiple 
logistic regression. 
Results 
Between 1 January 1995 and 31 December 1998,1139 
patients were registered with first stroke. Of these, 377 
(33.1%) died within the first 3 months after stroke and, 
of the survivors, 45 (5.9%) did not complete a 3-month 
follow-up questionnaire. Data from 717/1139 patients 
are therefore analysed. 
Patient characteristics are presented in Table 1. Most 
patients (558,87.5%) had at least one modifiable risk fac- 
tor at the time of stroke, and 280 (43.9%) had at least two. 
Of those not living in hospital, 317 (55.1%) saw a 
specialist in an out-patient clinic within the first 3 months 
TABLE I CharactrristiCS of patients (n = 717) 
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11 (%) 
Age of patients surviving to 3 months (mean no. of years) 69.5 
Sex 
Male 377 (52.6) 
Female 340 (47.4) 
Self-defined ethnicity 
White 547 (76.4) 
Black Caribbean 98 (13.7) 
Black African or other 37 (5.2) 
Social class (occupation) 
Manual (III manual, IV, V) 475 (66.3) 
Non-manual (1, II, 111 non-manual) 210 (29.3) 
Social class not known' 32 (4.5) 
Place of residence 
Living at home 553 (77.5) 
In hospital 101 (14.1) 
In a nursing home 47(b. 6) 
In residential care 13(l. 8) 
Functional ability 
Independent(B1= 20) 263(37.15) 
Moderate disability (BI = 10 <20) 311 (43.9) 
Severe disability (BI < 10) 134 (18.9) 
Missing data: ethnicity, one patient; place of residence, two patients; 
Barthel Index (BI), nine patients. 
" Of those whose social class was not known, 24 were retired. 
after stroke. Care of the elderly specialists were visited 
most commonly (121,21.0%), followed by general 
physicians (56,9.7%), rehabilitation specialists (44, 
7.7%), neurologists (38,6.6%) and others (55,9.6%). 
Two hundred and sixty-seven patients (44.7%) visited 
a GP surgery and a further 165 (27.6%) were visited by a 
GP at home. Patients not initially admitted were more 
likely to have seen a GP (111,80.4%) compared with only 
328 (70.2%) of those previously hospitalized (P = 0.02). 
Figure 1 illustrates the overlap between hospital and 
FIGURE I Proportion of patients followed-up by GPs and 
hospital specialists in the first 3 months after stroke. Based on 
571/605 patients who answered both questions. Twenty-six 
patients did not answer the question on out-patient attendance 
(15 had seen a GP, 11 had not), four patients did not answer the 
question on GP visits (two had seen a specialist, two had riot) 
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general practice follow-up. Of those who had no contact 
with any doctor after leaving hospital, 68 (90.7%) had 
at least one modifiable risk factor and 26 (34.7%) had at 
least two. Only patients living at home were eligible 
for district nurse support. Of these, 85 (14.2%) had seen 
a district nurse within the first 3 months. 
Associations between follow-up and patient character- 
istics are presented in Table 2. Table 3 illustrates rela- 
tionships between follow-up, patient characteristics and 
additional risk factors adjusting for all other factors. 
Disabled patients were less likely to have consulted 
a doctor in any setting (out-patients, GP surgery or at 
home), but just under two-thirds of severely disabled 
patients had been visited by a district nurse. Age was also 
related to GP care, those aged over 65 being less likely to 
be followed-up and, although elderly patients were more 
likely to have received support from district nurses, only 
a quarter of those aged 80 years or more had done so. 
Those living in nursing homes or residential care rarely 
attended out-patients although they were equally likely 
to have seen a GP (all but one receiving a domiciliary visit 
from the doctor). After adjusting for age and disability, 
no associations were found between follow-up and 
gender, ethnicity or social class. 
There was no obvious relationship between having 
additional risk factors at the time of stroke and contact 
with health professionals. Patients with a diagnosis of 
diabetes or hypertension were more likely to have been 
visited by a district nurse, but no other associations were 
statistically significant. 
Ischaemic stroke patients who had seen either a 
specialist or a GP were more likely to be prescribed 
medication (Table 4); however, having contact with both 
did not improve the likelihood of treatment. 
No association was found between follow-up and 
smoking cessation or reduction of heavy drinking. 
Discussion 
This is the first study investigating opportunities for 
secondary prevention in the stroke population. Since 
TABLE 2 Associations between patient characteristics and health care follow-up in the first 3 months after stroke 
Visit out-patients' clinic' Visit or receive visit from GP' Have district nurse support' 
Total patients n (%) P-value Total patients n (%) P-value Total patients if (%) P-value 
Total 575 
Age 
<65 years 177 
65-79 years 269 






Black Caribbean 71 
Black African or other 55 
Physical functioning 
Independent (BI =20) 252 
Moderate disability 253 
(BI = 10 < 20) 
Severe disability (BI < 10) 70 
Social class 
Manual (III manual, IV, V) 392 
Non manual 164 
(I, II, III non-manual) 
Retired, class n/k 19 
Place of residence 
Nursing home or 55 
residential care 
At home 520 
317 (55.1) 
120 (67.8) <0.001 
145 (53.9) 
52 (40.3) 
172 (56.8) 0.41 
145 (53.3) 
246 (54.8) 0.74 
42 (59.2) 
29 (52.7) 
169 (67.1) <0.001 
136 (53.8) 
12 (17.1) 
215 (54.9) 0.44 
94 (57.3) 
8(42.1) 
7 (12.7) <0.001 
310 (59.6) 
597 391 (72.5) 556 85 (15.3) 
181 150 (82.9) 0.001 178 14(7.9) <0.001 
280 189 (67.5) 266 43 (16.2) 
136 93 (68.3) 112 28 (25.2) 
314 244 (77.7) 0.002 300 35 (11.7) 0.01 
283 188 (66.4) 256 50(19.5) 
462 330 (71.4) 0.58 462 55 (12.9) 0.015 
77 57 (74.0) 72 20 (27.8) 
58 45(77.6) 58 10(17.2) 
257 208 (80.9) <0.001 258 11 (4.3) <0.001 
265 173 (65.2) 260 51 (19.6) 
75 51 (68.0) 38 23 (60.5) 
406 295 (72.7) 0.90 382 64 (16.8) 0.14 
169 122 (72.2) 157 17 (10.8) 
22 15 (68.2) 17 4(23.5) 
58 41 (70.7) 0.76 545 84 (15.4) 0.56 
539 391 (72.5) 11 1(9.1) 
Chi-square tests comparing follow-up between different patient groups (unadjusted). 
Missing data: Barthel Index (BI), nine patients; socio-demographic characteristics, four patients; out-patient attendance, 29 patients; 
GP contact, seven patients; district nurse support, two patients. 
" Based on patients discharged from hospital 3 months post-stroke. 
Based on patients discharged from hospital and not living in nursing homes 3 months post-stroke. 
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TABLE 3 Health service follow-up adjusting for patient characteristics and risk factors within first 3 months after stroke 
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Visit out-patients' clinic' Visit GP or receive visit from GP" Have district nurse support" 
OR 95% Cl P-value OR 95% Cl P-value OR 95% Cl P-value 
Age 
<65 years 1 0.10 1 0.04 1 0.03 
65-79 years 0.62 (0.39,1.00) 0.52 (0.30,0.88) 2.13 (0.96,4.75) 
a80 years 0.55 (0.29,1.02) 0.70 (0.36, t. 38) 3.54 (1.38,9.07) 
Female 1.27 (0.83,1.95) 0.27 0.75 (0.48,1.17) 0.20 1.33 (0.71,2.51) 0.37 
White 1 0.66 1 0.86 1 0.19 
Black Caribbean 0.91 (0.49,1.71) 0.98 (0.52,1.87) 2.18 (0.96,4.98) 
Black African or other 0.72 (0.36,1.45) 1.23 (0.56,2.67) 1.21 (0.43,3.45) 
Physical functioning` 
Independent (BI =20) 1 <0.001 1 0.01 1 <0.001 
Moderate disability 0.62 (0.41,0.94) 0.50 (0.32,0.79) 3.55 (1.70,7.42) 
(BI = 10 < 20) 
Severe disability (BI < 10) 0.17 (0.07,0.41) 0.53 (0.25,1.13) 26.78 (9.58,74.86) 
Social class 
Non-manual 1 0.67 1 0.85 1 0.08 
(I, It, III non-manual) 
Manual (III manual, IV, V) 0.84 (0.54,1.29) 0.88 (0.56,1.38) 2.00 (0.96,4.20) 
Retired, class n/k 1.11 (0.32,3.90) 0.93 (0.29,2.95) 3.93 (0.80,19.37) 
Living in nursing home or 0.19 (0.07,0.55) 0.002 1.09 (0.51,2.35) 0.83 0.11 (0.01,1.56) 0.11 
residential care 
Behavioural risk factors 
Smokers 0.98 (0.63,1.54) 0.95 0.99 (0.62,1.59) 0.98 1.18 (0.60,2.35) 0.63 
Alcohol use 
Non-drinker 1 0.13 1 0.14 1 0.49 
Moderate drinker 1.54 (0.98,2.42) 1.58 (1.01,2.47) 0.81 (0.43,1.51) 
Heavy drinker'' 1.74 (0.89,3.44) 1.30 (0.64,2.64) 1.36 (0.51,3.64) 
High waist-hip ratio 0.67 (0.45,1.01) 0.06 0.89 (0.58,1.35) 0.57 1.11 (0.60,2.07) 0.73 
Clinical risk factors: 
Atrial fibrillation 1.43 (0.78,2.64) 0.25 1.84 (0.97,3.52) 0.40 1.08 (0.48,2.45) 0.85 
Diabetes 1.39 (0.80,2.42) 0.24 1.32 (0.74,2.34) 0.58 2.93 (1.47,5.84) <0.01 
Hypertension 0.97 (0.66,1.43) 0.87 0.90 (0.60,1.36) 0.98 1.89 (1.02,3.50) 0.05 
Coronary heart disease 0.74 (0.47,1.14) 0.17 0.80 (0.51,1.25) 0.83 1.11 (0.59,2.09) 0.75 
Odds ratios (ORs) adjusted for all other factors. 
' Based on patients discharged from hospital 3 months post-stroke. 
"Based on patients discharged from hospital and not living in nursing homes 3 months post-stroke. 
' BI = Barthel Index. 
Heavy drinking defined as >14 units a week for women; >21 units a week for men (where I unit = half pint of beer, one small glass of wine or 
spirits). 
most patients had at least one contact with health 
services in the first 3 months after stroke, there were 
opportunities for providing secondary prevention. 
However, 14% did not see any doctor, a quarter did not 
see a GP and -10% of those who attended out-patient 
clinics did not see a stroke-related specialist. Because 
data were not collected on the reason for patients' con- 
tact with professionals, we cannot assume that appro- 
priate secondary prevention was provided to those who 
were followed-up. 
Patients with disabilities were less likely to be followed- 
up by any doctor. Older patients were less likely to see a 
GP These apparent inequalities in service provision 
require explanation. 
Health professionals are encouraged to target those 
most at risk, 64 but in this study patients with additional 
risk factors were no more likely to be followed-up. 
Follow-up was not associated with behavioural risk 
factor change. his is difficult to interpret, but may 
reflect difficulties in changing behaviours (e. g. quitting 
smoking). Alternatively, health professionals may choose 
not to prioritize behavioural risk factors. GPs may be less 
interested in health promotion or behavioural change, "" 
finding it difficult to discuss lifestyle issues with 
patients. " 
Since all patients are at risk after stroke, all patients 
require secondary prevention. Patients with disabilities, 
the elderly and those living in residential homes may need 
348 
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TABLE 4 Associations between risk factor management and health care follow-up 
Followed-up by hospital No contact 
specialist or GP within 3 months 
Total patients n (%) Total patients n (yý) P-value 
Treated with antihypertensives 315 224 (71.1) 54 26 (48.2) 0.001 
Treated with anticoagulants 40 14 (35.0) 10 1 (-) 0.246' 
Treated with antiplatclets 322 273 (84.8) 59 42 (71.2) 0.011 
Given up smoking 179 54 (30.2) 25 10 (40.0) 0.321 
Reduced heavy drinkingb 82 56 (68.3) 6 3 (-) 0.391 
Chi-square tests comparing those followed-up versus those having no contact with professionals. 
° Small numbers; data should be interpreted with caution. 
Heavy drinking defined as >14 units a week for women; >21 units a week for men (where 1 unit = half pint of beer, one small glass of wine or spirits) 
specific targeting to ensure equitable access to those who 
can prescribe and monitor their treatment. However, 
attending services does not in itself constitute risk factor 
management. Further work is needed to establish what 
is provided during follow-up and identify facilitators of 
and barriers to secondary prevention provision. 
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Appendix 2. Topic guide for patient interviews (intervention 
development) 
General understanding of stroke and experiences of prevention 
The stroke experience 
Tell me a bit about your stroke [prompt: what happened to the patient] 
Affect of stroke on patients' life - changes since the stroke 
People who have been important to patient since the stroke [prompt: health 
professionals, family, friends] 
Monitoring 
Hospital outpatient visits [prompt reason for attendance] 
GP visits [prompt reason for attendance, frequency] 
Follow up about stroke [prompt frequency, what happened/happens at visit] 
Understanding of stroke in general 
Why patient had the stroke 
Things that can cause strokes in general 
What type of stroke patient had [prompt: haemorrhage, ischaemic] 
Definition of what their type of stroke is 
Future health 
Things patient worries about these days 
Worries about health [prompt future health] 
Worries about stroke [prompt future stroke] 
Chances of patient having another stroke [prompt how much of a risk, why 
patient perceives they are at risk/not at risk] 
Things that can be done to prevent strokes [prompt: things to prevent the 
patient having another stroke] 
Information and education 
How patient has learnt about stroke and prevention of stroke 
Information received about stroke and prevention [prompt written or verbal; who 
from, when received, quality of information] 
Anything patient would have liked to know about the stroke or stroke prevention 




Current medication taken 
Current medication for stroke [prompt aspirin] 
Length of time taken [prompt pre stroke/post stroke] 
The name of the medication [if don't know prompt for the type of medication 
group] 
What the medication is for 
Previously prescribed medication [prompt changes to medication] 
Decisions about treatment 
Current medication taking 
How/When the patient takes the medication 
Concordance with medication [prompt frequency, prompt stopping medication] 
Problems with the medication [prompt side effects] 
Barriers/Difficulties taking medication [prompt remembering, problems getting a 
prescription] 
Monitoring of medication [prompt repeat prescription, whether see doctor or 
practice nurse] 
Written information about medications [prompt content, quality] 
Understanding of medications 
How the medication works 
Whether the patient can tell the medication is working 
Feelings about taking the medication 
Whether the medication will stop the patient having another stroke 
Risk factors clinical 
Blood pressure 
Whether patient knows their blood pressure [prompt who told patient] 
What a normal blood pressure is [prompt who told patient] 
Whether patient has high blood pressure [prompt how know blood pressure is 
high/OK] 
Definition of what high blood pressure is 
What having high blood pressure means to the patient 
Last blood pressure check 
Current medication for blood pressure 
Prior medication for blood pressure 
What you eat and blood pressure 
Advice about blood pressure 
Written information about blood pressure 
Looking after blood pressure and stroke prevention 
Cholesterol 
What patient's cholesterol is [prompt who told patient] 
What a normal cholesterol is [prompt who told patient] 
Whether patient has high cholesterol 
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Definition of what cholesterol/high cholesterol is 
What having high cholesterol means to the patient 
Whether cholesterol was related to the patient's stroke 
Last cholesterol check 
Medication for cholesterol 
Medication for cholesterol prior to stroke 
What you eat and cholesterol 
Advice about cholesterol 
Written information about cholesterol 
Looking after cholesterol and stroke prevention 
Atrial Fibrillation 
Whether patient has any heart problems [prompt whether patient has atrial 
fibrillation, how the patient knows, tests the patient has had] 
Definition of what atrial fibrillation is 
What having atrial fibrillation means to the patient 
Whether atrial fibrillation was related to the patient's stroke 
Medication for atrial fibrillation [prompt: how long been taking, how medication 
works] 
Prior medication for atrial fibrillation 
Monitoring of medication [check postal patient] 
Advice about anticoagulants and antiplatelets 
Written information about anticoagulants and antiplatelets 
Looking after atrial fibrillation and stroke prevention 
Diabetes 
Whether patient has diabetes 
Definition of what diabetes is 
Last recorded HbAlc 
What a normal HbAlc is 
What having diabetes means to the patient [in terms of changes to their lives, 
monitoring, medication etc. ] 
Whether diabetes was related to the patient's stroke 
Monitoring of diabetes 
Medication for diabetes 
What you eat and diabetes 
Looking after diabetes and stroke prevention 
Lifestyle 
Smoking 
Whether patient smokes 
Whether smoking is a perceived health problem [prompt for whether smoking 
anything is a health problem, amount that is OK] 
Whether smoking was related to the patient's stroke 
Attempts to quit smoking/cut down [prompt whether since stroke, what 
happened, strategies for giving up] 
Reasons for giving up 
Barriers to giving up [prompt generally, and from experience) 
Health professional advice to give up [prompt, who, when, content and quality of 
advice] 
352 
Written information about smoking [prompt, who provided, when, content and 
quality of advice 
Smoking support [medications (patches, gum), smoking clinics] 
Giving up and stroke prevention 
Alcohol 
Whether patient drinks alcohol 
Whether drinking alcohol is healthy/a health problem [prompt for how much 
alcohol is healthy] 
Whether drinking alcohol was related to the patient's stroke 
Attempts to change alcohol use [prompt whether happened since the stroke, 
what happened, strategies for changing drinking patterns] 
Reasons for changing drinking patterns 
Barriers to changing drinking patterns 
Health professional advice to cut down/give up [prompt, who, when] 
Information about alcohol use [prompt written, verbal, who provided, quality of 
information] 
Alcohol use support [drinking clinics] 
Alcohol and stroke prevention 
Diet 
Whether what you eat is important for being healthy 
What eating 'healthy food' means to the patient [prompt for good, bad foods] 
Whether patient eats healthy food 
Whether patient's diet was related to their stroke 
Types of food that are bad for you after a stroke [prompt: salt, high cholesterol 
foods, sweet foods if diabetic] 
Changes to diet since the stroke [prompt: what changes, what happened, 
strategies for changing diet] 
Reasons for changing diet 
Barriers to changing diet 
Health professional advice to change patient's diet [prompt, who, when] 
Written information about diet [prompt who provided, when, quality of 
information] 
Dietary support [nutritionist, dietician] 
Diet and stroke prevention 
Obesity 
Weight 
What overweight means? 
Attempts to lose weight [prompt what happened, strategies for giving up] 
Attempts to lose weight since the stroke [prompt what happened, strategies for 
giving up] 
Reasons for losing weight/trying to lose weight 
Barriers to losing weight 
Health professional advice to lose weight [prompt, who, when] 
Written information about losing weight [prompt who provided, when, quality of 
information] 
Support [nutritionist, dietician etc] 
Beliefs about weight/obesity and stroke prevention 
353 
Exercise 
Whether exercise is important for being healthy 
Amount of exercise patient does [prompt for examples of exercise 
What 'exercise' means [prompt for type of exercise] 
Whether exercise had anything to do with their stroke 
Attempts to change exercise pattern since the stroke[prompt what happened, 
strategies for giving up] 
Reasons for trying to changing exercise 
Barriers to exercising 
Health professional advice about exercise [prompt who, when] 
Written information about exercise [prompt who provided, when, quality of 
information] 
Exercise support [e. g. health centres specialising in exercise for those with 
disabilities] 
Exercise and stroke prevention 
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Appendix 3. Observation Schedule (intervention development) 
Clinic date: Hospital: [Hospital A]/[Hospital B] 
Doctor 
Serial no: Time start: Time stop: 
Age: Q DOB: 
Sex: male / female Ethnicity: 
Date of stroke: 
Time since last episode: 
[--] weeks F1 months 17 years 
Type of patient: New / follow-up 
Mobility: Walking / walk with stick / wheelchair 
Communication: No problem / problems / interpreter 
Carers: No carer / partner / relative / friend / formal / other / dk 
Type of stroke: Ischaemic / haemorrhage / TIA / suspected stroke / not stroke 
Behavioural risk factors: Smoker / drinker / obesity 
Clinical risk factors: Hypertension / AF / diabetes / cholesterol 
Medication: Aspirin / antiplatelet / anticoagulant 
Antihypertensives / cholesterol lowering / diabetes treatment 
Blood pressure: 
I- I 
Fine/ too high / other / not specified 
Outcome: Discharged / follow-up / referred elsewhere 
Secondary prevention recurrence explicit: yes / no 
Risk size: % given / other / no risk size 
No. questions asked by doctor: No. questions asked by patient: 
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Appendix 4. Topic guide for trial staff interviews 
Staff experiences of working on the trial 
Can you describe your experience of working on Stop Stroke over the 
past year? 
prompt what has been easy, difficult, challenging, enjoyable 
What have been the biggest challenges for you? 
How have you managed to overcome these challenges? 
Any unresolved issues/problems that you would like to discuss? 
Who they go to if you have problems or issues you wish to raise? 
Specific challenge questions: 
There have been a number of staff changes in the past year, How has this 
affected the trial? 
[Prompt each SLSR1, FUP1 Admin1 leaving, FUP2 SLSR3 starting]. 
The neuro-vascular clinic was set up in the last year. I know there have been 
some problems with SLSR recruitment from this clinic - can you describe what 
are the main problems? 
How have the challenges affected SLSR recruitment/ the trial and intervention 
delivery 
Roles and responsibilities 
You are the [trial coordinator/research assistant], what are the main tasks 
that you do? 
What are the easiest tasks? 
What are the most difficult tasks? 
How have your main tasks changed over the past year? 
Are there any other people involved in the Stop Stroke process and what tasks 
do they do? 
Specific role questions: 
Annual leave - what happens to the intervention if members of staff go on leave. 
Staff absence and workload - SLSR3 being too busy to do aspects of SLSR 
work - how has this affected the trial? 
Satisfaction 
Are you happy with the way the trial is running? 
Things which could be improved 
What is needed to improve these things 
The intervention/trial 
Can you describe the intervention to me? 
What exactly are the components of the intervention? 
Who gets the intervention? 
Are there any people who are not eligible for the intervention? 
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Have there been any changes to the intervention over the past year - 
Changes to content of the intervention? 
Changes to who gets the intervention? 
Other changes influencing the intervention process? 
What do you understand by the term `pragmatic trial'? 
Reassure: It is OK if you don't understand the term. 
Communication 
You were asked to keep diaries during the first year - how difficult was 
this? 
Did the diaries help you to identify problems? 
Did the diaries help resolve any problems? 
We have started having weekly meetings about the trial do you find these 
meetings helpful? 
Did you have meetings throughout the past year? 
If no - what did you have instead? 
Specific questions to clarify individual tasks 
For Research Assistant: 
Blood test data collection. 
Prompts: 
What the blood tests are for? 
Delays in taking bloods? If yes - when did this start, how was it? If no - when 
do you think the blood tests will start? 
How will the blood testing process happen? 
What were the main reasons for the delay in taking bloods? 
Training in phlebotomy 
Confidence in taking bloods 
Support 
In the last Stop Stroke meeting you mentioned that you did not feel supported in 
your tasks, is there anything you want to say about this? 
For Trial Coordinator. 
Trial administration 
Intervention delivery 
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Appendix 6. Topic guide for patient interviews (intervention 
evaluation) 
Patients' experiences of secondary prevention 
Can you tell me a bit about what has happened to you since the stroke? 
Prompts: 
Hospital visits 
Whether patient has been (back) to the hospital since your stroke? 
If yes, what happened, who saw, purpose of appointment, advice given, 
treatments, did they do any tests] 
If no, reasons why not - have any appointments been booked, missed] 
GP care 
Whether patient has seen their GP since your stroke? 
If yes, what for, how many times, what was covered, did they check blood 
pressure, prescribe treatments, check medication, give you any advice... ] 
What happened the last time they visited the doctor - did they talk about the 
stroke 
Does anyone go to the doctor with them - if so who 
Community services 
Whether they have seen any other health professions since the stroke? 
District nurse, day hospital, physiotherapist. If yes, what for, what did they 
do/talk about? ] 
Tests and investigations 
Have they had any tests or investigations for your stroke 
Blood pressure checks, diabetes, cholesterol, hospital tests 
Medication 
Whether they have been given any medication for the stroke 
If yes - what are the medications, what are they for - check preventive 
medications, how do they get hold of them, how do they take them, do they 
have any strategies for remembering them, advice about taking medication 
If not already mentioned, does anyone help you with your medication, how do 
they help? 
Prevention advice 
Whether they have been given any advice about how to prevent future strokes? 
If yes - what sort of advice, who gave it to them, when did they get it, what did it 
say, what did they think of it, did they make any changes as a result of the 
advice 
If person has help getting to doctor/taking medication did that person have any 
information after the stroke? 
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Written information 
Whether they have been given any written information about preventing further 
strokes. 
If yes - what sort of advice, who gave it to them, when did they get it, what did it 
say, what did they think of it, did they make any changes as a result of the 
advice. 
Was the advice designed specifically for them? How did you know this? If yes, 
what sort of information was specifically about you 
Unanswered questions 
Whether there is anything they would like to know more about, questions they 
would like to ask your doctor. 
Whether they have asked the doctor these questions, whether they would ask 
them, whether this info was covered in the advice they had? 
Patient understanding of stroke secondary prevention 
Can you tell me a bit about what you know about your stroke? 
Prompts: 
Why the stroke happened 
Do you know why you had a stroke? 
[prompt subjective - your stroke not why people have strokes in general, how 
do you this? ] 
Risk factors for stroke 
Is there anything else that contributed to your stroke? 
[what sorts of things - prompt smoking, having high blood pressure. How do you 
know this? ] 
The future 
How do you see your future in terms of your stroke? 
[is stroke over with now? Why see future like this - is it because you 
have/haven't fully recovered yet? ] 
If stroke not over/not recovered, do you think the stroke will ever been over and 
done with? [if yes, when, how will you know? ] 
Do you think it is possible to have more strokes in the future? 
[why think this, who told this] 
Do you worry about having another stroke? 
Preventing future strokes 
Is there anything that can be done to prevent further strokes (general) 
[if yes prompt what sorts of things, if no prompt why not] 
Is there anything that can be done to prevent you having another stroke? 
[what sorts of things are you doing - medication, will they work, how will they 
work. Do you think these things will work? How do you know] 
Is there anything the doctors can do to prevent you having another stroke? 
[what sorts of things can be done, which of these are they doing, will they 
work? ] 
How important is it to try and prevent further strokes? 
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Specific Questions on the intervention 
If not already mentioned... 
As part of our research project you were meant to have received a pack 




How did you get hold of the pack? 
When did you get the pack? 
Content 
What was in the pack? 
What did the pack tell you? 
[prompt did it say anything about blood pressure, smoking, diabetes] 
What did you think of the pack? 
[could you understand the information, how helpful was it] 
Was there anything specific about the pack that you liked/disliked? 
Did the pack answer any of the questions you had about your stroke? 
[if yes what were the questions? If no, what questions would you like to ask? ] 
Actions taken 
What did you do with the pack? 
[did you keep it, where do you keep it? ] 
Have you ever shown the pack to your doctor? 
[what happened, what did he/she think of it? ] 
Do you do anything specific as a result of the information provided in the pack? 
[did you see the doctor, change what you eat, give up smoking, start taking any 
medication, take up exercise? ] 
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Appendix 7. Intervention Plans 
This appendix includes the individualised secondary prevention plans for patients and 
professionals: 
Patient initial plan (yellow) 
Patient 3-month follow up plan (green) 
Patient 6-month follow up plan (peach) 
Professional initial plan (yellow) 
Professional 3-month follow up plan (green) 
Professional 6-month follow up plan (peach) 
A covering letter is provided with each plan. The plans have been formatted to fit into 
this thesis. Original patient plans are presented using a minimum font size of 16 point 
Arial font. Patient plans are folded in half together with specific numbered laminated 
information sheets (Appendix 9). Plans and information sheets are provided in a clear 
plastic A5 wallet with the patient's name on the front. 
Original professional plans have a minimum font size of 8 point Arial font. The 
professional plan is a single sided sheet folded in half to make an A5 booklet, designed 
to fit into the patient's general practice notes. 
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Mr P Patient 
1 The High Street 
London 
SE1 1AB 
12 January 2007 
Dear Mr P Patient 
Keeping well after stroke 
This is your plan for keeping well after stroke. The plan will help 
you prevent any further strokes. It was designed specifically for 
you using information about the type of stroke you had. If there is 
anything in the plan that you don't understand, please contact your 
doctor or nurse. 
Your doctor or nurse has probably already told you there is a 
chance you could have another stroke in the future. No one knows 
what the risk is for you personally, but the chance may be as high as 
1 in 5 in the next year. But don't panic! There is quite a lot that you 
can do to prevent further strokes. 
What to do now: 
Read the next page. There is a list of things you and your doctor 
can do to help prevent further strokes. For each of these things on 
your list, read the numbered sheets for more advice. 
Keep your plan somewhere safe. It is a good idea to show your 
plan to your friends, relatives or carers so you can talk about what 
you are doing to prevent further strokes. Take it to your doctor or 
nurse next time you see them. 
Yours sincerely 
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Mr P Patient 
1 The High Street 
London 
SE1 1AB 
12 January 2007 
Dear Mr Patient 
Keeping well after stroke 
(3-month update) 
This is your 3-month plan for keeping well after your stroke. The 
plan will help you prevent further strokes. It was designed 
specifically for you using information about the type of stroke you 
had. If there is anything in the plan that you don't understand, 
please contact your doctor or nurse. 
What to do now: 
Read the next page. There is a list of things you and your doctor 
can do to help prevent further strokes. For each of these things on 
your list, read the numbered sheets for more advice. 
Keep your plan somewhere safe. It is a good idea to show your 
plan to your friends, relatives or carers so you can talk about what 
you are doing to prevent further strokes. Take it to your doctor or 
nurse next time you see them. 
Don't forget to get regular blood pressure checks at your GP 
surgery. 
Yours sincerely 
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Mr P Patient 
1 The High Street 
London 
SE1 1AB 
12 January 2007 
Dear Mr Patient 
Keeping well after stroke 
(6-month update) 
This is your 6-month plan for keeping well after your stroke. The 
plan will help you prevent further strokes. It was designed 
specifically for you using information about the type of stroke you 
had. If there is anything in the plan that you don't understand, 
please contact your doctor or nurse. 
What to do now: 
Read the next page. There is a list of things you and your doctor 
can do to help prevent further strokes. For each of these things on 
your list, read the numbered sheets for more advice. 
Keep your plan somewhere safe. It is a good idea to show your plan 
to your friends, relatives or carers so you can talk about what you 
are doing to prevent further strokes. Take it to your doctor or nurse 
next time you see them. 
Don't forget to get regular blood pressure checks at your GP 
surgery. 
Yours sincerely 
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Dr G. Practitioner 
The Surgery 
10 Healthy Road 
London 
S1 DEF 
12 January 2007 
Dear Dr Practitioner 
Stop Stroke Secondary Prevention Plan 
Please find attached the Stop Stroke Secondary Prevention plan for your 
patient Mr P Patient. Mr P Patient had a stroke on 5/5/2006 and has 
consented to take part in the Stop Stroke Trial. A patient version of this plan 
has been sent to Mr P Patient. He has been advised to get his blood pressure 
checked within the next two weeks and to contact you if he has any queries 
about secondary prevention. 
We will contact you in 3 months time to update the plan. If in the meantime 
you have any queries about Stop Stroke please contact the South London 
Stroke Register on 020 7848 6612 or email stroke-reiister(cýkcl. ac. uk. 
Yours sincerely 
The Stroke Research Team 
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Dr G. Practitioner 
The Surgery 
10 Healthy Road 
London 
S1 DEF 
12 January 2007 
Dear Dr Practitioner 
Stop Stroke Secondary Prevention Plan 
(3-month update) 
Please find attached the updated Stop Stroke secondary prevention plan for 
your patient Mr P Patient. Mr P Patient had a stroke on 17/2/2006 and has 
consented to take part in the Stop Stroke Trial. The plan contains information on 
his risk factors including cardiovascular read codes where appropriate (Meditel 
Emis version 4.3 and Vamp, Emis version 5, Seetec). 
Fred Livermore has been advised to get regular blood pressure checks and to 
contact you if he has any queries about secondary prevention. 
We will contact you in 3 months time to update the plan. If in the meantime you 
have any queries about Stop Stroke please contact the South London Stroke 
Register on 020 7848 6612 or email stroke-register kcl. ac. uk. 
Yours sincerely 
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Dr G. Practitioner 
The Surgery 
10 Healthy Road 
London 
S1 DEF 
12 January 2007 
Dear Dr Practitioner 
Stop Stroke Secondary Prevention Plan 
(6-month update) 
Please find enclosed the updated Stop Stroke Secondary Prevention plan for your 
patient Mr P Patient. Mr P Patient had a stroke on 3/1/2006 and has consented to 
take part in the Stop Stroke Trial. The plan contains information on heris risk 
factors 6 months post stroke including cardiovascular read codes (Meditel, Emis 
version 4.3 and Vamp, Emis version 5, Seetec) 
Mr P Patient has been advised to get regular blood pressure checks and to 
contact you if she has any queries about secondary prevention. 
If in the meantime you have any queries about Stop Stroke please do not hesitate 
to contact the South London Stroke Register on 020 7848 6612 or email 
stroke-registerc kcl. ac. uk. 
Yours sincerely 
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Appendix 8. Proposal for developing intervention components 
Background 
Stop Stroke research has identified a need for more appropriate information and 
guidelines to be provided to health professionals and patients on how to manage their 
risk factors. Current information tends to be generalised, often not relevant to the needs 
and concerns of the individual patient and not provided at a time when secondary 
prevention is priority (Wiles et al., 1998). Thus current care may be missing 
opportunities to inform patients about secondary prevention. This intervention aims to 
overcome previous inadequacies by providing individualised information and guidelines 
on management to patients and professionals and timely reminders to those whose risk 
factor management is less than optimal. 
Aim: To develop system of providing management plans and follow up reminders 
for patients and health professionals tailored to the individual patient using a 
chronic disease register. 
Objectives: 
1. Redesign SLSR questions for collection of data on patient characteristics and risk 
factors to be used in the management plan. 
2. Design a hard copy individualised management plan (or plans) for patients 
integrating data from the SLSR and RCP guidelines on best management practice 
3. Design a hard copy individualised management plan (or plans) for health 
professionals integrating data from the SLSR and RCP guidelines on best 
management practice 
4. Design indkidualised reminder letters to inform patients and health professionals 
when patients need follow up or monitoring of their risk factors 
5. Develop a computer based system of converting SLSR data into hard copy 
individualised management plans and reminder letters for patients and health 
professionals 
Redesign SLSR questions for collection of data on patient characteristics and risk 
factors to be used in the management plan. 
The SLSR currently collects data on a range of patient sociodemographic and clinical 
characteristics including pre and post stroke clinical and behavioural risk factors, 
treatments, and resource use. Data are currently collected at the time of stroke, 3 
months, 12 months and annually post stroke. These data can be used to provide 
information on indiv iduals' risk factors and appropriate treatments. However some of 
the questions are not currently detailed enough to draw conclusions about where 
secondary prevention should be targeted. It would be useful to know the patient's actual 
blood pressure rather than a blood pressure category. It would also be useful to know 
the patient's cholesterol levels. Current resource questions ask about general follow up 
rather than stroke related follow up or prevention related follow up. Current medication 
questions ask about medication patients `are on' and do not distinguish between 
medication prescribed v-s medication actually taken. Data on smoking status is currently 
collected but not on the quantity smoked or on attempts to quit. By adapting the 
377 
questions in the SI. SR additional information could be collected useful for patient 
management , 
in particular more detailed information on: 
" type of information sought by patients and provided by health professionals 
" type of tollo%% up (H hether stroke related) and secondary prevention issues covered 
" blood pressure and cholesterol measurements 
" concordance issues, including medication taken as well as medication prescribed 
" attempts to change behaviour (e. g. number of cigarettes smokes, attempts to quit 
smoking) 
Current questionnaires %c ill be revised and feedback on questionnaire revisions will be 
gained from clinicians, statisticians, register staff and field workers. The questionnaires 
will piloted for appropriateness with the South London Patient Advisory Group. 
To design a hard copy individualised management plan for patients integrating 
data from the SLSR and RCP guidelines on best management practice 
Current information provided to patients tends to be in leaflet or booklet form providing 
general ad% ice about stroke, risk factors (smoking cessation leaflets, dietary advice, 
hypertension management). However generalised information is often not relevant to 
the patient. Generalised information (because it is often necessary to cover so many 
diverse issues) often does not include details relevant to the individual patient (Wiles et 
al., 1998). Current advice also often makes assumptions about patients' understanding 
of the health ss stem, and process of follow up (Redfern et al., 2001). Treatment plans 
will be designed for the management of each risk factor (e. g. separate plans on aspirin 
use, high blood pressure treatments, blood pressure monitoring for non-hypertensive 
patients). Different management plans will be produced to take into account differences 
between patients, for example [NOT SURE ABOUT THIS, NEED INPUT FROM 
CLINICIANS] for African Caribbean patients a section on diet will include information 
on cooking with African Caribbean foods rather than on advice relating to a traditional 
British diet. Equally patients who are severely disabled will have different advice on 
collecting prescriptions compared to those who are independent. 
Plans will be written in lay terminology and in a font size which is easy to see even with 
poor eyesight. Each plan will be formatted to an A5 size so that it can be slotted into a 
folder or pack and so that additional sections can be added if and when required. Leaflet 
design, readability and content will be piloted among the South London Stroke Patient 
Advisory Group. 
" Hard copy management plans will be designed for patients to provide to 
individualised information on: 
" the type of stroke the patient has had 
" risk factors: diagnoses, investigations and test results and how management of these 
can help prevent a subsequent stroke 
" lay guidelines on risk factor management (based on RCP lay guidelines) including 
explanation of treatments and concordance issues 
" health care processes (how to get a prescription, appointment dates/times/location, 
how to make an appointment) 
" the health care team (who is responsible for care including contact details) 
To design hard copy individualised management plans for health professionals 
integrating data from the SLSR and RCP guidelines on best management practice. 
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Guidelines on the best practice for secondary prevention management of stroke patients 
have been produced by the Royal College of Physicians (Royal College of Physicians 
2000). However RCP guidelines may not be accessible to the health professional at the 
point of contact with the patient. Providing individualised guidelines to health 
professionals which can be placed in patients' notes so that they are to hand in 
consultations may help get evidence into practice. Equally, medical decision making is 
dependent on individual patient information (e. g. on risk factors and treatments) being 
available to the health professional at the point of contact. The information provided in 
current referral letters is variable. A North Ireland study reported that only 17% of 
letters sent from hospital to GP gave details of the risks associated with treatments or 
the need for regular GP monitoring (Corry et al., 2000). A more detailed description of 
patients' risk factors and treatment generated from SLSR data may help inform decision 
making. Plans will be piloted with hospital doctors and general practitioners for 
readability, and content. 
Hard copy management plans will be designed for health professionals providing 
information and guidelines on: 
" stroke subtype 
" risk score (evaluation of how high a patients' risk is and the effect of risk factor 
management on recurrence) 
" details of risk factors and risk factor change 
" test results and investigations 
" RCP guidelines on management of risk factors 
" Current medication (prescribed medication, contraindications to medication and 
concordance issues) 
" Lifestyle issues 
" Recommended follow up and monitoring plan 
To design an individualised reminder letter to inform patients and health 
professionals that patients need follow up and monitoring of their risk factors. 
The majority of patients receive at least one follow up appointment within 3 months of 
their stroke, however over half do not see a stroke specialist and 14% do not see a 
doctor at all (Redfern et al., submitted). Equally a one-off visit may not be enough to 
ensure that secondary prevention issues are addressed. Although some patients get 
organised stroke secondary prevention, others rely on opportunistic or lay management. 
(Redfern et al., 2000). Individualised reminder letters will inform patients and 
professionals when risk factors need monitoring (e. g. patients with high blood pressure 
need check ups until their blood pressure is adequately controlled and then annually 
thereafter). Individualised reminder letters will be sent out before an appointment is 
required giving details of risk factors needing attention (non managed risk factors) and 
the appropriate course of action (make an appointment with hospital doctor, GP, 
practice nurse). 
To develop a computer based system for converting SLSR data into hard copy 
individualised management plans and reminder letters for patients and health 
professionals 
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After data collection, SLSR data are currently entered into a database using Epilnfo and 
analysed for research purposed using statistical software (STATA). In order to make the 
system practical, user friendly and generalisable to other organisations or disease groups 
this study aims to develop a system using computer software which is widely available 
and does not require specialist skills to use. The proposed system uses STATA and 
Microsoft Word. 
The proposed system combines STATA and Microsoft Word software packages and is 
divided into 2 parts: 
Creating a management database: Using STATA, Algorithms will be designed to code 
existing variables into categories which define patients' risk factors and their 
appropriate treatments (e. g. patients with atrial fibrillation can be categorised into those 
who are appropriate for anticoagulants and those appropriate for antiplatelets depending 
on their comorbidities and contraindications to medication). These new variables 
together with data on patient characteristics (e. g. age, sex, ethnicity, disability date of 
stroke, resource use) saved into a Word (or text friendly) database. Although this system 
will be designed in STATA, but most statistical packages including SPSS for Windows 
would have the capability to produce a management file using the algorithms. Therefore 
the system would be generalisable even with different databases using different 
statistical software. 
Creating a mail merge template: Patient and Health Professional Management Plans 
and reminder letters will be created as Mail merge document templates in Microsoft 
Word. Individual patient variables from the management database will form merge 
fields which can be inserted into the template. Appropriate information and guidelines 
can be inserted into the document using word fields and logic statements (e. g. if [blood 
pressure >160/90] insert text your blood pressure is too high"). Separate mail merge 
documents can be created for each type of risk factor. Mail merge has a filter facility 
which can be used to ensure documents are only produced for those patients who need 
them (e. g. a high blood pressure treatment plan is only produced for patients with 
hypertension). Filtering can also be used to create reminder letters prior to appointment 
dates and at 3 month, 6 month and yearly intervals. Given that Microsoft word is widely 
available, it would be possible to send mail merge documents electronically to patients 
or health professionals if preferred. 
Resources: 
" Computing facilities: Epi Info, STATA, Microsoft Word 
" Paper for management plans and reminder letters 
" Folders or packs for management plans 
" Envelopes and postage costs for sending reminders 
Time Frame: 
It is estimated that design of the templates and database would take approximately 4-6 
weeks. Piloting of the plans would take a further 1-2 months. 
Staff: 
" Researcher to develop computer based system 
" Statistical support to ensure the STATA commands are accurate 
" Clinician support in the development of the management algorithm 
380 
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Appendix 9. Patient Information Sheets 
This Appendix contains the patient information sheet component of the Stop Stroke 
intervention. Each sheet is numbered and links to the corresponding number on the 
individualised patient plans. Each patient receives only the information sheets relevant 
to him or her. The sheet si ze has been modified to fit into this thesis. Each sheet is 
single or double-sided A5 and printed on white paper that is subsequently laminated. 
The minimum font size is 16 point Arial font. There are 21 sheets in total: 
High Blood Pressure. Diabetes Diet 
Haemorrhage Diabetes Medicine 
Blood pressure tablets High cholesterol 
Healthy eating Cholesterol tablets 
Stroke advice Smoking 
Atrial Fibrillation Alcohol men 
Warfarin Alcohol - women 
Aspirin Obesity 
Aspirin, Dipyridamole and Exercise 
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